AP880929-0168 <DOCNO>
Federal <NNP>
health <NN>
officials <NNS>
said <VBD>
Thursday <NNP>
that <IN>
hospitalization <NN>
rates <NNS>
have <VBP>
fallen <VBN>
in <IN>
the <DT>
1980s <CD>
for <IN>
four <CD>
major <JJ>
types <NNS>
of <IN>
cancer <NN>
, <,>
even <RB>
though <IN>
the <DT>
number <NN>
of <IN>
people <NNS>
suffering <VBG>
from <IN>
the <DT>
diseases <NNS>
has <VBZ>
not <RB>
fallen <VBN>
in <IN>
all <DT>
cases <NNS>
. <.>
The <DT>
national <JJ>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
reported <VBD>
that <IN>
hospitalization <NN>
rates <NNS>
for <IN>
breast <JJ>
cancer <NN>
, <,>
lung <JJ>
cancer <NN>
, <,>
colon <NN>
and <CC>
rectal <JJ>
cancer <NN>
, <,>
and <CC>
cervical <JJ>
cancer <NN>
all <DT>
have <VBP>
declined <VBN>
during <IN>
the <DT>
decade <NN>
. <.>
The <DT>
rates <NNS>
are <VBP>
calculated <VBN>
by <IN>
looking <NN>
at <IN>
records <NNS>
of <IN>
hospital <JJ>
discharges <NNS>
. <.>
Hospitalization <NN>
rates <NNS>
do <VBP>
not_necessarily <RB>
reflect <VB>
trends <NNS>
in <IN>
the <DT>
numbers <NNS>
of <IN>
people <NNS>
with <IN>
various <JJ>
cancers <NNS>
, <,>
said <VBD>
Dr._James_Mendlein <NNP>
, <,>
a <DT>
CDC <NNP>
researcher <NN>
. <.>
Some <DT>
cancers <NNS>
may <MD>
require <VB>
more <RBR>
follow-up <JJ>
hospital <NN>
stays <NNS>
than <IN>
others <NNS>
, <,>
and <CC>
the <DT>
effort <NN>
to <TO>
cut <VB>
the <DT>
cost <NN>
of <IN>
health_care <NN>
also <RB>
can <MD>
influence <VB>
the <DT>
number <NN>
of <IN>
times <NNS>
a <DT>
patient <NN>
is <VBZ>
hospitalized <VBN>
, <,>
he <PRP>
noted <VBD>
. <.>
`` <``>
This <DT>
gives <VBZ>
you <PRP>
just <RB>
one <CD>
measure <NN>
of <IN>
the <DT>
health_care_impact <NN>
( <:>
of <IN>
various <JJ>
cancers <NNS>
) <:>
, <,>
'' <''>
Mendlein <NNP>
said <VBD>
. <.>
The <DT>
drop <NN>
in <IN>
hospitalization <NN>
rates <NNS>
parallels <VBZ>
the <DT>
drop <NN>
in <IN>
the <DT>
rate <NN>
of <IN>
occurrence <NN>
of <IN>
cervical <JJ>
cancer <NN>
, <,>
colorectal <JJ>
cancer <NN>
and <CC>
male <JJ>
lung_cancer <NN>
, <,>
Mendlein <NNP>
said <VBD>
. <.>
On <IN>
the <DT>
other <JJ>
hand <NN>
, <,>
while <IN>
hospitalizations <NNS>
for <IN>
breast <JJ>
cancer <NN>
and <CC>
female <JJ>
lung_cancer <NN>
are <VBP>
declining <VBG>
somewhat <RB>
, <,>
the <DT>
incidence <NN>
of <IN>
those <DT>
two <CD>
diseases <NNS>
continues <VBZ>
to <TO>
increase <VB>
, <,>
he <PRP>
said <VBD>
. <.>
For <IN>
1986 <CD>
, <,>
the <DT>
latest <JJS>
year <NN>
for <IN>
which <WDT>
figures <NNS>
are <VBP>
available <JJ>
, <,>
the <DT>
CDC <NNP>
estimates <VBZ>
hospital <JJ>
discharge <NN>
rates <NNS>
as <IN>
: <:>
_Breast <NNP>
cancer <NN>
, <,>
172 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
people <NNS>
, <,>
down_from <IN>
a <DT>
peak <NN>
of <IN>
199 <CD>
in <IN>
1983 <CD>
. <.>
_Lung <NNP>
cancer <NN>
, <,>
male <JJ>
, <,>
142 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
, <,>
down_from <IN>
a <DT>
peak <NN>
of <IN>
182 <CD>
in <IN>
1984 <CD>
. <.>
_Lung <NNP>
cancer <NN>
, <,>
female <JJ>
, <,>
83 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
, <,>
down_from <IN>
a <DT>
peak <NN>
of <IN>
100 <CD>
in <IN>
1983 <CD>
. <.>
_Colorectal <NNP>
cancer <NN>
, <,>
86 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
, <,>
down_from <IN>
a <DT>
peak <NN>
of <IN>
92 <CD>
in <IN>
1981 <CD>
. <.>
_Cervical <NNP>
cancer <NN>
, <,>
46 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
, <,>
down_from <IN>
a <DT>
peak <NN>
of <IN>
89 <CD>
in <IN>
1976 <CD>
. <.>
A <DT>
National_Cancer_Institute <NNP>
report <NN>
earlier <JJR>
this <DT>
year <NN>
put <VBD>
breast <JJ>
cancer <NN>
at <IN>
its <PRP$>
highest <JJS>
rate <NN>
in <IN>
history <NN>
, <,>
and <CC>
it <PRP>
is <VBZ>
still <RB>
the <DT>
leading <VBG>
cause <NN>
of <IN>
cancer_death <NN>
among <IN>
women <NNS>
. <.>
Lung <NNP>
cancer <NN>
, <,>
the <DT>
leading <VBG>
cause <NN>
of <IN>
cancer <NN>
deaths <NNS>
overall <JJ>
, <,>
is <VBZ>
increasing <VBG>
among <IN>
women <NNS>
and <CC>
decreasing <VBG>
among <IN>
men <NNS>
. <.>
When <WRB>
studying <VBG>
hospital <JJ>
discharge <NN>
rates <NNS>
, <,>
`` <``>
incidence <NN>
or <CC>
occurrence <NN>
is <VBZ>
just <RB>
one <CD>
of <IN>
the <DT>
forces <NNS>
, <,>
'' <''>
Mendlein <NNP>
said <VBD>
. <.>
`` <``>
There <EX>
are <VBP>
other <JJ>
, <,>
economic <JJ>
forces <NNS>
as <IN>
well <RB>
. <.>
'' <''>
He <PRP>
noted <VBD>
that <IN>
such <JJ>
factors <NNS>
as <IN>
shifts <NNS>
in <IN>
Medicare <NNP>
policy <NN>
and <CC>
trends <NNS>
in <IN>
outpatient_treatment <NN>
could <MD>
change <VB>
the <DT>
rates <NNS>
of <IN>
hospital <JJ>
visits <NNS>
for <IN>
various <JJ>
diseases <NNS>
FT944-3521 <DOCNO>
. <.>
Advice <NNP>
for <IN>
avoiding <VBG>
cancer <NN>
: <:>
Do <NNP>
n't <RB>
smoke <VB>
. <.>
Hide <NNP>
from <IN>
the <DT>
sun <NN>
. <.>
Eat <NNP>
fruit <NN>
and <CC>
vegetables <NNS>
. <.>
Join <NNP>
the <DT>
upper <JJ>
classes <NNS>
. <.>
Employ <NNP>
a <DT>
chauffeur <NN>
and <CC>
do <VBP>
n't <RB>
look <VB>
out <RP>
of <IN>
the <DT>
car_window <NN>
. <.>
Epidemiologists <NNS>
estimate <VBP>
75-80 <CD>
per <IN>
cent <NN>
of <IN>
all <DT>
cancers <NNS>
are <VBP>
preventable <JJ>
, <,>
in <IN>
the <DT>
sense <NN>
that <IN>
they <PRP>
are <VBP>
triggered <VBN>
by <IN>
features <NNS>
of <IN>
the <DT>
individual <JJ>
's <POS>
lifestyle <NN>
and <CC>
environment <NN>
. <.>
The <DT>
problem <NN>
is <VBZ>
identifying <VBG>
the <DT>
avoidable <JJ>
risks <NNS>
. <.>
A <DT>
few <JJ>
are <VBP>
well <RB>
known <VBN>
and <CC>
easy <JJ>
to <TO>
act <VB>
on <IN>
; <:>
much <JJ>
the <DT>
most <RBS>
obvious <JJ>
example <NN>
is <VBZ>
smoking <VBG>
. <.>
Most <JJS>
risks <NNS>
, <,>
however <RB>
, <,>
are <VBP>
less <JJR>
well <RB>
defined <VBN>
and <CC>
harder <JJR>
to <TO>
avoid <VB>
. <.>
For <IN>
instance <NN>
, <,>
cancer <NN>
as <IN>
a <DT>
whole <JJ>
is <VBZ>
more <RBR>
common <JJ>
- <:>
and <CC>
more <JJR>
likely <JJ>
to <TO>
be <VB>
fatal <JJ>
- <:>
among <IN>
the <DT>
'lower <JJ>
' <POS>
social <JJ>
classes <NNS>
. <.>
This <DT>
is <VBZ>
true <JJ>
even <RB>
when <WRB>
the <DT>
statistics <NNS>
are <VBP>
adjusted <VBN>
to <TO>
take <VB>
account <NN>
of <IN>
all <DT>
known <VBN>
risk <NN>
factors <NNS>
such <JJ>
as <IN>
smoking <NN>
, <,>
diet <JJ>
and <CC>
access <NN>
to <TO>
health_care <NN>
. <.>
Researchers <NNS>
are <VBP>
coming <VBG>
to <TO>
the <DT>
conclusion <NN>
that <IN>
there <EX>
is <VBZ>
something <NN>
intrinsically <RB>
unhealthy <JJ>
about <IN>
being <VBG>
near <IN>
the <DT>
bottom <NN>
of <IN>
the <DT>
social <JJ>
pecking_order <NN>
, <,>
even <RB>
if <IN>
you <PRP>
follow <VBP>
the <DT>
rules <NNS>
for <IN>
healthy <JJ>
living <NN>
. <.>
Sally <RB>
Macintyre <NNP>
, <,>
director <NN>
of <IN>
the <DT>
Medical_Research_Council <NNP>
's <POS>
Medical_Sociology_Unit <NNP>
in <IN>
Glasgow <NNP>
, <,>
says <VBZ>
the <DT>
mechanism <NN>
of <IN>
this <DT>
effect <NN>
is <VBZ>
far <RB>
from <IN>
clear <JJ>
, <,>
though <IN>
it <PRP>
appears <VBZ>
that <IN>
'repeated_psycho-social <JJ>
stress <NN>
' <''>
somehow <NN>
depresses <NNS>
the <DT>
immune_system <NN>
. <.>
Hundreds <NNS>
of <IN>
different <JJ>
risk <NN>
factors <NNS>
have <VBP>
been_suggested <VBN>
for <IN>
cancer <NN>
- <:>
some <DT>
of <IN>
them <PRP>
an <DT>
inextricable <JJ>
part <NN>
of <IN>
modern <JJ>
life <NN>
. <.>
For <IN>
example <NN>
, <,>
Australian <JJ>
research <NN>
has <VBZ>
shown <VBN>
a <DT>
statistical <JJ>
correlation <NN>
between <IN>
driving <VBG>
and <CC>
cancer <NN>
. <.>
The <DT>
theory <NN>
is <VBZ>
that <IN>
the <DT>
brain <NN>
responds <NNS>
to <TO>
moving <VBG>
surroundings <NNS>
by <IN>
priming <VBG>
the <DT>
body <NN>
chemically <RB>
for <IN>
movement <NN>
that <WDT>
never <RB>
takes <VBZ>
place <NN>
; <:>
the <DT>
resulting <VBG>
chemical <JJ>
imbalance <NN>
may <MD>
trigger <VB>
cancers <NNS>
. <.>
More <JJR>
concern <NN>
has <VBZ>
been_expressed <VBN>
about <IN>
man-made <JJ>
hormones <NNS>
, <,>
particularly <RB>
in <IN>
the <DT>
contraceptive <JJ>
pill <NN>
. <.>
Clinical <JJ>
studies <NNS>
involving <VBG>
tens <NNS>
of <IN>
thousands <NNS>
of <IN>
women <NNS>
have <VBP>
shown <VBN>
no <DT>
general <JJ>
increase <NN>
in <IN>
cancer <NN>
among <IN>
long-term <JJ>
pill <NN>
users <NNS>
, <,>
though <IN>
some <DT>
groups <NNS>
may <MD>
be <VB>
at <IN>
slightly <RB>
greater <JJR>
risk <NN>
of <IN>
developing <VBG>
breast <JJ>
or <CC>
cervical <JJ>
cancer <NN>
. <.>
But <CC>
epidemiologists <NNS>
say <VBP>
people <NNS>
should <MD>
not <RB>
be <VB>
too <RB>
concerned <VBN>
about <IN>
minor <JJ>
or <CC>
speculative <JJ>
causes <NNS>
of <IN>
cancer <NN>
, <,>
when <WRB>
smoking <NN>
and <CC>
poor <JJ>
diet <NN>
are <VBP>
so_much <RB>
more <RBR>
important <JJ>
. <.>
'One <NN>
of <IN>
the <DT>
biggest <JJS>
myths <NNS>
in <IN>
recent <JJ>
years <NNS>
is <VBZ>
that <IN>
there <EX>
is <VBZ>
a <DT>
cancer <NN>
epidemic <JJ>
caused <VBN>
by <IN>
exposure <NN>
to <TO>
radiation <NN>
, <,>
pollution <NN>
, <,>
pesticides <VBZ>
and <CC>
food <NN>
additives <NNS>
, <,>
' <''>
says <VBZ>
Sir_Richard_Doll <NNP>
of <IN>
the <DT>
Imperial_Cancer_Research_Fund <NNP>
's <POS>
cancer <NN>
studies <NNS>
unit <NN>
in <IN>
Oxford <NNP>
. <.>
'These <JJ>
factors <NNS>
have <VBP>
very_little <RB>
to <TO>
do <VB>
with <IN>
the <DT>
majority <NN>
of <IN>
cancers <NNS>
. <.>
' <POS>
Epidemiologists <NNS>
are <VBP>
confident <JJ>
tobacco <NN>
is <VBZ>
implicated <VBN>
in_about <IN>
30 <CD>
per <IN>
cent <NN>
of <IN>
cancer <NN>
deaths <NNS>
in <IN>
Europe <NNP>
and <CC>
North_America <NNP>
. <.>
They <PRP>
are <VBP>
far <RB>
less <RBR>
sure <JJ>
about <IN>
food <NN>
and <CC>
drink <NN>
; <:>
a <DT>
typical <JJ>
estimate <NN>
is <VBZ>
that <IN>
diet <JJ>
is <VBZ>
involved <VBN>
in <IN>
35 <CD>
per <IN>
cent <NN>
of <IN>
cancer <NN>
deaths <NNS>
. <.>
Because <IN>
there <EX>
can <MD>
be <VB>
a <DT>
delay <NN>
of <IN>
several <JJ>
decades <NNS>
between <IN>
starting <VBG>
to <TO>
smoke <VB>
and <CC>
the <DT>
onset <NN>
of <IN>
disease <NN>
, <,>
the <DT>
big <JJ>
rise <NN>
in <IN>
lung <JJ>
cancer <NN>
did <VBD>
not <RB>
begin <VB>
until <IN>
the <DT>
1940s <CD>
among <IN>
men <NNS>
and <CC>
the <DT>
1970s <CD>
among <IN>
women <NNS>
( <:>
see <VB>
chart <NN>
) <:>
. <.>
The <DT>
male <JJ>
lung_cancer_rate <NN>
is <VBZ>
falling <VBG>
in <IN>
countries <NNS>
such <JJ>
as <IN>
the <DT>
US <NNP>
and <CC>
UK <NNP>
where <WRB>
large <JJ>
numbers <NNS>
of <IN>
men <NNS>
gave <VBP>
up <RP>
smoking <VBG>
in <IN>
the <DT>
1960s <CD>
and <CC>
1970s <CD>
, <,>
but <CC>
it <PRP>
is <VBZ>
rising <VBG>
throughout <IN>
the <DT>
developing <VBG>
world <NN>
. <.>
Female <NNP>
lung <VBD>
cancer <NN>
rates <NNS>
are <VBP>
increasing <VBG>
everywhere <RB>
. <.>
Although <IN>
lung <JJ>
cancer <NN>
is <VBZ>
the <DT>
most <RBS>
obvious <JJ>
effect <NN>
of <IN>
smoking <NN>
, <,>
12 <CD>
other <JJ>
cancers <NNS>
are <VBP>
linked <VBN>
to <TO>
the <DT>
habit <NN>
, <,>
as <IN>
well <RB>
as <IN>
cardiovascular <JJ>
and <CC>
other <JJ>
diseases <NNS>
. <.>
However <RB>
, <,>
if <IN>
an <DT>
individual_smoker <NN>
gives <VBZ>
up <RP>
before <IN>
becoming <VBG>
ill <NN>
, <,>
he <PRP>
or <CC>
she <PRP>
can <MD>
avoid <VB>
most <RBS>
of <IN>
the <DT>
risk <NN>
of <IN>
dying <VBG>
from <IN>
tobacco <NN>
. <.>
Ten <CD>
years <NNS>
after <IN>
stopping <VBG>
, <,>
half <DT>
of <IN>
the <DT>
smoker <NN>
's <POS>
additional <JJ>
cancer_risk <NN>
will <MD>
have <VB>
disappeared <VBN>
. <.>
In <IN>
contrast <NN>
to <TO>
smoking <NN>
and <CC>
lung <JJ>
cancer <NN>
, <,>
there <EX>
is <VBZ>
no <DT>
cancer <NN>
epidemic <JJ>
clearly <RB>
linked <VBN>
to <TO>
changing_diet <NN>
. <.>
On <IN>
the <DT>
contrary <NN>
, <,>
the <DT>
most <RBS>
striking <JJ>
trend <NN>
is <VBZ>
the <DT>
long-term <JJ>
decline <NN>
in <IN>
stomach_cancer <NN>
in <IN>
Europe <NNP>
and <CC>
North_America <NNP>
- <:>
a <DT>
fall <NN>
widely <RB>
attributed <VBN>
to <TO>
modern <JJ>
methods <NNS>
of <IN>
food_preservation <NN>
and <CC>
storage <NN>
which <WDT>
prevent <NN>
the <DT>
formation <NN>
of <IN>
carcinogenic <JJ>
decay <NN>
products <NNS>
. <.>
Although <IN>
colo-rectal <JJ>
cancer <NN>
rates <NNS>
have <VBP>
remained <VBN>
steady <JJ>
for <IN>
several <JJ>
decades <NNS>
in <IN>
the <DT>
west <NN>
, <,>
those <DT>
in <IN>
Japan <NNP>
have <VBP>
risen <VBN>
rapidly <RB>
to <TO>
European <JJ>
levels <NNS>
- <:>
probably <RB>
because <IN>
the <DT>
Japanese <JJ>
diet <NN>
has <VBZ>
become_westernised <VBN>
with <IN>
more <JJR>
meat <JJ>
and <CC>
fat <JJ>
eaten <NN>
. <.>
Epidemiologists <NNS>
say <VBP>
there <RB>
is <VBZ>
overwhelming <VBG>
evidence <NN>
that <IN>
a <DT>
diet <NN>
rich <WDT>
in <IN>
fruit <NN>
and <CC>
vegetables_reduces <NNS>
the <DT>
risk <NN>
of <IN>
cancer <NN>
. <.>
But <CC>
they <PRP>
do <VBP>
not <RB>
know <VB>
how <WRB>
the <DT>
protective <JJ>
effect <NN>
works <NNS>
. <.>
A <DT>
favourite_scientific <JJ>
theory <NN>
is <VBZ>
that <IN>
anti-oxidant <JJ>
nutrients <NNS>
, <,>
such <JJ>
as <IN>
vitamins <NNS>
E <NNP>
and <CC>
C <NNP>
and <CC>
beta-carotene <JJ>
, <,>
play <NN>
a <DT>
protective <JJ>
role <NN>
by <IN>
scavenging <NN>
'free <JJ>
radicals <NNS>
' <POS>
which <WDT>
can <MD>
damage <VB>
a <DT>
cell <NN>
's <POS>
genetic <JJ>
material <NN>
. <.>
Food <NNP>
supplements <NNS>
containing <VBG>
these <DT>
nutrients <NNS>
have <VBP>
become <VBN>
very <RB>
popular <JJ>
. <.>
as <IN>
a <DT>
result <NN>
, <,>
although <IN>
there <EX>
is <VBZ>
not_yet <RB>
conclusive_clinical <JJ>
evidence <NN>
to <TO>
prove <VB>
their <PRP$>
effectiveness <NN>
. <.>
The <DT>
next <JJ>
stage <NN>
, <,>
according <VBG>
to <TO>
speakers <NNS>
at <IN>
the <DT>
UK_Biochemical_Society_Conference <NNP>
this <DT>
week <NN>
, <,>
will <MD>
be <VB>
genetic <JJ>
engineering <NN>
of <IN>
crops <NNS>
to <TO>
make <VB>
more <JJR>
of <IN>
these <DT>
protective <JJ>
nutrients <NNS>
. <.>
Catherine <NNP>
Rice-Evans <NNS>
, <,>
a <DT>
biochemistry_professor <NN>
at <IN>
Guy <NNP>
's <POS>
Hospital <NNP>
, <,>
London <NNP>
, <,>
predicts <VBZ>
: <:>
'The <DT>
introduction <NN>
of <IN>
plants <NNS>
that <WDT>
have <VBP>
been_manipulated <VBN>
to <TO>
produce <VB>
more <JJR>
effective <JJ>
anti-oxidants <NNS>
should <MD>
be <VB>
possible <JJ>
within <IN>
five <CD>
years <NNS>
. <.>
' <POS>
IN <IN>
THIS <DT>
SERIES <NN>
: <:>
NOVEMBER <NNP>
29 <CD>
Introduction <NNP>
. <.>
The <DT>
growing <VBG>
toll <NN>
of <IN>
cancer_worldwide <NN>
. <.>
Why <WRB>
the <DT>
disease <NN>
is <VBZ>
responding <VBG>
better <JJR>
to <TO>
treatment <NN>
in <IN>
the <DT>
young <JJ>
. <.>
The <DT>
worldwide_market <NN>
for <IN>
cancer <NN>
drugs <NNS>
. <.>
Who <WP>
is <VBZ>
spending <VBG>
what <WP>
on <IN>
research <NN>
. <.>
JANUARY_Diagnosis <NNP>
and <CC>
screening <VBG>
. <.>
Genetic <JJ>
susceptibility <NN>
. <.>
Scans <NNS>
. <.>
Identifying <VBG>
cancer <NN>
markers <NNS>
in <IN>
the <DT>
blood <NN>
. <.>
Politics <NNS>
and <CC>
economics <NNS>
of <IN>
screening <VBG>
. <.>
FEBRUARY_Chemotherapy <NNP>
. <.>
Drugs <NNS>
to <TO>
kill <VB>
rapidly <RB>
dividing <VBG>
cancer <NN>
cells <NNS>
. <.>
Reducing <VBG>
multi-drug_resistance <NN>
. <.>
Anti-nausea <NN>
drugs <NNS>
and <CC>
other <JJ>
ways <NNS>
of <IN>
reducing <VBG>
side <NN>
effects <NNS>
. <.>
Hormone-based <JJ>
treatments <NNS>
. <.>
Photodynamic <JJ>
therapy <NN>
. <.>
Herbal <NNP>
and <CC>
alterative <JJ>
remedies <NNS>
. <.>
MARCH_Radiotherapy <NNP>
. <.>
X-rays <NNS>
. <.>
Gamma <NNP>
rays <VBZ>
. <.>
Neutron <NNP>
beams <NNS>
. <.>
Heavy <NNP>
ions <NNS>
. <.>
Magic <NNP>
bullets <NNS>
. <.>
Antibodies <NNS>
and <CC>
fusion <NN>
toxins <NNS>
aimed <VBN>
at <IN>
cancer <NN>
cells <NNS>
. <.>
APRIL_Genetic <NNP>
treatment <NN>
and <CC>
other <JJ>
biotech <NN>
approaches <NNS>
. <.>
Gene <NNP>
therapy <NN>
and <CC>
anti-sense <JJ>
. <.>
Cell <NNP>
migration <NN>
and <CC>
adhesion <NN>
. <.>
Apoptosis <NNP>
and <CC>
cell_suicide <NN>
. <.>
Immunostimulants <NNS>
. <.>
Cell <NNP>
growth <NN>
factors <NNS>
. <.>
Interferons <NNS>
and <CC>
interleukins <NNS>
WSJ900521-0110 <DOCNO>
. <.>
Mrs._Lupro <NNP>
, <,>
38 <CD>
years <NNS>
old <JJ>
, <,>
believes <VBZ>
a <DT>
new <JJ>
treatment <NN>
, <,>
involving <VBG>
an <DT>
`` <``>
autologous <JJ>
bone_marrow_transplant <NN>
, <,>
'' <''>
or <CC>
ABMT <NNP>
, <,>
could <MD>
kill <VB>
lingering <VBG>
tumor <NN>
cells <NNS>
and <CC>
buy <VB>
her <PRP$>
a <DT>
lot <NN>
of <IN>
time <NN>
. <.>
But <CC>
her <PRP$>
health_insurer <NN>
, <,>
Travelers <NNPS>
Corp. <NNP>
, <,>
says <VBZ>
the <DT>
procedure <NN>
is <VBZ>
still <RB>
experimental <JJ>
, <,>
hence <NN>
not <RB>
covered <VBN>
. <.>
Without <IN>
an <DT>
insurer <NN>
's <POS>
promise <NN>
to <TO>
pay <VB>
, <,>
hospitals <NNS>
wo <MD>
n't <RB>
begin <VB>
the <DT>
costly <JJ>
treatment <NN>
, <,>
which <WDT>
employs <NNS>
a <DT>
dangerous <JJ>
, <,>
high-dose <JJ>
blast <NN>
of <IN>
conventional <JJ>
anti-cancer <NN>
drugs <NNS>
. <.>
`` <``>
I <PRP>
'm <VBP>
not <RB>
as <IN>
mad <JJ>
as <IN>
my <PRP$>
husband <NN>
, <,>
'' <''>
says <VBZ>
Mrs._Lupro <NNP>
, <,>
who <WP>
says <VBZ>
she <PRP>
may <MD>
sue <VB>
Travelers <NNPS>
to <TO>
get <VB>
an <DT>
ABMT <NNP>
. <.>
`` <``>
It <PRP>
's <VBZ>
harder <JJR>
on <IN>
him <PRP>
. <.>
`` <``>
A <DT>
Travelers <NNPS>
spokeswoman <NN>
says <VBZ>
the <DT>
Lupro <NNP>
case <NN>
is <VBZ>
`` <``>
being <VBG>
reviewed <VBN>
with <IN>
an <DT>
outside <JJ>
oncologist <NN>
. <.>
`` <``>
The <DT>
Lupros <NNP>
are <VBP>
caught <VBN>
up <RP>
in <IN>
one <CD>
of <IN>
the <DT>
nation <NN>
's <POS>
fiercest_health-care <NN>
debates <VBZ>
. <.>
Preliminary <NNP>
studies <NNS>
on <IN>
ABMT <NNP>
for <IN>
breast <JJ>
cancer_indicate <NN>
it <PRP>
may <MD>
work <VB>
better <JJR>
than <IN>
conventional <JJ>
alternatives <NNS>
for <IN>
some <DT>
women <NNS>
. <.>
A <DT>
recent <JJ>
report <NN>
in <IN>
Tokyo <NNP>
showed <VBD>
that_about <IN>
one-third <NN>
of <IN>
258 <CD>
metastatic <JJ>
breast-cancer <NN>
patients <NNS>
treated <VBD>
with <IN>
ABMT <NNP>
after <IN>
standard <JJ>
chemotherapy <NN>
showed <VBD>
no <DT>
signs <NNS>
of <IN>
the <DT>
disease <NN>
in <IN>
follow-up <JJ>
periods <NNS>
of <IN>
12 <CD>
to <TO>
42 <CD>
months <NNS>
, <,>
according <VBG>
to <TO>
Bristol-Myers <NNS>
Squibb_Co. <NNP>
, <,>
which <WDT>
sponsored <VBN>
the <DT>
meeting <NN>
. <.>
Karen_Antman <NNP>
, <,>
a <DT>
researcher <NN>
at <IN>
the <DT>
Dana-Farber <JJ>
Cancer_Institute <NNP>
in <IN>
Boston <NNP>
, <,>
told <VBD>
the <DT>
meeting <NN>
that <IN>
the <DT>
frequency <NN>
of <IN>
tumor_disappearance <NN>
in <IN>
certain <JJ>
patients <NNS>
is <VBZ>
`` <``>
much <RB>
higher <JJR>
'' <''>
than_with <IN>
standard <JJ>
chemotherapy <NN>
. <.>
But <CC>
the <DT>
treatment <NN>
, <,>
which <WDT>
typically <RB>
costs <VBZ>
$ <$>
100 <CD>
, <,>
000 <CD>
or <CC>
more <JJR>
, <,>
is <VBZ>
risky <JJ>
. <.>
About <IN>
9 <CD>
% <NN>
of <IN>
patients <NNS>
with <IN>
various <JJ>
stages <NNS>
of <IN>
breast <JJ>
cancer <NN>
have <VBP>
died <VBN>
from <IN>
complications <NNS>
after <IN>
the <DT>
therapy <NN>
, <,>
according <VBG>
to <TO>
Dr._Antman <NNP>
. <.>
Most <JJS>
doctors <NNS>
say <VBP>
that <IN>
more <JJR>
data <NNS>
on <IN>
ABMT <NNP>
is <VBZ>
needed <VBN>
to <TO>
establish <VB>
whether <IN>
it <PRP>
's <VBZ>
better <JJR>
than <IN>
alternative <JJ>
treatments <NNS>
. <.>
`` <``>
I <PRP>
think <VBP>
the <DT>
insurance <NN>
companies <NNS>
are <VBP>
right <RB>
. <.>
ABMT <NN>
is <VBZ>
very <RB>
experimental <JJ>
for <IN>
breast <JJ>
cancer <NN>
, <,>
'' <''>
says <VBZ>
Subhash_Gulati <NNP>
, <,>
chief <NN>
of <IN>
the <DT>
ABMT <NNP>
team <NN>
at <IN>
New_York <NNP>
's <POS>
Memorial_Sloan-Kettering_Cancer_Center <NNP>
. <.>
Still <RB>
, <,>
he <PRP>
adds <VBZ>
, <,>
early <RB>
results <NNS>
with <IN>
it <PRP>
are <VBP>
'' <''>
encouraging <VBG>
, <,>
'' <''>
warranting <VBG>
further <RB>
studies <NNS>
. <.>
Some <DT>
doctors <NNS>
are <VBP>
less <JJR>
optimistic <JJ>
. <.>
Based <VBN>
on <IN>
available <JJ>
data <NNS>
, <,>
'' <''>
I <PRP>
certainly <RB>
ca <MD>
n't <RB>
conclude <VB>
that <IN>
{ <CD>
breast-cancer <NN>
} <:>
patients <NNS>
are <VBP>
better <RBR>
off_with <IN>
ABMT <NNP>
, <,>
'' <''>
says <VBZ>
David_Eddy <NNP>
, <,>
a <DT>
Duke_University_health-policy <NNP>
professor <NN>
and <CC>
a <DT>
consultant <NN>
to <TO>
the <DT>
Blue_Cross <NNP>
& <CC>
amp <VB>
; <:>
Blue_Shield_Association <NNP>
. <.>
The <DT>
stakes <NNS>
in <IN>
the <DT>
ABMT <NNP>
debate <NN>
are <VBP>
large <JJ>
. <.>
The <DT>
rate <NN>
of <IN>
breast-cancer_incidence <NN>
in <IN>
the <DT>
U.S. <NNP>
has <VBZ>
risen <VBN>
sharply <RB>
in <IN>
the <DT>
past <JJ>
decade <NN>
, <,>
though <IN>
the <DT>
mortality_rate <NN>
has <VBZ>
held <VBN>
steady <JJ>
. <.>
This <DT>
year <NN>
, <,>
about <IN>
150 <CD>
, <,>
000 <CD>
women <NNS>
will <MD>
be <VB>
diagnosed <VBN>
with <IN>
the <DT>
disease <NN>
. <.>
The <DT>
metastatic <JJ>
form <NN>
will <MD>
develop <VB>
in_about <IN>
30 <CD>
% <NN>
of <IN>
those <DT>
women <NNS>
, <,>
with <IN>
most <JJS>
patients <NNS>
dying <VBG>
within <IN>
two <CD>
years <NNS>
. <.>
Doctors <NNS>
testing <VBG>
ABMT <NNP>
for <IN>
breast <JJ>
cancer_estimate <NN>
that <WDT>
one-fourth <JJ>
to <TO>
one-half <JJ>
of <IN>
metastatic <JJ>
cases <NNS>
may <MD>
be <VB>
good <JJ>
candidates <NNS>
for <IN>
the <DT>
procedure <NN>
-- <:>
if <IN>
it <PRP>
's <VBZ>
proved <VBN>
effective <JJ>
. <.>
Physicians <NNS>
also <RB>
are <VBP>
testing <VBG>
ABMT <NNP>
to <TO>
treat <VB>
high-risk <JJ>
patients <NNS>
before <IN>
metastasis <NN>
, <,>
as <IN>
well <RB>
as <IN>
people <NNS>
with <IN>
testicular <JJ>
cancer <NN>
and <CC>
melanoma <NN>
. <.>
For <IN>
certain_other <JJ>
cancers <NNS>
, <,>
such <JJ>
as <IN>
leukemia <NN>
, <,>
ABMT <NNP>
already <RB>
is <VBZ>
an <DT>
accepted <VBN>
treatment <NN>
covered <VBN>
by <IN>
insurers <NNS>
. <.>
`` <``>
It <PRP>
's <VBZ>
too <RB>
early <JJ>
to <TO>
say <VB>
this <DT>
approach <NN>
is <VBZ>
right <RB>
for <IN>
public <JJ>
consumption <NN>
, <,>
'' <''>
says <VBZ>
Jacob_Bitran <NNP>
, <,>
a <DT>
University <NNP>
of <IN>
Chicago <NNP>
cancer_researcher_testing <NN>
ABMT <NNP>
. <.>
`` <``>
But <CC>
I <PRP>
've <VBP>
never <RB>
seen <VBN>
metastatic <JJ>
breast_cancer <NN>
patients <NNS>
respond <VBP>
as_frequently <RB>
'' <''>
as <IN>
they <PRP>
do <VBP>
with <IN>
ABMT <NNP>
, <,>
he <PRP>
says <VBZ>
. <.>
Its <PRP$>
promise <NN>
appears <VBZ>
greatest <NN>
with <IN>
breast-cancer <JJ>
patients <NNS>
whose <WP$>
cancers <NNS>
respond <VBP>
to <TO>
conventional <JJ>
chemotherapy <NN>
, <,>
says <VBZ>
Nancy_Davidson <NNP>
, <,>
a <DT>
Johns_Hopkins_University <NNP>
researcher <NN>
. <.>
A <DT>
higher <JJR>
dose <NN>
of <IN>
the <DT>
same <JJ>
drugs <NNS>
is <VBZ>
likely <JJ>
to <TO>
wipe <VB>
out <RP>
even <RB>
more <RBR>
breast <JJ>
cancer <NN>
cells <NNS>
in <IN>
those <DT>
patients <NNS>
, <,>
she <PRP>
says <VBZ>
, <,>
raising <VBG>
the <DT>
chances <NNS>
of <IN>
long-term <JJ>
remission <NN>
. <.>
But <CC>
at <IN>
high <JJ>
doses <NNS>
, <,>
the <DT>
drugs <NNS>
cripple <VBP>
the <DT>
immune_system <NN>
, <,>
leaving <VBG>
patients <NNS>
vulnerable <JJ>
to <TO>
fatal <JJ>
infections <NNS>
. <.>
To <TO>
prevent <VB>
that <IN>
, <,>
doctors <NNS>
using <VBG>
ABMT <NNP>
extract_marrow <NN>
cells <NNS>
from <IN>
patients <NNS>
' <POS>
pelvic <JJ>
bones <NNS>
through <IN>
needles <NNS>
before <IN>
giving <VBG>
them <PRP>
anti-cancer <JJ>
drugs <NNS>
. <.>
The <DT>
extracts <NNS>
contain <VBP>
immune-cell <JJ>
precursors <NNS>
that <WDT>
, <,>
when <WRB>
reinfused <VBN>
after <IN>
chemotherapy <NN>
, <,>
`` <``>
rescue <NN>
'' <''>
patients <NNS>
' <POS>
immune <NN>
systems <NNS>
. <.>
Unlike <IN>
conventional <JJ>
chemotherapy <NN>
, <,>
which <WDT>
requires <VBZ>
shots <NNS>
over <IN>
months <NNS>
or <CC>
years <NNS>
, <,>
anti-cancer <JJ>
drugs <NNS>
with <IN>
ABMT <NNP>
are <VBP>
administered <VBN>
in <IN>
intense <JJ>
doses <NNS>
over <IN>
several <JJ>
days <NNS>
. <.>
The <DT>
procedure <NN>
typically <RB>
requires <VBZ>
three <CD>
or <CC>
more <JJR>
weeks <NNS>
of <IN>
hospitalization <NN>
for <IN>
immune-system <JJ>
recovery <NN>
. <.>
That <DT>
's <VBZ>
what <WP>
makes <VBZ>
it <PRP>
so <RB>
expensive <JJ>
. <.>
But <CC>
the <DT>
advent <NN>
of <IN>
`` <``>
colony <NN>
stimulating <VBG>
factors <NNS>
'' <''>
-- <:>
experimental <JJ>
drugs <NNS>
to <TO>
speed <VB>
immune-cell <JJ>
growth <NN>
-- <:>
and <CC>
other_recent <JJ>
advances <NNS>
`` <``>
are <VBP>
knocking <VBG>
four <CD>
or <CC>
five <CD>
days <NNS>
off <IN>
'' <''>
that <WDT>
period <NN>
, <,>
says <VBZ>
Chicago <NNP>
's <POS>
Dr._Bitran <NNP>
. <.>
He <PRP>
estimates <VBZ>
that <IN>
the <DT>
procedure <NN>
's <POS>
costs <NNS>
now <RB>
are <VBP>
`` <``>
pretty <RB>
close <JJ>
'' <''>
to <TO>
those <DT>
of <IN>
a <DT>
typical <JJ>
course <NN>
of <IN>
conventional <JJ>
chemotherapy <NN>
for <IN>
metastatic <JJ>
breast_cancer <NN>
. <.>
The <DT>
improvements <NNS>
also <RB>
are <VBP>
narrowing <VBG>
patients <NNS>
' <POS>
windows <NNS>
of <IN>
vulnerability <NN>
to <TO>
fatal <JJ>
infections <NNS>
, <,>
such <JJ>
as <IN>
pneumonia <NN>
. <.>
Deaths <NNS>
from <IN>
the <DT>
treatment <NN>
now <RB>
occur <VBP>
in_about <IN>
4 <CD>
% <NN>
to <TO>
9 <CD>
% <NN>
of <IN>
patients <NNS>
who <WP>
are <VBP>
treated <VBN>
by <IN>
doctors <NNS>
experienced <VBN>
with <IN>
it <PRP>
, <,>
compared <VBN>
with <IN>
20 <CD>
% <NN>
in <IN>
one <CD>
early <JJ>
study <NN>
, <,>
says <VBZ>
Andrew_Dorr <NNP>
, <,>
a <DT>
National_Cancer_Institute <NNP>
researcher <NN>
. <.>
Dr._Dorr <NNP>
adds <VBZ>
that <IN>
the <DT>
NCI <NNP>
plans <VBZ>
this <DT>
fall <NN>
to <TO>
organize <VB>
a <DT>
large_clinical <JJ>
study <NN>
of <IN>
the <DT>
new <JJ>
therapy <NN>
and <CC>
breast <JJ>
cancer <NN>
. <.>
But <CC>
the <DT>
study <NN>
, <,>
which <WDT>
doctors <NNS>
agree <VBP>
is <VBZ>
sorely <RB>
needed <VBN>
, <,>
may <MD>
spark <VB>
controversies <NNS>
of <IN>
its <PRP$>
own <JJ>
. <.>
One <CD>
issue <NN>
is <VBZ>
whether <IN>
insurers <NNS>
should <MD>
help_pay <VB>
for <IN>
it <PRP>
. <.>
In <IN>
any <DT>
case <NN>
, <,>
many <JJ>
women <NNS>
feel <VBP>
they <PRP>
do <VBP>
n't <RB>
have <VB>
time <NN>
to <TO>
wait <VB>
for <IN>
definitive <JJ>
studies <NNS>
. <.>
One <CD>
is <VBZ>
Pam_Pirozzi <NNP>
, <,>
a <DT>
35-year-old <JJ>
mother <NN>
in <IN>
Tracy <NNP>
's <POS>
Landing <NNP>
, <,>
Md. <NNP>
, <,>
diagnosed <VBD>
with <IN>
breast <JJ>
cancer <NN>
last <JJ>
year <NN>
. <.>
She <PRP>
sued <VBD>
her <PRP$>
insurer <NN>
, <,>
Blue_Cross/Blue_Shield <NNP>
of <IN>
Virginia <NNP>
, <,>
to <TO>
force <VB>
it <PRP>
to <TO>
pay <VB>
for <IN>
an <DT>
ABMT <NNP>
. <.>
Last <JJ>
month <NN>
, <,>
a <DT>
federal <JJ>
judge <NN>
in <IN>
Alexandria <NNP>
, <,>
Va. <NNP>
, <,>
ruled <VBD>
in <IN>
her <PRP$>
favor <NN>
, <,>
potentially <RB>
setting <VBG>
an <DT>
important <JJ>
precedent <NN>
. <.>
But <CC>
during <IN>
her <PRP$>
legal <JJ>
battle <NN>
, <,>
says <VBZ>
Mrs._Pirozzi <NNP>
, <,>
her <PRP$>
cancer_spread <NN>
to <TO>
her <PRP$>
cranium <NN>
. <.>
Now <RB>
she <PRP>
's <VBZ>
undergoing <VBG>
conventional <JJ>
therapy <NN>
, <,>
hoping <VBG>
to <TO>
follow <VB>
it <PRP>
up <RP>
with <IN>
ABMT <NNP>
this <DT>
fall <NN>
AP890105-0004 <DOCNO>
. <.>
A <DT>
new <JJ>
study <NN>
suggests <VBZ>
that <IN>
women <NNS>
under <IN>
45 <CD>
who <WP>
use <NN>
birth <VBP>
control <NN>
pills <NNS>
face <VBP>
a <DT>
greater <JJR>
risk <NN>
of <IN>
breast_cancer <NN>
_ <NNP>
a <DT>
finding <NN>
that <WDT>
contradicts <VBZ>
earlier <JJR>
research <NN>
. <.>
The <DT>
study <NN>
results <NNS>
were <VBD>
being <VBG>
presented <VBN>
today <NN>
at <IN>
a <DT>
hearing <NN>
of <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
. <.>
Researchers <NNS>
at <IN>
the <DT>
Boston_University_School <NNP>
of <IN>
Medicine <NNP>
found <VBD>
that <IN>
women <NNS>
who <WP>
used <VBN>
oral <JJ>
contraceptives <NNS>
had <VBD>
twice <NN>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
compared <VBN>
to <TO>
women <NNS>
who <WP>
have <VBP>
never <RB>
used <VBN>
the <DT>
pill <NN>
. <.>
For <IN>
women <NNS>
who <WP>
have <VBP>
used <VBN>
the <DT>
pill <NN>
for <IN>
10 <CD>
years <NNS>
or <CC>
more <JJR>
, <,>
the <DT>
study <NN>
found <VBD>
, <,>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
was <VBD>
four <CD>
times <NNS>
greater <JJR>
. <.>
The <DT>
issue <NN>
is <VBZ>
of <IN>
particular <JJ>
concern <NN>
because <IN>
oral <JJ>
contraceptives <NNS>
are <VBP>
the <DT>
most <RBS>
popular <JJ>
form <NN>
of <IN>
birth <JJ>
control <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
, <,>
and <CC>
breast <JJ>
cancer <NN>
is <VBZ>
the <DT>
second <JJ>
most <JJS>
common_fatal <JJ>
cancer <NN>
in <IN>
women <NNS>
. <.>
An <DT>
estimated <VBN>
13.2_million <CD>
American <JJ>
women <NNS>
take <VBP>
birth <JJ>
control <NN>
pills <NNS>
, <,>
according <VBG>
to <TO>
the <DT>
Alan_Guttmacher_Institute <NNP>
, <,>
which <WDT>
specializes <VBZ>
in <IN>
reproductive <JJ>
biology <NN>
. <.>
About <IN>
42 <CD>
, <,>
000 <CD>
women <NNS>
die <VB>
of <IN>
breast <JJ>
cancer <NN>
each <DT>
year <NN>
, <,>
according <VBG>
to <TO>
the <DT>
American_Cancer_Society <NNP>
. <.>
The <DT>
Boston_University <NNP>
findings <NNS>
were <VBD>
based <VBN>
on <IN>
a <DT>
study <NN>
of <IN>
407 <CD>
women <NNS>
with <IN>
breast <JJ>
cancer <NN>
and <CC>
a <DT>
cancer-free <JJ>
control_group <NN>
of <IN>
424 <CD>
. <.>
All <DT>
were <VBD>
patients <NNS>
in <IN>
hospitals <NNS>
in <IN>
Boston <NNP>
, <,>
New_York <NNP>
, <,>
Philadelphia <NNP>
and <CC>
Baltimore <NNP>
. <.>
Dr._Samuel_Shapiro <NNP>
, <,>
director <NN>
of <IN>
the <DT>
Slone_Epidemiology_Unit <NNP>
at <IN>
Boston_University <NNP>
, <,>
said <VBD>
in <IN>
a <DT>
news_release <NN>
the <DT>
new <JJ>
study <NN>
contradicts_findings <NNS>
in <IN>
earlier <JJR>
studies <NNS>
, <,>
which <WDT>
indicated <VBD>
there <RB>
was <VBD>
no <DT>
association <NN>
between <IN>
use <NN>
of <IN>
the <DT>
pill <NN>
and <CC>
development <NN>
of <IN>
breast_cancer <NN>
. <.>
`` <``>
Whereas <IN>
early <JJ>
studies <NNS>
, <,>
including <VBG>
our <PRP$>
own <JJ>
, <,>
were <VBD>
reassuring <VBG>
about <IN>
the <DT>
use <NN>
of <IN>
oral <JJ>
contraceptives <NNS>
and <CC>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
, <,>
recent <JJ>
studies <NNS>
reopen <VBP>
the <DT>
question <NN>
, <,>
but <CC>
do <VBP>
not <RB>
, <,>
by <IN>
any <DT>
means <NNS>
, <,>
answer <NN>
it <PRP>
, <,>
'' <''>
said <VBD>
Shapiro <NNP>
. <.>
The <DT>
effect <NN>
of <IN>
the <DT>
new <JJ>
findings <NNS>
, <,>
the <DT>
researchers <NNS>
said <VBD>
, <,>
is <VBZ>
to <TO>
show <VB>
that <IN>
further <JJ>
studies <NNS>
are <VBP>
needed <VBN>
`` <``>
to <TO>
reconcile <VB>
the <DT>
different <JJ>
findings <NNS>
and <CC>
to <TO>
overcome <VB>
the <DT>
methodologic <JJ>
limitations <NNS>
of <IN>
earlier <JJR>
ones <NNS>
. <.>
'' <''>
A <DT>
recent <JJ>
study <NN>
by <IN>
Dr._Clifford_R._Kay <NNP>
and <CC>
Philip_C._Hannaford <NNP>
of <IN>
Manchester <NNP>
, <,>
England <NNP>
, <,>
found <VBD>
no <DT>
overall <JJ>
increase <NN>
in <IN>
breast_cancer <NN>
among <IN>
women <NNS>
who <WP>
had <VBD>
taken <VBN>
birth <JJ>
control <NN>
pills <NNS>
, <,>
but <CC>
did <VBD>
find <RP>
a <DT>
threefold_increase <NN>
in <IN>
breast <NN>
cancers <NNS>
in <IN>
women <NNS>
30 <CD>
to <TO>
34 <CD>
years <NNS>
old <JJ>
who <WP>
were <VBD>
former <JJ>
pill <NN>
users <NNS>
. <.>
There <EX>
was <VBD>
no <DT>
elevation <NN>
in <IN>
breast_cancer <NN>
rates <NNS>
among <IN>
women <NNS>
who <WP>
were <VBD>
younger <JJR>
or <CC>
older <JJR>
than <IN>
this <DT>
group <NN>
. <.>
The <DT>
Boston_University <NNP>
researchers <NNS>
said <VBD>
it <PRP>
is <VBZ>
possible <JJ>
the <DT>
results <NNS>
of <IN>
their <PRP$>
study <NN>
were <VBD>
biased <VBN>
and <CC>
the <DT>
association <NN>
between <IN>
oral <JJ>
contraceptives <NNS>
and <CC>
breast <JJ>
cancer <NN>
`` <``>
may <MD>
not <RB>
be <VB>
one <CD>
of <IN>
cause <NN>
and <CC>
effect <NN>
. <.>
'' <''>
Further <NNP>
details <NNS>
of <IN>
the <DT>
study <NN>
were <VBD>
to <TO>
be <VB>
revealed <VBN>
at <IN>
the <DT>
FDA <NNP>
hearing <NN>
and <CC>
will <MD>
be <VB>
published <VBN>
next <JJ>
month <NN>
in <IN>
the <DT>
American_Journal <NNP>
of <IN>
Epidemiology <NNP>
. <.>
Oral <NNP>
contraceptives <VBZ>
are <VBP>
pills <NNS>
that <IN>
generally <RB>
contain <VBP>
a <DT>
combination <NN>
of <IN>
the <DT>
hormones <NNS>
estrogen <VBP>
and <CC>
progestin <NN>
. <.>
Usually <RB>
taken <VBN>
daily <RB>
for <IN>
three <CD>
weeks <NNS>
, <,>
the <DT>
pills <NNS>
prevent <VBP>
conception <NN>
by <IN>
inhibiting_ovulation <NN>
. <.>
In <IN>
recent <JJ>
years <NNS>
, <,>
the <DT>
amount <NN>
of <IN>
hormone <NN>
in <IN>
each <DT>
pill <NN>
has <VBZ>
generally <RB>
been_reduced <VBN>
as <IN>
researchers <NNS>
learned <VBD>
that <IN>
higher <JJR>
doses <NNS>
were <VBD>
unneeded <VBN>
to <TO>
prevent <VB>
conception <NN>
. <.>
Side <NNP>
effects <NNS>
, <,>
some <DT>
of <IN>
them <PRP>
serious <JJ>
, <,>
have <VBP>
been_experienced <VBN>
among <IN>
some <DT>
women <NNS>
taking <VBG>
the <DT>
pill <NN>
, <,>
but <CC>
the <DT>
accepted <VBN>
medical <JJ>
practice <NN>
now <RB>
is <VBZ>
to <TO>
prescribe <VB>
the <DT>
pill <NN>
for <IN>
healthy <JJ>
women <NNS>
until <IN>
the <DT>
age <NN>
of <IN>
35 <CD>
. <.>
Women <NNS>
over <IN>
that <DT>
age <NN>
, <,>
particularly <RB>
smokers <NNS>
, <,>
who <WP>
have <VBP>
used <VBN>
the <DT>
pill <NN>
for <IN>
more <JJR>
than <IN>
five <CD>
years <NNS>
are <VBP>
known <VBN>
to <TO>
be <VB>
at <IN>
greater <JJR>
risk <NN>
for <IN>
heart_attack <NN>
and <CC>
stroke <NN>
AP891124-0037 <DOCNO>
. <.>
A <DT>
new <JJ>
drug <NN>
derived <VBN>
from <IN>
a <DT>
Chinese <JJ>
tree <NN>
has <VBZ>
triggered <VBN>
remissions <NNS>
of <IN>
colon_cancer <NN>
in <IN>
laboratory_mice <NN>
, <,>
doctors <NNS>
said <VBD>
in <IN>
a <DT>
preliminary <JJ>
report <NN>
. <.>
`` <``>
In <IN>
20 <CD>
years <NNS>
in <IN>
this <DT>
lab <NN>
, <,>
we <PRP>
've <VBP>
never <RB>
seen <VBN>
anything <NN>
like <IN>
this <DT>
. <.>
We <PRP>
have <VBP>
animals <NNS>
that <IN>
are <VBP>
tumor-free <JJ>
, <,>
'' <''>
said <VBD>
Dr._John_Stehlin <NNP>
, <,>
scientific <JJ>
director <NN>
at <IN>
the <DT>
Stehlin_Foundation <NNP>
for <IN>
Cancer_Research <NNP>
at <IN>
Houston <NNP>
's <POS>
St._Joseph_Hospital <NNP>
. <.>
During <IN>
two <CD>
years <NNS>
of <IN>
experiments <NNS>
, <,>
researchers <NNS>
said <VBD>
they <PRP>
treated <VBD>
about <IN>
100 <CD>
mice <NN>
with <IN>
three <CD>
kinds <NNS>
of <IN>
human <JJ>
colon_cancer <NN>
: <:>
slow- <JJ>
, <,>
medium- <JJ>
and <CC>
fast-growing <JJ>
. <.>
Once <RB>
the <DT>
mice <NN>
began <VBD>
developing <VBG>
tumors <NNS>
, <,>
they <PRP>
were <VBD>
divided <VBN>
into <IN>
two <CD>
groups <NNS>
: <:>
those <DT>
receiving <VBG>
the <DT>
new <JJ>
drug <NN>
, <,>
9-amino <CD>
Camptothecin <NNP>
, <,>
or <CC>
9-AC <CD>
; <:>
and <CC>
those <DT>
receiving <VBG>
no <DT>
treatment <NN>
. <.>
Most <JJS>
mice <NN>
showed <VBD>
no <DT>
trace <NN>
of <IN>
residual <JJ>
cancer <NN>
after <IN>
being <VBG>
treated <VBN>
with <IN>
9-AC <CD>
for <IN>
several <JJ>
months <NNS>
, <,>
doctors <NNS>
said <VBD>
. <.>
The <DT>
untreated <VBN>
mice <NN>
died <VBD>
. <.>
Some <DT>
mice <NN>
treated <VBD>
with <IN>
9-AC <CD>
are <VBP>
still <RB>
alive <JJ>
after <IN>
surviving <VBG>
the <DT>
equivalent <NN>
, <,>
in <IN>
human <NN>
terms <NNS>
, <,>
of <IN>
20 <CD>
years <NNS>
, <,>
Stehlin <NNP>
said <VBD>
at <IN>
a <DT>
briefing <NN>
this <DT>
week <NN>
. <.>
The <DT>
findings <NNS>
were <VBD>
published <VBN>
today <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
`` <``>
This <DT>
is <VBZ>
a <DT>
preliminary <JJ>
report <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
`` <``>
Obviously <RB>
, <,>
more <JJR>
work <NN>
needs <VBZ>
to <TO>
be <VB>
done <VBN>
with <IN>
additional <JJ>
colon <NN>
cancers <NNS>
and <CC>
other <JJ>
forms <NNS>
of <IN>
cancer <NN>
that <IN>
are <VBP>
not <RB>
responsive <JJ>
to <TO>
the <DT>
standard <JJ>
anti-cancer <NN>
agents <NNS>
. <.>
'' <''>
Colon <NNP>
cancer <NN>
is <VBZ>
the <DT>
third <JJ>
most <JJS>
common <JJ>
cancer <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
with <IN>
147 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
reported <VBN>
each <DT>
year <NN>
. <.>
The <DT>
disease <NN>
, <,>
most <JJS>
commonly <RB>
treated <VBN>
by <IN>
surgery <NN>
, <,>
takes <VBZ>
about <RB>
60 <CD>
, <,>
000 <CD>
lives <NNS>
annually <RB>
. <.>
Beppino_Giovanella <NNP>
, <,>
director <NN>
of <IN>
the <DT>
St._Joseph_Hospital_Laboratory <NNP>
for <IN>
Cancer_Research <NNP>
, <,>
said <VBD>
all <DT>
three <CD>
tumors <NNS>
used <VBN>
in <IN>
the <DT>
experiments <NNS>
had <VBD>
not <RB>
responded <VBN>
to <TO>
major <JJ>
known_anti-cancer <NN>
drugs <NNS>
administered <VBD>
at <IN>
maximum <NN>
tolerable <JJ>
doses <NNS>
. <.>
Giovanella <NNP>
also <RB>
said <VBD>
two <CD>
mice <NN>
injected <VBD>
with <IN>
lung <JJ>
cancer <NN>
have <VBP>
shown <VBN>
a <DT>
regression <NN>
of <IN>
their <PRP$>
cancer <NN>
after <IN>
being <VBG>
treated <VBN>
with <IN>
9-AC <CD>
. <.>
Very <NNP>
little <RB>
progress <NN>
has <VBZ>
been_made <VBN>
in <IN>
colon_cancer_treatment <NN>
in <IN>
the <DT>
past <JJ>
40 <CD>
years <NNS>
, <,>
Stehlin <NNP>
said <VBD>
. <.>
Chemotherapy <NNP>
and <CC>
immunotherapy <NN>
have <VBP>
had <VBN>
little <JJ>
effect <NN>
and <CC>
the <DT>
use <NN>
of <IN>
the <DT>
drug_levamisole <NN>
with <IN>
5-fluorouracil <CD>
improves <NNS>
the <DT>
survival_rate <NN>
in_about <IN>
15 <CD>
percent <NN>
of <IN>
patients <NNS>
, <,>
he <PRP>
said <VBD>
. <.>
Researchers <NNS>
said <VBD>
mice <NN>
with <IN>
the <DT>
slow-growing <JJ>
cancer <NN>
responded <VBD>
to <TO>
9-AC <CD>
within <IN>
10 <CD>
days <NNS>
and <CC>
by <IN>
20 <CD>
days <NNS>
were <VBD>
tumor-free <JJ>
. <.>
The <DT>
mice <NN>
with <IN>
the <DT>
medium-growing <JJ>
cancer <NN>
took <VBD>
about <IN>
10 <CD>
days <NNS>
to <TO>
start <VB>
reacting <NN>
and <CC>
in_about <IN>
25 <CD>
days <NNS>
were <VBD>
in <IN>
remission <NN>
, <,>
according <VBG>
to <TO>
researchers <NNS>
. <.>
Mice <NNP>
treated <VBD>
with <IN>
the <DT>
fast-growing <JJ>
cancer <NN>
took <VBD>
21 <CD>
days <NNS>
before <IN>
responding <VBG>
to <TO>
9-AC <CD>
. <.>
The <DT>
9-AC <JJ>
drug <NN>
is <VBZ>
a <DT>
derivative <JJ>
of <IN>
camptothecin <NN>
, <,>
an <DT>
alkaloid <JJ>
extracted <VBN>
from <IN>
a <DT>
Chinese <JJ>
tree <NN>
. <.>
Dr._Monroe_Wall <NNP>
of <IN>
the <DT>
Research_Triangle_Institute <NNP>
in <IN>
North_Carolina <NNP>
isolated <VBD>
camptothecin <NN>
in <IN>
the <DT>
1960s <CD>
. <.>
It <PRP>
was <VBD>
tested <VBN>
on <IN>
humans <NNS>
but <CC>
was <VBD>
soon <RB>
discarded <VBN>
because_of <IN>
its <PRP$>
excessive <JJ>
toxicity <NN>
. <.>
Researchers <NNS>
are <VBP>
hoping <VBG>
to <TO>
find <VB>
out <RP>
whether <IN>
9-AC <CD>
is <VBZ>
as <RB>
toxic <JJ>
as <IN>
its <PRP$>
parent <NN>
. <.>
If <IN>
approved <VBN>
by <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
, <,>
the <DT>
researchers <NNS>
could <MD>
start <VB>
tests <NNS>
on <IN>
humans <NNS>
as <IN>
early <JJ>
as <IN>
next <JJ>
year <NN>
. <.>
Doctors <NNS>
at <IN>
Johns_Hopkins_School <NNP>
of <IN>
Medicine <NNP>
in <IN>
Baltimore <NNP>
have <VBP>
identified <VBN>
camptothecin <NN>
as <IN>
a <DT>
potent_inhibitor <NN>
of <IN>
topoisomerase <NN>
I <PRP>
, <,>
an <DT>
enzyme_present <NN>
in <IN>
animal <JJ>
cells <NNS>
which <WDT>
controls <NNS>
cell <VBP>
division <NN>
. <.>
Studies <NNS>
at <IN>
New_York_University <NNP>
say <VBP>
cancerous <JJ>
colons <NNS>
usually <RB>
have <VBP>
more <JJR>
topoisomerase <NN>
I <PRP>
than <IN>
normal <JJ>
colons <NNS>
WSJ880715-0070 <DOCNO>
. <.>
Researchers <NNS>
studying <VBG>
the <DT>
gene <NN>
that <IN>
causes <NNS>
retinoblastoma <VBP>
, <,>
a <DT>
rare_childhood_eye_tumor <NN>
, <,>
discovered <VBN>
a <DT>
surprising <JJ>
link <NN>
between <IN>
the <DT>
gene <NN>
and <CC>
small-cell <NNP>
lung_cancer <NN>
, <,>
a <DT>
malignancy <NN>
that <WDT>
afflicts <VBZ>
smokers <NNS>
. <.>
The <DT>
study <NN>
suggests <VBZ>
that <IN>
the <DT>
eye-cancer_oncogene <NN>
plays <NNS>
a <DT>
role <NN>
in <IN>
the <DT>
genesis <NN>
of <IN>
the <DT>
adult_malignancy <NN>
that <WDT>
affects <VBZ>
about <IN>
25 <CD>
, <,>
000 <CD>
to <TO>
30 <CD>
, <,>
000 <CD>
people <NNS>
a <DT>
year <NN>
, <,>
one-fourth <JJ>
of <IN>
all <DT>
lung-cancer <JJ>
cases <NNS>
. <.>
Moreover <RB>
, <,>
some <DT>
scientists <NNS>
speculate <VBP>
that <IN>
the <DT>
link <NN>
to <TO>
the <DT>
gene <NN>
may <MD>
supply <RB>
a <DT>
potential <JJ>
reason <NN>
why <WRB>
some <DT>
smokers <NNS>
get <VBP>
the <DT>
cancer <NN>
and <CC>
some <DT>
do <VBP>
not <RB>
. <.>
The <DT>
study <NN>
, <,>
which <WDT>
appears <VBZ>
in <IN>
today <NN>
's <POS>
edition <NN>
of <IN>
the <DT>
journal <NN>
Science <NNP>
, <,>
is <VBZ>
by <IN>
J._William_Harbour <NNP>
and <CC>
Frederic_J._Kaye <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
with <IN>
colleagues <NNS>
Shinn-Liang <JJ>
Lai <NNP>
, <,>
Jacqueline_Whang-Peng <NNP>
, <,>
Adi_F._Gazdar <NNP>
and <CC>
John_D._Minna <NNP>
. <.>
Oncogenes <NNS>
are <VBP>
genes <NNS>
or <CC>
hereditary <JJ>
units <NNS>
with <IN>
the <DT>
potential <JJ>
to <TO>
cause <VB>
normal <JJ>
cells <NNS>
to <TO>
turn <VB>
cancerous <JJ>
. <.>
The <DT>
retinoblastoma <NN>
, <,>
or <CC>
Rb <NNP>
, <,>
gene <NN>
, <,>
located <VBN>
on <IN>
chromosome <NN>
13 <CD>
, <,>
is <VBZ>
a <DT>
`` <``>
recessive <JJ>
oncogene <NN>
, <,>
'' <''>
which <WDT>
means <VBZ>
that <DT>
it <PRP>
triggers <VBZ>
cancer <NN>
only <RB>
when <WRB>
it <PRP>
is <VBZ>
damaged <VBN>
or <CC>
inactivated <VBN>
. <.>
Other <JJ>
oncogenes <NNS>
, <,>
such <JJ>
as <IN>
those <DT>
in <IN>
the <DT>
myc_family <NN>
, <,>
also <RB>
implicated <VBD>
in <IN>
small-cell <NNP>
lung_cancer <NN>
, <,>
cause <VB>
cancer <NN>
when <WRB>
they <PRP>
are <VBP>
hyperactive <JJ>
or <CC>
overexpressed <VBN>
. <.>
The <DT>
study <NN>
in <IN>
Science <NNP>
found <VBD>
that <IN>
the <DT>
Rb <NNP>
gene <NN>
was <VBD>
structurally <RB>
damaged <VBN>
in <IN>
18 <CD>
% <NN>
of <IN>
small-cell <NNP>
lung_cancer_cell <NN>
lines <NNS>
, <,>
and <CC>
nonfunctional <JJ>
in <IN>
a <DT>
startling <JJ>
60 <CD>
% <NN>
of <IN>
the <DT>
cell <NN>
lines <NNS>
. <.>
In <IN>
contrast <NN>
, <,>
the <DT>
gene <NN>
was <VBD>
found <VBN>
to <TO>
be <VB>
intact <NN>
in <IN>
90 <CD>
% <NN>
of <IN>
other <JJ>
types <NNS>
lung <IN>
cancer <NN>
, <,>
as <IN>
well <RB>
as_in <IN>
normal <JJ>
lung_tissue <NN>
. <.>
Many <JJ>
mysteries <NNS>
persist <VBP>
about <IN>
the <DT>
two <CD>
previously <RB>
unrelated <VBN>
tumors <NNS>
. <.>
Retinoblastoma <NNP>
, <,>
while <IN>
very <RB>
rare <JJ>
, <,>
is <VBZ>
hereditary <JJ>
and <CC>
occurs <NNS>
in <IN>
familial <JJ>
patterns <NNS>
in <IN>
40 <CD>
% <NN>
of <IN>
all <DT>
cases <NNS>
. <.>
Yet <CC>
small-cell <NNP>
lung_cancer <NN>
has <VBZ>
no <DT>
clear <JJ>
family_pattern <NN>
, <,>
and <CC>
does <VBZ>
n't <RB>
coincide <VB>
with <IN>
retinoblastoma <NN>
, <,>
either <DT>
within <NN>
families <NNS>
or <CC>
in <IN>
the <DT>
same <JJ>
patient <NN>
. <.>
Still <RB>
, <,>
the <DT>
two <CD>
share <NN>
certain <JJ>
similarities <NNS>
; <:>
for <IN>
example <NN>
, <,>
both <DT>
are <VBP>
hormone-secreting <JJ>
tumors <NNS>
. <.>
What <WP>
is <VBZ>
most <JJS>
intriguing <VBG>
to <TO>
many <JJ>
is <VBZ>
the <DT>
link <NN>
between <IN>
the <DT>
environmental <JJ>
and <CC>
genetic <JJ>
roots <NNS>
in <IN>
small-cell <NNP>
lung_cancer <NN>
, <,>
a <DT>
virulent_killer <NN>
. <.>
Dr._Minna <NNP>
, <,>
a <DT>
co-author <NN>
of <IN>
the <DT>
paper <NN>
, <,>
said <VBD>
the <DT>
work <NN>
contributes <VBZ>
to <TO>
the <DT>
`` <``>
two-hit <JJ>
'' <''>
theory <NN>
of <IN>
lung_cancer <NN>
. <.>
`` <``>
It <PRP>
is <VBZ>
possible <JJ>
that <IN>
one <CD>
hit <NN>
could <MD>
come <VB>
from <IN>
your <PRP$>
parents <NNS>
, <,>
'' <''>
he <PRP>
said <VBD>
, <,>
in <IN>
the <DT>
form <NN>
of <IN>
the <DT>
gene <NN>
, <,>
`` <``>
and <CC>
that_a <DT>
second <JJ>
hit <NN>
from <IN>
smoking <NN>
, <,>
or <CC>
from <IN>
living <VBG>
in <IN>
a <DT>
house <NN>
with <IN>
high <JJ>
radon <NN>
. <.>
`` <``>
The <DT>
paper <NN>
suggests <VBZ>
smoking <NN>
may <MD>
supply <RB>
the <DT>
necessary <JJ>
damage <NN>
to <TO>
the <DT>
Rb <NNP>
gene <NN>
that <WDT>
unleashes <VBZ>
cancer <NN>
. <.>
`` <``>
Small-cell <JJ>
lung_cancer <NN>
is <VBZ>
closely <RB>
associated <VBN>
with <IN>
heavy <JJ>
cigarette_smoking <NN>
, <,>
and <CC>
carcinogen_exposure <NN>
from <IN>
tobacco <NN>
may <MD>
generate <VB>
an <DT>
increased <VBN>
mutation_rate <NN>
in <IN>
the <DT>
bronchial <JJ>
epithelium <NN>
, <,>
'' <''>
or <CC>
lining <VBG>
of <IN>
the <DT>
lung <NN>
, <,>
the <DT>
paper <NN>
said <VBD>
. <.>
The <DT>
Rb <NNP>
gene <NN>
, <,>
a <DT>
large <JJ>
gene <NN>
, <,>
may <MD>
be <VB>
especially <RB>
susceptible <JJ>
to <TO>
mutation <NN>
and <CC>
thus <RB>
may <MD>
commonly <RB>
become <VB>
damaged <JJ>
in <IN>
the <DT>
lungs <NNS>
of <IN>
cigarette <NN>
smokers <NNS>
. <.>
Moreover <RB>
, <,>
the <DT>
Rb <NNP>
gene <NN>
is <VBZ>
now <RB>
a <DT>
suspect <NN>
in <IN>
several <JJ>
cancers <NNS>
. <.>
Eva_Lee <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
California <NNP>
at <IN>
San_Diego <NNP>
, <,>
author <NN>
of <IN>
a <DT>
study <NN>
on <IN>
Rb <NNP>
and <CC>
breast <JJ>
cancer <NN>
, <,>
called <VBN>
the <DT>
cancer_institute_study <NN>
`` <``>
important <JJ>
'' <''>
in <IN>
further <JJ>
understanding <NN>
the <DT>
oncogene <NN>
's <POS>
role <NN>
. <.>
`` <``>
Since <IN>
cloning <NN>
of <IN>
the <DT>
gene <NN>
, <,>
we <PRP>
have <VBP>
been <VBN>
able <JJ>
to <TO>
look <VB>
into <IN>
other <JJ>
tumors <NNS>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
`` <``>
It <PRP>
is <VBZ>
now <RB>
clear <JJ>
Rb <NNP>
is <VBZ>
involved <VBN>
not_only <RB>
in <IN>
retinoblastoma <NN>
, <,>
but <CC>
also <RB>
in <IN>
osteosarcoma <NN>
( <:>
a <DT>
bone_tumor <NN>
) <:>
, <,>
lung <JJ>
cancer <NN>
and <CC>
breast <JJ>
cancer <NN>
. <.>
`` <``>
While <IN>
it <PRP>
will <MD>
be <VB>
years <NNS>
before <IN>
the <DT>
study <NN>
yields <NNS>
practical <JJ>
results <NNS>
, <,>
such <JJ>
work <NN>
contributes <VBZ>
to <TO>
the <DT>
belief <NN>
that <IN>
it <PRP>
may <MD>
one <CD>
day <NN>
be <VB>
possible <JJ>
to <TO>
screen <VB>
people <NNS>
for <IN>
genetic <JJ>
susceptibility <NN>
to <TO>
certain <JJ>
tumors <NNS>
, <,>
and <CC>
thus <RB>
to <TO>
warn <VB>
them <PRP>
to <TO>
avoid <VB>
the <DT>
carcinogens <NNS>
that <WDT>
take <VB>
advantage <NN>
of <IN>
their <PRP$>
vulnerability <NN>
AP890524-0044 <DOCNO>
. <.>
Nuclear-tipped <JJ>
antibodies <NNS>
that <WDT>
seek <NN>
and <CC>
destroy_cancer_inside <NN>
the <DT>
body_show_promise <NN>
of <IN>
giving <VBG>
doctors <NNS>
a <DT>
new <JJ>
way <NN>
to <TO>
attack <VB>
tumors <NNS>
, <,>
researchers <NNS>
say <VBP>
. <.>
The <DT>
goal <NN>
is <VBZ>
to <TO>
blitz <VB>
cancer <NN>
cells <NNS>
with <IN>
huge <JJ>
doses <NNS>
of <IN>
killer <JJR>
radiation <NN>
. <.>
Doctors <NNS>
launch <VBP>
the <DT>
attack <NN>
with <IN>
protein <NN>
probes <NNS>
that <WDT>
hunt <NN>
down <IN>
the <DT>
cancer_deep <NN>
within <IN>
the <DT>
body <NN>
. <.>
In <IN>
initial <JJ>
experimental_use <NN>
, <,>
researchers <NNS>
found <VBD>
that <IN>
the <DT>
strategy <NN>
wiped <VBD>
out <RP>
all <DT>
detectable <JJ>
cancer <NN>
in <IN>
people <NNS>
who <WP>
were <VBD>
not <RB>
helped <VBN>
by <IN>
ordinary <JJ>
treatment <NN>
. <.>
However <RB>
, <,>
far <RB>
more <RBR>
study <JJ>
will <MD>
be <VB>
necessary <JJ>
before <IN>
researchers <NNS>
know <VBP>
for <IN>
sure <RB>
whether <IN>
this <DT>
approach <NN>
will <MD>
cure <VB>
cancer <NN>
. <.>
The <DT>
findings <NNS>
were <VBD>
presented <VBN>
Tuesday <NNP>
by <IN>
Dr._Oliver_W._Press <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Washington <NNP>
to <TO>
the <DT>
annual <JJ>
meeting <NN>
of <IN>
the <DT>
American_Society <NNP>
of <IN>
Clinical_Oncology <NNP>
. <.>
Press <NN>
is <VBZ>
one <CD>
of <IN>
several <JJ>
researchers <NNS>
around <IN>
the <DT>
country <NN>
who <WP>
are <VBP>
working <VBG>
with <IN>
radioactive <JJ>
antibodies <NNS>
to <TO>
combat <VB>
cancer <NN>
. <.>
However <RB>
, <,>
he <PRP>
said <VBD>
his <PRP$>
group <NN>
is <VBZ>
using <VBG>
the <DT>
highest <JJS>
doses <NNS>
of <IN>
radiation <NN>
yet <RB>
tried <VBD>
. <.>
`` <``>
We <PRP>
're <VBP>
trying <VBG>
to <TO>
blast <VB>
them <PRP>
out <RP>
of <IN>
the <DT>
water <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
Antibodies <NNS>
are <VBP>
natural <JJ>
hunters <NNS>
produced <VBN>
by <IN>
the <DT>
body <NN>
to <TO>
find <VB>
germs <NNS>
, <,>
cancer <NN>
and <CC>
other_dangerous <JJ>
invaders <NNS>
. <.>
Scientists <NNS>
can <MD>
now <RB>
produce <VB>
large <JJ>
quantities <NNS>
of <IN>
antibodies <NNS>
that <WDT>
look <NN>
for <IN>
cancer <NN>
, <,>
and <CC>
they <PRP>
have <VBP>
fitted <VBN>
them <PRP>
with <IN>
powerful <JJ>
warheads <NNS>
of <IN>
radioactive <JJ>
iodine <NN>
. <.>
With <IN>
this <DT>
strategy <NN>
, <,>
doctors <NNS>
believe <VBP>
they <PRP>
can <MD>
deliver <VB>
far <RB>
higher <JJR>
doses <NNS>
of <IN>
radiation <NN>
than <IN>
would <MD>
otherwise_be <VB>
possible <JJ>
and <CC>
still <RB>
spare <VBP>
healthy <JJ>
tissue <NN>
from <IN>
harm <NN>
. <.>
Press <NN>
and <CC>
colleagues <NNS>
have <VBP>
given <VBN>
the <DT>
treatment <NN>
to <TO>
seven <CD>
people <NNS>
with <IN>
the <DT>
blood_cancer_lymphoma <NN>
. <.>
All <DT>
had <VBD>
failed <VBN>
an <DT>
average <JJ>
of <IN>
four <CD>
kinds <NNS>
of <IN>
chemotherapy <NN>
. <.>
The <DT>
treatment <NN>
wiped <VBD>
out <RP>
all <DT>
visible <JJ>
signs <NNS>
of <IN>
the <DT>
cancer <NN>
in <IN>
five <CD>
of <IN>
them <PRP>
. <.>
`` <``>
The <DT>
percentage <NN>
of <IN>
patients <NNS>
responding <VBG>
is <VBZ>
much <JJ>
greater <NN>
than <IN>
we <PRP>
would <MD>
expect <VB>
from <IN>
conventional <JJ>
chemotherapy <NN>
, <,>
'' <''>
said <VBD>
Dr._Bruce_Cheson <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
In <IN>
other <JJ>
research <NN>
presented <VBD>
at <IN>
the <DT>
meeting <NN>
: <:>
_Dr <NNP>
. <.>
Donald_S._Kaufman <NNP>
of <IN>
Massachusetts_General_Hospital <NNP>
reported <VBD>
preliminary <JJ>
evidence <NN>
that <IN>
a <DT>
combination <NN>
of <IN>
three <CD>
drugs <NNS>
followed <VBD>
by <IN>
radiation <NN>
can <MD>
eliminate <VB>
bladder_cancer <NN>
. <.>
If <IN>
this <DT>
approach <NN>
works <VBZ>
out <RP>
, <,>
it <PRP>
would <MD>
provide <VB>
an <DT>
alternative <JJ>
to <TO>
surgical <JJ>
removal <NN>
of <IN>
the <DT>
bladder <NN>
, <,>
which <WDT>
is <VBZ>
now <RB>
standard <JJ>
treatment <NN>
. <.>
_Many <NNP>
doctors <NNS>
are <VBP>
reluctant <JJ>
to <TO>
give <VB>
chemotherapy <JJ>
to <TO>
women <NNS>
with <IN>
early <JJ>
breast_cancer <NN>
, <,>
because <IN>
most <JJS>
can <MD>
be <VB>
cured <VBN>
by <IN>
surgery <NN>
alone <RB>
. <.>
Dr._Alexander_Paterson <NNP>
of <IN>
Cross_Cancer_Institute <NNP>
in <IN>
Edmonton <NNP>
, <,>
Alberta <NNP>
, <,>
has <VBZ>
found <VBN>
that <IN>
those <DT>
who <WP>
relapse <NN>
often <RB>
carry <VBP>
multiple <JJ>
copies <NNS>
of <IN>
an <DT>
abnormal <JJ>
gene <NN>
, <,>
known <VBN>
as <IN>
an <DT>
oncogene <NN>
, <,>
inside <NN>
their <PRP$>
tumors <NNS>
. <.>
Checking <VBG>
for <IN>
this <DT>
gene <NN>
may <MD>
help <VB>
doctors <NNS>
target <VB>
chemotherapy <NN>
to <TO>
those <DT>
who <WP>
are <VBP>
most <JJS>
likely <JJ>
to <TO>
benefit <VB>
. <.>
_Dr <NNP>
. <.>
Gastan_Rivera <NNP>
of <IN>
St._Jude_Children <NNP>
's <POS>
Research_Hospital <NNP>
in <IN>
Memphis <NNP>
, <,>
Tenn. <NNP>
, <,>
said <VBD>
a <DT>
review <NN>
shows <VBZ>
that_about <IN>
two-thirds <NNS>
of <IN>
all <DT>
youngsters <NNS>
with <IN>
acute_lymphocytic <JJ>
leukemia <NN>
, <,>
the <DT>
most <RBS>
common <JJ>
childhood_cancer <NN>
, <,>
can <MD>
now <RB>
be <VB>
cured <VBN>
. <.>
He <PRP>
attributed <VBD>
the <DT>
improved <VBN>
outlook <NN>
for <IN>
this <DT>
disease <NN>
, <,>
which <WDT>
was <VBD>
once_almost_uniformly <RB>
fatal <JJ>
, <,>
to <TO>
continued <VBD>
improvement <NN>
in <IN>
chemotherapy <NN>
. <.>
_Dr <NNP>
. <.>
James_D._Levine <NNP>
of <IN>
New_England_Deaconess_Hospital <NNP>
in <IN>
Boston <NNP>
said <VBD>
a <DT>
new <JJ>
treatment <NN>
can <MD>
overcome <VB>
low <JJ>
levels <NNS>
of <IN>
white <JJ>
blood <NN>
cells <NNS>
, <,>
which <WDT>
are <VBP>
a <DT>
common <JJ>
side_effect <NN>
of <IN>
treatment <NN>
with <IN>
the <DT>
drug <NN>
AZT <NNP>
in <IN>
AIDS <NNP>
patients <NNS>
. <.>
The <DT>
therapy <NN>
, <,>
called <VBN>
granulocyte-macrophage <JJ>
colony <NN>
stimulating <VBG>
factor <NN>
, <,>
prompts <VBZ>
the <DT>
body <NN>
to <TO>
produce <VB>
more <JJR>
blood <NN>
cells <NNS>
. <.>
_Dr <NNP>
. <.>
Gregory_Wolf <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Michigan <NNP>
said <VBD>
a <DT>
combination <NN>
of <IN>
chemotherapy <NN>
and <CC>
radiation <NN>
shows <NNS>
promise <VBP>
of <IN>
allowing <VBG>
doctors <NNS>
to <TO>
avoid <VB>
removing <NN>
the <DT>
voicebox <NN>
in <IN>
victims <NNS>
of <IN>
advanced <JJ>
throat_cancer <NN>
. <.>
People <NNS>
who <WP>
received <VBD>
the <DT>
new <JJ>
treatment_appear <NN>
to <TO>
have <VB>
as <IN>
good <JJ>
a <DT>
chance <NN>
of <IN>
survival <NN>
as <IN>
do <VB>
surgery <NN>
patients <NNS>
, <,>
and <CC>
most <JJS>
retain <NN>
their <PRP$>
ability <NN>
to <TO>
speak <VB>
. <.>
_Dr <NNP>
. <.>
Harinder_Garewal <NNP>
of <IN>
the <DT>
Veterans <NNPS>
Administration_Medical_Center <NNP>
in <IN>
Tucson <NNP>
said <VBD>
initial <JJ>
studies <NNS>
suggest <VBP>
that <IN>
a <DT>
nutrient <NN>
called <VBN>
beta_carotene <NN>
can <MD>
reverse <VB>
precancerous <JJ>
growths <NNS>
in <IN>
the <DT>
mouth <NN>
. <.>
This <DT>
condition <NN>
, <,>
known <VBN>
as <IN>
oral <JJ>
leukoplakia <NN>
, <,>
is <VBZ>
common <JJ>
in <IN>
smokers <NNS>
. <.>
Many <JJ>
vegetables <NNS>
are <VBP>
high <JJ>
in <IN>
beta_carotene <NN>
, <,>
which <WDT>
the <DT>
body <NN>
converts <NNS>
to <TO>
vitamin <VB>
A <DT>
WSJ911202-0097 <DOCNO>
. <.>
A <DT>
drop <NN>
in <IN>
blood_cholesterol <NN>
levels <NNS>
is <VBZ>
presumed <VBN>
to <TO>
reduce <VB>
the <DT>
women <NNS>
's <POS>
risk <NN>
of <IN>
coronary <JJ>
heart_disease <NN>
and <CC>
heart_attack <NN>
. <.>
The <DT>
incidence <NN>
of <IN>
heart <NN>
attacks <NNS>
in <IN>
women_rises <NNS>
sharply <RB>
after <IN>
menopause <NN>
and <CC>
are <VBP>
the <DT>
most <RBS>
common <JJ>
cause <NN>
of <IN>
death <NN>
in <IN>
women <NNS>
over <IN>
60 <CD>
years <NNS>
old <JJ>
. <.>
The <DT>
incidence <NN>
of <IN>
breast <JJ>
cancer <NN>
also <RB>
rises <VBZ>
sharply <RB>
after <IN>
age <NN>
60 <CD>
. <.>
Tamoxifen <NNP>
is <VBZ>
sold <VBN>
in <IN>
the <DT>
U.S. <NNP>
as <IN>
Nolvadex <NNP>
by <IN>
the <DT>
ICI_Pharmaceuticals <NNP>
unit <NN>
of <IN>
Imperial <JJ>
Chemical <NNP>
Industries <NNPS>
PLC <NNP>
of <IN>
Britain <NNP>
. <.>
Although <IN>
tamoxifen <VBN>
was <VBD>
first <JJ>
marketed <VBN>
in <IN>
1977 <CD>
for <IN>
treating <NN>
advanced <VBD>
breast_cancer <NN>
, <,>
research <NN>
in <IN>
the <DT>
last <JJ>
five <CD>
years <NNS>
or <CC>
so <RB>
has <VBZ>
indicated <VBN>
the <DT>
drug <NN>
can <MD>
prevent <VB>
breast <JJ>
cancer <NN>
. <.>
It <PRP>
has <VBZ>
become <VBN>
almost <RB>
routine <JJ>
for <IN>
all <DT>
breast <JJ>
cancer <NN>
patients <NNS>
to <TO>
take <VB>
it <PRP>
after <IN>
surgery <NN>
. <.>
A <DT>
large-scale <JJ>
trial <NN>
is <VBZ>
being <VBG>
planned <VBN>
to <TO>
see <VB>
if <IN>
it <PRP>
can <MD>
reduce <VB>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
in <IN>
women <NNS>
who <WP>
have <VBP>
n't_yet <RB>
had <VBD>
the <DT>
disease <NN>
but <CC>
who <WP>
have <VBP>
a <DT>
family_history <NN>
of <IN>
breast_cancer <NN>
. <.>
Tamoxifen <NNP>
originally <RB>
was <VBD>
thought <VBN>
to <TO>
prevent <VB>
the <DT>
recurrence <NN>
of <IN>
breast <JJ>
cancer <NN>
by <IN>
blocking <NN>
the <DT>
tendency <NN>
of <IN>
breast <JJ>
cancer <NN>
cells <NNS>
to <TO>
be <VB>
stimulated <VBN>
by <IN>
estrogen <NN>
, <,>
the <DT>
female <JJ>
sex_hormone <NN>
. <.>
Hence <NN>
, <,>
it <PRP>
is <VBZ>
known <VBN>
technically <RB>
as <IN>
an <DT>
anti-estrogen <JJ>
. <.>
More <JJR>
recent <JJ>
research <NN>
, <,>
however <RB>
, <,>
indicates <VBZ>
the <DT>
drug <NN>
may <MD>
have <VB>
a <DT>
multitude <NN>
of <IN>
other <JJ>
effects <NNS>
in <IN>
the <DT>
body <NN>
, <,>
some <DT>
of <IN>
which <WDT>
are <VBP>
similar <JJ>
to <TO>
the <DT>
effects <NNS>
of <IN>
estrogen <NN>
. <.>
Thus <RB>
, <,>
researchers <NNS>
are <VBP>
considering <VBG>
the <DT>
possibility <NN>
that <IN>
tamoxifen <NN>
could <MD>
be <VB>
used <VBN>
for <IN>
hormone_replacement_therapy <NN>
much <RB>
as <IN>
estrogen_therapy <NN>
is <VBZ>
now <RB>
used <VBN>
in <IN>
post-menopausal <JJ>
women <NNS>
. <.>
The <DT>
new <JJ>
evidence <NN>
on <IN>
tamoxifen <NN>
's <POS>
effects <NNS>
on <IN>
cholesterol <NN>
, <,>
for <IN>
example <NN>
, <,>
lends <NNS>
support <NN>
to <TO>
a <DT>
suggested_large-scale <JJ>
trial <NN>
in <IN>
healthy <JJ>
older <NN>
women <NNS>
to <TO>
see <VB>
if <IN>
the <DT>
drug <NN>
can <MD>
reduce <VB>
the <DT>
incidence <NN>
of <IN>
breast <JJ>
cancer <NN>
, <,>
heart_disease <NN>
and <CC>
bone <NN>
fractures <NNS>
due <JJ>
to <TO>
osteoporosis <NNS>
, <,>
the <DT>
weakening <NN>
of <IN>
the <DT>
bones <NNS>
commonly <RB>
seen <VBN>
in <IN>
women <NNS>
after <IN>
menopause <NN>
, <,>
the <DT>
Wisconsin <NNP>
researchers <NNS>
stated <VBD>
in <IN>
the <DT>
report <NN>
in <IN>
the <DT>
Dec. <NNP>
1 <CD>
issue <NN>
of <IN>
the <DT>
Annals <NNPS>
of <IN>
Internal_Medicine <NNP>
. <.>
The <DT>
researchers <NNS>
, <,>
headed <VBD>
by <IN>
Richard_R._Love <NNP>
of <IN>
the <DT>
university <NN>
's <POS>
Clinical_Cancer_Center <NNP>
, <,>
said <VBD>
they <PRP>
had <VBD>
done <VBN>
periodic <JJ>
blood <NN>
tests <NNS>
on <IN>
64 <CD>
women <NNS>
who <WP>
were <VBD>
taking <VBG>
tamoxifen <VBN>
in <IN>
an <DT>
experiment <NN>
to <TO>
see <VB>
if <IN>
the <DT>
drug <NN>
would <MD>
reduce <VB>
the <DT>
recurrence <NN>
of <IN>
breast <JJ>
cancers <NNS>
. <.>
They <PRP>
did <VBD>
similar <JJ>
blood <NN>
tests <NNS>
on <IN>
62 <CD>
women <NNS>
who <WP>
were <VBD>
taking <VBG>
an <DT>
inert_pill <NN>
that <WDT>
looked <VBD>
like <IN>
tamoxifen <NN>
, <,>
a <DT>
so-called <JJ>
placebo <NN>
. <.>
The <DT>
women <NNS>
ranged <VBD>
from <IN>
46 <CD>
to <TO>
64 <CD>
years <NNS>
old <JJ>
and <CC>
all <DT>
were <VBD>
past <JJ>
menopause <NN>
. <.>
They <PRP>
had <VBD>
been_diagnosed <VBN>
and <CC>
successfully <RB>
treated <VBN>
for <IN>
early <JJ>
stage_breast_cancer <NN>
less <RBR>
than <IN>
10 <CD>
years <NNS>
previously <RB>
. <.>
The <DT>
mean <JJ>
cholesterol_level <NN>
of <IN>
the <DT>
women <NNS>
who <WP>
had <VBD>
been <VBN>
taking <VBG>
tamoxifen <VBN>
for <IN>
two <CD>
years <NNS>
was <VBD>
12 <CD>
% <NN>
lower <JJR>
than <IN>
that <DT>
of <IN>
the <DT>
women <NNS>
who <WP>
took <VBD>
the <DT>
placebo <NN>
for <IN>
two <CD>
years <NNS>
. <.>
At <IN>
the <DT>
start <NN>
of <IN>
the <DT>
experiment <NN>
, <,>
the <DT>
total <JJ>
cholesterol <NN>
levels <NNS>
of <IN>
the <DT>
tamoxifen-treated <JJ>
women <NNS>
ranged <VBD>
between <IN>
209 <CD>
and <CC>
233 <CD>
milligrams <NNS>
per <IN>
deciliter <NN>
of <IN>
blood <NN>
, <,>
After <NNP>
two <CD>
years <NNS>
of <IN>
tamoxifen <JJ>
the <DT>
levels <NNS>
dropped <VBD>
by <IN>
19 <CD>
to <TO>
32 <CD>
milligrams <NNS>
with <IN>
the <DT>
sharpest <JJS>
drops <NNS>
occurring <VBG>
in <IN>
women <NNS>
with <IN>
the <DT>
higher <JJR>
levels <NNS>
. <.>
In <IN>
contrast <NN>
, <,>
the <DT>
women <NNS>
taking <VBG>
the <DT>
placebo <NN>
started <VBD>
with <IN>
cholesterol <NN>
levels <NNS>
of <IN>
220 <CD>
to <TO>
237 <CD>
milligrams <NNS>
. <.>
Over <IN>
the <DT>
two <CD>
years <NNS>
, <,>
they <PRP>
experienced <VBD>
drops <NNS>
of <IN>
only <RB>
one <CD>
to <TO>
11 <CD>
milligrams <NNS>
of <IN>
cholesterol <NN>
per <IN>
deciliter <NN>
of <IN>
blood <NN>
. <.>
The <DT>
tamoxifen-treated <JJ>
women <NNS>
showed <VBD>
even <RB>
sharper <JJR>
declines <NNS>
in <IN>
the <DT>
LDL-type <NN>
of <IN>
cholesterol <NN>
, <,>
the <DT>
`` <``>
bad <JJ>
'' <''>
variety <NN>
of <IN>
cholesterol <NN>
that <IN>
has <VBZ>
been <VBN>
strongly <RB>
linked <VBN>
to <TO>
coronary <JJ>
heart_disease <NN>
. <.>
The <DT>
mean <JJ>
level <NN>
of <IN>
LDL-cholesterol <NN>
was <VBD>
20 <CD>
% <NN>
lower <JJR>
in <IN>
the <DT>
tamoxifen-treated <JJ>
women <NNS>
than_in <IN>
the <DT>
placebo-taking <JJ>
women <NNS>
. <.>
The <DT>
levels <NNS>
of <IN>
HDL-cholesterol <JJ>
, <,>
the <DT>
`` <``>
good <JJ>
'' <''>
form <NN>
of <IN>
cholesterol <NN>
that <IN>
seems <VBZ>
to <TO>
protect <VB>
people <NNS>
against <IN>
heart_disease <NN>
, <,>
dropped <VBD>
slightly <RB>
in <IN>
both <DT>
groups <NNS>
of <IN>
women <NNS>
. <.>
By <IN>
the <DT>
end <NN>
of <IN>
two <CD>
years <NNS>
, <,>
the <DT>
drop <NN>
in <IN>
HDL-cholesterol <JJ>
levels <NNS>
was <VBD>
about <IN>
the <DT>
same <JJ>
in <IN>
both <DT>
groups <NNS>
AP890728-0022 <DOCNO>
. <.>
Smoking <VBG>
among <IN>
American <NNP>
men <NNS>
has <VBZ>
been <VBN>
dropping <VBG>
since <IN>
the <DT>
early <JJ>
1950s <CD>
, <,>
but <CC>
federal <JJ>
researchers <NNS>
say <VBP>
women <NNS>
kept <VBD>
taking <VBG>
up <RP>
the <DT>
habit <NN>
into <IN>
the <DT>
next <JJ>
decade <NN>
and <CC>
are <VBP>
now <RB>
paying <VBG>
the <DT>
price <NN>
with <IN>
higher <JJR>
rates <NNS>
of <IN>
lung <JJ>
cancer <NN>
. <.>
`` <``>
Unless <IN>
women <NNS>
start <VBP>
quitting <VBG>
in <IN>
significant <JJ>
numbers <NNS>
, <,>
the <DT>
public_health_problem <NN>
is <VBZ>
going <VBG>
to <TO>
get <VB>
more <JJR>
significant <JJ>
_ <NNP>
no <DT>
question <NN>
about <IN>
it <PRP>
, <,>
'' <''>
said <VBD>
Dr._Edward_J._Sondik <NNP>
, <,>
a <DT>
National_Cancer_Institute <NNP>
specialist <NN>
who <WP>
helped <VBN>
prepare <VBP>
a <DT>
federal <JJ>
health_report <NN>
on <IN>
smoking <NN>
and <CC>
cancer <NN>
. <.>
The <DT>
Atlanta-based <JJ>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
reported <VBD>
Thursday <NNP>
that <IN>
lung <JJ>
cancer <NN>
deaths <NNS>
increased <VBD>
15 <CD>
percent <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
between <IN>
1979 <CD>
and <CC>
1986 <CD>
, <,>
to <TO>
a <DT>
rate <NN>
of <IN>
about <RB>
50 <CD>
deaths <NNS>
per <IN>
100 <CD>
, <,>
000 <CD>
people <NNS>
. <.>
More <JJR>
men <NNS>
than <IN>
women <NNS>
die <VB>
of <IN>
lung <JJ>
cancer <NN>
_ <NNP>
about <IN>
74 <CD>
deaths <NNS>
per <IN>
100 <CD>
, <,>
000 <CD>
for <IN>
males <NNS>
in <IN>
1986 <CD>
, <,>
compared <VBN>
to <TO>
27 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
for <IN>
women <NNS>
. <.>
But <CC>
the <DT>
mortality_rate <NN>
from <IN>
lung <JJ>
cancer <NN>
among <IN>
women <NNS>
is <VBZ>
soaring <VBG>
compared <VBN>
to <TO>
the <DT>
rate <NN>
for <IN>
men <NNS>
. <.>
Between <IN>
1979 <CD>
and <CC>
1986 <CD>
, <,>
the <DT>
lung_cancer_death_rate <NN>
for <IN>
women <NNS>
jumped <VBD>
44 <CD>
percent <NN>
, <,>
while <IN>
the <DT>
rate <NN>
for <IN>
men <NNS>
was <VBD>
up_just <RB>
7 <CD>
percent <NN>
. <.>
The <DT>
CDC <NNP>
said <VBD>
male <JJ>
smoking <NN>
has <VBZ>
been <VBN>
on <IN>
the <DT>
decline <NN>
since <IN>
the <DT>
early <JJ>
1950s <CD>
, <,>
but <CC>
smoking <NN>
among <IN>
women <NNS>
peaked <VBD>
at_about <IN>
1965 <CD>
. <.>
The <DT>
recent <JJ>
dropoff <NN>
in <IN>
smoking <NN>
among <IN>
women <NNS>
_ <NNP>
from <IN>
32 <CD>
percent <NN>
in <IN>
1965 <CD>
to <TO>
27 <CD>
percent <NN>
in <IN>
1987 <CD>
studies <NNS>
_ <NNP>
is <VBZ>
n't_nearly <RB>
as <IN>
sharp <JJ>
as <IN>
the <DT>
drop <NN>
in <IN>
smoking <NN>
by <IN>
men <NNS>
_ <NNP>
from <IN>
50 <CD>
percent <NN>
to <TO>
32 <CD>
percent <NN>
. <.>
`` <``>
The <DT>
men <NNS>
are <VBP>
in <IN>
a <DT>
very <RB>
significant <JJ>
downward_trend <NN>
, <,>
while <IN>
the <DT>
women <NNS>
_ <NNP>
a <DT>
lot <NN>
of <IN>
them <PRP>
were <VBD>
taking <VBG>
up <RP>
smoking <VBG>
( <NN>
in <IN>
the <DT>
1950s <CD>
and <CC>
'60s_) <CD>
, <,>
'' <''>
Sondik <NNP>
said <VBD>
. <.>
Statistically <RB>
, <,>
the <DT>
CDC <NNP>
reported <VBD>
, <,>
peaks <NNS>
in <IN>
smoking_seem <NN>
to <TO>
be <VB>
followed <VBN>
by <IN>
peaks <NNS>
in <IN>
lung <JJ>
cancer <NN>
deaths <NNS>
about <IN>
35 <CD>
years <NNS>
later <RBR>
. <.>
More <JJR>
than <IN>
eight <CD>
out_of <IN>
10 <CD>
lung <JJ>
cancer <NN>
deaths <NNS>
are <VBP>
believed <VBN>
to <TO>
be <VB>
caused <VBN>
by <IN>
smoking <NN>
. <.>
`` <``>
The <DT>
burden <NN>
of <IN>
lung_cancer <NN>
and <CC>
other_smoking-related_chronic <JJ>
diseases <NNS>
( <:>
such <JJ>
as <IN>
bronchitis <NNS>
and <CC>
emphysema <NN>
) <:>
will <MD>
be <VB>
substantially <RB>
higher <JJR>
... <:>
for <IN>
many <JJ>
decades <NNS>
because_of <IN>
the <DT>
long <JJ>
latency <NN>
periods <NNS>
between <IN>
exposure <NN>
to <TO>
tobacco <VB>
and <CC>
onset <VB>
of <IN>
these <DT>
diseases <NNS>
, <,>
'' <''>
the <DT>
CDC <NNP>
said <VBD>
. <.>
That <DT>
, <,>
the <DT>
agency <NN>
said <VBD>
, <,>
means <NNS>
the <DT>
death_rate <NN>
from <IN>
lung <JJ>
cancer <NN>
among <IN>
women <NNS>
continues <VBZ>
to <TO>
climb <VB>
, <,>
and <CC>
will <MD>
do <VB>
so <RB>
until <IN>
the <DT>
turn <NN>
of <IN>
the <DT>
century <NN>
or <CC>
possibly <RB>
longer <JJR>
, <,>
assuming <VBG>
the <DT>
35-year <JJ>
lag <NN>
between <IN>
peak_smoking <NN>
and <CC>
peak <NN>
deaths <NNS>
. <.>
The <DT>
CDC <NNP>
noted <VBD>
that <IN>
lung <JJ>
cancer <NN>
already <RB>
has <VBZ>
passed <VBN>
breast <JJ>
cancer <NN>
as <IN>
the <DT>
most <RBS>
common <JJ>
cause <NN>
of <IN>
cancer_death <NN>
among <IN>
women <NNS>
. <.>
While <IN>
almost <RB>
half <DT>
of <IN>
all <DT>
Americans <NNPS>
who <WP>
ever <RB>
took <VBD>
up <RP>
smoking <NN>
have <VBP>
quit <NN>
, <,>
the <DT>
CDC <NNP>
said <VBD>
, <,>
more <RBR>
than <IN>
50_million <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
continue <VBP>
to <TO>
smoke <VB>
. <.>
In <IN>
1986 <CD>
, <,>
the <DT>
last <JJ>
year <NN>
statistics <NNS>
are <VBP>
available <JJ>
, <,>
85 <CD>
, <,>
050 <CD>
men <NNS>
died <VBD>
of <IN>
lung <JJ>
cancer <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
, <,>
compared <VBN>
to <TO>
40 <CD>
, <,>
461 <CD>
women <NNS>
, <,>
the <DT>
CDC <NNP>
said <VBD>
. <.>
Nearly <RB>
two-thirds <NNS>
of <IN>
those <DT>
deaths <NNS>
were <VBD>
people <NNS>
over <IN>
65 <CD>
. <.>
The <DT>
lung_cancer_death <NN>
rates <NNS>
are <VBP>
about <IN>
the <DT>
same <JJ>
for <IN>
white <JJ>
females <NNS>
and <CC>
black <JJ>
females <NNS>
_ <NNP>
27.4 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
for <IN>
white <JJ>
women <NNS>
and <CC>
26.4 <CD>
for <IN>
black <JJ>
women <NNS>
in <IN>
1986 <CD>
. <.>
The <DT>
death_rate <NN>
among <IN>
males <NNS>
, <,>
however <RB>
, <,>
is <VBZ>
higher <JJR>
for <IN>
blacks <NNS>
, <,>
98.4 <CD>
to <TO>
72.3 <CD>
. <.>
The <DT>
highest <JJS>
lung_cancer_death_rate <NN>
among <IN>
the <DT>
states <NNS>
in <IN>
1986 <CD>
was <VBD>
in <IN>
Alaska <NNP>
, <,>
with <IN>
148 <CD>
such <JJ>
deaths <NNS>
for <IN>
a <DT>
rate <NN>
of <IN>
70.5 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
people <NNS>
. <.>
The <DT>
lowest <JJS>
was <VBD>
in <IN>
Utah <NNP>
, <,>
with <IN>
275 <CD>
such <JJ>
deaths <NNS>
, <,>
or <CC>
a <DT>
rate <NN>
of <IN>
24.3 <CD>
SJMN91-06122127 <DOCNO>
. <.>
Stark <NNP>
studied <VBD>
55 <CD>
women <NNS>
with <IN>
breast <JJ>
cancer <NN>
and <CC>
136 <CD>
without <IN>
the <DT>
disease <NN>
. <.>
She <PRP>
found <VBD>
that <IN>
women <NNS>
who <WP>
carried <VBN>
most <JJS>
of <IN>
their <PRP$>
weight <NN>
above <IN>
their <PRP$>
hips <NNS>
were <VBD>
60 <CD>
percent <NN>
more <JJR>
likely <JJ>
to <TO>
develop <VB>
breast <JJ>
cancer <NN>
than <IN>
were <VBD>
those <DT>
whose <WP$>
weight <NN>
was <VBD>
mostly <RB>
on <IN>
their <PRP$>
hips <NNS>
. <.>
; <:>
Those <DT>
at <IN>
most <JJS>
risk <VB>
were <VBD>
women <NNS>
who <WP>
weighed <VBN>
over <RP>
their <PRP$>
ideal_weight <NN>
and <CC>
had <VBD>
a <DT>
lot <NN>
of <IN>
abdominal_fat <JJ>
, <,>
said <VBD>
Stark <NNP>
of <IN>
the <DT>
Arizona_Cancer_Center <NNP>
at <IN>
the <DT>
University <NNP>
of <IN>
Arizona <NNP>
. <.>
; <:>
The <DT>
ideal_weight <NN>
for <IN>
a <DT>
5-foot-5-inch <JJ>
woman <NN>
is <VBZ>
about <IN>
112 <CD>
pounds <NNS>
; <:>
for <IN>
a <DT>
5-foot-7-inch <JJ>
woman <NN>
, <,>
about <IN>
124 <CD>
pounds <NNS>
. <.>
; <:>
Stark <NNP>
also <RB>
found <VBD>
that <IN>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
was <VBD>
linked <VBN>
to <TO>
the <DT>
age <NN>
and <CC>
weight <NN>
of <IN>
women <NNS>
when <WRB>
they <PRP>
had <VBD>
their <PRP$>
first <JJ>
periods <NNS>
. <.>
; <:>
Women <NNP>
in <IN>
the <DT>
study <NN>
who <WP>
recalled <VBN>
being <VBG>
obese <JJ>
, <,>
or <CC>
20 <CD>
percent <NN>
over <IN>
their <PRP$>
ideal_weight <NN>
, <,>
at <IN>
the <DT>
time <NN>
of <IN>
their <PRP$>
first <JJ>
period <NN>
had <VBD>
about <IN>
a <DT>
three-fold <JJ>
increased <VBN>
risk <NN>
of <IN>
getting <VBG>
breast <JJ>
cancer <NN>
. <.>
; <:>
Women <NNP>
who <WP>
had <VBD>
their <PRP$>
periods <NNS>
before <IN>
age <NN>
14 <CD>
had <VBD>
about <IN>
four <CD>
times <NNS>
the <DT>
risk <NN>
, <,>
she <PRP>
said <VBD>
. <.>
; <:>
Other <JJ>
studies <NNS>
have <VBP>
found <VBN>
that <IN>
women <NNS>
with <IN>
a <DT>
mother <NN>
, <,>
sister <NN>
or <CC>
aunt <NN>
who <WP>
developed <VBD>
the <DT>
disease <NN>
have <VBP>
about <IN>
three <CD>
times <NNS>
the <DT>
risk <NN>
of <IN>
getting <VBG>
breast <JJ>
cancer <NN>
. <.>
; <:>
A <DT>
high-fat <JJ>
diet <NN>
also <RB>
may <MD>
be <VB>
linked <VBN>
to <TO>
the <DT>
disease <NN>
. <.>
The <DT>
American_Cancer_Society <NNP>
recommends <VBZ>
that <IN>
women <NNS>
with <IN>
a <DT>
family_history <NN>
of <IN>
the <DT>
disease_try <NN>
to <TO>
limit <VB>
their <PRP$>
fat <JJ>
intake <NN>
to <TO>
about <IN>
20 <CD>
percent <NN>
of <IN>
their <PRP$>
total <JJ>
calories <NNS>
. <.>
; <:>
Breast <NNP>
cancer <NN>
, <,>
which <WDT>
strikes <VBZ>
about <IN>
one <CD>
in <IN>
nine <CD>
women <NNS>
, <,>
is <VBZ>
the <DT>
second-leading <JJ>
cause <NN>
of <IN>
cancer_death <NN>
in <IN>
women <NNS>
behind <IN>
lung <JJ>
cancer <NN>
, <,>
according <VBG>
to <TO>
the <DT>
American_Cancer_Society <NNP>
. <.>
About <IN>
175 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
of <IN>
breast <JJ>
cancer <NN>
are <VBP>
diagnosed <VBN>
each <DT>
year <NN>
SJMN91-06025221 <DOCNO>
. <.>
Since <IN>
1980 <CD>
, <,>
the <DT>
society <NN>
said <VBD>
, <,>
reported <VBD>
cases <NNS>
of <IN>
breast <JJ>
cancer <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
have <VBP>
increased <VBN>
more <RBR>
than <IN>
30 <CD>
percent <NN>
, <,>
making <VBG>
it <PRP>
the <DT>
most <RBS>
common <JJ>
cancer <NN>
, <,>
excluding <VBG>
those <DT>
of <IN>
the <DT>
skin <NN>
. <.>
It <PRP>
is <VBZ>
the <DT>
second <JJ>
leading <VBG>
cancer_killer <NN>
for <IN>
women <NNS>
, <,>
surpassed <VBD>
only <RB>
by <IN>
lung <JJ>
cancer <NN>
. <.>
; <:>
About <IN>
175 <CD>
, <,>
000 <CD>
American <NNP>
women <NNS>
will <MD>
develop <VB>
breast <JJ>
cancer <NN>
this <DT>
year <NN>
and <CC>
nearly <RB>
45 <CD>
, <,>
000 <CD>
women <NNS>
will <MD>
die <VB>
from <IN>
the <DT>
disease <NN>
, <,>
according <VBG>
to <TO>
the <DT>
Cancer_Society <NNP>
's <POS>
annual <JJ>
projections <NNS>
. <.>
; <:>
`` <``>
This <DT>
increase <NN>
in <IN>
incidence <NN>
represents <NNS>
frightening <VBG>
prospects <NNS>
for <IN>
American <JJ>
women <NNS>
, <,>
'' <''>
Dr._Stephen_Weiss <NNP>
, <,>
president <NN>
of <IN>
the <DT>
Cancer_Society <NNP>
's <POS>
Philadelphia <NNP>
division <NN>
, <,>
said <VBD>
at <IN>
a <DT>
news_conference <NN>
called <VBN>
to <TO>
announce <NN>
the <DT>
new <JJ>
statistics <NNS>
. <.>
; <:>
Lawrence_Garfinkel <NNP>
, <,>
a <DT>
senior <JJ>
consultant <NN>
in <IN>
epidemiology <NN>
and <CC>
statistics <NNS>
for <IN>
the <DT>
Cancer_Society <NNP>
, <,>
said <VBD>
the <DT>
rise <NN>
in <IN>
breast <JJ>
cancer <NN>
rates <NNS>
during <IN>
the <DT>
last <JJ>
decade <NN>
was <VBD>
in <IN>
part <NN>
because_of <IN>
an <DT>
increased <VBN>
use <NN>
of <IN>
mammography <NN>
, <,>
which <WDT>
has <VBZ>
meant <VBN>
that <IN>
more <JJR>
cases <NNS>
are <VBP>
detected <VBN>
. <.>
But <CC>
he <PRP>
said <VBD>
better <RBR>
detection <NN>
and <CC>
the <DT>
already <RB>
known <VBN>
risk <NN>
factors <NNS>
for <IN>
breast <JJ>
cancer <NN>
could <MD>
not <RB>
account <VB>
entirely <RB>
for <IN>
the <DT>
increased <VBN>
incidence <NN>
. <.>
; <:>
`` <``>
I <PRP>
think <VBP>
there <RB>
is <VBZ>
another <DT>
factor <NN>
we <PRP>
really <RB>
have <VBP>
n't <RB>
been <VBN>
able <JJ>
to <TO>
identify <VB>
, <,>
'' <''>
he <PRP>
said <VBD>
, <,>
'' <''>
because <IN>
I <PRP>
do <VBP>
n't <RB>
think <VB>
the <DT>
factors <NNS>
we <PRP>
can <MD>
identify <VB>
can <MD>
account <VB>
for <IN>
all <PDT>
this <DT>
. <.>
`` <``>
; <:>
Garfinkel <NNP>
said <VBD>
he <PRP>
expected <VBD>
that_by <IN>
the <DT>
time <NN>
1990 <CD>
breast_cancer <NN>
figures <NNS>
were <VBD>
analyzed <VBN>
, <,>
a <DT>
woman <NN>
's <POS>
chances <NNS>
for <IN>
getting <VBG>
breast_cancer <NN>
would <MD>
be <VB>
one <CD>
in <IN>
eight <CD>
. <.>
The <DT>
one-in-nine <JJ>
risk <NN>
is <VBZ>
based <VBN>
on <IN>
1987 <CD>
breast_cancer <NN>
figures <NNS>
. <.>
; <:>
Edward_Sondik <NNP>
, <,>
an <DT>
official <NN>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
said <VBD>
Thursday <NNP>
that <IN>
the <DT>
increased <VBN>
risk <NN>
for <IN>
breast_cancer <NN>
calculated <VBD>
by <IN>
the <DT>
Cancer_Society <NNP>
showed <VBD>
that <IN>
'' <''>
basically <RB>
people <NNS>
are <VBP>
living <VBG>
longer <JJR>
, <,>
and <CC>
if <IN>
people <NNS>
live <VBP>
longer <JJR>
, <,>
the <DT>
risk <NN>
of <IN>
disease <NN>
goes <VBZ>
up <RP>
. <.>
`` <``>
; <:>
Sondik <NNP>
said <VBD>
greater <JJR>
use <NN>
of <IN>
mammograms <NNS>
, <,>
or <CC>
breast <JJ>
X-rays <NNS>
, <,>
accounted <VBD>
for <IN>
most <JJS>
of <IN>
the <DT>
increase <NN>
because <IN>
detection <NN>
is <VBZ>
made <VBN>
easier <JJR>
. <.>
; <:>
'' <''>
( <:>
Other <JJ>
) <NN>
factors <NNS>
that <WDT>
have <VBP>
been_identified <VBN>
are <VBP>
later <JJ>
childbearing <VBG>
, <,>
diet <JJ>
, <,>
use <NN>
of <IN>
estrogen <NN>
, <,>
but <CC>
no <DT>
one <NN>
has <VBZ>
been <VBN>
able <JJ>
to <TO>
prove <VB>
the <DT>
actual <JJ>
increases <NNS>
we <PRP>
are <VBP>
seeing <VBG>
are <VBP>
related <VBN>
to <TO>
these <DT>
factors <NNS>
, <,>
'' <''>
said <VBD>
Sondik <NNP>
, <,>
who <WP>
is <VBZ>
deputy_director <NN>
of <IN>
the <DT>
institute <NN>
's <POS>
division <NN>
of <IN>
cancer_prevention <NN>
and <CC>
control <NN>
. <.>
; <:>
The <DT>
Cancer_Society <NNP>
's <POS>
latest <JJS>
cancer <NN>
statistics <NNS>
are <VBP>
bound <VBN>
to <TO>
provide <VB>
more <JJR>
ammunition <NN>
for <IN>
women <NNS>
's <POS>
advocacy <NN>
and <CC>
health <NN>
groups <NNS>
, <,>
which <WDT>
are <VBP>
becoming <VBG>
increasingly <RB>
vocal <JJ>
in <IN>
their <PRP$>
demands <NNS>
that <WDT>
the <DT>
government_spend <NN>
more <RBR>
for <IN>
breast <JJ>
cancer_research <NN>
. <.>
; <:>
The <DT>
National_Cancer_Institute <NNP>
will <MD>
spend <VB>
about <IN>
$ <$>
90_million <CD>
on <IN>
breast <JJ>
cancer_research <NN>
this <DT>
year <NN>
-- <:>
up_from <IN>
$ <$>
81_million <CD>
in <IN>
1990 <CD>
. <.>
Advocacy <NN>
groups <NNS>
argue <VBP>
that_that <IN>
amount <NN>
is <VBZ>
just <RB>
a <DT>
fraction <NN>
of <IN>
the <DT>
more <RBR>
than <IN>
$ <$>
1_billion <CD>
spent <NN>
on <IN>
AIDS <NNP>
research <NN>
last <JJ>
year <NN>
. <.>
; <:>
There <EX>
are <VBP>
some <DT>
acknowledged <JJ>
risk <NN>
factors <NNS>
for <IN>
breast <JJ>
cancer <NN>
, <,>
including <VBG>
having <NN>
a <DT>
family_history <NN>
of <IN>
the <DT>
disease <NN>
, <,>
delaying <VBG>
childbearing <NN>
until_after <IN>
age <NN>
30 <CD>
and <CC>
having <VBG>
an <DT>
early <JJ>
onset <NN>
of <IN>
menstruation <NN>
or <CC>
late <JJ>
onset <NN>
of <IN>
menopause <NN>
. <.>
However <RB>
, <,>
studies <NNS>
to <TO>
pinpoint <VB>
other <JJ>
risk <NN>
factors <NNS>
-- <:>
such <JJ>
as <IN>
birth <JJ>
control <NN>
pills <NNS>
and <CC>
estrogen_replacement_therapy <NN>
-- <:>
have <VBP>
produced <VBN>
confusing <VBG>
and <CC>
sometimes <RB>
conflicting <VBG>
information <NN>
AP890310-0065 <DOCNO>
. <.>
Nancy_Reagan <NNP>
's <POS>
triumph <NN>
over <IN>
breast <JJ>
cancer <NN>
and <CC>
a <DT>
publicity_campaign <NN>
about <IN>
the <DT>
disease <NN>
may <MD>
have <VB>
sent <VBN>
thousands <NNS>
of <IN>
women <NNS>
to <TO>
their <PRP$>
doctors <NNS>
for <IN>
potentially <RB>
life-saving <JJ>
mammograms <NNS>
, <,>
federal <JJ>
health <NN>
officials <NNS>
reported <VBD>
. <.>
A <DT>
survey <NN>
of <IN>
health_behavior <NN>
in <IN>
33 <CD>
states <NNS>
by <IN>
the <DT>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
found <VBD>
that <IN>
38 <CD>
percent <NN>
of <IN>
women <NNS>
age <NN>
50 <CD>
and <CC>
older <JJR>
questioned <VBN>
in <IN>
November <NNP>
and <CC>
December <NNP>
1987 <CD>
said <VBD>
they <PRP>
had <VBD>
received <VBN>
a <DT>
mammogram <NN>
for <IN>
breast_cancer <NN>
within <IN>
a <DT>
year <NN>
. <.>
Those <DT>
findings <NNS>
, <,>
shortly <RB>
after <IN>
the <DT>
then <RB>
first <JJ>
lady <NN>
's <POS>
October <NNP>
diagnosis <NN>
, <,>
marked <VBD>
an <DT>
increase <NN>
of <IN>
nearly <RB>
50 <CD>
percent <NN>
over <IN>
the <DT>
26 <CD>
percent <NN>
the <DT>
survey <NN>
found <VBD>
in <IN>
the <DT>
first <JJ>
two <CD>
months <NNS>
of <IN>
that <DT>
year <NN>
. <.>
Medical <JJ>
centers <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
reported <VBD>
after <IN>
Mrs._Reagan's <NNP>
diagnosis <NN>
that <WDT>
the <DT>
demand <NN>
for <IN>
mammograms <NNS>
had <VBD>
gone <VBN>
up <RP>
. <.>
She <PRP>
was <VBD>
later <JJ>
honored <VBN>
with <IN>
an <DT>
American <JJ>
Cancer <NN>
Society <NNP>
award <NN>
for <IN>
her <PRP$>
efforts <NNS>
to <TO>
encourage <VB>
women <NNS>
to <TO>
check <VB>
for <IN>
breast <JJ>
cancer <NN>
. <.>
A <DT>
springtime <NN>
media <NNS>
campaign <NN>
by <IN>
the <DT>
cancer_society <NN>
promoted <VBD>
screening <VBG>
for <IN>
breast <JJ>
cancer <NN>
, <,>
and <CC>
data <NNS>
from <IN>
the <DT>
survey <NN>
`` <``>
suggest <VBP>
that_the <DT>
media_events <NNS>
and <CC>
educational <JJ>
activities <NNS>
were <VBD>
accompanied <VBN>
by <IN>
increases <NNS>
in <IN>
screening <VBG>
mammograms <NNS>
, <,>
'' <''>
the <DT>
CDC <NNP>
said <VBD>
. <.>
The <DT>
increases <NNS>
in <IN>
mammograms <NNS>
`` <``>
may <MD>
be <VB>
related <VBN>
to <TO>
enhanced <VBN>
public <JJ>
awareness <NN>
during <IN>
the <DT>
ACS <NNP>
spring_campaign <NN>
and <CC>
after <IN>
Mrs._Reagan's <NNP>
diagnosis <NN>
, <,>
'' <''>
the <DT>
CDC <NNP>
said <VBD>
, <,>
although <IN>
the <DT>
agency <NN>
added <VBD>
that <IN>
the <DT>
data <NNS>
can <MD>
not_directly <RB>
prove <VBP>
such <JJ>
a <DT>
connection <NN>
statistically <RB>
. <.>
The <DT>
cancer_society <NN>
recommends <NNS>
that <WDT>
all <DT>
women <NNS>
50 <CD>
or <CC>
older <JJR>
have <VBP>
a <DT>
mammogram <NN>
each <DT>
year <NN>
. <.>
Overall <JJ>
, <,>
in <IN>
the <DT>
CDC <NNP>
's <POS>
1987 <CD>
behavioral <JJ>
risk_factor_survey <NN>
, <,>
29 <CD>
percent <NN>
of <IN>
the <DT>
women <NNS>
50 <CD>
and <CC>
up <IN>
said <VBD>
they <PRP>
had <VBD>
been_screened <VBN>
for <IN>
breast <JJ>
cancer <NN>
in <IN>
the <DT>
preceding <NN>
12 <CD>
months <NNS>
. <.>
The <DT>
survey <NN>
excluded <VBD>
women <NNS>
who <WP>
had <VBD>
mammograms <NNS>
because_of <IN>
a <DT>
specific <JJ>
health_problem <NN>
or <CC>
history <NN>
, <,>
or <CC>
those <DT>
who <WP>
had <VBD>
n't <RB>
seen <VBN>
a <DT>
doctor <NN>
for <IN>
a <DT>
routine_examination <NN>
at <IN>
all <DT>
. <.>
Other <JJ>
studies <NNS>
also <RB>
have <VBP>
found <VBN>
that <IN>
most <JJS>
American <JJ>
women <NNS>
50 <CD>
or <CC>
older <JJR>
have <VBP>
never <RB>
had <VBD>
a <DT>
mammogram <NN>
, <,>
despite <IN>
recommendations <NNS>
that <WDT>
they <PRP>
should <MD>
. <.>
Cancer <NN>
specialists <NNS>
at <IN>
the <DT>
CDC <NNP>
and <CC>
elsewhere <RB>
say <VB>
increased <VBN>
use <NN>
of <IN>
mammograms <NNS>
would <MD>
increase <VB>
early <JJ>
detection <NN>
of <IN>
breast <JJ>
cancer <NN>
, <,>
raising <VBG>
survival <NN>
rates <NNS>
for <IN>
patients <NNS>
. <.>
Aside <NNP>
from <IN>
annual <JJ>
mammograms <NNS>
for <IN>
women <NNS>
50 <CD>
and <CC>
up <IN>
, <,>
the <DT>
American_Cancer_Society <NNP>
recommends <VBZ>
that <IN>
women <NNS>
between <IN>
35 <CD>
and <CC>
40 <CD>
have <VBP>
one <CD>
initial <JJ>
mammogram <NN>
, <,>
and <CC>
that <IN>
women <NNS>
40-49 <CD>
have <VBP>
one <CD>
each <DT>
year <NN>
or <CC>
two <CD>
. <.>
Breast <NNP>
cancer <NN>
, <,>
second <JJ>
to <TO>
lung <JJ>
cancer <NN>
as <IN>
a <DT>
cause <NN>
of <IN>
cancer <NN>
deaths <NNS>
among <IN>
women <NNS>
, <,>
kills <NNS>
about <IN>
40 <CD>
, <,>
000 <CD>
U.S. <NNP>
women <NNS>
each <DT>
year <NN>
AP900327-0127 <DOCNO>
. <.>
Preliminary <NNP>
studies <NNS>
in <IN>
mice_suggest <NN>
that <IN>
an <DT>
air_pollutant <NN>
may <MD>
hasten <VB>
the <DT>
spread <NN>
of <IN>
cancer <NN>
within <IN>
the <DT>
body <NN>
, <,>
a <DT>
researcher <NN>
said <VBD>
Tuesday <NNP>
. <.>
Mice <NNP>
with <IN>
cancer <NN>
that <IN>
breathed <JJ>
air <NN>
containing <VBG>
nitrogen_dioxide <NN>
, <,>
which <WDT>
is <VBZ>
found <VBN>
in <IN>
smog <NN>
, <,>
showed <VBD>
higher <JJR>
numbers <NNS>
of <IN>
cancer-cell <NNP>
colonies <NNS>
in <IN>
their <PRP$>
lungs <NNS>
than <IN>
mice <NN>
than <IN>
breathed <JJ>
purified <VBN>
air <NN>
, <,>
said <VBD>
Arnis_Richters <NNP>
. <.>
`` <``>
It <PRP>
is <VBZ>
very <RB>
difficult <JJ>
to <TO>
say <VB>
at <IN>
this <DT>
point <NN>
, <,>
what <WP>
does <VBZ>
it <PRP>
mean <VB>
for <IN>
human <JJ>
populations <NNS>
, <,>
'' <''>
said <VBD>
Richters <NNP>
, <,>
an <DT>
associate_professor <NN>
of <IN>
pathology <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Southern_California_School <NNP>
of <IN>
Medicine <NNP>
in <IN>
Los_Angeles <NNP>
. <.>
He <PRP>
spoke <VBD>
at <IN>
a <DT>
science <NN>
writers <NNS>
seminar <NN>
sponsored <VBD>
by <IN>
the <DT>
American_Cancer_Society <NNP>
. <.>
In <IN>
other <JJ>
presentations <NNS>
, <,>
researchers <NNS>
said <VBD>
doctors <NNS>
often <RB>
overlook <VBP>
a <DT>
warning <VBG>
sign <NN>
for <IN>
cancer <NN>
in <IN>
the <DT>
mouth <NN>
, <,>
and <CC>
said <VBD>
a <DT>
new <JJ>
treatment_strategy <NN>
appears <VBZ>
promising <VBG>
for <IN>
cancer <NN>
of <IN>
the <DT>
esophagus <NN>
. <.>
About <IN>
11 <CD>
, <,>
500 <CD>
new <JJ>
cases <NNS>
of <IN>
cancer <NN>
of <IN>
the <DT>
mouth <NN>
are <VBP>
diagnosed <VBN>
each <DT>
year <NN>
; <:>
an <DT>
estimated <VBN>
10 <CD>
, <,>
600 <CD>
new <JJ>
cases <NNS>
of <IN>
cancer <NN>
of <IN>
the <DT>
esophagus <NN>
are <VBP>
expected <VBN>
to <TO>
be <VB>
diagnosed <VBN>
this <DT>
year <NN>
, <,>
and <CC>
9 <CD>
, <,>
500 <CD>
people <NNS>
will <MD>
die <VB>
from <IN>
it <PRP>
. <.>
In <IN>
the <DT>
mouse_study <NN>
, <,>
animals <NNS>
breathed <VBD>
air <NN>
with <IN>
nitrogen_dioxide <NN>
levels <NNS>
ranging <VBG>
from <IN>
0.25 <CD>
to <TO>
0.5 <CD>
parts <NNS>
per <IN>
million <CD>
. <.>
Such <JJ>
levels <NNS>
can <MD>
be <VB>
reached <VBN>
in <IN>
Los_Angeles <NNP>
' <POS>
notoriously <RB>
dirty_air <NN>
, <,>
Richters <NNP>
said <VBD>
. <.>
After <IN>
breathing <VBG>
the <DT>
air <NN>
for <IN>
six <CD>
weeks <NNS>
to <TO>
six <CD>
months <NNS>
, <,>
the <DT>
mice <NN>
were <VBD>
injected <VBN>
with <IN>
skin-cancer <JJ>
cells <NNS>
. <.>
Sixty <NNP>
days <NNS>
later <JJ>
, <,>
their <PRP$>
lungs <NNS>
were <VBD>
examined <VBN>
to <TO>
see <VB>
if <IN>
cancer <NN>
had <VBD>
colonized <VBN>
there <RB>
. <.>
The <DT>
mice <NN>
were <VBD>
particularly <RB>
prone <VBN>
to <TO>
get <VB>
lung <JJ>
colonies <NNS>
from <IN>
the <DT>
skin_cancer <NN>
, <,>
Richters <NNP>
said <VBD>
. <.>
Studies <NNS>
showed <VBD>
that <IN>
breathing_air <NN>
with <IN>
nitrogen_dioxide <NN>
damaged <VBD>
the <DT>
linings <NNS>
of <IN>
tiny <JJ>
blood <NN>
vessels <NNS>
in <IN>
the <DT>
lung <NN>
, <,>
which <WDT>
may <MD>
trap <VB>
circulating <VBG>
cancer <NN>
cells <NNS>
and <CC>
provide <VB>
an <DT>
environment <NN>
for <IN>
them <PRP>
to <TO>
grow <VB>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
pollutant <NN>
also <RB>
reduced <VBD>
numbers <NNS>
of <IN>
cells <NNS>
that <WDT>
form_part <NN>
of <IN>
the <DT>
disease-fighting <JJ>
immune_system <NN>
, <,>
he <PRP>
said <VBD>
. <.>
He <PRP>
recommended <VBD>
that <IN>
cancer <NN>
specialists <NNS>
try <VBP>
to <TO>
find <VB>
places <NNS>
with <IN>
filtered <JJ>
air <NN>
for <IN>
their <PRP$>
patients <NNS>
just <RB>
before <IN>
and <CC>
after <IN>
surgery <NN>
, <,>
when <WRB>
more <JJR>
cancer <NN>
cells <NNS>
may <MD>
be <VB>
released <VBN>
into <IN>
the <DT>
bloodstream <NN>
. <.>
Common <JJ>
cancers <NNS>
in <IN>
humans <NNS>
that <WDT>
tend <VBP>
to <TO>
spread <VB>
to <TO>
the <DT>
lung <NN>
, <,>
a <DT>
process <NN>
called <VBN>
metastasis <NN>
, <,>
include <VBP>
those <DT>
of <IN>
the <DT>
colon <NN>
, <,>
breast <JJ>
and <CC>
prostate <JJ>
. <.>
Lance <NN>
Liotta <NNP>
, <,>
chief <NN>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
's <POS>
section <NN>
of <IN>
tumor_invasion <NN>
and <CC>
metastasis <NN>
, <,>
said <VBD>
the <DT>
concept <NN>
of <IN>
Richters' <NNP>
paper <NN>
`` <``>
makes <VBZ>
sense <NN>
. <.>
'' <''>
Previous <NNP>
work <NN>
has <VBZ>
shown <VBN>
that <IN>
lung <JJ>
damage <NN>
can <MD>
increase <VB>
the <DT>
efficiency <NN>
of <IN>
metastasis <NN>
to <TO>
the <DT>
lung <NN>
, <,>
he <PRP>
said <VBD>
. <.>
But <CC>
he <PRP>
said <VBD>
it <PRP>
will <MD>
be <VB>
difficult <JJ>
to <TO>
see <VB>
whether <IN>
air_pollution <NN>
raises <VBZ>
lung <JJ>
metastasis <NN>
in <IN>
humans <NNS>
because <IN>
so <RB>
many_other <JJ>
factors <NNS>
are <VBP>
involved <VBN>
. <.>
In <IN>
another <DT>
presentation <NN>
, <,>
Dr._Arthur_Mashberg <NNP>
of <IN>
the <DT>
Veterans <NNPS>
Administration_Medical_Center <NNP>
in <IN>
East_Orange <NNP>
, <,>
N.J. <NNP>
, <,>
said <VBD>
dentists <NNS>
and <CC>
doctors <NNS>
often <RB>
overlook <VBP>
an <DT>
early <JJ>
sign <NN>
of <IN>
cancer <NN>
of <IN>
the <DT>
mouth <NN>
. <.>
Doctors <NNS>
tend <VBP>
to <TO>
look <VB>
for <IN>
white <JJ>
growths <NNS>
called <VBN>
leukoplakia <NN>
as <IN>
an <DT>
early <JJ>
sign <NN>
of <IN>
the <DT>
cancer <NN>
, <,>
but <CC>
a <DT>
red <VBN>
lesion <NN>
that <IN>
persists <NNS>
for <IN>
10 <CD>
to <TO>
14 <CD>
days <NNS>
with <IN>
no <DT>
apparent <NN>
ongoing <VBG>
irritation <NN>
is <VBZ>
actually <RB>
more <RBR>
ominous <JJ>
, <,>
he <PRP>
said <VBD>
. <.>
Only <RB>
about <IN>
11 <CD>
percent <NN>
of <IN>
leukoplakias <NNS>
are <VBP>
cancerous <JJ>
, <,>
but <CC>
some <DT>
64 <CD>
percent <NN>
of <IN>
red <VBN>
lesions <NNS>
called <VBN>
mucosal <NN>
erythroplasias <NNS>
are <VBP>
cancerous <JJ>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
third <JJ>
presentation_dealt <NN>
with <IN>
treating <VBG>
cancer <NN>
of <IN>
the <DT>
esophagus <NN>
. <.>
Traditional <JJ>
treatment <NN>
includes <VBZ>
radiation <NN>
or <CC>
surgery <NN>
. <.>
Dr._Lawrence_Coia <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Pennsylvania_School <NNP>
of <IN>
Medicine <NNP>
reported <VBD>
on <IN>
a <DT>
combined <JJ>
treatment <NN>
of <IN>
chemotherapy <NN>
and <CC>
radiation <NN>
, <,>
without <IN>
surgery <NN>
. <.>
Being <VBG>
able <JJ>
to <TO>
avoid <VB>
surgery <NN>
is <VBZ>
an <DT>
advantage <NN>
, <,>
because <IN>
the <DT>
operation <NN>
itself <PRP>
is <VBZ>
dangerous <JJ>
and <CC>
survival <NN>
from <IN>
the <DT>
disease <NN>
still <RB>
is <VBZ>
low <JJ>
, <,>
commented <VBN>
Roy_Sessions <NNP>
of <IN>
Georgetown_University <NNP>
. <.>
Coia <NNP>
said <VBD>
half <DT>
of <IN>
patients <NNS>
whose <WP$>
disease <NN>
had <VBD>
been_confined <VBN>
to <TO>
the <DT>
esophagus <NN>
lived <VBD>
more <JJR>
than <IN>
18 <CD>
months <NNS>
after <IN>
the <DT>
experimental <JJ>
treatment <NN>
, <,>
with <IN>
a <DT>
corresponding_figure <NN>
of <IN>
eight <CD>
months <NNS>
for <IN>
those <DT>
with <IN>
more <JJR>
advanced <JJ>
disease <NN>
. <.>
Under <IN>
traditional <JJ>
treatment <NN>
with <IN>
either <DT>
surgery <NN>
or <CC>
radiation <NN>
, <,>
half <DT>
of <IN>
patients <NNS>
die <VB>
within <IN>
a <DT>
year <NN>
, <,>
he <PRP>
said <VBD>
WSJ911226-0048 <DOCNO>
. <.>
The <DT>
researchers <NNS>
estimated <VBD>
that_of <IN>
the <DT>
176 <CD>
, <,>
000 <CD>
women <NNS>
who <WP>
develop <VB>
breast <JJ>
cancer <NN>
each <DT>
year <NN>
, <,>
between <IN>
7 <CD>
% <NN>
and <CC>
14 <CD>
% <NN>
may <MD>
be <VB>
carrying <VBG>
the <DT>
A-T <JJ>
gene <NN>
. <.>
The <DT>
new <JJ>
finding <NN>
is <VBZ>
likely <JJ>
to <TO>
heighten <VB>
the <DT>
debate <NN>
over_whether <IN>
women <NNS>
younger <JJR>
than <IN>
50 <CD>
years <NNS>
of <IN>
age <NN>
should <MD>
undergo <VB>
periodic_mammographic <JJ>
examinations <NNS>
that <WDT>
involve <VB>
exposing <VBG>
the <DT>
breast <NN>
to <TO>
weak <VB>
or <CC>
`` <``>
soft <JJ>
'' <''>
X-rays <VBZ>
. <.>
Since <IN>
breast_cancer <NN>
is <VBZ>
less <JJR>
common <JJ>
among <IN>
younger <JJR>
women <NNS>
, <,>
various_medical <JJ>
groups <NNS>
have <VBP>
argued <VBN>
heatedly <RB>
whether <IN>
the <DT>
mammography <NN>
uncovers <NNS>
enough <RB>
curable <JJ>
breast <NN>
cancers <NNS>
to <TO>
outweigh <VB>
the <DT>
possibility <NN>
that <IN>
the <DT>
X-rays <NNS>
might <MD>
induce <VB>
some <DT>
new <JJ>
breast <NN>
cancers <NNS>
. <.>
The <DT>
new <JJ>
finding <NN>
, <,>
however <RB>
, <,>
is <VBZ>
n't <RB>
likely <JJ>
to <TO>
change <VB>
prevailing <VBG>
medical <JJ>
opinion <NN>
that <WDT>
periodic <JJ>
mammography <NN>
for <IN>
women <NNS>
over <IN>
50 <CD>
years <NNS>
of <IN>
age <NN>
pays <NNS>
off <IN>
. <.>
Repeated <NNP>
studies <NNS>
of <IN>
this <DT>
age_group <NN>
, <,>
where <WRB>
breast <JJ>
cancer <NN>
is <VBZ>
most <JJS>
common <JJ>
, <,>
show <NN>
that <IN>
periodic <JJ>
mammograms <NNS>
detect <VBP>
enough <RB>
breast <JJ>
cancers <NNS>
at <IN>
a <DT>
curable <JJ>
stage <NN>
to <TO>
extend <VB>
the <DT>
average <JJ>
life_expectancy <NN>
of <IN>
older <JJR>
women <NNS>
. <.>
However <RB>
, <,>
`` <``>
We <PRP>
would <MD>
like <VB>
to <TO>
see <VB>
all <PDT>
older <JJR>
mammography <NN>
machines <NNS>
that <WDT>
give <JJ>
higher <JJR>
doses <NNS>
of <IN>
radiation <NN>
retired <VBN>
immediately <RB>
'' <''>
in <IN>
favor <NN>
of <IN>
newer <JJR>
, <,>
low-dose <JJ>
machines <NNS>
, <,>
said <VBD>
medical <JJ>
geneticist <NN>
Michael_Swift <NNP>
who <WP>
headed <VBD>
the <DT>
University <NNP>
of <IN>
North_Carolina-Chapel_Hill <NNP>
team <NN>
that <WDT>
reported <VBD>
the <DT>
new <JJ>
finding <NN>
in <IN>
this <DT>
week <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
The <DT>
A-T <JJ>
gene <NN>
is <VBZ>
so <RB>
named <VBN>
because <IN>
people <NNS>
who <WP>
are <VBP>
unlucky_enough <JJ>
to <TO>
inherit <VB>
two <CD>
copies <NNS>
of <IN>
the <DT>
gene <NN>
, <,>
one <CD>
from <IN>
each <DT>
parent <NN>
, <,>
develop <VB>
a <DT>
rare_disease <NN>
called <VBN>
ataxia-telangiectasia <-NONE->
. <.>
The <DT>
disease <NN>
affects <VBZ>
the <DT>
immune_system <NN>
but <CC>
involves <VBZ>
such <JJ>
symptoms <NNS>
as <IN>
stumbling <VBG>
and <CC>
uncoordinated <VBD>
movements <NNS>
( <:>
ataxia <NN>
) <:>
and <CC>
red <VBD>
splotches <NNS>
on <IN>
the <DT>
skin <NN>
( <:>
telangiectasia <NN>
) <:>
. <.>
A-T <JJ>
patients <NNS>
also <RB>
are <VBP>
61 <CD>
to <TO>
184 <CD>
times <NNS>
more <JJR>
likely <JJ>
to <TO>
develop <VB>
cancer <NN>
than <IN>
those <DT>
in <IN>
the <DT>
general <JJ>
population <NN>
. <.>
In <IN>
light <JJ>
of <IN>
this <DT>
fact <NN>
, <,>
the <DT>
North_Carolina <NNP>
researchers <NNS>
launched <VBD>
an <DT>
effort <NN>
to <TO>
see <VB>
if <IN>
having <VBG>
a <DT>
single <JJ>
copy <NN>
of <IN>
the <DT>
gene <NN>
also <RB>
boosted <VBD>
the <DT>
risk <NN>
of <IN>
developing <VBG>
cancer <NN>
, <,>
as <IN>
some <DT>
previous <JJ>
studies <NNS>
had <VBD>
hinted <VBN>
. <.>
In <IN>
1982 <CD>
the <DT>
researchers <NNS>
began <VBD>
following <VBG>
the <DT>
lives <NNS>
and <CC>
deaths <NNS>
of <IN>
1 <CD>
, <,>
599 <CD>
adult_blood <NN>
relatives <NNS>
of <IN>
161 <CD>
families <NNS>
in <IN>
which <WDT>
at <IN>
least <JJS>
one <CD>
person <NN>
had <VBD>
been_born <VBN>
with <IN>
ataxia-telangiectasia <NNP>
. <.>
The <DT>
prevalence <NN>
of <IN>
people <NNS>
carrying <VBG>
a <DT>
single <JJ>
copy <NN>
of <IN>
the <DT>
A-T <JJ>
gene <NN>
would <MD>
be <VB>
far <RB>
higher <JJR>
among <IN>
blood <NN>
relatives <NNS>
of <IN>
such <JJ>
patients <NNS>
than_among <IN>
the <DT>
general <JJ>
population <NN>
. <.>
Among <IN>
these <DT>
blood <NN>
relatives <NNS>
, <,>
it <PRP>
was <VBD>
fairly <RB>
certain <JJ>
that <IN>
294 <CD>
possessed <VBN>
one <CD>
copy <NN>
of <IN>
the <DT>
A-T <JJ>
gene <NN>
because_of <IN>
their <PRP$>
geneological <JJ>
relationship <NN>
with <IN>
an <DT>
A-T <JJ>
patient <NN>
. <.>
It <PRP>
was <VBD>
presumed <VBN>
that <IN>
other <JJ>
blood <NN>
relatives <NNS>
probably <RB>
possessed <VBN>
one <CD>
copy <NN>
of <IN>
the <DT>
gene <NN>
but <CC>
their <PRP$>
position <NN>
in <IN>
the <DT>
family_tree <NN>
could <MD>
n't <RB>
distinguish <VB>
them <PRP>
. <.>
The <DT>
researchers <NNS>
found <VBD>
that_within <IN>
five <CD>
years <NNS>
18 <CD>
new <JJ>
cancers <NNS>
developed <VBD>
among <IN>
those <DT>
known <VBN>
to <TO>
have <VB>
one <CD>
copy <NN>
of <IN>
the <DT>
A-T <JJ>
gene <NN>
. <.>
Statisticians <NNS>
calculated <VBD>
that <IN>
possessing <NN>
a <DT>
single <JJ>
copy <NN>
of <IN>
the <DT>
gene <NN>
boosted <VBD>
the <DT>
risk <NN>
of <IN>
cancer <NN>
by <IN>
3.8-fold <JJ>
for <IN>
men <NNS>
and <CC>
3.5-fold <JJ>
for <IN>
women <NNS>
over <IN>
the <DT>
risk <NN>
of <IN>
the <DT>
general <JJ>
population <NN>
. <.>
Of <IN>
the <DT>
18 <CD>
cancers <NNS>
, <,>
the <DT>
most <RBS>
common <JJ>
was <VBD>
breast <JJ>
cancer <NN>
, <,>
of <IN>
which <WDT>
there <EX>
were <VBD>
five <CD>
cases <NNS>
. <.>
This <DT>
indicated <VBN>
that <IN>
the <DT>
single <JJ>
A-T_gene <NN>
boosted <VBD>
the <DT>
risk <NN>
of <IN>
breast_cancer <NN>
by <IN>
fivefold <NN>
. <.>
Not <RB>
all_the <DT>
women <NNS>
who <WP>
carried <VBN>
a <DT>
single <JJ>
copy <NN>
of <IN>
the <DT>
A-T <JJ>
gene <NN>
developed <VBD>
breast <JJ>
cancer <NN>
, <,>
or <CC>
any <DT>
cancer <NN>
, <,>
the <DT>
researchers <NNS>
noted <VBD>
. <.>
This <DT>
indicated <VBN>
that_while <IN>
the <DT>
gene <NN>
may <MD>
render <VB>
the <DT>
women <NNS>
susceptible <JJ>
to <TO>
cancer <NN>
some <DT>
environmental <JJ>
agent <NN>
has <VBZ>
to <TO>
strike <VB>
to <TO>
actually <RB>
cause <VB>
the <DT>
cancer <NN>
. <.>
To <TO>
find <VB>
the <DT>
environmental <JJ>
trigger <NN>
of <IN>
breast <JJ>
cancer <NN>
, <,>
the <DT>
researchers <NNS>
looked <VBD>
into <IN>
the <DT>
medical <JJ>
backgrounds <NNS>
of <IN>
19 <CD>
female <JJ>
blood <NN>
relatives <NNS>
who <WP>
had <VBD>
developed <VBN>
breast <JJ>
cancer <NN>
. <.>
Ten <CD>
of <IN>
them <PRP>
, <,>
or <CC>
more <JJR>
than <IN>
half <PDT>
, <,>
had <VBD>
had_chest <VBN>
or <CC>
abdominal <JJ>
exposures <NNS>
to <TO>
X-rays <NNS>
for <IN>
either <DT>
medical <JJ>
or <CC>
occupational <JJ>
reasons <NNS>
. <.>
In <IN>
contrast <NN>
, <,>
only <RB>
19 <CD>
% <NN>
of <IN>
a <DT>
group <NN>
of <IN>
`` <``>
control <NN>
'' <''>
women <NNS>
of <IN>
similar <JJ>
age <NN>
and <CC>
background <NN>
, <,>
who <WP>
were <VBD>
being <VBG>
monitored <VBN>
simultaneously <RB>
, <,>
had <VBD>
been_exposed <VBN>
to <TO>
such <JJ>
X-rays <NNS>
. <.>
The <DT>
data <NNS>
`` <``>
are <VBP>
consistent <JJ>
with <IN>
a <DT>
fivefold <JJ>
to <TO>
sixfold <VB>
excess <JJ>
risk <NN>
of <IN>
breast_cancer <NN>
among <IN>
blood <NN>
relatives <NNS>
'' <''>
of <IN>
A-T <JJ>
patients <NNS>
who <WP>
have <VBP>
had <VBD>
single <JJ>
or <CC>
multiple <NN>
X-ray <JJ>
examinations <NNS>
of <IN>
the <DT>
chest <JJS>
or <CC>
abdomen <NNS>
, <,>
Dr <NNP>
. <.>
Swift <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
concluded <VBD>
. <.>
They <PRP>
noted <VBD>
that <IN>
1.4 <CD>
% <NN>
of <IN>
the <DT>
population <NN>
may <MD>
unwittingly <RB>
harbor <VB>
a <DT>
single <JJ>
copy <NN>
of <IN>
the <DT>
A-T <JJ>
gene <NN>
but <CC>
that <IN>
a <DT>
test <NN>
to <TO>
detect <VB>
it <PRP>
is <VBZ>
n't_yet <RB>
available <JJ>
. <.>
`` <``>
Until <IN>
that <DT>
is <VBZ>
possible <JJ>
it <PRP>
may <MD>
be <VB>
prudent <VBN>
to <TO>
take <VB>
into <IN>
account <NN>
the <DT>
1 <CD>
%_chance <NN>
that <IN>
anyone <NN>
'' <''>
can <MD>
possess <VB>
a <DT>
single_A-T <JJ>
gene <NN>
`` <``>
and <CC>
to <TO>
take <VB>
the <DT>
most <JJS>
stringent <NN>
measures <NNS>
possible <JJ>
to <TO>
minimize <VB>
incidental_diagnostic_X-ray <JJ>
exposure <NN>
of <IN>
the <DT>
female <JJ>
breast <NN>
, <,>
'' <''>
they <PRP>
said <VBD>
AP881229-0052 <DOCNO>
. <.>
Studies <NNS>
of <IN>
nearly <RB>
29 <CD>
, <,>
000 <CD>
breast-cancer <NN>
patients <NNS>
leave <VBP>
no <DT>
doubt <NN>
that <IN>
drug <NN>
and <CC>
hormone <NN>
therapies <NNS>
improve <VBP>
chances <NNS>
of <IN>
surviving <VBG>
the <DT>
disease <NN>
, <,>
the <DT>
second-leading <JJ>
cancer_killer <NN>
of <IN>
American <JJ>
women <NNS>
, <,>
researchers <NNS>
say <VBP>
. <.>
Analysis <NNP>
of <IN>
61 <CD>
studies <NNS>
showed <VBD>
that <IN>
a <DT>
synthetic <JJ>
hormone <NN>
called <VBN>
tamoxifen <NN>
improves <NNS>
the <DT>
survival <NN>
of <IN>
breast <JJ>
cancer <NN>
victims <NNS>
over <IN>
age <NN>
50 <CD>
, <,>
while <IN>
chemotherapy <NN>
helps <NNS>
younger <JJR>
women <NNS>
. <.>
During <IN>
the <DT>
first <JJ>
five <CD>
years <NNS>
after <IN>
treatment <NN>
, <,>
tamoxifen_reduced <VBN>
the <DT>
odds <NNS>
of <IN>
death <NN>
among <IN>
older <JJR>
women <NNS>
by_about <IN>
one-fifth <JJ>
, <,>
the <DT>
analysis <NN>
revealed <VBD>
, <,>
while <IN>
a <DT>
combination <NN>
of <IN>
chemotherapy <NN>
drugs <NNS>
reduced <VBD>
the <DT>
odds <NNS>
by_about <IN>
one-quarter <JJ>
for <IN>
younger <JJR>
victims <NNS>
. <.>
The <DT>
studies <NNS>
were <VBD>
started <VBN>
as <IN>
far_back <RB>
as <IN>
20 <CD>
years <NNS>
ago <RB>
. <.>
The <DT>
analysis <NN>
`` <``>
has <VBZ>
established <VBN>
beyond <IN>
reasonable <JJ>
doubt <NN>
that <WDT>
both <DT>
tamoxifen <NN>
and <CC>
cytotoxic <JJ>
chemotherapy <NN>
can <MD>
reduce <VB>
five-year <JJ>
mortality <NN>
, <,>
'' <''>
the <DT>
researchers <NNS>
wrote <VBD>
in <IN>
today <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
The <DT>
treatments <NNS>
already <RB>
are <VBP>
widely <RB>
used <JJ>
for <IN>
women <NNS>
after <IN>
surgery <NN>
to <TO>
remove <VB>
breast <JJ>
tumors <NNS>
. <.>
In <IN>
most <JJS>
of <IN>
those <DT>
studied <VBN>
, <,>
the <DT>
disease <NN>
had <VBD>
spread <VBN>
to <TO>
their <PRP$>
lymph <NN>
nodes <NNS>
but <CC>
had <VBD>
n't <RB>
invaded <VBN>
other <JJ>
organs <NNS>
. <.>
`` <``>
There <EX>
have <VBP>
been_continued <VBN>
critics <NNS>
who <WP>
argue <NN>
that <IN>
either <DT>
chemotherapy <NN>
or <CC>
tamoxifen <VBN>
or <CC>
both <DT>
used_early <JJ>
on <IN>
did <VBD>
n't <RB>
change <VB>
survival <NN>
, <,>
'' <''>
said <VBD>
Dr <NNP>
. <.>
I._Craig_Henderson <NNP>
of <IN>
the <DT>
Dana-Farber <JJ>
Cancer_Institute <NNP>
in <IN>
Boston <NNP>
. <.>
Henderson <NNP>
, <,>
one <CD>
of <IN>
79 <CD>
co-authors <NNS>
of <IN>
the <DT>
analysis <NN>
, <,>
said <VBD>
that_while <IN>
the <DT>
treatments <NNS>
do <VBP>
not_necessarily <RB>
cure <VB>
the <DT>
cancer <NN>
, <,>
the <DT>
review <NN>
shows <VBZ>
that <IN>
`` <``>
they <PRP>
substantially <RB>
delay <VBP>
death <NN>
. <.>
'' <''>
Many <NNP>
of <IN>
the <DT>
studies <NNS>
in <IN>
the <DT>
analysis <NN>
were <VBD>
too <RB>
small <JJ>
to <TO>
clearly <RB>
demonstrate <VB>
any <DT>
effect <NN>
from <IN>
the <DT>
treatments <NNS>
. <.>
But <CC>
after <IN>
their <PRP$>
results <NNS>
were <VBD>
combined <VBN>
, <,>
the <DT>
impact <NN>
became <VBD>
apparent <NN>
. <.>
The <DT>
overview_method <NN>
`` <``>
takes <VBZ>
out <RP>
the <DT>
wrinkles <NNS>
from <IN>
all_the <DT>
studies <NNS>
, <,>
'' <''>
said <VBD>
Dr._Nicholas_Robert <NNP>
of <IN>
New_England_Medical_Center <NNP>
. <.>
`` <``>
We <PRP>
can <MD>
use <VB>
conclusions <NNS>
with <IN>
a <DT>
strong_statistical <JJ>
foundation <NN>
about <IN>
the <DT>
benefit <NN>
and <CC>
lack <NN>
of <IN>
benefit <NN>
of <IN>
treatments <NNS>
. <.>
'' <''>
Breast <NNP>
cancer <NN>
is <VBZ>
second <JJ>
to <TO>
lung <JJ>
cancer <NN>
as <IN>
a <DT>
cancer_killer <NN>
of <IN>
American <JJ>
women <NNS>
. <.>
An <DT>
estimated <VBN>
135 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
of <IN>
breast <JJ>
cancer <NN>
were <VBD>
diagnosed <VBN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
this <DT>
year <NN>
, <,>
and <CC>
42 <CD>
, <,>
300 <CD>
women <NNS>
died <VBD>
of <IN>
the <DT>
disease <NN>
. <.>
Many <JJ>
cancer <NN>
specialists <NNS>
already <RB>
are <VBP>
familiar <JJ>
with <IN>
the <DT>
findings <NNS>
, <,>
since <IN>
they <PRP>
have <VBP>
been_presented <VBN>
at <IN>
medical <JJ>
meetings <NNS>
during <IN>
the <DT>
past <JJ>
three <CD>
years <NNS>
. <.>
`` <``>
These <DT>
data <NNS>
have <VBP>
already <RB>
had <VBD>
a <DT>
major <JJ>
impact <NN>
on <IN>
the <DT>
way <NN>
women <NNS>
are <VBP>
treated <VBN>
in <IN>
this <DT>
country <NN>
. <.>
Now <RB>
physicians <VBZ>
will <MD>
have <VB>
the <DT>
actual <JJ>
numbers <NNS>
in <IN>
hand <NN>
, <,>
'' <''>
said <VBD>
another <DT>
co-author <NN>
, <,>
Dr._William_Wood <NNP>
of <IN>
Massachusetts_General_Hospital <NNP>
. <.>
The <DT>
data <NNS>
were <VBD>
reviewed <VBN>
by <IN>
a <DT>
consensus_panel <NN>
of <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
before <IN>
it <PRP>
recommended <VBD>
in <IN>
1985 <CD>
that <WDT>
tamoxifen <CD>
and <CC>
chemotherapy <NN>
be <VB>
used <VBN>
for <IN>
breast <JJ>
cancer <NN>
that <WDT>
has <VBZ>
spread <VBN>
to <TO>
the <DT>
lymph <NN>
nodes <VBZ>
. <.>
Last <JJ>
May <NNP>
, <,>
the <DT>
National_Cancer_Institute <NNP>
told <VBD>
doctors <NNS>
that <IN>
the <DT>
treatment <NN>
could <MD>
be <VB>
extended <VBN>
to <TO>
women <NNS>
in <IN>
the <DT>
earliest <NN>
stages <NNS>
of <IN>
breast <JJ>
cancer <NN>
that <WDT>
is <VBZ>
not_yet <RB>
evident <JJ>
in <IN>
the <DT>
lymph <NN>
nodes <VBZ>
. <.>
The <DT>
institute <NN>
based <VBN>
its <PRP$>
recommendation <NN>
on <IN>
three <CD>
unpublished <JJ>
studies <NNS>
showing <VBG>
that <IN>
cancer <NN>
was <VBD>
slower <JJR>
to <TO>
return <VB>
when <WRB>
these <DT>
women <NNS>
were <VBD>
treated <VBN>
after <IN>
surgery <NN>
to <TO>
remove <VB>
their <PRP$>
tumors <NNS>
. <.>
However <RB>
, <,>
that <IN>
recommendation <NN>
remains <VBZ>
controversial <JJ>
. <.>
Some <DT>
specialists <NNS>
contend <VBP>
that <IN>
tamoxifen <WRB>
and <CC>
chemotherapy <NN>
should <MD>
not <RB>
be <VB>
routinely <RB>
given <VBN>
to <TO>
women <NNS>
with <IN>
very <RB>
early <JJ>
breast_cancer <NN>
until <IN>
there <EX>
is <VBZ>
proof <JJ>
that <IN>
the <DT>
treatment <NN>
actually <RB>
makes <VBZ>
them <PRP>
live <VBP>
longer <RB>
. <.>
Others <NNS>
say <VBP>
that <IN>
even <RB>
if <IN>
the <DT>
drugs <NNS>
do <VBP>
n't <RB>
lengthen <VB>
survival <NN>
, <,>
they <PRP>
still <RB>
may <MD>
improve <VB>
the <DT>
quality <NN>
of <IN>
women <NNS>
's <POS>
lives <NNS>
by <IN>
giving <VBG>
them <PRP>
more <JJR>
time <NN>
without <IN>
cancer <NN>
. <.>
Chemotherapy <NNP>
often <RB>
carries <VBZ>
unpleasant <JJ>
side <NN>
effects <NNS>
, <,>
such <JJ>
as <IN>
nausea <NN>
and <CC>
hair_loss <NN>
. <.>
Tamoxifen <NNP>
is <VBZ>
much <JJ>
milder <NN>
, <,>
although <IN>
some <DT>
women <NNS>
complain <VBP>
of <IN>
hot <JJ>
flashes <NNS>
, <,>
but <CC>
its <PRP$>
long-term <JJ>
effects <NNS>
on <IN>
the <DT>
body <NN>
are <VBP>
not <RB>
known <VBN>
. <.>
Many <JJ>
doctors <NNS>
are <VBP>
reluctant <JJ>
to <TO>
subject <VB>
all <DT>
women <NNS>
with <IN>
early <JJ>
breast_cancer <NN>
to <TO>
these <DT>
powerful <JJ>
medicines <NNS>
, <,>
especially <RB>
when <WRB>
many <JJ>
will <MD>
remain <VB>
free <JJ>
of <IN>
cancer <NN>
with <IN>
surgery <NN>
alone <RB>
. <.>
The <DT>
analysis <NN>
was <VBD>
organized <VBN>
by <IN>
Dr._Richard_Peto <NNP>
of <IN>
Oxford_University <NNP>
and <CC>
combined <VBD>
the <DT>
results <NNS>
of <IN>
61 <CD>
comparison <NN>
studies <NNS>
, <,>
conducted <VBD>
mostly <RB>
in <IN>
Europe <NNP>
and <CC>
North_America <NNP>
, <,>
on <IN>
28 <CD>
, <,>
896 <CD>
women <NNS>
. <.>
The <DT>
researchers <NNS>
sought <VBD>
out <IN>
all_the <DT>
studies <NNS>
that <WDT>
had <VBD>
been_conducted <VBN>
, <,>
including <VBG>
those <DT>
that <WDT>
found <VBD>
no <DT>
benefit <NN>
of <IN>
treatment <NN>
, <,>
since <IN>
these <DT>
are <VBP>
less <RBR>
likely <JJ>
than <IN>
positive <JJ>
studies <NNS>
to <TO>
be <VB>
published <VBN>
in <IN>
medical <JJ>
journals <NNS>
. <.>
`` <``>
We <PRP>
wanted <VBD>
the <DT>
whole <JJ>
story <NN>
, <,>
'' <''>
said <VBD>
Wood <NNP>
. <.>
`` <``>
The <DT>
goal <NN>
was <VBD>
to <TO>
be <VB>
comprehensive <JJ>
. <.>
FBIS4-20345 <DOCNO>
'' <''>
BFN <NNP>
[ <:>
By_Susie_Weldon_]_[_Text_]_Viral <NNP>
hepatitis <VBZ>
infections <NNS>
surged <VBD>
in <IN>
1992 <CD>
, <,>
with <IN>
more <JJR>
than <IN>
twice <NN>
as <IN>
many <JJ>
cases <NNS>
recorded <VBN>
as <RB>
in <IN>
the <DT>
previous <JJ>
year <NN>
, <,>
according <VBG>
to <TO>
statistics <NNS>
just <RB>
released <VBN>
by <IN>
the <DT>
Department <NNP>
of <IN>
Health <NNP>
. <.>
More <JJR>
people <NNS>
were <VBD>
also <RB>
diagnosed <VBN>
as <IN>
having <NN>
sexually <RB>
transmitted <VBN>
diseases <NNS>
, <,>
died <VBD>
of <IN>
lung <JJ>
cancer <NN>
and <CC>
heart_disease <NN>
, <,>
or <CC>
were <VBD>
admitted <VBN>
to <TO>
hospital <JJ>
because_of <IN>
injury <NN>
or <CC>
poisoning <VBG>
. <.>
The <DT>
department <NN>
's <POS>
annual <JJ>
report <NN>
for <IN>
1992-93 <CD>
shows <NNS>
that <WDT>
4 <CD>
, <,>
357 <CD>
hepatitis_cases <NNS>
were <VBD>
reported <VBN>
in <IN>
1992 <CD>
compared <VBN>
with <IN>
1 <CD>
, <,>
801 <CD>
in <IN>
1991 <CD>
. <.>
Almost <RB>
all <DT>
were <VBD>
hepatitis <NNS>
A <DT>
, <,>
157 <CD>
were <VBD>
hepatitis <NNS>
B <NNP>
and <CC>
301 <CD>
were <VBD>
classified <VBN>
as <IN>
neither_A <DT>
nor <NN>
B <NNP>
. <.>
The <DT>
report <NN>
said <VBD>
the <DT>
infections <NNS>
were <VBD>
due <JJ>
to <TO>
eating <VBG>
raw <NN>
or <CC>
badly <RB>
cooked <VBN>
seafood <NN>
from <IN>
Hong_Kong <NNP>
's <POS>
polluted <VBN>
waters <NNS>
. <.>
Other <JJ>
figures <NNS>
in <IN>
the <DT>
report_show <NN>
Hong_Kong <NNP>
people <NNS>
died <VBD>
from <IN>
the <DT>
same_serious <JJ>
diseases <NNS>
, <,>
in_about <IN>
the <DT>
same <JJ>
proportions <NNS>
, <,>
in <IN>
1992 <CD>
as_in <IN>
the <DT>
previous <JJ>
year <NN>
. <.>
The <DT>
biggest <JJS>
killers <NNS>
were <VBD>
cancers <NNS>
, <,>
heart <NN>
diseases <NNS>
and <CC>
cerebrovascular <JJ>
diseases <NNS>
, <,>
which <WDT>
together <RB>
accounted <VBD>
for <IN>
almost <RB>
two-thirds <NNS>
of <IN>
all <DT>
deaths <NNS>
. <.>
As_in <IN>
the <DT>
previous <JJ>
year <NN>
, <,>
lung <JJ>
cancer <NN>
killed <VBD>
more <JJR>
men <NNS>
and <CC>
women <NNS>
than <IN>
any <DT>
other <JJ>
tumour <NN>
, <,>
causing <VBG>
2 <CD>
, <,>
761 <CD>
deaths <NNS>
in <IN>
1992 <CD>
. <.>
Most <JJS>
of <IN>
these <DT>
were <VBD>
due <JJ>
to <TO>
smoking <NN>
, <,>
the <DT>
department <NN>
said <VBD>
. <.>
Liver <RB>
cancer <NN>
and <CC>
naspharyngeal_cancer <NN>
were <VBD>
the <DT>
second <JJ>
and <CC>
third <JJ>
most <RBS>
common <JJ>
tumours <NNS>
among <IN>
men <NNS>
, <,>
compared <VBN>
to <TO>
breast <VB>
and <CC>
colon_cancer <NN>
among <IN>
women <NNS>
. <.>
Although <IN>
slightly <RB>
fewer <JJR>
people <NNS>
died <VBD>
of <IN>
a <DT>
heart_attack <NN>
in <IN>
1992 <CD>
-- <:>
1 <CD>
, <,>
785 <CD>
men <NNS>
and <CC>
women <NNS>
-- <:>
overall <JJ>
deaths <NNS>
from <IN>
heart_disease <NN>
rose <VBD>
by_about <IN>
400 <CD>
, <,>
to <TO>
5 <CD>
, <,>
359 <CD>
. <.>
More <JJR>
babies <NNS>
died <VBD>
in <IN>
that <DT>
year <NN>
because <IN>
they <PRP>
were <VBD>
born <VBN>
too <RB>
small <JJ>
. <.>
Almost <RB>
24 <CD>
percent <NN>
( <:>
83 <CD>
deaths <NNS>
) <:>
of <IN>
infant <JJ>
mortalities <NNS>
in <IN>
1992 <CD>
were <VBD>
blamed <VBN>
on <IN>
immaturity <NN>
, <,>
compared <VBN>
with <IN>
about <RB>
15 <CD>
percent <NN>
( <:>
67 <CD>
deaths <NNS>
) <:>
the <DT>
previous <JJ>
year <NN>
. <.>
A <DT>
staggering <NN>
82 <CD>
, <,>
800 <CD>
patients <NNS>
were <VBD>
treated <VBN>
in <IN>
hospital <NN>
because_of <IN>
injury <NN>
and <CC>
poisoning <VBG>
in <IN>
1992 <CD>
, <,>
making <VBG>
the <DT>
category <NN>
the <DT>
leading <VBG>
cause <NN>
of <IN>
hospital_admission <NN>
. <.>
Of <IN>
the <DT>
1 <CD>
, <,>
693 <CD>
deaths <NNS>
from <IN>
injury <NN>
and <CC>
poisoning <VBG>
-- <:>
the <DT>
fifth <JJ>
biggest_cause <NN>
of <IN>
death <NN>
in <IN>
1992 <CD>
-- <:>
almost <RB>
45 <CD>
percent <NN>
were <VBD>
self <PRP>
inflicted <VBN>
or <CC>
due <JJ>
to <TO>
suicide <VB>
. <.>
The <DT>
other <JJ>
main <NN>
causes <NNS>
of <IN>
hospital <JJ>
admission <NN>
were <VBD>
circulatory <NN>
diseases <NNS>
( <:>
67 <CD>
, <,>
800 <CD>
) <:>
, <,>
cancer <NN>
( <:>
65 <CD>
, <,>
000 <CD>
) <:>
and <CC>
normal <JJ>
delivery <NN>
( <:>
54 <CD>
, <,>
600 <CD>
) <:>
. <.>
Nearly <RB>
3 <CD>
, <,>
000 <CD>
more <JJR>
people <NNS>
were <VBD>
diagnosed <VBN>
with <IN>
sexually <RB>
transmitted <VBN>
diseases <NNS>
in <IN>
1992 <CD>
, <,>
making <VBG>
a <DT>
total <NN>
of <IN>
13 <CD>
, <,>
257 <CD>
cases <NNS>
. <.>
Almost <RB>
60 <CD>
percent <NN>
of <IN>
these <DT>
were <VBD>
in <IN>
men <NNS>
aged <VBD>
between <IN>
2040 <CD>
years <NNS>
. <.>
One <CD>
man <NN>
died <VBD>
from <IN>
syphilis <NNS>
. <.>
More <JJR>
than <IN>
5 <CD>
, <,>
000 <CD>
people <NNS>
were <VBD>
treated <VBN>
in <IN>
hospital <NN>
for <IN>
`` <``>
the <DT>
effects <NNS>
of <IN>
a <DT>
foreign <JJ>
body <NN>
entering <VBG>
through <IN>
orifice <NN>
, <,>
'' <''>
while_about <IN>
2 <CD>
, <,>
560 <CD>
were <VBD>
admitted <VBN>
because_of <IN>
complications <NNS>
arising <VBG>
from <IN>
previous_medical <JJ>
or <CC>
surgical <JJ>
care <NN>
. <.>
Doctors <NNS>
were <VBD>
unable <JJ>
to <TO>
diagnose <VB>
the <DT>
illness <NN>
in_about <IN>
11 <CD>
, <,>
300 <CD>
cases <NNS>
. <.>
Almost <RB>
3 <CD>
, <,>
400 <CD>
people <NNS>
died <VBD>
because <IN>
they <PRP>
were <VBD>
killed <VBN>
or <CC>
fatally <RB>
injured <VBN>
by <IN>
other <JJ>
people <NNS>
. <.>
One <CD>
person <NN>
died <VBD>
because_of <IN>
injuries <NNS>
resulting <VBG>
from <IN>
`` <``>
operation <NN>
of <IN>
war <NN>
'' <''>
in <IN>
1992 <CD>
, <,>
the <DT>
report <NN>
says <VBZ>
AP880726-0024 <DOCNO>
. <.>
A <DT>
gene <NN>
found <VBD>
to <TO>
be <VB>
defective <JJ>
in <IN>
a <DT>
rare_eye_cancer <NN>
has <VBZ>
been_linked <VBN>
to <TO>
breast <VB>
cancer <NN>
and <CC>
a <DT>
common <JJ>
form <NN>
of <IN>
lung_cancer <NN>
, <,>
researchers <NNS>
say <VBP>
. <.>
The <DT>
gene <NN>
was <VBD>
the <DT>
first <JJ>
of <IN>
a <DT>
new <JJ>
group <NN>
of <IN>
anti-cancer <NN>
genes <NNS>
that <WDT>
normally <RB>
protect <VBP>
against <IN>
cancer <NN>
but <CC>
allow <RB>
cancer <NN>
to <TO>
appear <VB>
when <WRB>
defective <JJ>
, <,>
said <VBD>
Ray_White <NNP>
of <IN>
the <DT>
Howard_Hughes_Medical_Institute <NNP>
at <IN>
the <DT>
University <NNP>
of <IN>
Utah <NNP>
in <IN>
Salt_Lake_City <NNP>
. <.>
Similar <JJ>
anti-cancer <NN>
genes <NNS>
now <RB>
have <VBP>
also <RB>
been_linked <VBN>
to <TO>
colon <VB>
cancer <NN>
, <,>
another <DT>
common <JJ>
and <CC>
lethal <JJ>
form <NN>
of <IN>
cancer <NN>
. <.>
The <DT>
findings <NNS>
that <IN>
the <DT>
gene <NN>
is <VBZ>
linked <VBN>
to <TO>
breast <VB>
cancer <NN>
and <CC>
so-called_small-cell <JJ>
lung_cancer <NN>
suggest <VBP>
that <IN>
it <PRP>
and <CC>
other <JJ>
anti-cancer <NN>
genes <NNS>
could <MD>
play <VB>
a <DT>
major <JJ>
role <NN>
in <IN>
many <JJ>
types <NNS>
of <IN>
human <JJ>
cancer <NN>
, <,>
White <NNP>
told <VBD>
genetics_students <NNS>
at <IN>
the <DT>
Jackson_Laboratory <NNP>
in <IN>
Bar_Harbor <NNP>
on <IN>
Monday <NNP>
. <.>
Identifying <VBG>
those <DT>
genes <NNS>
and <CC>
determining <VBG>
how <WRB>
they <PRP>
go <VBP>
wrong <JJ>
does <NNS>
not <RB>
mean <VB>
cancer <NN>
will <MD>
then <RB>
be <VB>
eliminated <VBN>
, <,>
White <NNP>
said <VBD>
. <.>
But <CC>
the <DT>
understanding <NN>
of <IN>
these <DT>
genetic <JJ>
abnormalities <NNS>
is <VBZ>
crucial <JJ>
to <TO>
ultimately <RB>
being <VBG>
able <JJ>
to <TO>
wipe <VB>
out <RP>
cancer <NN>
, <,>
he <PRP>
said <VBD>
. <.>
Over <IN>
the <DT>
shorter_term <NN>
, <,>
he <PRP>
said <VBD>
, <,>
understanding <NN>
the <DT>
genetics <NNS>
of <IN>
cancer <NN>
might <MD>
allow <VB>
doctors <NNS>
to <TO>
diagnose <VB>
subtypes <NNS>
of <IN>
common <JJ>
cancers <NNS>
and <CC>
learn <VB>
to <TO>
treat <VB>
them <PRP>
better <JJR>
. <.>
The <DT>
gene <NN>
was <VBD>
identified <VBN>
in <IN>
children <NNS>
with <IN>
a <DT>
rare <JJ>
eye_cancer <NN>
known <VBN>
as <IN>
retinoblastoma <NN>
. <.>
White <NNP>
and <CC>
Webster_Cavenee <NNP>
at <IN>
the <DT>
Ludwig_Institute <NNP>
for <IN>
Cancer_Research <NNP>
in <IN>
Montreal <NNP>
were <VBD>
among <IN>
the <DT>
scientists <NNS>
who <WP>
made <VBN>
that <IN>
initial <JJ>
discovery <NN>
and <CC>
learned <VBD>
how <WRB>
the <DT>
gene <NN>
worked <VBD>
. <.>
Later <JJ>
, <,>
those <DT>
retinoblastoma <NN>
children <NNS>
were <VBD>
found <VBN>
to <TO>
develop <VB>
osteosarcoma <NN>
, <,>
a <DT>
bone_cancer <NN>
, <,>
also <RB>
as <IN>
a <DT>
result <NN>
of <IN>
defects <NNS>
in <IN>
the <DT>
retinoblastoma_gene <NN>
. <.>
More <JJR>
recently <RB>
, <,>
researchers <NNS>
at <IN>
the <DT>
University <NNP>
of <IN>
California <NNP>
, <,>
San_Francisco <NNP>
, <,>
led <VBD>
by <IN>
Wen-Hwa_Lee <NNP>
and <CC>
Eva_Lee <NNP>
, <,>
have <VBP>
found <VBN>
that <IN>
the <DT>
gene <NN>
is <VBZ>
defective <JJ>
in <IN>
certain <JJ>
breast_cancer <NN>
cells <NNS>
grown <VBN>
in <IN>
the <DT>
laboratory <NN>
. <.>
About <IN>
the <DT>
same <JJ>
time <NN>
, <,>
Frederic_Kaye <NNP>
and <CC>
colleagues <NNS>
at <IN>
the <DT>
National_Cancer_Institute-Navy_Medical_Oncology_Branch <NNP>
reported <VBD>
seeing <VBG>
retinoblastoma_gene <NN>
defects <NNS>
in <IN>
small-cell <NNP>
lung_cancer <NN>
cells <NNS>
in <IN>
the <DT>
laboratory <NN>
. <.>
`` <``>
It <PRP>
may <MD>
well <RB>
be <VB>
that <IN>
the <DT>
majority <NN>
of <IN>
small-cell <NNP>
lung <NN>
cancers <NNS>
involve <VBP>
a <DT>
lesion <NN>
in <IN>
the <DT>
retinoblastoma_gene <NN>
as <IN>
well <RB>
as <IN>
several <JJ>
others <NNS>
, <,>
'' <''>
said <VBD>
White <NNP>
. <.>
Retinoblastoma <NNP>
affects <NNS>
perhaps <RB>
1 <CD>
, <,>
000 <CD>
Americans <NNS>
annually <RB>
, <,>
but <CC>
small-cell <NNP>
lung_cancer <NN>
strikes <VBZ>
30 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
every <DT>
year <NN>
, <,>
and <CC>
breast <JJ>
cancer <NN>
strikes <VBZ>
130 <CD>
, <,>
000 <CD>
. <.>
Suddenly <RB>
, <,>
a <DT>
gene <NN>
that <WDT>
was <VBD>
important <JJ>
only <RB>
in <IN>
a <DT>
rare_disease <NN>
is <VBZ>
now <RB>
seen <VBN>
to <TO>
be <VB>
significant <JJ>
in <IN>
two <CD>
of <IN>
the <DT>
most <RBS>
important <JJ>
and <CC>
most <JJS>
devastating <VBG>
human <NN>
cancers <NNS>
. <.>
Meanwhile <RB>
, <,>
White <NNP>
had <VBD>
identified <VBN>
a <DT>
similar <JJ>
anti-cancer_gene <NN>
in <IN>
a <DT>
rare_form <NN>
of <IN>
inherited <VBN>
colon_cancer <NN>
. <.>
He <PRP>
said <VBD>
Monday <NNP>
he <PRP>
has <VBZ>
now <RB>
shown <VBN>
that <IN>
this <DT>
anti-cancer_gene <NN>
plays <NNS>
a <DT>
role <NN>
in <IN>
the <DT>
much <JJ>
more <JJR>
common_non-inherited <JJ>
form <NN>
of <IN>
colon_cancer <NN>
that <WDT>
is <VBZ>
another <DT>
one <CD>
of <IN>
the <DT>
country <NN>
's <POS>
leading <VBG>
cancer <NN>
killers <NNS>
. <.>
Bert_Vogelstein <NNP>
of <IN>
the <DT>
Johns_Hopkins_University_School <NNP>
of <IN>
Medicine <NNP>
in <IN>
Baltimore <NNP>
also <RB>
has <VBZ>
identified <VBN>
several_other_genetic <JJ>
defects <NNS>
associated <VBN>
with <IN>
colon_cancer <NN>
. <.>
He <PRP>
estimated <VBD>
that <IN>
perhaps <RB>
as <IN>
many <JJ>
as <IN>
seven <CD>
genetic <JJ>
defects <NNS>
must <MD>
occur <VB>
for <IN>
colon_cancer <NN>
to <TO>
develop <VB>
. <.>
He <PRP>
said <VBD>
he <PRP>
and <CC>
White <NNP>
have <VBP>
now <RB>
identified <VBN>
five <CD>
of <IN>
those <DT>
defects <NNS>
. <.>
`` <``>
You <PRP>
can <MD>
look <VB>
at <IN>
these <DT>
genetic <JJ>
alterations <NNS>
as <IN>
the <DT>
causes <NNS>
of <IN>
cancer <NN>
_ <NNP>
just <RB>
as <IN>
you <PRP>
can <MD>
look <VB>
at <IN>
bacteria <NN>
as <IN>
the <DT>
causes <NNS>
of <IN>
infection <NN>
, <,>
'' <''>
Vogelstein <NNP>
said <VBD>
in <IN>
a <DT>
telephone_interview <NN>
. <.>
`` <``>
Except <IN>
it <PRP>
's <VBZ>
more <JJR>
complicated <JJ>
in <IN>
cancer <NN>
. <.>
AP891002-0293 <DOCNO>
'' <''>
T._Franklin_Williams <NNP>
, <,>
a <DT>
geriatrics_physician <NN>
, <,>
is <VBZ>
director <NN>
of <IN>
the <DT>
National_Institute <NNP>
on <IN>
Aging <NNP>
, <,>
one <CD>
of <IN>
the <DT>
13 <CD>
institutes <NNS>
that <WDT>
comprise <VBP>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
of <IN>
the <DT>
Department <NNP>
of <IN>
Health <NNP>
and <CC>
Human <NNP>
Services <NNPS>
. <.>
More <JJR>
than <IN>
half <PDT>
of <IN>
all <DT>
cancers <NNS>
occur <VBP>
in <IN>
people <NNS>
65 <CD>
and <CC>
older <JJR>
, <,>
but <CC>
many <JJ>
people <NNS>
mistakenly <RB>
assume <JJ>
that <IN>
once <RB>
they <PRP>
reach <VBP>
retirement_age <NN>
they <PRP>
are <VBP>
powerless <RB>
to <TO>
prevent <VB>
the <DT>
disease <NN>
_ <NNP>
that <IN>
it <PRP>
's <VBZ>
just_too <RB>
late <JJ>
to <TO>
try <NN>
. <.>
Age <NN>
is <VBZ>
one <CD>
of <IN>
the <DT>
greatest <JJS>
risk <NN>
factors <NNS>
for <IN>
developing <VBG>
cancer <NN>
. <.>
At <IN>
25 <CD>
, <,>
the <DT>
chance <NN>
of <IN>
being <VBG>
diagnosed <VBN>
with <IN>
cancer <NN>
within <IN>
five <CD>
years <NNS>
is <VBZ>
one <CD>
in <IN>
700 <CD>
; <:>
at <IN>
65 <CD>
it <PRP>
is <VBZ>
one <CD>
in <IN>
14 <CD>
. <.>
However <RB>
, <,>
scientists <NNS>
are <VBP>
convinced <VBN>
we <PRP>
can <MD>
improve <VB>
those <DT>
odds <NNS>
. <.>
It <PRP>
's <VBZ>
never_too <RB>
late <JJ>
to <TO>
prevent <VB>
cancer <NN>
. <.>
Here <RB>
's <VBZ>
how <WRB>
. <.>
Stop <NNP>
smoking <NN>
. <.>
Cigarette <NNP>
smoking <NN>
causes <NNS>
85 <CD>
percent <NN>
of <IN>
lung <NN>
cancers <NNS>
in <IN>
men <NNS>
and <CC>
75 <CD>
percent <NN>
in <IN>
women <NNS>
. <.>
Smokers <NNS>
also <RB>
are <VBP>
more <RBR>
likely <JJ>
to <TO>
develop <VB>
cancers <NNS>
of <IN>
the <DT>
mouth <NN>
, <,>
throat <JJ>
, <,>
esophagus <VBZ>
, <,>
pancreas <RB>
and <CC>
bladder <NN>
. <.>
Once <RB>
you <PRP>
quit <VBP>
_ <NNP>
no <DT>
matter <NN>
what <WP>
your <PRP$>
age <NN>
_ <NNP>
your <PRP$>
risk <NN>
of <IN>
cancer <NN>
begins <VBZ>
to <TO>
decline <VB>
right_away <RB>
. <.>
Eat <NNP>
a <DT>
variety <NN>
of <IN>
good <JJ>
foods <NNS>
. <.>
Researchers <NNS>
have <VBP>
found <VBN>
that <IN>
a <DT>
high-fat <JJ>
diet <NN>
increases <NNS>
the <DT>
risk <NN>
of <IN>
breast <NN>
, <,>
colon <NN>
and <CC>
prostate <VB>
cancers <NNS>
, <,>
which <WDT>
are <VBP>
common <JJ>
in <IN>
older <JJR>
people <NNS>
; <:>
a <DT>
well-balanced <JJ>
diet <NN>
reduces <NNS>
the <DT>
risk <NN>
. <.>
In <IN>
particular <JJ>
, <,>
eat <NN>
more <JJR>
high-fiber <JJ>
foods <NNS>
( <:>
whole-grain <JJ>
cereals <NNS>
, <,>
fruits <NNS>
and <CC>
vegetables <NNS>
) <:>
and <CC>
fewer <JJR>
fatty <NN>
foods <NNS>
( <:>
butter <NN>
, <,>
cream <NN>
and <CC>
high-fat <JJ>
cheese <NN>
) <:>
. <.>
It <PRP>
's <VBZ>
not <RB>
as <IN>
hard <JJ>
as <IN>
it <PRP>
sounds <VBZ>
. <.>
You <PRP>
do <VBP>
n't <RB>
have <VB>
to <TO>
give <VB>
up <IN>
all <DT>
of <IN>
the <DT>
foods <NNS>
you <PRP>
like <IN>
; <:>
eat <NN>
more <JJR>
of <IN>
the <DT>
foods <NNS>
that <WDT>
reduce <VB>
your <PRP$>
risk <NN>
of <IN>
cancer <NN>
and <CC>
less <JJR>
of <IN>
those <DT>
that <WDT>
increase <NN>
it <PRP>
. <.>
Drink_alcohol <NN>
only <RB>
in <IN>
moderation <NN>
. <.>
Cancers <NNS>
of <IN>
the <DT>
mouth <NN>
, <,>
throat <JJ>
, <,>
esophagus <VBZ>
and <CC>
liver <RB>
occur <VBP>
more <JJR>
often <RB>
among <IN>
heavy <JJ>
drinkers <NNS>
of <IN>
alcohol <NN>
. <.>
Avoid <NNP>
too <RB>
much <JJ>
sun <NN>
. <.>
Almost <RB>
all <DT>
skin <NN>
cancers <NNS>
are <VBP>
caused <VBN>
by <IN>
exposure <NN>
to <TO>
the <DT>
sun <NN>
. <.>
Repeated <NNP>
exposure <NN>
is <VBZ>
especially <RB>
dangerous <JJ>
for <IN>
people <NNS>
with <IN>
fair <JJ>
skin <NN>
and <CC>
those <DT>
who <WP>
freckle <NN>
easily <RB>
. <.>
The <DT>
sun <NN>
is <VBZ>
strongest <JJS>
from <IN>
11 <CD>
a.m. <NNP>
to <TO>
2 <CD>
p.m. <NN>
Sunscreen <NNP>
lotions <NNS>
and <CC>
protective <JJ>
clothing <NN>
, <,>
like <IN>
a <DT>
hat <JJ>
or <CC>
long-sleeved <JJ>
shirt <NN>
, <,>
can <MD>
help <VB>
. <.>
Use <NN>
hormones <NNS>
carefully <RB>
. <.>
Estrogen <NNP>
has <VBZ>
been_associated <VBN>
with <IN>
higher-than-average <JJ>
rates <NNS>
of <IN>
uterine_cancer <NN>
. <.>
Women <NNS>
who <WP>
take <VB>
it <PRP>
to <TO>
relieve <VB>
hot <JJ>
flashes <NNS>
and <CC>
other <JJ>
symptoms <NNS>
of <IN>
menopause <NN>
should <MD>
discuss <VB>
the <DT>
benefits <NNS>
and <CC>
risks <NNS>
with <IN>
their <PRP$>
doctor <NN>
. <.>
In <IN>
addition <NN>
to <TO>
changing <VBG>
your <PRP$>
lifestyle <NN>
, <,>
enlist <NN>
your <PRP$>
doctor <NN>
. <.>
The <DT>
chances <NNS>
of <IN>
surviving <VBG>
cancer <NN>
are <VBP>
greatest <JJS>
with <IN>
early <JJ>
detection <NN>
and <CC>
prompt_treatment <NN>
. <.>
Even <RB>
before <IN>
symptoms <NNS>
appear <VBP>
, <,>
doctors <NNS>
can <MD>
detect <VB>
cancers <NNS>
of <IN>
the <DT>
breast <JJ>
, <,>
colon <NN>
, <,>
prostate <JJ>
and <CC>
cervix <NN>
. <.>
As <IN>
part <NN>
of <IN>
your <PRP$>
regular <JJ>
checkup <NN>
, <,>
your <PRP$>
doctor <NN>
may <MD>
recommend <VB>
a <DT>
number <NN>
of <IN>
tests <NNS>
to <TO>
look <VB>
for <IN>
these <DT>
and <CC>
other <JJ>
forms <NNS>
of <IN>
cancer <NN>
. <.>
For <IN>
example <NN>
, <,>
all <DT>
women <NNS>
should <MD>
have <VB>
their <PRP$>
breasts <NNS>
examined <VBD>
regularly <RB>
by <IN>
a <DT>
doctor <NN>
, <,>
and <CC>
should <MD>
learn <VB>
how <WRB>
to <TO>
perform <VB>
monthly <JJ>
breast_self-examination <NN>
. <.>
After <IN>
menopause <NN>
, <,>
women <NNS>
should <MD>
examine <VB>
their <PRP$>
breasts <NNS>
the <DT>
same <JJ>
day <NN>
each <DT>
month <NN>
. <.>
An <DT>
X-ray <JJ>
of <IN>
the <DT>
breast <JJ>
(_mammogram <NN>
) <:>
can <MD>
detect <VB>
a <DT>
cancer <NN>
too <RB>
small <JJ>
to <TO>
be <VB>
felt <VBN>
. <.>
Beginning <VBG>
at <IN>
50 <CD>
, <,>
women <NNS>
should <MD>
have <VB>
a <DT>
mammogram <NN>
each <DT>
year <NN>
or <CC>
as <IN>
recommended <JJ>
by <IN>
a <DT>
doctor <NN>
. <.>
Men <NNS>
and <CC>
women <NNS>
over <IN>
40 <CD>
should <MD>
have <VB>
a <DT>
digital <JJ>
rectal_exam <NN>
on <IN>
an <DT>
initial <JJ>
visit <NN>
to <TO>
a <DT>
primary <JJ>
care_doctor <NN>
and <CC>
at <IN>
least <JJS>
every <DT>
three <CD>
years <NNS>
after <IN>
that <DT>
. <.>
This <DT>
is <VBZ>
the <DT>
most <RBS>
reliable <JJ>
test <NN>
for <IN>
prostate <JJ>
cancer <NN>
in <IN>
men <NNS>
; <:>
it <PRP>
also <RB>
can <MD>
detect <VB>
cancer <NN>
of <IN>
the <DT>
rectum <NN>
in <IN>
men <NNS>
and <CC>
women <NNS>
. <.>
The <DT>
stool_blood_test <NN>
for <IN>
rectal <JJ>
and <CC>
colon <NN>
cancers <NNS>
is <VBZ>
recommended <VBN>
yearly <RB>
after <IN>
age <NN>
50 <CD>
. <.>
In <IN>
addition <NN>
, <,>
most <JJS>
cancer <NN>
specialists <NNS>
recommend <VBP>
sigmoidoscopy <NN>
, <,>
an <DT>
examination <NN>
of <IN>
the <DT>
colon <NN>
and <CC>
rectum <NN>
with <IN>
a <DT>
thin <JJ>
, <,>
hollow <JJ>
, <,>
lighted <VBN>
instrument <NN>
which <WDT>
can <MD>
detect <VB>
cancer <NN>
and <CC>
noncancerous <JJ>
growths <NNS>
. <.>
This <DT>
exam <NN>
is <VBZ>
recommended <VBN>
at <IN>
least <JJS>
once <RB>
after <IN>
age <NN>
50 <CD>
and <CC>
then <RB>
every <DT>
three <CD>
to <TO>
five <CD>
years <NNS>
after <IN>
two <CD>
negative <JJ>
exams <NNS>
a <DT>
year_apart <NN>
. <.>
Most <JJS>
cases <NNS>
of <IN>
cervical <JJ>
cancer <NN>
could <MD>
be <VB>
prevented <VBN>
if <IN>
every <DT>
woman <NN>
had <VBD>
a <DT>
Pap <NNP>
test <NN>
and <CC>
pelvic <JJ>
exam <NN>
regularly <RB>
. <.>
The <DT>
Pap <NNP>
test <NN>
detects <NNS>
cancerous <JJ>
cells <NNS>
in <IN>
and <CC>
around <IN>
the <DT>
cervix <NN>
. <.>
After <IN>
women <NNS>
have <VBP>
normal <JJ>
test <NN>
results <NNS>
three <CD>
years <NNS>
in <IN>
a <DT>
row <NN>
, <,>
their <PRP$>
doctors <NNS>
may <MD>
suggest <VB>
they <PRP>
have <VBP>
a <DT>
Pap <NNP>
test <NN>
less <JJR>
often <RB>
. <.>
Many <JJ>
people <NNS>
automatically <RB>
attribute <JJ>
aches <NNS>
and <CC>
pains <NNS>
to <TO>
growing <VBG>
older <JJR>
. <.>
They <PRP>
may <MD>
ignore <VB>
their <PRP$>
symptoms <NNS>
, <,>
assuming <VBG>
they <PRP>
are <VBP>
an <DT>
unavoidable <JJ>
part <NN>
of <IN>
aging <VBG>
. <.>
Most <JJS>
symptoms <NNS>
are <VBP>
not <RB>
serious <JJ>
, <,>
but <CC>
only <RB>
a <DT>
doctor <NN>
can <MD>
tell <VB>
for <IN>
sure <RB>
. <.>
To <TO>
be <VB>
safe <JJ>
, <,>
tell <NN>
your <PRP$>
doctor <NN>
about <IN>
any <DT>
unusual <JJ>
symptoms <NNS>
that <WDT>
last <JJ>
two <CD>
weeks <NNS>
or <CC>
more <JJR>
. <.>
Cancer <NN>
frightens <NNS>
everyone <NN>
. <.>
But <CC>
many <JJ>
older <NN>
people <NNS>
are <VBP>
reluctant <JJ>
to <TO>
discuss <VB>
it <PRP>
with <IN>
their <PRP$>
families <NNS>
or <CC>
doctors <NNS>
because <IN>
they <PRP>
believe <VBP>
a <DT>
number <NN>
of <IN>
myths <NNS>
about <IN>
the <DT>
disease <NN>
and <CC>
its <PRP$>
treatment <NN>
. <.>
When <WRB>
they <PRP>
grew <VBP>
up <RP>
, <,>
nothing <NN>
could <MD>
stop <VB>
cancer <NN>
's <POS>
deadly <RB>
progress <NN>
. <.>
Even <RB>
the <DT>
word <NN>
was <VBD>
whispered <VBN>
behind <IN>
the <DT>
patient <NN>
's <POS>
back <NN>
. <.>
Today <NN>
, <,>
however <RB>
, <,>
many <JJ>
cancers <NNS>
can <MD>
be <VB>
treated <VBN>
successfully <RB>
if <IN>
found <VBN>
early <JJ>
. <.>
Even <RB>
better <JJR>
news <NN>
is <VBZ>
that <IN>
the <DT>
chances <NNS>
of <IN>
surviving <VBG>
are <VBP>
greater <JJR>
than <IN>
ever <RB>
. <.>
The <DT>
best <JJS>
news <NN>
of <IN>
all <DT>
is <VBZ>
that <IN>
many <JJ>
cancers <NNS>
can <MD>
even <RB>
be <VB>
prevented <VBN>
. <.>
For <IN>
the <DT>
free <JJ>
fact_sheet <NN>
`` <``>
Cancer <NN>
Facts <NNS>
for <IN>
People <NNS>
Over <IN>
50 <CD>
, <,>
'' <''>
send <NN>
a <DT>
postcard <NN>
to <TO>
the <DT>
NIA_Information_Center_@_Cancer <NNP>
, <,>
P.O <NNP>
. <.>
Box <NNP>
8057 <CD>
, <,>
Gaithersburg <NNP>
, <,>
Md <NNP>
. <.>
20898-8057 <CD>
. <.>
More <JJR>
information <NN>
about <IN>
cancer <NN>
is <VBZ>
also <RB>
available <JJ>
by <IN>
calling <NN>
the <DT>
toll-free <JJ>
Cancer_Information_Service <NNP>
at <IN>
1-800-4-CANCER_(_422-6237_) <CD>
AP890512-0042 <DOCNO>
. <.>
Researchers <NNS>
report <VBP>
in <IN>
a <DT>
study <NN>
published <VBN>
today <NN>
that <IN>
a <DT>
gene <NN>
previously <RB>
linked <VBD>
to <TO>
breast <VB>
cancer <NN>
also <RB>
can <MD>
also <RB>
be <VB>
found <VBN>
in <IN>
ovarian <JJ>
tumors <NNS>
. <.>
The <DT>
study <NN>
, <,>
published <VBD>
today <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
, <,>
suggests <VBZ>
that <IN>
testing <NN>
for <IN>
the <DT>
presence <NN>
of <IN>
the <DT>
gene <NN>
may <MD>
provide <VB>
a <DT>
way <NN>
of <IN>
tailoring <VBG>
cancer_treatment <NN>
to <TO>
the <DT>
precise <NN>
needs <VBZ>
of <IN>
a <DT>
patient <NN>
. <.>
In <IN>
a <DT>
cooperative <JJ>
study <NN>
by <IN>
seven <CD>
laboratories <NNS>
, <,>
researchers <NNS>
found <VBD>
that <IN>
a <DT>
specific_cancer-related <JJ>
gene <NN>
, <,>
called <VBN>
the <DT>
HER-2 <-NONE->
@ <:>
neu_oncogene <NN>
, <,>
was <VBD>
present <JJ>
in <IN>
tumors <NNS>
of <IN>
both_the <DT>
breasts <NNS>
and <CC>
the <DT>
ovaries <NNS>
. <.>
An <DT>
analysis <NN>
of <IN>
samples <NNS>
from <IN>
668 <CD>
breast <NN>
tumors <NNS>
and <CC>
120 <CD>
ovarian <JJ>
tumors <NNS>
also <RB>
showed <VBD>
that <IN>
the <DT>
oncogene <NN>
was <VBD>
actively <RB>
producing <VBG>
a <DT>
protein <NN>
within <IN>
the <DT>
tumors <NNS>
, <,>
suggesting <VBG>
that <IN>
the <DT>
gene <NN>
plays <VBZ>
an <DT>
important <JJ>
role <NN>
in <IN>
the <DT>
disease_process <NN>
. <.>
Dr._Michael_Press <NNP>
, <,>
a <DT>
University <NNP>
of <IN>
Southern_California <NNP>
researcher <NN>
who <WP>
participated <VBN>
in <IN>
the <DT>
study <NN>
, <,>
said <VBD>
the <DT>
finding <NN>
raises <VBZ>
the <DT>
possibility <NN>
that <IN>
diagnostic <JJ>
tests <NNS>
to <TO>
detect <VB>
the <DT>
gene <NN>
in <IN>
breast <NN>
and <CC>
ovarian <JJ>
cancers <NNS>
could <MD>
help <VB>
doctors <NNS>
determine <VB>
the <DT>
precise_level <NN>
of <IN>
treatment <NN>
required <VBN>
by <IN>
each <DT>
patient <NN>
. <.>
Earlier <JJR>
studies <NNS>
showed <VBD>
that <IN>
the <DT>
numbers <NNS>
of <IN>
HER-2 <-NONE->
@ <:>
neu <NN>
oncogenes <NNS>
in <IN>
a <DT>
breast_tumor <NN>
could <MD>
predict <VB>
the <DT>
outcome <NN>
of <IN>
a <DT>
specific <JJ>
disease <NN>
. <.>
An <DT>
amplification <NN>
, <,>
or <CC>
elevated <VBN>
number <NN>
, <,>
of <IN>
the <DT>
oncogenes <NNS>
lead <VBP>
to <TO>
a <DT>
quicker_relapse <NN>
and <CC>
a <DT>
shorter_period <NN>
of <IN>
survival <NN>
of <IN>
breast <JJ>
cancer <NN>
patients <NNS>
. <.>
Finding <VBG>
the <DT>
oncogene <NN>
in <IN>
ovarian <JJ>
cancers <NNS>
, <,>
said <VBD>
Press <NNP>
, <,>
may <MD>
give <VB>
clinicians <NNS>
a <DT>
predictor <NN>
of <IN>
the <DT>
disease_progress <NN>
in <IN>
these <DT>
patients <NNS>
also <RB>
. <.>
`` <``>
This <DT>
gene <NN>
might <MD>
be <VB>
a <DT>
way <NN>
of <IN>
identifying <VBG>
patients <NNS>
who <WP>
would <MD>
have <VB>
a <DT>
less <JJR>
favorable_clinical <JJ>
outcome <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
`` <``>
If <IN>
one <CD>
could <MD>
identify <VB>
such <JJ>
patients <NNS>
, <,>
then <RB>
they <PRP>
could <MD>
be <VB>
singled <VBN>
out <RP>
for <IN>
more <JJR>
aggressive <JJ>
therapy <NN>
. <.>
'' <''>
This <DT>
would <MD>
be <VB>
particularly <RB>
important <JJ>
for <IN>
ovarian <JJ>
cancers <NNS>
. <.>
Press <NN>
said <VBD>
doctors <NNS>
now <RB>
can <MD>
gauge <VB>
the <DT>
level <NN>
of <IN>
treatment <NN>
for <IN>
breast_cancer <NN>
patients <NNS>
based <VBN>
on_whether <IN>
or <CC>
not <RB>
cancer <NN>
cells <NNS>
are <VBP>
found <VBN>
in <IN>
nearby <JJ>
lymph <NN>
nodes <VBZ>
. <.>
There <EX>
currently <RB>
is <VBZ>
no <DT>
such_prognostic <JJ>
indicator <NN>
for <IN>
ovarian <JJ>
cancer <NN>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
exact <JJ>
role <NN>
that <WDT>
HEF-2 <-NONE->
@ <VBP>
neu <NN>
plays <NNS>
in <IN>
development <NN>
of <IN>
cancer <NN>
tumors <NNS>
is <VBZ>
not <RB>
understood <VBN>
. <.>
But <CC>
Press <NNP>
said <VBD>
it <PRP>
clearly <RB>
is <VBZ>
an <DT>
oncogene <NN>
, <,>
a <DT>
genetic <JJ>
molecule <NN>
with <IN>
a <DT>
normal <JJ>
function <NN>
that <WDT>
is <VBZ>
changed <VBN>
or <CC>
activated <VBN>
in <IN>
some <DT>
way <NN>
to <TO>
become <VB>
part <NN>
of <IN>
the <DT>
cancer_disease_process <NN>
. <.>
`` <``>
Why <WRB>
that <DT>
is <VBZ>
and <CC>
what <WP>
the <DT>
gene <NN>
does_is <VBZ>
unknown <VBN>
at <IN>
this <DT>
point <NN>
, <,>
'' <''>
said <VBD>
Press <NNP>
. <.>
`` <``>
We <PRP>
're <VBP>
assuming <VBG>
that <IN>
the <DT>
gene <NN>
is <VBZ>
important <JJ>
because <IN>
it <PRP>
codes <VBZ>
for <IN>
a <DT>
protein <NN>
, <,>
but <CC>
we <PRP>
do <VBP>
n't <RB>
know <VB>
what <WP>
the <DT>
function <NN>
of <IN>
that <DT>
protein <NN>
is <VBZ>
. <.>
'' <''>
Press <NNP>
said <VBD>
the <DT>
researchers <NNS>
looked <VBD>
unsuccessfully <RB>
for <IN>
the <DT>
same <JJ>
oncogene <NN>
in <IN>
tumors <NNS>
from <IN>
cancers <NNS>
of <IN>
the <DT>
lung <NN>
, <,>
adrenal <JJ>
gland <NN>
and <CC>
colon <NN>
. <.>
The <DT>
researchers <NNS>
also <RB>
did <VBD>
a <DT>
statistical <JJ>
study <NN>
to <TO>
relate <VB>
amplification <NN>
, <,>
or <CC>
the <DT>
numbers <NNS>
of <IN>
the <DT>
oncogene_present <NN>
in <IN>
a <DT>
tumor <NN>
, <,>
with <IN>
the <DT>
outcome <NN>
of <IN>
the <DT>
disease <NN>
. <.>
Press <NN>
said <VBD>
the <DT>
results <NNS>
show <VBP>
that <IN>
the <DT>
greater <JJR>
the <DT>
amplification <NN>
, <,>
the <DT>
poorer <NN>
the <DT>
prognosis <NN>
. <.>
With <IN>
ovarian <JJ>
cancer <NN>
patients <NNS>
having <VBG>
only <RB>
one <CD>
copy <NN>
of <IN>
the <DT>
oncogene <NN>
in <IN>
tumor <NN>
cells <NNS>
, <,>
the <DT>
median <JJ>
survival_time <NN>
was <VBD>
1 <CD>
, <,>
879 <CD>
days <NNS>
. <.>
For <IN>
patients <NNS>
with <IN>
a <DT>
two- <JJ>
to <TO>
a <DT>
five-fold <JJ>
amplification <NN>
, <,>
the <DT>
median <JJ>
survival <NN>
was <VBD>
959 <CD>
days <NNS>
. <.>
Those <DT>
with <IN>
a <DT>
greater <JJR>
than <IN>
five-fold <JJ>
amplification <NN>
had <VBD>
a <DT>
median <JJ>
survival <NN>
of <IN>
only <RB>
243 <CD>
days <NNS>
. <.>
A <DT>
similar <JJ>
pattern <NN>
was <VBD>
shown <VBN>
earlier <JJR>
among <IN>
breast <JJ>
cancer <NN>
patients <NNS>
. <.>
Breast <NNP>
and <CC>
ovarian <JJ>
cancers <NNS>
account <VBP>
for <IN>
one-third <NN>
, <,>
or <CC>
about <IN>
162 <CD>
, <,>
000 <CD>
, <,>
of <IN>
all_the <DT>
cancers <NNS>
diagnosed <VBD>
annually <RB>
in <IN>
American <NNP>
women <NNS>
. <.>
These <DT>
types <NNS>
of <IN>
cancers <NNS>
account <VBP>
for_about <IN>
25 <CD>
percent <NN>
of <IN>
all <DT>
cancer <NN>
deaths <NNS>
in <IN>
women <NNS>
. <.>
Co-investigators <NNS>
with <IN>
Press <NNP>
in <IN>
the <DT>
study <NN>
were <VBD>
Judith_Udove <NNP>
of <IN>
USC <NNP>
; <:>
William_Godolphin <NNP>
of <IN>
the <DT>
Vancouver_General_Hospital <NNP>
, <,>
Canada <NNP>
; <:>
Lovell_Jones <NNP>
, <,>
M.D. <NNP>
, <,>
of <IN>
Anderson_Hospital <NNP>
, <,>
Houston <NNP>
; <:>
John_Holt <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Chicago_Medical_Center <NNP>
; <:>
Steven_Wong <NNP>
, <,>
Duane_Keith <NNP>
and <CC>
Wendy_Level <NNP>
of <IN>
UCLA <NNP>
; <:>
Susan_Stuart <NNP>
at <IN>
Triton <NNP>
Biosciences <NNPS>
, <,>
Alameda <NNP>
, <,>
Calif. <NNP>
, <,>
and <CC>
Axel_Ullrich <NNP>
of <IN>
Genentech <NNP>
, <,>
South_San_Francisco <NNP>
, <,>
Calif._Science <NNP>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
WSJ880311-0012 <DOCNO>
. <.>
A <DT>
woman <NN>
who <WP>
undergoes <VBZ>
an <DT>
X-ray <JJ>
breast_examination <NN>
every <DT>
year <NN>
during <IN>
her <PRP$>
40s <CD>
would <MD>
cut <VB>
her <PRP>
risk <VB>
of <IN>
dying <VBG>
of <IN>
breast <JJ>
cancer <NN>
by <IN>
26 <CD>
% <NN>
. <.>
But <CC>
urging <VBG>
annual <JJ>
mammography <NN>
for <IN>
all <DT>
women <NNS>
between <IN>
ages <NNS>
40 <CD>
and <CC>
50 <CD>
years <NNS>
would <MD>
boost <VB>
the <DT>
nation <NN>
's <POS>
medical <JJ>
bill <NN>
by <IN>
more <RBR>
than <IN>
$ <$>
400_million <CD>
for <IN>
the <DT>
year <NN>
2000 <CD>
while <IN>
saving <NN>
373 <CD>
women <NNS>
from <IN>
dying <VBG>
of <IN>
breast <JJ>
cancer <NN>
that <WDT>
year <NN>
. <.>
So <IN>
concluded <VBN>
an <DT>
unusual_cost-benefit <JJ>
analysis <NN>
of <IN>
X-ray <NNP>
mammography <NN>
by <IN>
researchers <NNS>
from <IN>
Duke_University <NNP>
and <CC>
the <DT>
American_Medical_Association <NNP>
, <,>
published <VBD>
this <DT>
week <NN>
in <IN>
the <DT>
association <NN>
's <POS>
journal <JJ>
. <.>
The <DT>
analysis <NN>
sought <VBD>
to <TO>
determine <VB>
the <DT>
benefits <NNS>
, <,>
risks <NNS>
and <CC>
costs <NNS>
of <IN>
recommending <VBG>
annual <JJ>
mammography <NN>
for <IN>
women <NNS>
in <IN>
their <PRP$>
40s <CD>
. <.>
Most <JJS>
medical <JJ>
groups <NNS>
currently <RB>
agree <VBP>
that <IN>
women <NNS>
age <VBP>
50 <CD>
and <CC>
over <IN>
should <MD>
have <VB>
annual <JJ>
mammography <NN>
examinations <NNS>
. <.>
Breast <NNP>
cancer <NN>
is <VBZ>
most <JJS>
common <JJ>
among <IN>
older <JJR>
women <NNS>
, <,>
and <CC>
a <DT>
variety <NN>
of <IN>
studies <NNS>
show <VBP>
that <IN>
such_annual <JJ>
exams <NNS>
can <MD>
reduce <VB>
the <DT>
number <NN>
of <IN>
breast-cancer <NN>
deaths <NNS>
among <IN>
women <NNS>
over <IN>
50 <CD>
by <IN>
50 <CD>
% <NN>
over <IN>
a <DT>
five-year <JJ>
period <NN>
. <.>
Medical <JJ>
groups <NNS>
disagree <VBP>
, <,>
however <RB>
, <,>
on <IN>
the <DT>
value <NN>
of <IN>
mammography <NN>
for <IN>
women <NNS>
in <IN>
their <PRP$>
40s <CD>
, <,>
when <WRB>
mammography <JJ>
is <VBZ>
less <RBR>
effective <JJ>
in <IN>
detecting <NN>
early <RB>
cancers <NNS>
. <.>
The <DT>
American_Cancer_Society <NNP>
and <CC>
the <DT>
American_Medical_Association <NNP>
urge <NN>
women <NNS>
to <TO>
have <VB>
at <IN>
least <JJS>
one <CD>
mammogram <NN>
taken <VBN>
between <IN>
age <NN>
35 <CD>
and <CC>
40 <CD>
and <CC>
have <VBP>
additional <JJ>
mammograms <NNS>
every <DT>
year <NN>
or <CC>
two <CD>
through <IN>
age <NN>
49 <CD>
. <.>
But <CC>
the <DT>
federal <JJ>
government <NN>
's <POS>
National_Cancer_Institute <NNP>
, <,>
the <DT>
American_College <NNP>
of <IN>
Obstetricians <NNPS>
and <CC>
Gynecologists <NNPS>
and <CC>
others <NNS>
have <VBP>
declined <VBN>
to <TO>
recommend <VB>
mammography <JJ>
in <IN>
this <DT>
age_group <NN>
except_for <IN>
women <NNS>
with <IN>
a <DT>
family_history <NN>
of <IN>
breast_cancer <NN>
. <.>
The <DT>
analysis <NN>
looked <VBD>
first <JJ>
at <IN>
the <DT>
individual <JJ>
benefits <NNS>
and <CC>
risks <NNS>
of <IN>
annual <JJ>
mammograms <NNS>
for <IN>
a <DT>
40-year-old <JJ>
woman <NN>
who <WP>
has <VBZ>
n't <RB>
any <DT>
suspicious <JJ>
breast <NN>
lumps <NNS>
upon <IN>
physical <JJ>
examination <NN>
. <.>
The <DT>
odds <NNS>
are <VBP>
128 <CD>
out_of <IN>
10 <CD>
, <,>
000 <CD>
that <WDT>
she <PRP>
will <MD>
develop <VB>
breast <JJ>
cancer <NN>
before <IN>
she <PRP>
is <VBZ>
50 <CD>
, <,>
the <DT>
analysis <NN>
found <VBD>
. <.>
Her <PRP$>
chances <NNS>
of <IN>
dying <VBG>
of <IN>
a <DT>
breast <JJ>
cancer <NN>
that <WDT>
develops <VBZ>
during <IN>
this <DT>
time <NN>
is <VBZ>
82 <CD>
out_of <IN>
10 <CD>
, <,>
000 <CD>
. <.>
However <RB>
, <,>
these <DT>
odds <NNS>
are <VBP>
reduced <VBN>
to <TO>
60 <CD>
out_of <IN>
10 <CD>
, <,>
000 <CD>
if <IN>
she <PRP>
undergoes <VBZ>
annual <JJ>
mammography <NN>
during <IN>
her <PRP$>
40s <CD>
, <,>
a <DT>
26 <CD>
%_reduction <NN>
in <IN>
the <DT>
risk <NN>
of <IN>
dying <VBG>
of <IN>
a <DT>
breast <JJ>
cancer <NN>
that <WDT>
develops <VBZ>
before <IN>
age <NN>
50 <CD>
. <.>
The <DT>
estimates <NNS>
take <VBP>
into <IN>
account <NN>
that <IN>
there <EX>
's <VBZ>
a <DT>
1-in-25 <CD>
, <,>
000 <CD>
chance <NN>
that <IN>
the <DT>
annual <JJ>
X-rays <NNS>
, <,>
themselves <PRP>
, <,>
will <MD>
cause <VB>
a <DT>
breast <JJ>
cancer <NN>
. <.>
However <RB>
, <,>
there <EX>
also <RB>
is <VBZ>
a <DT>
1-in-100 <CD>
chance <NN>
that_after <IN>
each <DT>
mammogram <NN>
the <DT>
woman <NN>
will <MD>
require <VB>
a <DT>
surgical <JJ>
biopsy <NN>
for <IN>
a <DT>
suspicious <JJ>
feature <NN>
on <IN>
the <DT>
X-ray <NNP>
film <NN>
that <WDT>
turns <VBZ>
out <RP>
to <TO>
be <VB>
noncancerous <JJ>
. <.>
For <IN>
society <NN>
as <IN>
a <DT>
whole <JJ>
, <,>
the <DT>
researchers <NNS>
assumed <VBD>
that <IN>
, <,>
if <IN>
it <PRP>
were <VBD>
formally <RB>
recommended <VBN>
, <,>
about <IN>
4.5_million <CD>
women <NNS>
in <IN>
their <PRP$>
40s <CD>
, <,>
or <CC>
25 <CD>
% <NN>
of <IN>
women <NNS>
in <IN>
this <DT>
age_group <NN>
, <,>
would <MD>
be <VB>
following <VBG>
this <DT>
annual <JJ>
practice <NN>
in <IN>
the <DT>
year <NN>
2000 <CD>
. <.>
If <IN>
so <RB>
, <,>
they <PRP>
calculated <VBD>
, <,>
there <EX>
would <MD>
be <VB>
10 <CD>
, <,>
339 <CD>
deaths <NNS>
that <WDT>
year <NN>
among <IN>
women <NNS>
who <WP>
developed <VBD>
breast <VBP>
cancer_sometime <NN>
between <IN>
age <NN>
40 <CD>
and <CC>
49 <CD>
. <.>
This <DT>
would <MD>
be <VB>
373 <CD>
fewer <JJR>
deaths <NNS>
than_if <IN>
none <NN>
of <IN>
the <DT>
4.5_million <CD>
women <NNS>
had <VBD>
been <VBN>
having <VBG>
annual <JJ>
mammograms <NNS>
. <.>
The <DT>
cost <NN>
of <IN>
annual <JJ>
mammography <NN>
in <IN>
the <DT>
year <NN>
2000 <CD>
for <IN>
4.5_million <CD>
women <NNS>
would <MD>
be <VB>
$ <$>
361_million <CD>
in <IN>
1984 <CD>
dollars <NNS>
, <,>
they <PRP>
estimated <VBD>
. <.>
The <DT>
cost <NN>
of <IN>
biopsies <NNS>
for <IN>
women <NNS>
who <WP>
turn <NN>
out <IN>
to <TO>
be <VB>
`` <``>
false-positives <NNS>
'' <''>
would <MD>
add <VB>
almost <RB>
$ <$>
41_million <CD>
to <TO>
the <DT>
annual_medical <JJ>
bill <NN>
without <IN>
helping <VBG>
to <TO>
reduce <VB>
the <DT>
death_rate <NN>
. <.>
The <DT>
annual-mammography <JJ>
policy <NN>
would <MD>
save <VB>
about <IN>
$ <$>
5.2_million <CD>
in <IN>
expensive_terminal <JJ>
care <NN>
that <WDT>
year <NN>
for <IN>
women <NNS>
who <WP>
otherwise <RB>
would <MD>
have <VB>
died <VBN>
of <IN>
breast <JJ>
cancer <NN>
. <.>
However <RB>
, <,>
this <DT>
would <MD>
be <VB>
more <RBR>
than <IN>
offset <VBN>
by <IN>
almost <RB>
$ <$>
5.9_million <CD>
spent <NN>
on <IN>
trying <VBG>
to <TO>
cure <VB>
those <DT>
women <NNS>
who <WP>
were <VBD>
found <VBN>
by <IN>
mammography <NN>
to <TO>
have <VB>
cancer <NN>
. <.>
The <DT>
net <JJ>
cost <NN>
of <IN>
the <DT>
annual-mammography <JJ>
policy <NN>
for <IN>
this <DT>
age_group <NN>
, <,>
after <IN>
taking <VBG>
into <IN>
account <NN>
other_medical <JJ>
costs <NNS>
, <,>
would <MD>
be <VB>
$ <$>
402_million <CD>
in <IN>
the <DT>
year <NN>
2000 <CD>
, <,>
they <PRP>
calculated <VBD>
. <.>
Put <VB>
another <DT>
way <NN>
, <,>
it <PRP>
requires <VBZ>
more <JJR>
than <IN>
12 <CD>
, <,>
000 <CD>
mammography <NN>
exams <NNS>
in <IN>
the <DT>
year <NN>
2000 <CD>
, <,>
at <IN>
a <DT>
cost <NN>
of <IN>
more <JJR>
than <IN>
$ <$>
1_million <CD>
, <,>
to <TO>
reduce <VB>
the <DT>
number <NN>
of <IN>
breast-cancer <NN>
deaths <NNS>
by <IN>
one <CD>
, <,>
they <PRP>
calculated <VBD>
. <.>
The <DT>
researchers <NNS>
did <VBD>
n't <RB>
take <VB>
sides <NNS>
on_whether <IN>
medical <JJ>
groups <NNS>
should <MD>
recommend <VB>
annual <JJ>
mammography <NN>
for <IN>
women <NNS>
in <IN>
their <PRP$>
40s <CD>
. <.>
But <CC>
they <PRP>
did <VBD>
suggest <VBP>
that <IN>
`` <``>
mammography <NN>
should <MD>
be <VB>
made <VBN>
available <JJ>
to <TO>
women <NNS>
who <WP>
understand <VBP>
the <DT>
limits <NNS>
of <IN>
its <PRP$>
benefits <NNS>
, <,>
who <WP>
understand <NN>
its <PRP$>
risks <NNS>
, <,>
and <CC>
who <WP>
are <VBP>
willing <JJ>
to <TO>
pay <VB>
its <PRP$>
costs <NNS>
. <.>
`` <``>
A <DT>
survey <NN>
of <IN>
21 <CD>
medical <JJ>
centers <NNS>
found <VBD>
the <DT>
cost <NN>
of <IN>
a <DT>
mammography_exam <NN>
ranges <NNS>
between <IN>
$ <$>
35 <CD>
and <CC>
$ <$>
182 <CD>
. <.>
A <DT>
biopsy <NN>
resulting <VBG>
from <IN>
a <DT>
suspicious <JJ>
mammogram_cost <NN>
about <IN>
$ <$>
900 <CD>
in <IN>
1984 <CD>
, <,>
they <PRP>
noted <VBD>
AP900622-0042 <DOCNO>
. <.>
A <DT>
panel <NN>
of <IN>
experts <NNS>
says <VBZ>
removing <VBG>
a <DT>
cancerous <JJ>
tumor <NN>
in <IN>
the <DT>
early <JJ>
stages <NNS>
of <IN>
breast <JJ>
cancer <NN>
gives <VBZ>
as <IN>
good <JJ>
a <DT>
survival_chance <NN>
to <TO>
women <NNS>
as <IN>
more <JJR>
radical <JJ>
surgery <NN>
in <IN>
which <WDT>
the <DT>
entire <JJ>
breast <NN>
is <VBZ>
removed <VBN>
. <.>
Mastectomies <NNS>
, <,>
in <IN>
which <WDT>
the <DT>
entire <JJ>
breast <NN>
is <VBZ>
removed <VBN>
, <,>
and <CC>
lumpectomies <NNS>
, <,>
in <IN>
which <WDT>
only <RB>
the <DT>
tumor <NN>
is <VBZ>
removed <VBN>
, <,>
both <DT>
give <JJ>
`` <``>
excellent <NN>
'' <''>
results <NNS>
for <IN>
Stage_I <NNP>
and <CC>
Stage_II <NNP>
breast_cancer <NN>
, <,>
the <DT>
panel <NN>
said <VBD>
. <.>
The <DT>
committee <NN>
of <IN>
15 <CD>
experts <NNS>
was <VBD>
assembled <VBN>
by <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
to <TO>
consider <VB>
research <NN>
on <IN>
the <DT>
survival <NN>
of <IN>
women <NNS>
with <IN>
early <JJ>
stages <NNS>
of <IN>
breast <JJ>
cancer <NN>
and <CC>
to <TO>
develop <VB>
a <DT>
consensus <NN>
on <IN>
what <WP>
therapy <NN>
should <MD>
be <VB>
used <VBN>
to <TO>
treat <VB>
the <DT>
disease <NN>
. <.>
`` <``>
The <DT>
therapies <NNS>
appear <VBP>
to <TO>
be <VB>
equivalent <JJ>
in <IN>
survival <NN>
, <,>
'' <''>
said <VBD>
Dr._William_C._Wood <NNP>
, <,>
a <DT>
Harvard_Medical_School <NNP>
surgeon <NN>
and <CC>
chairman <NN>
of <IN>
the <DT>
committee <NN>
. <.>
`` <``>
We <PRP>
believe <VBP>
it <PRP>
is <VBZ>
preferable <JJ>
to <TO>
preserve <VB>
an <DT>
organ <NN>
. <.>
'' <''>
Mastectomy <NNP>
is <VBZ>
still <RB>
the <DT>
most <RBS>
commonly <RB>
used <JJ>
therapy <NN>
for <IN>
early <JJ>
stage_breast_cancer <NN>
, <,>
Wood <NNP>
said <VBD>
. <.>
A <DT>
lumpectomy <NN>
is <VBZ>
followed <VBN>
with <IN>
radiation_therapy <NN>
, <,>
and <CC>
Wood <NNP>
said <VBD>
some <DT>
patients <NNS>
choose <VBP>
mastectomy <NN>
because <IN>
they <PRP>
`` <``>
prefer <VBP>
to <TO>
lose <VB>
a <DT>
breast <JJ>
instead <NN>
of <IN>
have <NN>
six <CD>
weeks <NNS>
of <IN>
radiation_therapy <NN>
. <.>
'' <''>
In <IN>
its <PRP$>
report <NN>
, <,>
the <DT>
committee <NN>
said <VBD>
surgery <NN>
in <IN>
which <WDT>
the <DT>
breast <NN>
is <VBZ>
saved <VBN>
, <,>
or <CC>
conserved <VBN>
, <,>
`` <``>
is <VBZ>
an <DT>
appropriate <JJ>
method <NN>
of <IN>
primary <JJ>
therapy <NN>
for <IN>
the <DT>
majority <NN>
of <IN>
women <NNS>
with <IN>
Stage_I <NNP>
and <CC>
II <NNP>
breast_cancer <NN>
, <,>
and <CC>
is <VBZ>
preferable <JJ>
'' <''>
because <IN>
the <DT>
breast <NN>
is <VBZ>
preserved <VBN>
and <CC>
the <DT>
survival <NN>
chances <NNS>
are <VBP>
the <DT>
same <JJ>
as_for <IN>
mastectomy <NN>
. <.>
Wood <NNP>
said <VBD>
that <IN>
both <DT>
mastectomy <NN>
and <CC>
lumpectomy <NN>
involves <NNS>
the <DT>
removal <NN>
of <IN>
nearby <JJ>
lymph <NN>
nodes <VBZ>
. <.>
If <IN>
these <DT>
nodes <NNS>
are <VBP>
cancer-free <JJ>
and <CC>
the <DT>
primary <JJ>
tumor <NN>
is <VBZ>
smaller <JJR>
than <IN>
one <CD>
centimeter <NN>
, <,>
both <DT>
methods <NNS>
of <IN>
treatment <NN>
have <VBP>
about <IN>
a <DT>
90 <CD>
percent_chance <NN>
of <IN>
cure <NN>
. <.>
About <IN>
150 <CD>
, <,>
000 <CD>
American <NNP>
women <NNS>
will <MD>
be <VB>
diagnosed <VBN>
with <IN>
breast <JJ>
cancer <NN>
this <DT>
year <NN>
, <,>
the <DT>
committee_report <NN>
said <VBD>
. <.>
Between <IN>
75 <CD>
percent <NN>
and <CC>
80 <CD>
percent <NN>
of <IN>
this <DT>
group <NN>
will <MD>
have <VB>
Stage <NNP>
I <PRP>
or <CC>
Stage_II <NNP>
disease <NN>
, <,>
and <CC>
about <IN>
two-thirds <NNS>
of <IN>
these <DT>
will <MD>
have <VB>
cancer-free <JJ>
lymph <NN>
nodes <VBZ>
. <.>
Stage <NN>
I <PRP>
and <CC>
II <NNP>
cancers <NNS>
have <VBP>
not <RB>
spread <VBN>
beyond <IN>
the <DT>
breast <NN>
and <CC>
lymph <NN>
nodes <NNS>
. <.>
But <CC>
just <RB>
how <WRB>
to <TO>
treat <VB>
this <DT>
early-stage_breast_cancer <NN>
long <RB>
has <VBZ>
been <VBN>
controversial <JJ>
. <.>
Traditionally <RB>
, <,>
the <DT>
preferred <VBN>
treatment <NN>
has <VBZ>
been <VBN>
a <DT>
radical <JJ>
mastectomy <NN>
in <IN>
which <WDT>
the <DT>
entire <JJ>
breast <NN>
and <CC>
much <RB>
adjacent <JJ>
tissue <NN>
is <VBZ>
removed <VBN>
. <.>
During <IN>
the <DT>
past <JJ>
two <CD>
decades <NNS>
, <,>
there <EX>
have <VBP>
been <VBN>
a <DT>
number <NN>
of <IN>
studies <NNS>
comparing <VBG>
the <DT>
survival <NN>
results <NNS>
of <IN>
less <JJR>
extensive <JJ>
breast_surgery <NN>
, <,>
including <VBG>
lumpectomy <NN>
. <.>
The <DT>
committee <NN>
found <VBD>
that <IN>
, <,>
based <VBN>
on <IN>
the <DT>
studies <NNS>
, <,>
survival <NN>
rates <NNS>
are <VBP>
virtually <RB>
the <DT>
same <JJ>
for <IN>
the <DT>
two <CD>
types <NNS>
of <IN>
therapy <NN>
. <.>
The <DT>
experts <NNS>
said <VBD>
the <DT>
picture <NN>
was <VBD>
less <JJR>
clear <JJ>
for <IN>
follow-up <JJ>
treatment <NN>
using <VBG>
chemotherapy <NN>
or <CC>
a <DT>
drug <NN>
that <WDT>
blocks <VBZ>
the <DT>
hormone_estrogen <NN>
. <.>
The <DT>
studies <NNS>
show <VBP>
a <DT>
trend <NN>
that <WDT>
may <MD>
suggest <VB>
an <DT>
advantage <NN>
in <IN>
taking <NN>
the <DT>
follow <NN>
up <RP>
or <CC>
adjuvant <JJ>
therapy <NN>
, <,>
but <CC>
the <DT>
committee <NN>
said <VBD>
the <DT>
drugs <NNS>
may <MD>
be <VB>
toxic <JJ>
or <CC>
degrade <NN>
the <DT>
patient <NN>
's <POS>
quality <NN>
of <IN>
life <NN>
. <.>
For <IN>
patients <NNS>
with <IN>
very <RB>
small_primary <JJ>
tumors <NNS>
_ <NNP>
one <CD>
centimeter <NN>
or <CC>
less <JJR>
_ <NNP>
adjuvant_therapy <NN>
is <VBZ>
not <RB>
required <VBN>
, <,>
the <DT>
committee <NN>
said <VBD>
. <.>
The <DT>
committee <NN>
also <RB>
said <VBD>
that <IN>
the <DT>
use <NN>
of <IN>
lumpectomy <NN>
should <MD>
be <VB>
based <VBN>
on <IN>
an <DT>
individual_evaluation <NN>
of <IN>
each <DT>
patient <NN>
and <CC>
with <IN>
the <DT>
full <JJ>
understanding <NN>
by <IN>
the <DT>
patient <NN>
of <IN>
all_the <DT>
options <NNS>
. <.>
Lumpectomies <NNS>
are <VBP>
not <RB>
appropriate <JJ>
for <IN>
all <DT>
Stage <NNP>
I <PRP>
or <CC>
II <NNP>
patients <NNS>
because_of <IN>
the <DT>
size <NN>
of <IN>
the <DT>
breast <JJ>
, <,>
or <CC>
the <DT>
distribution <NN>
of <IN>
tumors <NNS>
or <CC>
calcified <VBN>
lumps <NNS>
within <IN>
the <DT>
breast <NN>
, <,>
the <DT>
committee <NN>
said <VBD>
LA021989-0064 <DOCNO>
. <.>
THE <DT>
DISEASE_There <NNP>
are <VBP>
more <JJR>
than <IN>
100 <CD>
types <NNS>
of <IN>
cancer <NN>
. <.>
Most <JJS>
fall <NN>
into <IN>
two <CD>
categories <NNS>
: <:>
sarcomas <NNS>
or <CC>
carcinomas <NNS>
. <.>
Carcinomas <NNP>
are <VBP>
cancers <NNS>
of <IN>
the <DT>
type <NN>
of <IN>
tissue <NN>
that <IN>
forms <NNS>
skin <VBP>
and <CC>
the <DT>
lining <NN>
of <IN>
major <JJ>
organs <NNS>
. <.>
Eighty <NNP>
percent <VBD>
to <TO>
90 <CD>
% <NN>
of <IN>
all <DT>
cancers <NNS>
are <VBP>
carcinomas <RB>
. <.>
Sarcomas <NNP>
are <VBP>
cancers <NNS>
of <IN>
the <DT>
connective <JJ>
tissue <NN>
, <,>
such <JJ>
as <IN>
bone <NN>
and <CC>
cartilage <NN>
. <.>
Cancer <NN>
cells <NNS>
differ <VBP>
from <IN>
normal <JJ>
cells <NNS>
in <IN>
three <CD>
main <JJ>
ways <NNS>
: <:>
They <PRP>
reproduce <VBP>
faster <JJR>
, <,>
migrate <JJ>
to <TO>
other <JJ>
parts <NNS>
of <IN>
the <DT>
body <NN>
and <CC>
do <VBP>
n't <RB>
have <VB>
specialized <VBN>
functions <NNS>
. <.>
THE <DT>
NUMBERS <NNP>
A <DT>
little <RB>
more <RBR>
than <IN>
1_million <CD>
Americans <NNS>
will <MD>
be <VB>
found <VBN>
to <TO>
have <VB>
cancer <NN>
this <DT>
year <NN>
. <.>
About <IN>
half_a <DT>
million <NN>
will <MD>
die <VB>
from <IN>
it <PRP>
. <.>
For <IN>
all <DT>
cancers <NNS>
combined <VBN>
, <,>
the <DT>
number <NN>
of <IN>
new <JJ>
cases <NNS>
each <DT>
year <NN>
increased <VBD>
10.7 <CD>
% <NN>
between <IN>
1973 <CD>
and <CC>
1985 <CD>
, <,>
the <DT>
latest <JJS>
year <NN>
for <IN>
which <WDT>
statistics <NNS>
are <VBP>
available <JJ>
. <.>
The <DT>
most <RBS>
dramatic <JJ>
increase <NN>
between <IN>
1973 <CD>
and <CC>
1985 <CD>
was <VBD>
for <IN>
melanoma <NN>
of <IN>
the <DT>
skin <NN>
, <,>
which <WDT>
increased <VBN>
60 <CD>
% <NN>
. <.>
Excessive <JJ>
sun_exposure <NN>
is <VBZ>
the <DT>
primary <JJ>
cause <NN>
. <.>
The <DT>
greatest <JJS>
decline <NN>
between <IN>
1973 <CD>
and <CC>
1985 <CD>
was <VBD>
for <IN>
cervical <JJ>
cancer <NN>
, <,>
which <WDT>
dropped <VBD>
35 <CD>
% <NN>
. <.>
Early <RB>
detection <NN>
and <CC>
greater <JJR>
use <NN>
of <IN>
Pap <NNP>
smears <NNS>
are <VBP>
credited <VBN>
. <.>
Lung <NNP>
cancer <NN>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
cancer <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
the <DT>
major <JJ>
cause <NN>
of <IN>
cancer_death <NN>
. <.>
Most <JJS>
lung <JJ>
cancer <NN>
is <VBZ>
caused <VBN>
by <IN>
cigarette_smoking <NN>
. <.>
Among <IN>
women <NNS>
, <,>
lung <JJ>
cancer_incidence <NN>
increased <VBD>
81 <CD>
% <NN>
between <IN>
1973 <CD>
and <CC>
1985 <CD>
. <.>
For <IN>
men <NNS>
, <,>
it <PRP>
increased <VBD>
14.3 <CD>
% <NN>
. <.>
THE <DT>
SURVIVAL_RATE_The <NNP>
rate <NN>
of <IN>
people <NNS>
who <WP>
survive <JJ>
cancer <NN>
and <CC>
are <VBP>
disease-free <JJ>
five <CD>
years <NNS>
after <IN>
the <DT>
diagnosis <NN>
is <VBZ>
now <RB>
about <IN>
50 <CD>
% <NN>
. <.>
Cancers <NNS>
with <IN>
higher <JJR>
survivability <NN>
rates <NNS>
are <VBP>
: <:>
testis <NNS>
, <,>
90 <CD>
% <NN>
; <:>
colon <NN>
, <,>
54 <CD>
% <NN>
, <,>
and <CC>
breast <JJ>
, <,>
74 <CD>
% <NN>
. <.>
Cancers <NNS>
with <IN>
lower <JJR>
rates <NNS>
are <VBP>
: <:>
leukemia <NNS>
, <,>
31 <CD>
% <NN>
; <:>
lung <NN>
, <,>
13 <CD>
% <NN>
, <,>
and <CC>
stomach <DT>
, <,>
16 <CD>
% <NN>
. <.>
THE <DT>
COSTS <NNS>
Taking <NNP>
into <IN>
account <NN>
hospital <JJ>
costs <NNS>
, <,>
the <DT>
loss <NN>
of <IN>
job_productivity <NN>
and <CC>
the <DT>
loss <NN>
of <IN>
employable <JJ>
years <NNS>
, <,>
cancer <NN>
costs <NNS>
about <IN>
$ <$>
72_billion <CD>
a <DT>
year <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
Cancer <NN>
accounts <NNS>
for_about <IN>
10 <CD>
% <NN>
of <IN>
the <DT>
cost <NN>
of <IN>
all <DT>
disease <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
On <IN>
average <JJ>
, <,>
the <DT>
person <NN>
who <WP>
dies <NNS>
from <IN>
cancer <NN>
dies <NNS>
15 <CD>
years <NNS>
earlier <RBR>
than <IN>
his <PRP$>
or <CC>
her <PRP$>
normal <JJ>
life_expectancy <NN>
. <.>
Lung <NNP>
cancer <NN>
accounts <NNS>
for <IN>
a <DT>
loss <NN>
of <IN>
about <RB>
1.8_million <CD>
years <NNS>
of <IN>
life <NN>
every <DT>
year <NN>
. <.>
THE <DT>
RECENT_BREAKTHROUGHS_The <NNP>
discovery <NN>
of <IN>
oncogenes <NNS>
has <VBZ>
probably <RB>
been <VBN>
the <DT>
most <RBS>
important <JJ>
cancer_research_discovery <NN>
in <IN>
the <DT>
past <JJ>
two <CD>
decades <NNS>
. <.>
Oncogenes <NNS>
are <VBP>
abnormal <JJ>
genes <NNS>
that <WDT>
appear <JJ>
to <TO>
be <VB>
capable <JJ>
of <IN>
`` <``>
ordering <VBG>
'' <''>
a <DT>
cell <NN>
to <TO>
become <VB>
a <DT>
cancer_cell <NN>
. <.>
Although <IN>
scientists <NNS>
have <VBP>
identified <VBN>
about <IN>
20 <CD>
human <NN>
oncogenes <NNS>
, <,>
they <PRP>
have <VBP>
yet <RB>
to <TO>
unravel <VB>
the <DT>
mysteries <NNS>
of <IN>
the <DT>
how <WRB>
the <DT>
`` <``>
ordering <VBG>
'' <''>
occurs <NNS>
. <.>
The <DT>
discovery <NN>
of <IN>
substances <NNS>
called <VBN>
anti-oncogenes <NNS>
may <MD>
prove <VB>
to <TO>
be <VB>
equally <RB>
important <JJ>
. <.>
Anti-oncogenes <NNS>
are <VBP>
substances <NNS>
that <IN>
somehow <WRB>
`` <``>
turn <VB>
off <RP>
'' <''>
cancer <NN>
cells <NNS>
and <CC>
transform <NN>
them <PRP>
back <RB>
to <TO>
normal <JJ>
cells <NNS>
. <.>
( <NN>
Proteoglycans <NNS>
, <,>
the <DT>
substance <NN>
that <IN>
the <DT>
La_Jolla_Cancer_Research_Foundation <NNP>
is <VBZ>
working <VBG>
with <IN>
, <,>
is <VBZ>
an <DT>
anti-oncogene <JJ>
. <.>
)_Research <NN>
on <IN>
anti-oncogenes <NNS>
is <VBZ>
at <IN>
an <DT>
early <JJ>
stage <NN>
and <CC>
the <DT>
potential <JJ>
for <IN>
use <NN>
in <IN>
treatment <NN>
is <VBZ>
unknown <VBN>
. <.>
Much <RB>
of <IN>
the <DT>
recent <JJ>
progress <NN>
in <IN>
research <NN>
can <MD>
be <VB>
credited <VBN>
to <TO>
the <DT>
discovery <NN>
of <IN>
monoclonal <JJ>
antibodies <NNS>
, <,>
genetically <RB>
engineered <VBN>
antibodies <NNS>
that <IN>
can <MD>
be <VB>
created <VBN>
in <IN>
great <JJ>
quantities <NNS>
in <IN>
the <DT>
laboratory <NN>
. <.>
The <DT>
human <JJ>
immune_system <NN>
creates <VBZ>
many <JJ>
kinds <NNS>
of <IN>
natural <JJ>
antibodies <NNS>
to <TO>
foreign <JJ>
proteins <NNS>
, <,>
such <JJ>
as <IN>
viruses <NNS>
. <.>
Some <DT>
natural <JJ>
antibodies <NNS>
may <MD>
neutralize <VB>
the <DT>
proteins <NNS>
; <:>
others <NNS>
may <MD>
not <RB>
. <.>
In <IN>
contrast <NN>
, <,>
monoclonal <JJ>
antibodies <NNS>
are <VBP>
designed <VBN>
to <TO>
seek <VB>
out <RP>
and <CC>
attack_specific <NN>
proteins <NNS>
. <.>
They <PRP>
have <VBP>
become <VBN>
an <DT>
important <JJ>
tool <NN>
for <IN>
isolating <NN>
and <CC>
identifying <VBG>
specific <JJ>
cell <NN>
parts <NNS>
and <CC>
cell <NN>
mechanisms <NNS>
. <.>
They <PRP>
are <VBP>
used <VBN>
to <TO>
a <DT>
limited <JJ>
degree <NN>
as <IN>
diagnostic <JJ>
tools <NNS>
. <.>
Scientists <NNS>
are <VBP>
also <RB>
working <VBG>
to <TO>
couple <VB>
monoclonal <JJ>
antibodies <NNS>
with <IN>
cancer-fighting <JJ>
drugs <NNS>
to <TO>
more <JJR>
effectively <RB>
target <VB>
treatment <NN>
. <.>
Progress <NN>
has <VBZ>
been_made <VBN>
with <IN>
conventional <JJ>
cancer <NN>
treatments <NNS>
, <,>
particularly <RB>
in <IN>
the <DT>
area <NN>
of <IN>
chemotherapy <NN>
. <.>
Doctors <NNS>
now <RB>
know <VBP>
that <IN>
combinations <NNS>
of <IN>
certain <JJ>
drugs <NNS>
can <MD>
effectively <RB>
treat <VB>
some <DT>
types <NNS>
of <IN>
leukemia <NN>
that <IN>
previously <RB>
would <MD>
not <RB>
respond <VB>
well <RB>
to <TO>
any <DT>
single <JJ>
drug <NN>
. <.>
New <NNP>
methods <NNS>
of <IN>
delivering <VBG>
anti-cancer <NN>
drugs <NNS>
also <RB>
have <VBP>
been_developed <VBN>
that <IN>
have <VBP>
proved <VBN>
more <RBR>
effective <JJ>
. <.>
At <IN>
UC_San_Diego_Cancer_Center <NNP>
, <,>
an <DT>
experimental <JJ>
treatment <NN>
for <IN>
ovarian <JJ>
cancer <NN>
has <VBZ>
shown <VBN>
promise <NN>
. <.>
It <PRP>
involves <VBZ>
administering <VBG>
high <JJ>
concentrations <NNS>
of <IN>
cancer <NN>
drugs <NNS>
through <IN>
an <DT>
abdominal <JJ>
catheter <NN>
and <CC>
applying <VBG>
more <JJR>
directly <RB>
greater <JJR>
doses <NNS>
of <IN>
drugs <NNS>
than <IN>
standard_intravenous <JJ>
treatment <NN>
currently <RB>
allows <VBZ>
Sources <NNS>
: <:>
Figures <NNS>
are <VBP>
taken <VBN>
from <IN>
the <DT>
National_Cancer_Institute <NNP>
's <POS>
1988 <CD>
`` <``>
Annual <JJ>
Cancer <NN>
Statistics_Review_Including_Cancer_Trends <NNP>
: <:>
1950-1985 <CD>
'' <''>
and <CC>
the <DT>
`` <``>
NCI_Fact_Book <NNP>
. <.>
`` <``>
AP900316-0097 <DOCNO>
Kathryn_Phillips <NNP>
Genetic <JJ>
tests <NNS>
on <IN>
women <NNS>
with <IN>
breast <JJ>
cancer <NN>
could <MD>
determine <VB>
the <DT>
risk <NN>
of <IN>
recurrence <NN>
for <IN>
some <DT>
patients <NNS>
, <,>
improving <VBG>
the <DT>
chance <NN>
of <IN>
treating <VBG>
women <NNS>
generally <RB>
thought <VBD>
to <TO>
be <VB>
safe <JJ>
, <,>
a <DT>
researcher <NN>
said <VBD>
Friday <NNP>
. <.>
Cancer <NN>
specialists <NNS>
also <RB>
report <NN>
that <WDT>
the <DT>
use <NN>
of <IN>
lumpectomy <NN>
and <CC>
radiation_therapy_appear <NN>
to <TO>
be <VB>
promising <VBG>
alternatives <NNS>
to <TO>
breast <VB>
removal <NN>
for <IN>
a <DT>
common <JJ>
form <NN>
of <IN>
early <JJ>
breast_cancer <NN>
. <.>
The <DT>
scientists <NNS>
' <POS>
findings <NNS>
are <VBP>
being <VBG>
presented <VBN>
this <DT>
week <NN>
at <IN>
the <DT>
American_College <NNP>
of <IN>
Radiology <NNP>
's <POS>
24th_annual <JJ>
National_Conference <NNP>
on <IN>
Breast_Cancer <NNP>
. <.>
Genetic <JJ>
, <,>
or <CC>
DNA <NNP>
, <,>
tests <NNS>
are <VBP>
run <VBN>
on <IN>
some <DT>
women <NNS>
, <,>
usually <RB>
those <DT>
with <IN>
large <JJ>
tumors <NNS>
, <,>
to <TO>
reveal <VB>
whether <IN>
cells <NNS>
are <VBP>
dividing <VBG>
rapidly <RB>
and <CC>
the <DT>
cancer <NN>
is <VBZ>
expected <VBN>
to <TO>
spread <VB>
, <,>
said <VBD>
Dr._Eva_Rubin <NNP>
, <,>
chief <NN>
of <IN>
the <DT>
mammography_section <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Alabama <NNP>
in <IN>
Birmingham <NNP>
. <.>
But <CC>
a <DT>
new <JJ>
study <NN>
shows <NNS>
that <WDT>
similar_genetic <JJ>
irregularities <NNS>
indicating <VBG>
aggressive <JJ>
cancer_show <NN>
up_in <IN>
large <JJ>
and <CC>
small <JJ>
tumors <NNS>
, <,>
a <DT>
finding <NN>
that <WDT>
could <MD>
signal <VB>
doctors <NNS>
to <TO>
begin <VB>
additional <JJ>
treatment <NN>
to <TO>
fight_recurrence <NN>
, <,>
Rubin <NNP>
said <VBD>
. <.>
Currently <RB>
, <,>
women <NNS>
with <IN>
small_cancerous <JJ>
breast <NN>
tumors <NNS>
that <WDT>
have <VBP>
not <RB>
spread <VBN>
to <TO>
the <DT>
lymph <NN>
nodes <VBZ>
have <VB>
surgery <NN>
or <CC>
a <DT>
lumpectomy <NN>
with <IN>
radiation_therapy <NN>
, <,>
Rubin <NNP>
said <VBD>
. <.>
Most <JJS>
do <VBP>
not <RB>
receive <VB>
follow-up <JJ>
chemotherapy <NN>
or <CC>
hormonal <JJ>
therapy <NN>
. <.>
But <CC>
30 <CD>
percent <NN>
of <IN>
those <DT>
patients <NNS>
later <JJ>
die <NN>
from <IN>
recurring <VBG>
cancer <NN>
, <,>
she <PRP>
said <VBD>
. <.>
The <DT>
Birmingham <NNP>
test <NN>
was <VBD>
designed <VBN>
to <TO>
determine <VB>
if <IN>
DNA <NNP>
test <NN>
results <NNS>
were <VBD>
different <JJ>
for <IN>
larger <JJR>
tumors <NNS>
that <WDT>
can <MD>
be <VB>
felt <VBN>
, <,>
and <CC>
non-palpable_cancerous <JJ>
tumors <NNS>
, <,>
she <PRP>
said <VBD>
. <.>
`` <``>
Of <IN>
the <DT>
21 <CD>
palpable <JJ>
and <CC>
24 <CD>
non-palpable <JJ>
cancers <NNS>
we <PRP>
reviewed <VBD>
, <,>
we <PRP>
found <VBD>
that <IN>
DNA <NNP>
characteristics <NNS>
of <IN>
small <JJ>
tumors <NNS>
are <VBP>
the <DT>
same <JJ>
as <IN>
larger <JJR>
tumors <NNS>
, <,>
'' <''>
Rubin <NNP>
said <VBD>
. <.>
A <DT>
DNA <NNP>
test <NN>
on <IN>
tissue <NN>
taken <VBN>
in <IN>
a <DT>
biopsy <NN>
can <MD>
show <VB>
if <IN>
the <DT>
cells <NNS>
are <VBP>
rapidly <RB>
dividing <VBG>
and <CC>
if <IN>
the <DT>
DNA <NNP>
has <VBZ>
more <JJR>
or <CC>
fewer <JJR>
chromosomes <NNS>
than <IN>
the <DT>
normal <JJ>
46 <CD>
. <.>
If <IN>
the <DT>
tumor <NN>
is <VBZ>
growing <VBG>
and <CC>
the <DT>
DNA <NNP>
test <NN>
is <VBZ>
abnormal <JJ>
, <,>
the <DT>
patient <NN>
's <POS>
cancer <NN>
is <VBZ>
likely <JJ>
to <TO>
be <VB>
aggressive <JJ>
, <,>
Rubin <NNP>
said <VBD>
. <.>
The <DT>
study <NN>
does <VBZ>
not <RB>
mean <VB>
that <IN>
all <DT>
patients <NNS>
with <IN>
breast <JJ>
cancer <NN>
should <MD>
have <VB>
the <DT>
DNA <NNP>
test <NN>
to <TO>
find <VB>
out <RP>
whether <IN>
the <DT>
tumor <NN>
is <VBZ>
aggressive <JJ>
, <,>
Rubin <NNP>
said <VBD>
, <,>
adding <NN>
that <IN>
more <JJR>
research <NN>
and <CC>
tests <NNS>
are <VBP>
needed <VBN>
before <IN>
recommendations <NNS>
are <VBP>
made <VBN>
. <.>
Yale_University <NNP>
researchers <NNS>
, <,>
meanwhile <RB>
, <,>
said <VBD>
they <PRP>
found <VBD>
that <IN>
a <DT>
lumpectomy <NN>
_ <NNP>
removing <NN>
a <DT>
cancerous <JJ>
tumor <NN>
and <CC>
some <DT>
surrounding <VBG>
tissue <NN>
_ <NNP>
combined <VBD>
with <IN>
radiation_therapy <NN>
can <MD>
be <VB>
a <DT>
good <JJ>
alternative <NN>
to <TO>
a <DT>
mastectomy <NN>
. <.>
Traditionally <RB>
, <,>
the <DT>
treatment <NN>
for <IN>
early <JJ>
cancer <NN>
limited <VBN>
to <TO>
the <DT>
ducts <NNS>
in <IN>
the <DT>
breast <NN>
has <VBZ>
been <VBN>
to <TO>
remove <VB>
the <DT>
breast <NN>
, <,>
said <VBD>
Dr._Bruce_Haffty <NNP>
of <IN>
Yale <NNP>
's <POS>
department <NN>
of <IN>
therapeutic <JJ>
radiology <NN>
. <.>
But <CC>
a <DT>
study <NN>
of <IN>
58 <CD>
patients <NNS>
at <IN>
New_Haven_Hospital <NNP>
shows <VBZ>
a <DT>
high <JJ>
success_rate <NN>
using <VBG>
the <DT>
less <JJR>
radical_surgical <JJ>
procedure <NN>
, <,>
he <PRP>
said <VBD>
. <.>
Only <RB>
three <CD>
of <IN>
the <DT>
patients <NNS>
had <VBD>
recurring <VBG>
cancer <NN>
. <.>
The <DT>
women <NNS>
studied_had <VBD>
received <VBN>
treatment <NN>
from <IN>
two <CD>
to <TO>
10 <CD>
years <NNS>
earlier <RBR>
. <.>
The <DT>
median <JJ>
follow-up_time <NN>
was <VBD>
four <CD>
years <NNS>
after <IN>
treatment <NN>
. <.>
`` <``>
Though <IN>
we <PRP>
feel <VBP>
it <PRP>
is <VBZ>
highly_unlikely <RB>
we <PRP>
have <VBP>
compromised <VBN>
patients <NNS>
in <IN>
using <VBG>
this <DT>
more <JJR>
conservative <JJ>
treatment <NN>
, <,>
we <PRP>
will <MD>
need <VB>
to <TO>
follow <VB>
them <PRP>
for <IN>
10 <CD>
to <TO>
20 <CD>
years <NNS>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
If <IN>
the <DT>
cancer <NN>
returns <NNS>
after <IN>
a <DT>
breast-saving <JJ>
lumpectomy <NN>
is <VBZ>
performed <VBN>
, <,>
a <DT>
mastectomy <NN>
could <MD>
still <RB>
be <VB>
an <DT>
option <NN>
, <,>
Haffty <NNP>
said <VBD>
. <.>
Some <DT>
physicians <NNS>
are <VBP>
reluctant <JJ>
to <TO>
use <VB>
the <DT>
breast-saving <JJ>
treatment <NN>
for <IN>
early <JJ>
duct_cancer <NN>
, <,>
believing <VBG>
that <IN>
the <DT>
breast <NN>
should <MD>
be <VB>
removed <VBN>
if <IN>
there <EX>
is <VBZ>
any <DT>
chance <NN>
that <IN>
the <DT>
cancer <NN>
could <MD>
recur <VB>
. <.>
The <DT>
Yale <NNP>
study <NN>
so <IN>
far <RB>
does <VBZ>
not <RB>
bear <VB>
out <RP>
this <DT>
concern <NN>
, <,>
Haffty <NNP>
said <VBD>
. <.>
`` <``>
A <DT>
main <JJ>
message <NN>
here <RB>
is <VBZ>
that <IN>
it <PRP>
's <VBZ>
important <JJ>
for <IN>
women <NNS>
to <TO>
be <VB>
screened <VBN>
by <IN>
mammography <NN>
so <IN>
these <DT>
tumors <NNS>
can <MD>
be <VB>
picked <VBN>
up <RP>
earlier <JJR>
, <,>
treated <VBN>
more <RBR>
conservatively <RB>
and <CC>
this <DT>
will <MD>
give <VB>
the <DT>
patient <NN>
a <DT>
much <RB>
better <RBR>
prognosis <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
AP890522-0155 <DOCNO>
. <.>
By <IN>
shrinking <NN>
tumors <NNS>
with <IN>
medicine <NN>
before <IN>
surgery <NN>
, <,>
doctors <NNS>
may <MD>
be <VB>
able <JJ>
to <TO>
eliminate <VB>
most <JJS>
mastectomies <NNS>
as <RB>
the <DT>
standard <JJ>
treatment <NN>
for <IN>
breast_cancer <NN>
, <,>
a <DT>
leading <VBG>
cancer_researcher <NN>
said <VBD>
Monday <NNP>
. <.>
Dr._Gianni_Bonadonna <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
of <IN>
Italy <NNP>
said <VBD>
his <PRP$>
study <NN>
showed <VBD>
that <IN>
the <DT>
new <JJ>
approach <NN>
could <MD>
eliminate <VB>
the <DT>
need <NN>
for <IN>
mastectomies <NNS>
in <IN>
87 <CD>
percent <NN>
of <IN>
women <NNS>
who <WP>
otherwise <RB>
would <MD>
have <VB>
had <VBD>
this <DT>
mutilating_surgery <NN>
. <.>
In <IN>
recent <JJ>
years <NNS>
, <,>
doctors <NNS>
have <VBP>
slowly <RB>
switched <VBN>
to <TO>
removing <NN>
just <RB>
the <DT>
lump <NN>
, <,>
not <RB>
the <DT>
whole <JJ>
breast <NN>
, <,>
when <WRB>
the <DT>
tumor <NN>
is <VBZ>
small <JJ>
. <.>
However <RB>
, <,>
this <DT>
conservative <JJ>
surgery <NN>
is <VBZ>
not_usually <RB>
considered <VBN>
possible <JJ>
when <WRB>
tumors <NNS>
are <VBP>
large <JJ>
. <.>
The <DT>
latest <JJS>
strategy <NN>
involves <NNS>
shrinking <VBG>
big <JJ>
tumors <NNS>
first <RB>
with <IN>
chemotherapy <NN>
so <IN>
they <PRP>
are <VBP>
small_enough <JJ>
to <TO>
be <VB>
taken <VBN>
out <RP>
with <IN>
a <DT>
breast-saving <JJ>
operation <NN>
called <VBN>
a <DT>
lumpectomy <NN>
, <,>
which <WDT>
generally <RB>
leaves <VBZ>
about <IN>
three-quarters <NNS>
of <IN>
the <DT>
breast <JJ>
intact <NN>
. <.>
The <DT>
chemotherapy <NN>
is <VBZ>
the <DT>
same <JJ>
as <IN>
that <DT>
commonly <RB>
used <JJ>
after <IN>
surgery <NN>
. <.>
The <DT>
procedure <NN>
was <VBD>
outlined <VBN>
by <IN>
Bonadonna <NNP>
at <IN>
the <DT>
annual <JJ>
meeting <NN>
of <IN>
the <DT>
American_Society <NNP>
of <IN>
Clinical_Oncology <NNP>
. <.>
Bonadonna <NNP>
predicted <VBD>
that_by <IN>
1994 <CD>
, <,>
the <DT>
100th <JJ>
anniversary <NN>
of <IN>
the <DT>
radical <JJ>
mastectomy <NN>
, <,>
this <DT>
common <JJ>
operation <NN>
`` <``>
will <MD>
be <VB>
very <RB>
, <,>
very <RB>
rare <JJ>
. <.>
'' <''>
Surgeons <NNS>
frequently <RB>
recommend <VBP>
against <IN>
trying <VBG>
to <TO>
spare <VB>
breasts <NNS>
containing <VBG>
larger <JJR>
tumors <NNS>
because <IN>
too_little <RB>
healthy <JJ>
tissue <NN>
is <VBZ>
left <VBN>
to <TO>
save <VB>
and <CC>
because <IN>
they <PRP>
fear <VBP>
the <DT>
cancer <NN>
will <MD>
be <VB>
more <RBR>
likely <JJ>
to <TO>
spread <VB>
to <TO>
other <JJ>
parts <NNS>
of <IN>
the <DT>
body <NN>
. <.>
So <IN>
far <RB>
, <,>
Bonadonna <NNP>
and <CC>
colleagues <NNS>
in <IN>
Italy <NNP>
have <VBP>
used <VBN>
the <DT>
new <JJ>
procedure <NN>
on <IN>
97 <CD>
patients <NNS>
beginning <VBG>
in <IN>
January <NNP>
1988 <CD>
. <.>
Although <IN>
none <NN>
of <IN>
their <PRP$>
cancers <NNS>
have <VBP>
returned <VBN>
, <,>
other <JJ>
experts <NNS>
caution <NN>
that <IN>
much <RB>
longer <RBR>
follow-up <JJ>
will <MD>
be <VB>
necessary <JJ>
to <TO>
know <VB>
whether <IN>
this <DT>
approach <NN>
is <VBZ>
as <IN>
good <JJ>
as <IN>
mastectomies <NNS>
at <IN>
saving <VBG>
lives <NNS>
. <.>
Despite <IN>
recent <JJ>
studies <NNS>
showing <VBG>
that_for <IN>
small <JJ>
tumors <NNS>
, <,>
at <IN>
least <JJS>
, <,>
breast-sparing <JJ>
surgery <NN>
appears <VBZ>
to <TO>
be <VB>
safe <JJ>
, <,>
some <DT>
physicians <NNS>
remain <VBP>
skeptical <JJ>
. <.>
`` <``>
I <PRP>
think <VBP>
there <RB>
is <VBZ>
still <RB>
a <DT>
lot <NN>
of <IN>
place <NN>
for <IN>
mastectomy <NN>
, <,>
'' <''>
because <IN>
the <DT>
chances <NNS>
of <IN>
cure <NN>
may <MD>
be <VB>
better <JJR>
, <,>
commented <VBN>
Dr._Hendre_Falkson <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Pretoria <NNP>
in <IN>
South_Africa <NNP>
. <.>
While <IN>
cautious <JJ>
, <,>
some <DT>
other <JJ>
physicians <NNS>
said <VBD>
they <PRP>
found <VBD>
Bonadonna <NNP>
's <POS>
findings <NNS>
intriguing <VBG>
. <.>
`` <``>
This <DT>
challenges <NNS>
the <DT>
conventional <JJ>
treatment <NN>
, <,>
'' <''>
said <VBD>
Dr._Nikolay_Dimitrov <NNP>
of <IN>
Michigan_State_University <NNP>
. <.>
`` <``>
It <PRP>
may <MD>
provide <VB>
a <DT>
revolutionary <JJ>
change <NN>
in <IN>
the <DT>
treatment <NN>
of <IN>
breast_cancer <NN>
. <.>
'' <''>
Added <VBN>
Dr._Jules_Harris <NNP>
of <IN>
Rush_Cancer <NNP>
in <IN>
Chicago <NNP>
: <:>
`` <``>
I <PRP>
think <VBP>
it's_interesting <JJ>
and <CC>
exciting <VBG>
and <CC>
will <MD>
give_rise <VB>
to <TO>
a <DT>
great <JJ>
deal <NN>
of <IN>
clinical <JJ>
investigation <NN>
. <.>
'' <''>
Breast <NNP>
cancer <NN>
is <VBZ>
the <DT>
leading <VBG>
cancer_killer <NN>
of <IN>
women <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
The <DT>
disease <NN>
strikes <VBZ>
one <CD>
in <IN>
10 <CD>
women <NNS>
at <IN>
some <DT>
time <NN>
during <IN>
their <PRP$>
lives <NNS>
and <CC>
caused <VBD>
42 <CD>
, <,>
000 <CD>
deaths <NNS>
last <JJ>
year <NN>
. <.>
In <IN>
Bonadonna <NNP>
's <POS>
study <NN>
, <,>
chemotherapy <NN>
was <VBD>
given <VBN>
to <TO>
women <NNS>
whose <WP$>
breast <JJ>
tumors <NNS>
were <VBD>
bigger <JJR>
than <IN>
three <CD>
centimeters <NNS>
, <,>
or <CC>
just <RB>
over <IN>
one <CD>
inch <NN>
. <.>
The <DT>
drugs <NNS>
could <MD>
bring <VB>
them <PRP>
down_below <IN>
three <CD>
centimeters <NNS>
in <IN>
87 <CD>
percent <NN>
of <IN>
the <DT>
women <NNS>
. <.>
The <DT>
largest <JJS>
tumor <NN>
was <VBD>
over <IN>
four <CD>
inches <NNS>
across <IN>
and <CC>
was <VBD>
shrunken <VBN>
small <JJ>
enough_so <RB>
doctors <NNS>
could <MD>
perform <VB>
a <DT>
lumpectomy <NN>
. <.>
The <DT>
average <JJ>
size <NN>
of <IN>
the <DT>
tumors <NNS>
before <IN>
treatment <NN>
was <VBD>
two <CD>
inches <NNS>
. <.>
After <IN>
the <DT>
operations <NNS>
, <,>
the <DT>
doctors <NNS>
treated <VBD>
the <DT>
women <NNS>
with <IN>
radiation_therapy <NN>
and <CC>
additional <JJ>
chemotherapy <NN>
AP891206-0071 <DOCNO>
. <.>
Researchers <NNS>
at <IN>
the <DT>
Pittsburgh_Cancer_Institute <NNP>
will <MD>
conduct <VB>
a <DT>
five-year <JJ>
study <NN>
of <IN>
the <DT>
rate <NN>
at <IN>
which <WDT>
some <DT>
people <NNS>
who <WP>
receive <JJ>
transplanted <VBD>
organs <NNS>
develop <VB>
cancer <NN>
. <.>
In <IN>
the <DT>
process <NN>
, <,>
the <DT>
$ <$>
5_million <CD>
study <NN>
_ <NNP>
funded <VBD>
by <IN>
the <DT>
National_Cancer_Institute__ <NNP>
may <MD>
provide <VB>
clues <NNS>
to <TO>
the <DT>
relationship <NN>
between <IN>
cancer <NN>
and <CC>
viruses <NNS>
and <CC>
the <DT>
way <NN>
in <IN>
which <WDT>
the <DT>
body <NN>
combats <NNS>
those <DT>
diseases <NNS>
, <,>
one <CD>
official <NN>
said <VBD>
Tuesday <NNP>
. <.>
`` <``>
It <PRP>
has <VBZ>
broad <JJ>
implications <NNS>
for <IN>
better <JJR>
understanding <NN>
of <IN>
mechanisms <NNS>
that <WDT>
lead <NN>
to <TO>
the <DT>
development <NN>
of <IN>
cancer <NN>
, <,>
'' <''>
said <VBD>
Dr._Theresa_Whiteside <NNP>
, <,>
director <NN>
of <IN>
the <DT>
institute <NN>
's <POS>
immunologic <JJ>
monitoring <NN>
and <CC>
diagnostic <JJ>
laboratory <NN>
and <CC>
a <DT>
professor <NN>
of <IN>
pathology <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Pittsburgh <NNP>
. <.>
About <IN>
400 <CD>
adults <NNS>
and <CC>
children <NNS>
who <WP>
have <VBP>
received <VBN>
transplants <NNS>
will <MD>
be <VB>
recruited <VBN>
to <TO>
participate <VB>
in <IN>
the <DT>
study <NN>
. <.>
Whiteside <NNP>
said <VBD>
one <CD>
of <IN>
the <DT>
most <RBS>
significant <JJ>
aspects <NNS>
of <IN>
the <DT>
study <NN>
is <VBZ>
that <IN>
researchers <NNS>
will <MD>
be <VB>
able <JJ>
to <TO>
study <NN>
a <DT>
large <JJ>
group <NN>
of <IN>
people <NNS>
, <,>
some <DT>
of <IN>
whom <WP>
they <PRP>
know <VBP>
will <MD>
develop <VB>
cancer <NN>
. <.>
It <PRP>
will <MD>
build <VB>
on <IN>
observations <NNS>
made <VBN>
in <IN>
1975 <CD>
by <IN>
Pittsburgh <NNP>
liver_transplant_pioneer <NN>
Dr._Thomas_Starzl <NNP>
, <,>
who <WP>
discovered <VBN>
when <WRB>
he <PRP>
was <VBD>
at <IN>
the <DT>
University <NNP>
of <IN>
Colorado <NNP>
that <IN>
2 <CD>
to <TO>
3 <CD>
percent <NN>
of <IN>
all <DT>
transplant <NN>
recipients <NNS>
developed <VBD>
cancer <NN>
. <.>
The <DT>
most <RBS>
common <JJ>
malignancies <NNS>
diagnosed <VBN>
among <IN>
those <DT>
patients <NNS>
were <VBD>
lymph_node_cancer <NN>
, <,>
liver <RB>
cancer <NN>
and <CC>
Kaposi <NNP>
's <POS>
sarcoma <NN>
, <,>
a <DT>
skin_cancer <NN>
also <RB>
common <JJ>
among <IN>
AIDS <NNP>
patients <NNS>
. <.>
Starzl <NNP>
, <,>
along_with <IN>
Dr._Israel_Penn <NNP>
, <,>
also <RB>
found <VBD>
that <IN>
the <DT>
risk <NN>
of <IN>
cancer <NN>
after <IN>
a <DT>
transplant <NN>
increased <VBN>
to <TO>
10 <CD>
percent <NN>
for <IN>
patients <NNS>
whose <WP$>
pre-transplant <JJ>
tests <NNS>
showed <VBD>
they <PRP>
did <VBD>
not <RB>
have <VB>
antibodies <NNS>
to <TO>
the <DT>
Epstein_Barr <NNP>
virus <VBZ>
, <,>
which <WDT>
causes <NNS>
mononucleosis <VBZ>
. <.>
About <IN>
80 <CD>
percent <NN>
of <IN>
those <DT>
patients <NNS>
become <VBP>
infected <VBN>
with <IN>
the <DT>
virus <NNS>
after <IN>
transplantation <NN>
, <,>
and <CC>
researchers <NNS>
believe <VBP>
there <RB>
is <VBZ>
some <DT>
correlation <NN>
between <IN>
that <DT>
and <CC>
the <DT>
development <NN>
of <IN>
cancer <NN>
, <,>
particularly <RB>
in <IN>
the <DT>
lymph <NN>
nodes <VBZ>
. <.>
Researchers <NNS>
also <RB>
will <MD>
try <VB>
to <TO>
determine <VB>
why <WRB>
liver_transplant <NN>
recipients <NNS>
whose <WP$>
previous <JJ>
liver <NN>
was <VBD>
removed <VBN>
because_of <IN>
cancer <NN>
often <RB>
develop <VB>
the <DT>
cancer <NN>
again <RB>
with <IN>
the <DT>
new <JJ>
organ <NN>
. <.>
In <IN>
such <JJ>
patients <NNS>
, <,>
the <DT>
cancer <NN>
does <VBZ>
not <RB>
show <VB>
up <RP>
in <IN>
other <JJ>
parts <NNS>
of <IN>
the <DT>
body <NN>
. <.>
`` <``>
We <PRP>
are <VBP>
not_even <RB>
sure <JJ>
if <IN>
it <PRP>
is <VBZ>
the <DT>
same <JJ>
cancer <NN>
that <IN>
returns <NNS>
to <TO>
the <DT>
new <JJ>
liver <NN>
or <CC>
a <DT>
new <JJ>
cancer <NN>
that <WDT>
arises <VBZ>
in <IN>
the <DT>
liver <NN>
. <.>
Nothing <NN>
is <VBZ>
known <VBN>
about <IN>
this <DT>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
The <DT>
return <NN>
of <IN>
cancer <NN>
, <,>
Whiteside <NNP>
said <VBD>
, <,>
must <MD>
have <VB>
something <NN>
to <TO>
do <VB>
with <IN>
a <DT>
person <NN>
's <POS>
immune_system <NN>
after <IN>
transplantation <NN>
or <CC>
the <DT>
immune <NN>
defenses <VBZ>
within <IN>
the <DT>
liver <NN>
itself <PRP>
. <.>
Transplant <NNP>
patients <NNS>
get <VBP>
drugs <NNS>
to <TO>
suppress <NN>
their <PRP$>
body <NN>
's <POS>
natural <JJ>
defenses <NNS>
after <IN>
surgery <NN>
to <TO>
prevent <VB>
rejection <NN>
of <IN>
the <DT>
new <JJ>
organs <NNS>
, <,>
and <CC>
the <DT>
drugs <NNS>
also <RB>
make <VBP>
the <DT>
patients <NNS>
susceptible <JJ>
to <TO>
other <JJ>
infections <NNS>
FT942-17260 <DOCNO>
. <.>
British <JJ>
scientists <NNS>
have <VBP>
developed <VBN>
an <DT>
experimental <JJ>
vaccine <NN>
for <IN>
bowel_cancer <NN>
, <,>
the <DT>
second <JJ>
most <JJS>
common <JJ>
cause <NN>
of <IN>
cancer <NN>
deaths <NNS>
in <IN>
industrialised <VBN>
countries <NNS>
. <.>
It <PRP>
is <VBZ>
being <VBG>
tested <VBN>
first <JJ>
as <IN>
a <DT>
potential <JJ>
treatment <NN>
for <IN>
patients <NNS>
with <IN>
advanced <JJ>
cancer <NN>
but <CC>
could <MD>
be <VB>
used <VBN>
eventually <RB>
as <IN>
a <DT>
preventive <JJ>
vaccine <NN>
for <IN>
people <NNS>
known <VBN>
to <TO>
be <VB>
genetically <RB>
at <IN>
risk <NN>
from <IN>
colo-rectal <JJ>
(_bowel <NN>
) <:>
cancer <NN>
. <.>
The <DT>
Cancer_Research_Campaign <NNP>
, <,>
which <WDT>
funded <VBN>
the <DT>
vaccine <NN>
's <POS>
development <NN>
at <IN>
Nottingham_University <NNP>
, <,>
said <VBD>
yesterday <NN>
: <:>
'The <DT>
first_clinical <JJ>
trials <NNS>
indicate <VBP>
impressive <JJ>
results <NNS>
in <IN>
patients <NNS>
. <.>
' <POS>
ImClone <NN>
Systems <NNS>
, <,>
a <DT>
New_York <NNP>
biotechnology_company <NN>
, <,>
has <VBZ>
signed <VBN>
an <DT>
exclusive <JJ>
worldwide_licensing_agreement <NN>
with <IN>
the <DT>
CRC <NNP>
for <IN>
commercial <JJ>
development <NN>
of <IN>
Vaccine <NNP>
105AD7 <CD>
, <,>
as <IN>
it <PRP>
is <VBZ>
known <VBN>
. <.>
ImClone <NN>
is <VBZ>
a <DT>
leader <NN>
in <IN>
the <DT>
fast-growing <JJ>
research_field <NN>
of <IN>
cancer <NN>
vaccines <NNS>
; <:>
it <PRP>
is <VBZ>
also <RB>
testing <VBG>
vaccines <NNS>
for <IN>
lung <JJ>
cancer <NN>
and <CC>
melanoma <NN>
. <.>
Dr_Lindy_Durrant <NNP>
and <CC>
Dr_Adrian_Robbins <NNP>
, <,>
who <WP>
developed <VBD>
105AD7 <CD>
at <IN>
Nottingham <NNP>
, <,>
said <VBD>
it <PRP>
not_only <RB>
had <VBD>
the <DT>
potential <JJ>
to <TO>
prevent <VB>
bowel_cancer <NN>
or <CC>
stop <VB>
the <DT>
disease <NN>
progressing <VBG>
, <,>
but <CC>
also <RB>
had <VBD>
the <DT>
advantage <NN>
of <IN>
producing <VBG>
no <DT>
toxic <JJ>
side-effects <NNS>
- <:>
unlike_conventional <JJ>
treatments <NNS>
. <.>
The <DT>
encouraging <NN>
first <RB>
results <NNS>
came <VBD>
from <IN>
tests <NNS>
on <IN>
a <DT>
dozen <NN>
patients <NNS>
with <IN>
advanced <JJ>
bowel_cancer <NN>
; <:>
they <PRP>
will <MD>
be <VB>
published <VBN>
next <JJ>
week <NN>
. <.>
The <DT>
CRC <NNP>
is <VBZ>
now <RB>
organising <VBG>
a <DT>
larger <JJR>
clinical <JJ>
trial <NN>
, <,>
based <VBN>
at <IN>
Nottingham <NNP>
, <,>
with <IN>
350 <CD>
patients <NNS>
, <,>
and <CC>
ImClone <NNP>
will <MD>
carry <VB>
out <RP>
an <DT>
extensive <JJ>
trial <NN>
in <IN>
the <DT>
US <NNP>
. <.>
Even <RB>
if <IN>
the <DT>
new <JJ>
vaccine <NN>
continues <VBZ>
to <TO>
perform <NN>
well <RB>
, <,>
it <PRP>
is <VBZ>
unlikely <RB>
to <TO>
be <VB>
approved <VBN>
as <IN>
a <DT>
commercial <JJ>
treatment <NN>
of <IN>
bowel_cancer <NN>
before <IN>
1997 <CD>
. <.>
Its <PRP$>
use <NN>
in <IN>
preventive <JJ>
vaccination <NN>
might <MD>
then <RB>
follow <VB>
four <CD>
years <NNS>
later <RBR>
. <.>
There <EX>
are <VBP>
several <JJ>
ways <NNS>
in <IN>
which <WDT>
researchers <NNS>
are <VBP>
planning <VBG>
to <TO>
use <VB>
vaccines <NNS>
to <TO>
prevent <VB>
cancer <NN>
. <.>
One <CD>
is <VBZ>
the <DT>
indirect <JJ>
approach <NN>
- <:>
immunising <VBG>
people <NNS>
against <IN>
viruses <NNS>
, <,>
such <JJ>
as <IN>
Epstein_Barr <NNP>
, <,>
which <WDT>
are <VBP>
associated <VBN>
with <IN>
certain <JJ>
cancers <NNS>
. <.>
The <DT>
CRC-ImClone_approach <NN>
, <,>
on <IN>
the <DT>
other <JJ>
hand <NN>
, <,>
is <VBZ>
aimed <VBN>
directly <RB>
at <IN>
tumour <PRP$>
cells <NNS>
. <.>
Vaccine <NNP>
105AD7 <CD>
is <VBZ>
designed <VBN>
to <TO>
mimic <JJ>
a <DT>
particular <JJ>
part <NN>
of <IN>
the <DT>
cell_surface <NN>
. <.>
This <DT>
primes <VBZ>
the <DT>
patient <NN>
's <POS>
immune_system <NN>
to <TO>
recognise <VB>
and <CC>
attack <VB>
the <DT>
cancer <NN>
cells <NNS>
themselves <PRP>
. <.>
Every <DT>
year <NN>
more <JJR>
than <IN>
28 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
UK <NNP>
are <VBP>
diagnosed <VBN>
as <IN>
having_bowel_cancer <NN>
. <.>
Only <RB>
9 <CD>
, <,>
000 <CD>
will <MD>
be <VB>
alive <JJ>
five <CD>
years <NNS>
later <RBR>
. <.>
In <IN>
the <DT>
US <NNP>
, <,>
the <DT>
disease <NN>
kills <NNS>
55 <CD>
, <,>
000 <CD>
people <NNS>
a <DT>
year <NN>
. <.>
'Bowel <JJ>
cancer <NN>
is <VBZ>
the <DT>
second <JJ>
most <JJS>
common <JJ>
cause <NN>
of <IN>
cancer_death <NN>
in <IN>
the <DT>
west <NN>
, <,>
' <''>
said <VBD>
Prof_Gordon_McVie <NNP>
, <,>
CRC <NNP>
scientific <JJ>
director <NN>
FBIS3-22640 <DOCNO>
. <.>
Language <NN>
: <:>
English <JJ>
Article_Type <NNP>
: <:>
CSO <NNP>
[ <:>
Text <NNP>
] <:>
Varanasi <NNP>
, <,>
Jan <NNP>
28 <CD>
-- <:>
There <EX>
are <VBP>
about <IN>
1.7_million <CD>
cancer <NN>
patients <NNS>
in <IN>
India <NNP>
and <CC>
about <IN>
30 <CD>
, <,>
000 <CD>
to <TO>
35 <CD>
, <,>
000 <CD>
people <NNS>
die <VB>
annually <RB>
from <IN>
this <DT>
disease <NN>
, <,>
a <DT>
medical <JJ>
expert <NN>
warned <VBD>
today <NN>
. <.>
Dr._S.P <NNP>
. <.>
Kohli <NNP>
, <,>
Deputy_Director_General <NNP>
, <,>
Ministry <NNP>
of <IN>
Health <NNP>
told <VBD>
the <DT>
first_international <JJ>
conference <NN>
of <IN>
the <DT>
Indian_Association <NNP>
of <IN>
Alliative_Care <NNP>
here <RB>
that <IN>
cancer <NN>
is <VBZ>
no <DT>
longer <NN>
a <DT>
problem <NN>
of <IN>
developed <VBN>
countries <NNS>
but <CC>
a <DT>
matter <NN>
of <IN>
concern <NN>
for <IN>
developing <VBG>
countries <NNS>
also <RB>
. <.>
She <PRP>
said <VBD>
the <DT>
problem <NN>
had <VBD>
acquired <VBN>
greater <JJR>
magnitude <NN>
due <JJ>
to <TO>
an <DT>
increase <NN>
in <IN>
life_expectancy <NN>
resulting <VBG>
in <IN>
a <DT>
greater <JJR>
ratio <NN>
of <IN>
old <JJ>
people <NNS>
in <IN>
the <DT>
population <NN>
, <,>
increase <NN>
in <IN>
population <NN>
, <,>
improved <VBN>
life_style <NN>
as <IN>
well <RB>
as <IN>
modernisation <NN>
. <.>
In <IN>
India <NNP>
, <,>
breast <JJ>
, <,>
cervix <NN>
and <CC>
uterus <VBZ>
cancer <NN>
was <VBD>
most <JJS>
common <JJ>
in <IN>
women <NNS>
while <IN>
men <NNS>
were <VBD>
more <JJR>
prone <NN>
to <TO>
mouth <VB>
, <,>
larynx <NN>
and <CC>
lung <JJ>
cancer <NN>
. <.>
These <DT>
types <NNS>
of <IN>
cancer <NN>
were <VBD>
tobacco-related <JJ>
and <CC>
could <MD>
be <VB>
prevented <VBN>
by <IN>
proper_education <NN>
, <,>
creating <VBG>
awareness <NN>
and <CC>
stopping <VBG>
tobacco_intake <NN>
. <.>
Lung <NNP>
cancer <NN>
was <VBD>
nearly <RB>
nine <CD>
times <NNS>
more <JJR>
common <JJ>
in <IN>
smokers <NNS>
than_in <IN>
non-smokers <NNS>
, <,>
Dr._Kohli <NNP>
said <VBD>
. <.>
Considering <VBG>
this <DT>
, <,>
the <DT>
Union_Government <NNP>
had <VBD>
chalked <VBN>
out <RP>
a <DT>
plan <NN>
of <IN>
action <NN>
for <IN>
prevention <NN>
of <IN>
cancer <NN>
at <IN>
an <DT>
early <JJ>
stage <NN>
, <,>
prevention <NN>
of <IN>
tobacco_intake <NN>
in <IN>
any <DT>
form <NN>
, <,>
early <RB>
diagnosis <VBZ>
of <IN>
cancer <NN>
specially <RB>
in <IN>
cervic <JJ>
, <,>
breast <JJ>
and <CC>
mouth <NN>
. <.>
She <PRP>
said <VBD>
that <IN>
it <PRP>
was <VBD>
most <JJS>
unfortunate <JJ>
that <IN>
most <JJS>
of <IN>
the <DT>
cancer <NN>
patients <NNS>
in <IN>
India <NNP>
reported <VBD>
at <IN>
a <DT>
very <RB>
advanced <VBN>
stage <NN>
in <IN>
hospitals <NNS>
and <CC>
regional <JJ>
cancer <NN>
centres <NNS>
, <,>
rendering <VBG>
the <DT>
therapy_ineffective <NN>
. <.>
She <PRP>
suggested <VBD>
that_since <IN>
there <EX>
were <VBD>
more <JJR>
advanced <VBN>
cancer <NN>
cases <NNS>
in <IN>
India <NNP>
, <,>
Palliative <NNP>
therapy <NN>
should <MD>
be <VB>
provided <VBN>
to <TO>
such <JJ>
patients <NNS>
effectively <RB>
. <.>
In <IN>
India <NNP>
, <,>
30 <CD>
percent <NN>
of <IN>
the <DT>
cancer <NN>
cases <NNS>
could <MD>
not <RB>
be <VB>
treated <VBN>
with <IN>
active <JJ>
therapy <NN>
and <CC>
`` <``>
we <PRP>
could <MD>
provide <VB>
only <RB>
palliative <JJ>
therapy <NN>
in <IN>
such <JJ>
cases <NNS>
, <,>
'' <''>
Dr._Kohli <NNP>
said <VBD>
. <.>
Cancer_pain <NN>
is <VBZ>
not <RB>
an <DT>
imitable <JJ>
part <NN>
of <IN>
cancer <NN>
, <,>
contrary <JJ>
to <TO>
common <JJ>
belief <NN>
. <.>
Little <RB>
is <VBZ>
done <VBN>
to <TO>
alleviate <VB>
pain <NN>
simply <RB>
due <JJ>
to <TO>
inadequacy <NN>
of <IN>
medical <JJ>
education <NN>
in <IN>
cancer_pain_therapy <NN>
, <,>
she <PRP>
said <VBD>
. <.>
Medical <JJ>
students <NNS>
were <VBD>
taught <VBN>
to <TO>
treat <VB>
cancer <NN>
but <CC>
not <RB>
cancer_pain <NN>
. <.>
She <PRP>
suggested <VBD>
introduction <NN>
of <IN>
pain_relief <NN>
and <CC>
palliative <JJ>
care_education <NN>
at <IN>
undergraduate <NN>
and <CC>
post-graduate <JJ>
teaching_level <NN>
. <.>
The <DT>
Union_Government <NNP>
had <VBD>
started <VBN>
producing <VBG>
oral <JJ>
morphine <NN>
in <IN>
collaboration <NN>
with <IN>
the <DT>
World_Health_Organisation <NNP>
directly <RB>
to <TO>
10 <CD>
identified_regional <JJ>
cancer <NN>
centres <NNS>
. <.>
There <EX>
was <VBD>
a <DT>
proposal <NN>
to <TO>
provide <VB>
oral <JJ>
morphine <NN>
to <TO>
other <JJ>
teaching_government <NN>
medical <JJ>
institutions <NNS>
, <,>
too <RB>
. <.>
She <PRP>
said <VBD>
that <IN>
morphine <NN>
was <VBD>
the <DT>
cheapest <JJS>
and <CC>
most <JJS>
effective <JJ>
pain_killer <NN>
in <IN>
cancer <NN>
. <.>
Pain <NNP>
could <MD>
be <VB>
minimised <VBN>
in <IN>
80 <CD>
to <TO>
98 <CD>
percent <NN>
of <IN>
cancer <NN>
cases <NNS>
if <IN>
right <JJ>
drug <NN>
in <IN>
right_dose <NN>
and <CC>
at <IN>
right_time <NN>
was <VBD>
given <VBN>
, <,>
she <PRP>
said <VBD>
AP890927-0030 <DOCNO>
. <.>
A <DT>
genetic <JJ>
abnormality <NN>
that <WDT>
appears <VBZ>
to <TO>
play <VB>
a <DT>
role <NN>
in <IN>
many_common <JJ>
cancers <NNS>
has <VBZ>
been <VBN>
solidly <RB>
linked <VBN>
to <TO>
lung <VB>
cancer <NN>
, <,>
raising <VBG>
hopes <NNS>
of <IN>
improved <VBN>
diagnosis <NN>
and <CC>
treatment <NN>
, <,>
scientists <NNS>
say <VBP>
. <.>
Researchers <NNS>
examining <VBG>
lung_cancer <NN>
tumors <NNS>
discovered <VBN>
a <DT>
series <NN>
of <IN>
abnormalities <NNS>
in <IN>
the <DT>
so-called <JJ>
p53 <NNP>
anti-cancer_gene <NN>
, <,>
according <VBG>
to <TO>
a <DT>
report <NN>
Tuesday <NNP>
by <IN>
Dr._John_Minna <NNP>
of <IN>
the <DT>
National_Cancer_Institute-Navy_Medical_Oncology_Branch <NNP>
in <IN>
Bethesda <NNP>
, <,>
Md <NNP>
. <.>
Defects <NNS>
in <IN>
the <DT>
gene <NN>
also <RB>
have <VBP>
been_linked <VBN>
to <TO>
colon <VB>
cancer <NN>
, <,>
to <TO>
an <DT>
uncommon_bone_cancer <NN>
called <VBN>
osteogenic <JJ>
sarcoma <NN>
and <CC>
to <TO>
chronic_myelogenous <JJ>
leukemia <NN>
, <,>
Minna <NNP>
said <VBD>
. <.>
`` <``>
Obviously <RB>
, <,>
everybody <NN>
is <VBZ>
going <VBG>
to <TO>
be <VB>
looking <VBG>
for <IN>
it <PRP>
in <IN>
everything <NN>
else <RB>
, <,>
'' <''>
Minna <NNP>
said <VBD>
. <.>
Bert_Vogelstein <NNP>
of <IN>
Johns_Hopkins_University <NNP>
in <IN>
Baltimore <NNP>
, <,>
who <WP>
identified <VBD>
p53 <NNP>
abnormalities <NNS>
in <IN>
colon_cancer <NN>
, <,>
said <VBD>
: <:>
`` <``>
From <IN>
what <WP>
I <PRP>
've <VBP>
heard <RB>
of <IN>
Dr._Minna <NNP>
's <POS>
work <NN>
, <,>
it <PRP>
seems <VBZ>
quite <RB>
clear <JJ>
that <IN>
the <DT>
p53 <NNP>
gene <NN>
will <MD>
play <VB>
an <DT>
important <JJ>
role <NN>
in <IN>
lung <NN>
tumors <NNS>
. <.>
`` <``>
Current <JJ>
evidence <NN>
suggests <VBZ>
that <IN>
p53 <NNP>
is <VBZ>
likely <JJ>
to <TO>
play <VB>
a <DT>
role <NN>
in <IN>
many_common <JJ>
cancers <NNS>
, <,>
'' <''>
including <VBG>
breast_cancer <NN>
, <,>
ovarian <JJ>
cancer <NN>
and <CC>
bladder_cancer <NN>
, <,>
he <PRP>
said <VBD>
. <.>
During <IN>
the <DT>
past_few <JJ>
years <NNS>
, <,>
researchers <NNS>
have <VBP>
found <VBN>
indirect <JJ>
evidence <NN>
that <IN>
defects <NNS>
in_at <IN>
least <JJS>
six <CD>
genes <NNS>
can <MD>
contribute <VB>
to <TO>
lung <VB>
cancer <NN>
, <,>
which <WDT>
afflicts <NNS>
an <DT>
estimated <VBN>
150 <CD>
, <,>
000 <CD>
Americans <NNS>
a <DT>
year <NN>
. <.>
The <DT>
new <JJ>
study <NN>
has <VBZ>
pinpointed <VBN>
chemical <JJ>
changes <NNS>
in <IN>
one <CD>
of <IN>
those <DT>
genes <NNS>
. <.>
That <DT>
should <MD>
be <VB>
useful <JJ>
for <IN>
identifying <NN>
people <NNS>
at <IN>
high <JJ>
risk <NN>
of <IN>
getting <VBG>
lung_cancer <NN>
, <,>
or <CC>
for <IN>
predicting <NN>
how <WRB>
deadly <RB>
a <DT>
particular <JJ>
case <NN>
of <IN>
lung_cancer <NN>
will <MD>
be <VB>
, <,>
Minna <NNP>
said <VBD>
. <.>
`` <``>
One_thing <NN>
you <PRP>
could <MD>
do <VB>
would <MD>
be <VB>
to <TO>
take <VB>
people <NNS>
's <POS>
tumors <NNS>
, <,>
see <VBP>
how <WRB>
many <JJ>
( <:>
genetic <JJ>
) <NN>
lesions <NNS>
they <PRP>
have <VBP>
, <,>
and <CC>
determine <NN>
how <WRB>
virulent <NN>
they <PRP>
are <VBP>
, <,>
'' <''>
Minna <NNP>
said <VBD>
Tuesday <NNP>
in <IN>
a <DT>
telephone_interview <NN>
from <IN>
Toronto <NNP>
, <,>
where <WRB>
he <PRP>
presented <VBD>
his <PRP$>
findings <NNS>
at <IN>
the <DT>
Bristol-Myers <NNS>
Cancer_Research_Symposium <NNP>
. <.>
Vogelstein <NNP>
has <VBZ>
found <VBN>
that <IN>
the <DT>
more <RBR>
genetic <JJ>
abnormalities <NNS>
a <DT>
colon_cancer_tumor <NN>
has <VBZ>
, <,>
the <DT>
more <RBR>
virulent <JJ>
it <PRP>
is <VBZ>
, <,>
Minna <NNP>
said <VBD>
. <.>
Minna <NNP>
said <VBD>
he <PRP>
is <VBZ>
beginning <VBG>
studies <NNS>
to <TO>
determine <VB>
if <IN>
the <DT>
same <JJ>
thing <NN>
is <VBZ>
true <JJ>
in <IN>
lung <JJ>
cancer <NN>
. <.>
Determination <NN>
of <IN>
a <DT>
tumor <NN>
's <POS>
virulence <NN>
could <MD>
lead <VB>
to <TO>
better <JJR>
decisions <NNS>
on <IN>
treatment <NN>
, <,>
he <PRP>
said <VBD>
. <.>
Minna <NNP>
also <RB>
said <VBD>
screening <VBG>
for <IN>
genetic <JJ>
abnormalities <NNS>
in <IN>
people <NNS>
who <WP>
do <VBP>
n't <RB>
have <VB>
lung <VBN>
cancer <NN>
could <MD>
reveal <VB>
those <DT>
who <WP>
are <VBP>
about <IN>
to <TO>
get <VB>
cancer <NN>
_ <NNP>
that <IN>
is <VBZ>
, <,>
people <NNS>
who <WP>
have <VBP>
some <DT>
, <,>
but <CC>
not <RB>
all <DT>
, <,>
of <IN>
the <DT>
genetic <JJ>
changes <NNS>
needed <VBN>
to <TO>
produce <VB>
a <DT>
tumor <NN>
. <.>
Such <JJ>
people <NNS>
could <MD>
be <VB>
followed <VBN>
closely <RB>
for <IN>
the <DT>
appearance <NN>
of <IN>
tumors <NNS>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
protein <NN>
made <VBD>
by <IN>
the <DT>
p53 <NNP>
gene <NN>
, <,>
located <VBN>
on <IN>
chromosome <NN>
17 <CD>
, <,>
normally <RB>
protects <VBZ>
the <DT>
body <NN>
against <IN>
cancer <NN>
. <.>
If <IN>
the <DT>
protein <NN>
is <VBZ>
defective <JJ>
, <,>
the <DT>
protective <JJ>
effect <NN>
is <VBZ>
lost <VBN>
and <CC>
one <CD>
step <NN>
has <VBZ>
been_taken <VBN>
toward <IN>
the <DT>
formation <NN>
of <IN>
a <DT>
tumor <NN>
, <,>
Minna <NNP>
explained <VBD>
. <.>
The <DT>
gene <NN>
is <VBZ>
called <VBN>
an <DT>
anti-cancer_gene <NN>
because <IN>
it <PRP>
normally <RB>
protects <VBZ>
against <IN>
cancer <NN>
. <.>
Minna <NNP>
said <VBD>
that_although <IN>
only <RB>
six <CD>
genetic <JJ>
abnormalities <NNS>
have <VBP>
so_far <RB>
been_linked <VBN>
to <TO>
lung <VB>
cancer <NN>
, <,>
there <EX>
may <MD>
be <VB>
as <RB>
many <JJ>
as <IN>
10 <CD>
or <CC>
20 <CD>
. <.>
Most <JJS>
of <IN>
the <DT>
evidence <NN>
for <IN>
the <DT>
six <CD>
abnormalities <NNS>
already <RB>
found <VBN>
consists <NNS>
of <IN>
studies <NNS>
with <IN>
genetic <JJ>
`` <``>
signposts <NNS>
'' <''>
called <VBN>
restriction_fragment_length <NN>
polymorphisms <NNS>
. <.>
These <DT>
studies <NNS>
show <VBP>
the <DT>
approximate_location <NN>
of <IN>
the <DT>
abnormalities <NNS>
on <IN>
chromosomes <NNS>
, <,>
but <CC>
do <VBP>
not <RB>
reveal <VB>
precisely <RB>
what <WDT>
the <DT>
abnormalities <NNS>
are <VBP>
. <.>
The <DT>
p53 <NNP>
gene <NN>
is <VBZ>
the <DT>
second <JJ>
anti-cancer_gene <NN>
to <TO>
be <VB>
carefully <RB>
studied <VBN>
, <,>
Minna <NNP>
said <VBD>
. <.>
The <DT>
first <JJ>
was <VBD>
a <DT>
gene <NN>
identified <VBD>
in <IN>
retinoblastoma <NN>
, <,>
a <DT>
rare <NN>
children <NNS>
's <POS>
eye_cancer <NN>
. <.>
The <DT>
retinoblastoma_gene <NN>
also <RB>
was <VBD>
shown <VBN>
recently <RB>
to <TO>
be <VB>
important <JJ>
in <IN>
lung <JJ>
cancer <NN>
, <,>
Minna <NNP>
said <VBD>
LA100490-0179 <DOCNO>
. <.>
Chemotherapy <NNP>
undergone <NN>
before <IN>
radiation_treatment <NN>
doubled <VBD>
the <DT>
survival_rate <NN>
of <IN>
a <DT>
group <NN>
of <IN>
patients <NNS>
with <IN>
the <DT>
most <RBS>
common <JJ>
type <NN>
of <IN>
inoperable <JJ>
lung_cancer <NN>
, <,>
according <VBG>
to <TO>
a <DT>
national <JJ>
study <NN>
released <VBN>
today <NN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
Of <IN>
the <DT>
patients <NNS>
who <WP>
underwent <NN>
only <RB>
radiation_therapy <NN>
, <,>
11 <CD>
% <NN>
survived <VBD>
three <CD>
years <NNS>
after <IN>
treatment <NN>
, <,>
contrasted <VBD>
with <IN>
23 <CD>
% <NN>
who <WP>
underwent <NN>
five <CD>
weeks <NNS>
of <IN>
chemotherapy <NN>
followed <VBN>
by <IN>
six <CD>
weeks <NNS>
of <IN>
daily <JJ>
radiation_therapy <NN>
, <,>
according <VBG>
to <TO>
the <DT>
lead_author <NN>
of <IN>
the <DT>
study <NN>
, <,>
Dr._Robert_O._Dillman <NNP>
, <,>
medical <JJ>
director <NN>
of <IN>
the <DT>
Hoag_Cancer_Center <NNP>
in <IN>
Newport_Beach <NNP>
. <.>
`` <``>
The <DT>
good <JJ>
news <NN>
is <VBZ>
that <IN>
just <RB>
by <IN>
adding <NN>
that <IN>
little <JJ>
bit <NN>
of <IN>
chemotherapy <NN>
, <,>
there <EX>
was <VBD>
a <DT>
doubling <NN>
in <IN>
the <DT>
survival_rate <NN>
, <,>
'' <''>
Dillman <NNP>
said <VBD>
. <.>
`` <``>
The <DT>
bad <JJ>
news <NN>
is <VBZ>
that <IN>
still <RB>
did <VBD>
n't <RB>
help <VB>
about <IN>
75 <CD>
% <NN>
of <IN>
the <DT>
patients <NNS>
. <.>
`` <``>
Dr._John_Glaspy <NNP>
, <,>
director <NN>
of <IN>
UCLA <NNP>
's <POS>
joint <JJ>
oncology <NN>
clinic <JJ>
, <,>
said <VBD>
the <DT>
study <NN>
proves <VBZ>
there <EX>
are <VBP>
benefits <NNS>
to <TO>
chemotherapy <VB>
. <.>
But <CC>
he <PRP>
noted <VBD>
that <IN>
even <RB>
the <DT>
improved <VBN>
survival <NN>
rates <NNS>
in <IN>
the <DT>
study <NN>
were <VBD>
not <RB>
good <JJ>
. <.>
`` <``>
The <DT>
big <JJ>
point <NN>
to <TO>
the <DT>
reader <NN>
is <VBZ>
, <,>
you <PRP>
'd <MD>
better <VB>
quit_smoking <NN>
-- <:>
quick <JJ>
, <,>
'' <''>
Glaspy <NNP>
said <VBD>
. <.>
`` <``>
Because <IN>
these <DT>
big <JJ>
breakthroughs <NNS>
are <VBP>
changing <VBG>
survival <NN>
rates <NNS>
by <IN>
four <CD>
months <NNS>
( <:>
on <IN>
average <JJ>
) <NN>
, <,>
and <CC>
that <IN>
ai <NN>
n't_much <RB>
. <.>
`` <``>
The <DT>
three-year <JJ>
study <NN>
began <VBD>
in <IN>
1984 <CD>
and <CC>
examined <VBD>
155 <CD>
patients <NNS>
with <IN>
inoperable_non-small-cell <JJ>
lung_cancer <NN>
, <,>
which <WDT>
affects <NNS>
as <IN>
many <JJ>
as <IN>
40 <CD>
, <,>
000 <CD>
Americans <NNS>
, <,>
Dillman <NNP>
said <VBD>
. <.>
It <PRP>
was <VBD>
sponsored <VBN>
by <IN>
the <DT>
National_Cancer_Institute <NNP>
and <CC>
conducted <VBD>
by <IN>
a <DT>
cooperative <JJ>
group <NN>
of <IN>
oncologists <NNS>
from <IN>
Hoag <NNP>
, <,>
Massachusetts_General_Hospital <NNP>
in <IN>
Boston <NNP>
, <,>
Dartmouth_College <NNP>
in <IN>
New_Hampshire <NNP>
, <,>
UC_San_Diego_Medical_Center <NNP>
, <,>
McGill_University <NNP>
in <IN>
Montreal <NNP>
and <CC>
the <DT>
University <NNP>
of <IN>
Missouri <NNP>
in <IN>
Columbia <NNP>
. <.>
Patients <NNS>
with <IN>
this <DT>
kind <NN>
of <IN>
inoperable <JJ>
cancer <NN>
were <VBD>
given <VBN>
a <DT>
five-week <JJ>
course <NN>
of <IN>
chemotherapy <NN>
-- <:>
two <CD>
doses <NNS>
of <IN>
the <DT>
drug_cisplatin <NN>
and <CC>
five <CD>
doses <NNS>
of <IN>
vinblastine <NN>
. <.>
The <DT>
duration <NN>
was <VBD>
short <JJ>
enough_so <RB>
that <IN>
patients <NNS>
were <VBD>
able <JJ>
to <TO>
tolerate <VB>
the <DT>
side <NN>
effects <NNS>
of <IN>
the <DT>
chemotherapy <NN>
and <CC>
still <RB>
benefit <JJ>
from <IN>
radiation_treatment <NN>
, <,>
Dillman <NNP>
said <VBD>
. <.>
This <DT>
was <VBD>
followed <VBN>
by <IN>
six <CD>
weeks <NNS>
of <IN>
daily <JJ>
treatments <NNS>
of <IN>
high-dose <JJ>
radiation_therapy <NN>
, <,>
concentrated <VBD>
on <IN>
the <DT>
chest_area <NN>
where <WRB>
the <DT>
cancer <NN>
was <VBD>
visible <JJ>
, <,>
Dillman <NNP>
said <VBD>
. <.>
Major <NNP>
tumor_shrinkage <NN>
was <VBD>
seen <VBN>
in <IN>
44 <CD>
% <NN>
of <IN>
the <DT>
patients <NNS>
who <WP>
got <VBD>
both <DT>
chemotherapy <NN>
and <CC>
radiation <NN>
, <,>
contrasted <VBD>
with <IN>
35 <CD>
% <NN>
in <IN>
patients <NNS>
who <WP>
received <VBN>
only <RB>
radiation <NN>
, <,>
the <DT>
study <NN>
said <VBD>
. <.>
After <IN>
one <CD>
year <NN>
of <IN>
treatment <NN>
, <,>
55 <CD>
% <NN>
of <IN>
those <DT>
who <WP>
underwent <NN>
chemotherapy <VBP>
and <CC>
radiation_therapy <NN>
survived <VBD>
, <,>
contrasted <VBN>
with <IN>
40 <CD>
% <NN>
among <IN>
the <DT>
radiation-only <JJ>
group <NN>
. <.>
Three <CD>
years <NNS>
after <IN>
treatment <NN>
, <,>
23 <CD>
% <NN>
of <IN>
the <DT>
chemotherapy-radiation_group <NN>
had <VBD>
survived <VBN>
, <,>
contrasted <VBN>
with <IN>
11 <CD>
% <NN>
for <IN>
the <DT>
radiation-only <JJ>
group <NN>
. <.>
The <DT>
three-year <JJ>
study <NN>
was <VBD>
followed <VBN>
by <IN>
three <CD>
more <JJR>
years <NNS>
of <IN>
tracking <VBG>
the <DT>
patients <NNS>
and <CC>
analyzing <VBG>
the <DT>
data <NNS>
, <,>
Dillman <NNP>
said <VBD>
. <.>
At <IN>
last <JJ>
count <NN>
, <,>
three <CD>
of <IN>
the <DT>
chemotherapy- <JJ>
radiation <NN>
patients <NNS>
were <VBD>
still <RB>
alive <JJ>
more <JJR>
than <IN>
four <CD>
years <NNS>
after <IN>
treatment <NN>
. <.>
Two <CD>
were <VBD>
from <IN>
Massachusetts_General_Hospital <NNP>
and <CC>
one <CD>
from <IN>
McGill_University <NNP>
. <.>
A <DT>
confirming_study <NN>
sponsored <VBD>
by <IN>
the <DT>
National_Cancer_Institute <NNP>
is <VBZ>
under <IN>
way <NN>
across <IN>
the <DT>
country <NN>
. <.>
Dillman <NNP>
said <VBD>
the <DT>
key <JJ>
finding <NN>
is <VBZ>
that <IN>
chemotherapy <NN>
, <,>
especially <RB>
in <IN>
earlier <JJR>
stages <NNS>
, <,>
is <VBZ>
more <RBR>
effective <JJ>
in <IN>
lung_cancer <NN>
than <IN>
many <JJ>
doctors <NNS>
realize <VBP>
. <.>
`` <``>
Most <RBS>
patients <NNS>
with <IN>
lung <JJ>
cancer <NN>
are <VBP>
diagnosed <VBN>
by <IN>
family <NN>
practitioners <NNS>
or <CC>
general <JJ>
internists <NNS>
, <,>
and <CC>
they <PRP>
often <RB>
have <VBP>
their <PRP$>
initial <JJ>
care <NN>
and <CC>
treatment <NN>
decisions <NNS>
made <VBN>
by <IN>
those <DT>
physicians <NNS>
, <,>
'' <''>
Dillman <NNP>
said <VBD>
. <.>
`` <``>
We <PRP>
know <VBP>
now <RB>
that_if <IN>
we <PRP>
wait <VBP>
until <IN>
( <NNP>
final <JJ>
stages <NNS>
of <IN>
lung <JJ>
cancer <NN>
) <:>
then <RB>
chemotherapy <JJ>
is <VBZ>
really_too <RB>
late <JJ>
. <.>
Patients <NNS>
will <MD>
have <VB>
severe <JJ>
side <NN>
effects <NNS>
, <,>
wo <MD>
n't <RB>
tolerate <VB>
the <DT>
therapy <NN>
, <,>
and <CC>
it <PRP>
wo <MD>
n't <RB>
help <VB>
. <.>
WSJ910425-0087 <DOCNO>
`` <``>
Moreover <RB>
, <,>
the <DT>
blood_test <NN>
may <MD>
make <VB>
preventive <JJ>
exams <NNS>
much <RB>
more <RBR>
common <JJ>
because <IN>
it <PRP>
is <VBZ>
more <RBR>
acceptable <JJ>
to <TO>
many <JJ>
patients <NNS>
than <IN>
rectal <JJ>
exams <NNS>
. <.>
Some <DT>
researchers <NNS>
urge <VBP>
that <IN>
the <DT>
blood_test <NN>
be <VB>
used <VBN>
for <IN>
early <JJ>
detection <NN>
of <IN>
prostate_cancer <NN>
, <,>
much <RB>
as <IN>
mammograms <NNS>
are <VBP>
used <VBN>
to <TO>
screen <VB>
for <IN>
breast <JJ>
cancer <NN>
in <IN>
women <NNS>
. <.>
`` <``>
It <PRP>
's <VBZ>
a <DT>
valuable_new <JJ>
tool <NN>
for <IN>
diagnosing_prostate_cancer <NN>
, <,>
an <DT>
area <NN>
where <WRB>
we <PRP>
're <VBP>
not <RB>
doing <VBG>
very_well <RB>
, <,>
'' <''>
says <VBZ>
William_J._Catalona <NNP>
, <,>
chief <NN>
of <IN>
urologic <JJ>
surgery <NN>
at <IN>
Washington_University_School <NNP>
of <IN>
Medicine <NNP>
and <CC>
Barnes_Hospital <NNP>
, <,>
St._Louis <NNP>
. <.>
He <PRP>
says <VBZ>
all <DT>
men <NNS>
age <NN>
50 <CD>
and <CC>
over <IN>
should <MD>
have <VB>
annual <JJ>
blood <NN>
tests <NNS>
to <TO>
check <VB>
for <IN>
prostate <JJ>
cancer <NN>
. <.>
He <PRP>
and <CC>
his <PRP$>
colleagues <NNS>
report <NN>
on <IN>
the <DT>
test <NN>
in <IN>
today <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
But <CC>
doctors <NNS>
are <VBP>
divided <VBN>
over <IN>
how <WRB>
effective <JJ>
any <DT>
broad <JJ>
screening_program <NN>
might <MD>
be <VB>
. <.>
It <PRP>
is <VBZ>
n't <RB>
known <VBN>
, <,>
for <IN>
instance <NN>
, <,>
whether <IN>
early <JJ>
detection <NN>
of <IN>
the <DT>
disease <NN>
will <MD>
lead <VB>
to <TO>
treatments <NNS>
that <IN>
actually <RB>
prolong <JJ>
life <NN>
. <.>
Moreover <RB>
, <,>
some <DT>
studies <NNS>
based <VBN>
on <IN>
autopsies <NNS>
show <VBP>
that <IN>
more <JJR>
than <IN>
30 <CD>
% <NN>
of <IN>
men <NNS>
over <IN>
50 <CD>
have <VBP>
evidence <NN>
of <IN>
prostate <JJ>
cancer <NN>
that <WDT>
remains <VBZ>
latent <NN>
and <CC>
never <RB>
causes <NNS>
clinical <JJ>
problems <NNS>
. <.>
Some <DT>
researchers <NNS>
worry <VBP>
that <IN>
screening <VBG>
programs <NNS>
might <MD>
pick <VB>
up <RP>
many <JJ>
of <IN>
these <DT>
men <NNS>
. <.>
`` <``>
The <DT>
detection <NN>
of <IN>
such <JJ>
tumors_exposes <NNS>
these <DT>
patients <NNS>
to <TO>
the <DT>
risks <NNS>
of <IN>
treatment <NN>
without <IN>
any <DT>
potential <JJ>
for <IN>
benefit <NN>
, <,>
'' <''>
Gerald_W._Chodak <NNP>
and <CC>
Glenn_S._Gerber <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Chicago_School <NNP>
of <IN>
Medicine <NNP>
said <VBD>
last <JJ>
month <NN>
in <IN>
the <DT>
Journal <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
About <IN>
100 <CD>
, <,>
000 <CD>
cases <NNS>
of <IN>
prostate <JJ>
cancer <NN>
are <VBP>
diagnosed <VBN>
in <IN>
the <DT>
U.S. <NNP>
each <DT>
year <NN>
, <,>
and <CC>
about <IN>
30 <CD>
, <,>
000 <CD>
men <NNS>
die <VB>
annually <RB>
of <IN>
the <DT>
disease <NN>
. <.>
One <CD>
in <IN>
10 <CD>
men <NNS>
will <MD>
develop <VB>
the <DT>
cancer <NN>
at <IN>
some <DT>
point <NN>
; <:>
the <DT>
risk <NN>
increases <NNS>
with <IN>
age <NN>
, <,>
and <CC>
among <IN>
men <NNS>
with <IN>
other <JJ>
family <NN>
members <NNS>
with <IN>
the <DT>
disease <NN>
. <.>
Remedies <NNS>
include <VBP>
surgical <JJ>
removal <NN>
of <IN>
the <DT>
prostate <NN>
as <IN>
well <RB>
as <IN>
hormonal <JJ>
and <CC>
radiation <NN>
treatments <NNS>
and <CC>
chemotherapy <NN>
. <.>
One <CD>
big <JJ>
reason <NN>
the <DT>
disease <NN>
often <RB>
goes <VBZ>
undetected <VBN>
until <IN>
it <PRP>
has <VBZ>
spread <VBN>
, <,>
Dr._Catalona <NNP>
says <VBZ>
, <,>
is <VBZ>
that <IN>
`` <``>
most <RBS>
men <NNS>
are <VBP>
reluctant <JJ>
to <TO>
have <VB>
a <DT>
rectal <JJ>
exam <NN>
'' <''>
unless <IN>
they <PRP>
already <RB>
have <VBP>
symptoms <NNS>
. <.>
But <CC>
most <JJS>
people <NNS>
readily <RB>
accept <JJ>
blood <NN>
tests <NNS>
for <IN>
cholesterol <NN>
levels <NNS>
, <,>
for <IN>
instance <NN>
, <,>
and <CC>
he <PRP>
thinks <VBZ>
that <IN>
the <DT>
blood_test <NN>
will <MD>
make <VB>
preventive <JJ>
exams <NNS>
much <RB>
more <RBR>
acceptable <JJ>
for <IN>
prostate <JJ>
cancer <NN>
. <.>
But <CC>
, <,>
he <PRP>
emphasized <VBD>
, <,>
`` <``>
the <DT>
test <NN>
is <VBZ>
not <RB>
a <DT>
substitute <NN>
-- <:>
it <PRP>
should <MD>
be <VB>
used <VBN>
in <IN>
combination <NN>
with <IN>
a <DT>
rectal <JJ>
exam <NN>
. <.>
`` <``>
Nor <CC>
is <VBZ>
it <PRP>
perfect <VBP>
. <.>
It <PRP>
is <VBZ>
only <RB>
an <DT>
indicator <NN>
of <IN>
problems <NNS>
-- <:>
a <JJ>
biopsy <NN>
is <VBZ>
required <VBN>
to <TO>
determine <VB>
whether <IN>
cancer <NN>
is <VBZ>
present <JJ>
-- <:>
and <CC>
it <PRP>
misses <VBZ>
some <DT>
abnormalities <NNS>
that <WDT>
show <NN>
up <RP>
in <IN>
rectal <JJ>
exams <NNS>
or <CC>
with <IN>
ultrasound <NN>
, <,>
another <DT>
diagnostic <JJ>
tool <NN>
. <.>
In <IN>
the <DT>
study <NN>
, <,>
it <PRP>
missed <VBD>
20 <CD>
% <NN>
of <IN>
the <DT>
cancers <NNS>
that <WDT>
were <VBD>
present <NN>
and <CC>
showed <VBD>
false <NN>
positives <NNS>
in <IN>
16 <CD>
% <NN>
of <IN>
cases <NNS>
-- <:>
a <DT>
significant <JJ>
error_rate <NN>
that <WDT>
lends <VBZ>
support <NN>
to <TO>
those <DT>
who <WP>
say <VBP>
the <DT>
evidence <NN>
does <VBZ>
n't <RB>
back <VB>
up <RP>
a <DT>
broad <JJ>
screening_effort <NN>
. <.>
Nearly <RB>
2 <CD>
, <,>
000 <CD>
men <NNS>
were <VBD>
included <VBN>
in <IN>
the <DT>
study <NN>
, <,>
financed <VBN>
in <IN>
part <NN>
by <IN>
Hybritech_Inc. <NNP>
, <,>
a <DT>
San_Diego <NNP>
, <,>
Calif. <NNP>
, <,>
company <NN>
that <WDT>
makes <VBZ>
the <DT>
blood_test <NN>
. <.>
The <DT>
test <NN>
is <VBZ>
used <VBN>
to <TO>
monitor <NN>
the <DT>
progress <NN>
of <IN>
prostate_cancer <NN>
, <,>
and <CC>
some <DT>
doctors <NNS>
already <RB>
use <VBP>
it <PRP>
in <IN>
diagnosis <NN>
. <.>
Researchers <NNS>
took <VBD>
blood <NN>
tests <NNS>
of <IN>
1 <CD>
, <,>
653 <CD>
healthy <JJ>
men <NNS>
over <IN>
50 <CD>
, <,>
with <IN>
no <DT>
evidence <NN>
of <IN>
cancer <NN>
or <CC>
benign_prostate_disease <NN>
, <,>
and <CC>
measured <VBD>
levels <NNS>
of <IN>
prostate-specific <JJ>
antigen <NN>
, <,>
or <CC>
PSA <NNP>
, <,>
a <DT>
protein <NN>
produced <VBN>
by <IN>
prostate <NN>
cells <NNS>
. <.>
PSA <NNP>
is <VBZ>
produced <VBN>
in <IN>
greater <JJR>
quantity <NN>
as <IN>
the <DT>
prostate <NN>
increases <NNS>
in <IN>
size <NN>
, <,>
indicating <VBG>
that <IN>
cancer <NN>
may <MD>
be <VB>
present <VBN>
. <.>
Results <NNS>
were <VBD>
compared <VBN>
with <IN>
those <DT>
for <IN>
300 <CD>
men <NNS>
who <WP>
had <VBD>
undergone <VBN>
biopsies <NNS>
to <TO>
examine <VB>
abnormal <JJ>
prostate_tissue <NN>
and <CC>
who <WP>
served <VBN>
as <IN>
experimental <JJ>
controls <NNS>
. <.>
The <DT>
researchers <NNS>
found <VBD>
that <IN>
92 <CD>
% <NN>
of <IN>
the <DT>
1 <CD>
, <,>
653 <CD>
men <NNS>
in <IN>
the <DT>
study <NN>
had <VBD>
normal <JJ>
PSA <NNP>
levels <NNS>
; <:>
6 <CD>
% <NN>
, <,>
or <CC>
107 <CD>
men <NNS>
, <,>
had <VBD>
mildly <RB>
elevated <VBN>
levels <NNS>
; <:>
and <CC>
2 <CD>
% <NN>
, <,>
or <CC>
30 <CD>
, <,>
had <VBD>
high <JJ>
levels <NNS>
. <.>
Overall <JJ>
, <,>
112 <CD>
men <NNS>
had <VBD>
biopsies <NNS>
, <,>
of <IN>
whom <WP>
37 <CD>
, <,>
or <CC>
33 <CD>
% <NN>
had <VBD>
cancer <NN>
. <.>
A <DT>
high <JJ>
PSA <NNP>
level <NN>
was <VBD>
a <DT>
major <JJ>
predictor <NN>
of <IN>
cancer <NN>
: <:>
22 <CD>
% <NN>
of <IN>
men <NNS>
with <IN>
mildly <RB>
elevated <VBN>
levels <NNS>
, <,>
and <CC>
67 <CD>
% <NN>
of <IN>
those <DT>
with <IN>
high <JJ>
levels <NNS>
, <,>
had <VBD>
cancer <NN>
. <.>
Men <NNS>
with <IN>
elevated <JJ>
PSA <NNP>
but <CC>
no <DT>
cancer <NN>
had <VBD>
benign <VBN>
prostate_disease <NN>
or <CC>
inflammation <NN>
of <IN>
the <DT>
gland <NN>
. <.>
The <DT>
researchers <NNS>
said <VBD>
that_among <IN>
the <DT>
37 <CD>
men <NNS>
with <IN>
cancer <NN>
, <,>
a <DT>
rectal <JJ>
exam_alone <NN>
missed <VBD>
12 <CD>
, <,>
or <CC>
one-third <NN>
, <,>
of <IN>
the <DT>
cancers <NNS>
. <.>
Ultrasound <NNP>
alone <RB>
missed <VBD>
43 <CD>
% <NN>
, <,>
they <PRP>
said <VBD>
. <.>
The <DT>
blood_test <NN>
`` <``>
is <VBZ>
not <RB>
going <VBG>
to <TO>
detect <VB>
every <DT>
prostate_cancer <NN>
out <IN>
there <EX>
, <,>
'' <''>
Dr._Catalona <NNP>
said <VBD>
, <,>
`` <``>
but <CC>
it <PRP>
will <MD>
be <VB>
a <DT>
lot_better <NN>
than <IN>
it <PRP>
is <VBZ>
now <RB>
. <.>
`` <``>
He <PRP>
said <VBD>
that_if <IN>
widely <RB>
used <VBN>
, <,>
perhaps <RB>
seven <CD>
in <IN>
10 <CD>
cases <NNS>
could <MD>
be <VB>
detected <VBN>
before <IN>
they <PRP>
spread <VBP>
beyond <IN>
the <DT>
prostate <NN>
itself <PRP>
. <.>
Though <IN>
he <PRP>
acknowledged <VBD>
that <IN>
no <DT>
study <NN>
has <VBZ>
proved <VBN>
early <RB>
detection <NN>
will <MD>
prolong <VB>
life <NN>
, <,>
prostate <JJ>
tumors <NNS>
, <,>
like <IN>
those <DT>
in <IN>
the <DT>
breast <NN>
in <IN>
women <NNS>
, <,>
grow <NN>
relatively_slowly <RB>
-- <:>
meaning <VBG>
early <RB>
treatment <NN>
has <VBZ>
a <DT>
chance <NN>
to <TO>
be <VB>
more <JJR>
effective <JJ>
. <.>
`` <``>
Logic <NNP>
tells <VBZ>
you <PRP>
that <IN>
the <DT>
reason_prostate_cancer <NN>
is <VBZ>
a <DT>
major <JJ>
killer <NN>
is <VBZ>
because <IN>
it <PRP>
's <VBZ>
picked <VBN>
up <RP>
late <JJ>
, <,>
'' <''>
he <PRP>
says <VBZ>
. <.>
The <DT>
National_Cancer_Institute <NNP>
plans <VBZ>
a <DT>
major <JJ>
study <NN>
of <IN>
the <DT>
effectiveness <NN>
of <IN>
screening <VBG>
and <CC>
early <RB>
treatment <NN>
, <,>
but <CC>
results <NNS>
wo <MD>
n't <RB>
be <VB>
known <VBN>
until <IN>
late <JJ>
in <IN>
the <DT>
next <JJ>
decade <NN>
AP900110-0062 <DOCNO>
. <.>
Rose_Kushner <NNP>
, <,>
a <DT>
medical <JJ>
writer <NN>
and <CC>
psychologist <NN>
and <CC>
forceful <JJ>
advocate <NN>
for <IN>
women <NNS>
with <IN>
breast <JJ>
cancer <NN>
, <,>
has <VBZ>
died <VBN>
of <IN>
the <DT>
disease <NN>
at <IN>
age <NN>
60 <CD>
. <.>
Kushner <NNP>
, <,>
who <WP>
resided <VBN>
in <IN>
Kensington <NNP>
, <,>
Md. <NNP>
, <,>
died <VBD>
Sunday <NNP>
, <,>
The_New_York_Times <NNP>
reported <VBD>
today <NN>
. <.>
She <PRP>
gained <VBD>
national <JJ>
fame <NN>
in <IN>
1975 <CD>
, <,>
with <IN>
the <DT>
publication <NN>
of <IN>
`` <``>
Why <WRB>
Me <NNP>
? <.>
What <WP>
Every <DT>
Woman_Should_Know_About_Breast_Cancer <NNP>
to <TO>
Save_Her_Life <NNP>
, <,>
'' <''>
an <DT>
account <NN>
of <IN>
her <PRP$>
own <JJ>
battle <NN>
with <IN>
the <DT>
disease <NN>
. <.>
Breast <NNP>
cancer <NN>
specialists <NNS>
initially <RB>
rejected <VBD>
many <JJ>
of <IN>
the <DT>
steps <NNS>
she <PRP>
advocated <VBD>
, <,>
including <VBG>
less <JJR>
radical <JJ>
surgery <NN>
, <,>
which <WDT>
now <RB>
are <VBP>
common <JJ>
. <.>
Kushner <NNP>
focused <VBD>
her <PRP>
energies <NNS>
on <IN>
the <DT>
breast_cancer_crusade <NN>
in <IN>
1974 <CD>
, <,>
when <WRB>
she <PRP>
discovered <VBD>
a <DT>
lump <NN>
in <IN>
her <PRP$>
breast <NN>
but <CC>
refused <VBD>
to <TO>
submit <VB>
to <TO>
the <DT>
then-routine <JJ>
`` <``>
one-step <JJ>
'' <''>
procedure <NN>
. <.>
In <IN>
the <DT>
mid-70s <JJ>
, <,>
a <DT>
woman <NN>
undergoing <VBG>
treatment <NN>
would <MD>
be <VB>
anesthetized <VBN>
, <,>
the <DT>
lump <NN>
removed <VBD>
for <IN>
biopsy <NN>
, <,>
and <CC>
, <,>
if <IN>
malignant <JJ>
, <,>
the <DT>
breast <NN>
would <MD>
be <VB>
removed <VBN>
. <.>
The <DT>
patient <NN>
would <MD>
not <RB>
know <VB>
until <IN>
she <PRP>
awoke <VBP>
whether <IN>
the <DT>
breast <JJ>
was <VBD>
gone <VBN>
. <.>
Kushner <NNP>
fought <VBD>
against <IN>
the <DT>
one-step <JJ>
procedure <NN>
, <,>
arguing <VBG>
that <IN>
women <NNS>
needed <VBD>
time <NN>
after <IN>
a <DT>
diagnosis <NN>
to <TO>
find <VB>
the <DT>
best <JJS>
surgeon <NN>
. <.>
After <IN>
18 <CD>
phone <NN>
calls <NNS>
, <,>
she <PRP>
finally <RB>
found <VBD>
a <DT>
general <JJ>
surgeon <NN>
who <WP>
would <MD>
remove <VB>
just <RB>
the <DT>
lump <NN>
. <.>
Now <RB>
, <,>
the <DT>
one-step <JJ>
procedure <NN>
is <VBZ>
no <DT>
longer <NN>
used <VBN>
. <.>
`` <``>
She <PRP>
is <VBZ>
probably <RB>
the <DT>
single <JJ>
most <JJS>
important <JJ>
person <NN>
in <IN>
leading <VBG>
to <TO>
this <DT>
major <JJ>
change <NN>
in <IN>
breast_surgery <NN>
, <,>
'' <''>
Dr._Bruce_A._Chabner <NNP>
once <RB>
said <VBD>
. <.>
Chabner <NNP>
is <VBZ>
the <DT>
director <NN>
of <IN>
the <DT>
division <NN>
of <IN>
cancer_treatment <NN>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
in <IN>
Bethesda <NNP>
, <,>
Md <NNP>
. <.>
`` <``>
I <PRP>
do <VBP>
n't <RB>
think <VB>
the <DT>
public <NN>
would <MD>
have <VB>
accepted <VBN>
it <PRP>
or <CC>
even <RB>
known <VBN>
about <IN>
it <PRP>
if <IN>
she <PRP>
had <VBD>
not <RB>
been <VBN>
so <RB>
persistent <JJ>
in <IN>
her <PRP$>
efforts <NNS>
. <.>
'' <''>
Kushner <NNP>
founded <VBD>
and <CC>
was <VBD>
director <NN>
of <IN>
the <DT>
Breast_Cancer_Advisory_Center <NNP>
, <,>
through <IN>
which <WDT>
she <PRP>
provided <VBD>
women <NNS>
with <IN>
information <NN>
about <IN>
their <PRP$>
options <NNS>
when <WRB>
faced <VBN>
with <IN>
the <DT>
disease <NN>
. <.>
This <DT>
year <NN>
, <,>
she <PRP>
was <VBD>
scheduled <VBN>
to <TO>
be <VB>
awarded <VBN>
the <DT>
James_Ewing <NNP>
award <NN>
from <IN>
the <DT>
Society <NNP>
of <IN>
Surgical_Oncology <NNP>
for <IN>
the <DT>
outstanding <JJ>
contribution <NN>
by <IN>
a <DT>
non-physician <JJ>
to <TO>
the <DT>
fight <NN>
against <IN>
cancer <NN>
. <.>
Her <PRP$>
husband <NN>
, <,>
Harvey_Kushner <NNP>
, <,>
called <VBN>
this <DT>
`` <``>
poetic <JJ>
justice <NN>
. <.>
'' <''>
In <IN>
1975 <CD>
the <DT>
society <NN>
's <POS>
members <NNS>
had <VBD>
booed <VBN>
her <PRP$>
off <NN>
the <DT>
stage <NN>
after <IN>
she <PRP>
challenged <VBD>
their <PRP$>
standard <JJ>
procedures <NNS>
. <.>
Kushner <NNP>
is <VBZ>
survived <VBN>
by <IN>
her <PRP$>
husband <NN>
; <:>
her <PRP$>
sons <NNS>
, <,>
Gantt <NNP>
of <IN>
Silver_Spring <NNP>
, <,>
Md <NNP>
, <,>
and <CC>
Todd <NNP>
of <IN>
Rockville_Md <NNP>
. <.>
; <:>
a <DT>
daughter <NN>
, <,>
Lesley_Kushner <NNP>
of <IN>
San_Francisco <NNP>
, <,>
and <CC>
three <CD>
brothers <NNS>
WSJ891031-0047 <DOCNO>
. <.>
Medical <JJ>
scientists <NNS>
are <VBP>
starting <VBG>
to <TO>
uncover <VB>
a <DT>
handful <NN>
of <IN>
genes <NNS>
which <WDT>
, <,>
if <IN>
damaged <JJ>
, <,>
unleash <NN>
the <DT>
chaotic <JJ>
growth <NN>
of <IN>
cells <NNS>
that <WDT>
characterizes <VBZ>
cancer <NN>
. <.>
Scientists <NNS>
say <VBP>
the <DT>
discovery <NN>
of <IN>
these <DT>
genes <NNS>
in <IN>
recent <JJ>
months <NNS>
is <VBZ>
painting <VBG>
a <DT>
new <JJ>
and <CC>
startling <JJ>
picture <NN>
of <IN>
how <WRB>
cancer <NN>
develops <NNS>
. <.>
An <DT>
emerging <VBG>
understanding <NN>
of <IN>
the <DT>
genes <NNS>
is <VBZ>
expected <VBN>
to <TO>
produce <VB>
an <DT>
array <NN>
of <IN>
new <JJ>
strategies <NNS>
for <IN>
future <JJ>
cancer_treatment <NN>
and <CC>
prevention <NN>
. <.>
That <DT>
is <VBZ>
for <IN>
the <DT>
future <NN>
. <.>
Already <RB>
, <,>
scientists <NNS>
are <VBP>
developing <VBG>
tests <NNS>
based <VBN>
on <IN>
the <DT>
newly <RB>
identified <VBD>
genes <NNS>
that <IN>
, <,>
for <IN>
the <DT>
first <JJ>
time <NN>
, <,>
can <MD>
predict <VB>
whether <IN>
an <DT>
otherwise <NN>
healthy_individual <JJ>
is <VBZ>
likely <JJ>
to <TO>
get <VB>
cancer <NN>
. <.>
`` <``>
It <PRP>
's <VBZ>
a <DT>
super-exciting <JJ>
set <NN>
of <IN>
discoveries <NNS>
, <,>
'' <''>
says <VBZ>
Bert_Vogelstein <NNP>
, <,>
a <DT>
Johns_Hopkins_University <NNP>
researcher <NN>
who <WP>
has <VBZ>
just <RB>
found <VBN>
a <DT>
gene_pivotal <NN>
to <TO>
the <DT>
triggering <NN>
of <IN>
colon_cancer <NN>
. <.>
`` <``>
Only <RB>
a <DT>
decade <NN>
ago <IN>
cancer <NN>
was <VBD>
a <DT>
black <JJ>
box <NN>
about <IN>
which <WDT>
we <PRP>
knew <VBD>
nothing <NN>
at <IN>
the <DT>
molecular <JJ>
level <NN>
. <.>
Today <NN>
, <,>
we <PRP>
know <VBP>
that <IN>
the <DT>
accumulation <NN>
of <IN>
several <JJ>
of <IN>
these <DT>
altered <VBN>
genes <NNS>
can <MD>
initiate <VB>
a <DT>
cancer <NN>
and <CC>
, <,>
then <RB>
, <,>
propel <NN>
it <PRP>
into <IN>
a <DT>
deadly <RB>
state <NN>
. <.>
`` <``>
Scientists <NNS>
call <VBP>
the <DT>
new <JJ>
class <NN>
of <IN>
genes_tumor-suppressors <NNS>
, <,>
or <CC>
simply <RB>
anti-cancer <JJ>
genes <NNS>
. <.>
When <WRB>
functioning <VBG>
normally <RB>
, <,>
they <PRP>
make <VBP>
proteins <NNS>
that <IN>
hold <JJ>
a <DT>
cell <NN>
's <POS>
growth <NN>
in <IN>
check <NN>
. <.>
But <CC>
if <IN>
the <DT>
genes <NNS>
are <VBP>
damaged <VBN>
-- <:>
perhaps <RB>
by <IN>
radiation <NN>
, <,>
a <DT>
chemical <JJ>
or <CC>
through <IN>
a <DT>
chance_accident <NN>
in <IN>
cell_division <NN>
-- <:>
their <PRP$>
growth-suppressing <JJ>
proteins <NNS>
no <DT>
longer_work <NN>
, <,>
and <CC>
cells <NNS>
normally <RB>
under <IN>
control_turn_malignant <NN>
. <.>
The <DT>
newly <RB>
identified <VBD>
genes <NNS>
differ <VBP>
from <IN>
a <DT>
family <NN>
of <IN>
genes <NNS>
discovered <VBN>
in <IN>
the <DT>
early <JJ>
1980s <CD>
called <VBN>
oncogenes <NNS>
. <.>
Oncogenes <NNS>
must <MD>
be <VB>
present <JJ>
for <IN>
a <DT>
cell <NN>
to <TO>
become <VB>
malignant <JJ>
, <,>
but <CC>
researchers <NNS>
have <VBP>
found <VBN>
them <PRP>
in <IN>
normal <JJ>
as <IN>
well <RB>
as_in <IN>
cancerous <JJ>
cells <NNS>
, <,>
suggesting <VBG>
that <IN>
oncogenes <NNS>
do <VBP>
n't <RB>
cause <VB>
cancer <NN>
by <IN>
themselves <PRP>
. <.>
In <IN>
recent <JJ>
months <NNS>
, <,>
researchers <NNS>
have <VBP>
come <VBN>
to <TO>
believe <VB>
the <DT>
two <CD>
types <NNS>
of <IN>
cancer <NN>
genes <NNS>
work <VBP>
in <IN>
concert <NN>
: <:>
An <DT>
oncogene <NN>
may <MD>
turn <VB>
proliferating <VBG>
cells <NNS>
malignant <JJ>
only <RB>
after <IN>
the <DT>
tumor-suppressor <JJ>
gene <NN>
has <VBZ>
been_damaged <VBN>
. <.>
Like <IN>
all <DT>
genes <NNS>
, <,>
tumor-suppressor <JJ>
genes <NNS>
are <VBP>
inherited <VBN>
in <IN>
two <CD>
copies <NNS>
, <,>
one <CD>
from <IN>
each <DT>
parent <NN>
. <.>
Either <DT>
copy <NN>
can <MD>
make <VB>
the <DT>
proteins <NNS>
needed <VBD>
to <TO>
control_cell_growth <NN>
, <,>
so <RB>
for <IN>
cancer <NN>
to <TO>
arise <VB>
, <,>
both <DT>
copies <NNS>
must <MD>
be <VB>
impaired <VBN>
. <.>
A <DT>
person <NN>
who <WP>
is <VBZ>
born <VBN>
with <IN>
one <CD>
defective <JJ>
copy <NN>
of <IN>
a <DT>
suppressor_gene <NN>
, <,>
or <CC>
in <IN>
whom <WP>
one <CD>
copy <NN>
is <VBZ>
damaged <VBN>
early <RB>
in <IN>
life <NN>
, <,>
is <VBZ>
especially <RB>
prone <VBN>
to <TO>
cancer <NN>
because <IN>
he <PRP>
need <VBP>
only <RB>
lose <JJ>
the <DT>
other <JJ>
copy <NN>
for <IN>
a <DT>
cancer <NN>
to <TO>
develop <VB>
. <.>
Emerging <VBG>
genetic <JJ>
tests <NNS>
will <MD>
be <VB>
able <JJ>
to <TO>
spot <NN>
such_cancer-susceptible <JJ>
individuals <NNS>
, <,>
ushering <VBG>
in <IN>
what <WP>
some <DT>
scientists <NNS>
believe <VBP>
is <VBZ>
a <DT>
new <JJ>
age <NN>
of <IN>
predictive <JJ>
cancer_diagnosis <NN>
. <.>
Bill <NNP>
and <CC>
Bonnie_Quinlan <NNP>
are <VBP>
among <IN>
the <DT>
first <JJ>
beneficiaries <NNS>
of <IN>
the <DT>
new <JJ>
findings <NNS>
. <.>
The <DT>
Dedham <NNP>
, <,>
Mass. <NNP>
, <,>
couple <NN>
knew <VBD>
even <RB>
before <IN>
Bonnie <NNP>
became <VBD>
pregnant <JJ>
in <IN>
1987 <CD>
that <WDT>
any <DT>
child <NN>
of <IN>
theirs <NNS>
had <VBD>
a <DT>
50 <CD>
%_chance <NN>
of <IN>
being <VBG>
at <IN>
risk <NN>
for <IN>
retinoblastoma <NN>
, <,>
an <DT>
eye_cancer <NN>
that <WDT>
occurs <VBZ>
about <IN>
once <RB>
every <DT>
20 <CD>
, <,>
000 <CD>
births <NNS>
. <.>
Mr._Quinlan <NNP>
, <,>
30 <CD>
years <NNS>
old <JJ>
, <,>
knew <JJ>
he <PRP>
carried <VBD>
a <DT>
damaged <JJ>
gene <NN>
, <,>
having <VBG>
lost <NN>
an <DT>
eye <NN>
to <TO>
the <DT>
rare_tumor <NN>
when <WRB>
he <PRP>
was <VBD>
only <RB>
two <CD>
months <NNS>
old <JJ>
-- <:>
after <IN>
his <PRP$>
mother <NN>
had <VBD>
suffered <VBN>
the <DT>
same <JJ>
fate <NN>
when <WRB>
she <PRP>
was <VBD>
a <DT>
baby <NN>
. <.>
Because_of <IN>
the <DT>
isolation <NN>
of <IN>
the <DT>
retinoblastoma_tumor-suppressor_gene <NN>
, <,>
it <PRP>
became <VBD>
possible_last <JJ>
January <NNP>
to <TO>
find <VB>
out <RP>
what <WP>
threat <NN>
the <DT>
Quinlan <NNP>
baby <NN>
faced <VBD>
. <.>
A <DT>
test <NN>
using <VBG>
new <JJ>
`` <``>
genetic <JJ>
probes <NNS>
'' <''>
showed <VBD>
that <IN>
little <JJ>
Will_Quinlan <NNP>
had <VBD>
not <RB>
inherited <VBN>
a <DT>
damaged <JJ>
retinoblastoma_supressor_gene <NN>
and <CC>
, <,>
therefore <RB>
, <,>
faced <VBN>
no <DT>
more <RBR>
risk <JJ>
than <IN>
other <JJ>
children <NNS>
of <IN>
developing <VBG>
the <DT>
rare_cancer <NN>
. <.>
`` <``>
It <PRP>
made <VBD>
our <PRP$>
New_Year <NNP>
, <,>
'' <''>
says <VBZ>
Mr._Quinlan <NNP>
. <.>
This <DT>
test <NN>
was <VBD>
the <DT>
first <JJ>
to <TO>
predict <VB>
reliably <RB>
whether <IN>
an <DT>
individual <NN>
could <MD>
expect <VB>
to <TO>
develop <VB>
cancer <NN>
. <.>
Equally <RB>
important <JJ>
, <,>
the <DT>
initial <JJ>
discovery <NN>
of <IN>
the <DT>
gene <NN>
that <IN>
controls <NNS>
retinal <JJ>
cell_growth <NN>
, <,>
made <VBN>
by <IN>
a <DT>
Boston <NNP>
doctor <NN>
named <VBD>
Thaddeus_Dryja <NNP>
, <,>
has <VBZ>
opened <VBN>
a <DT>
field <NN>
of <IN>
cancer_study <NN>
, <,>
which <WDT>
in <IN>
recent <JJ>
months <NNS>
has <VBZ>
exploded <VBN>
. <.>
`` <``>
It <PRP>
turns <VBZ>
out <RP>
that <IN>
studying <VBG>
a <DT>
tragic <JJ>
but <CC>
uncommon <JJ>
tumor <NN>
made <VBD>
possible <JJ>
some <DT>
fundamental <JJ>
insights <NNS>
about <IN>
the <DT>
most <RBS>
basic <JJ>
workings <NNS>
of <IN>
cancer <NN>
, <,>
'' <''>
says <VBZ>
Samuel_Broder <NNP>
, <,>
director <NN>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
`` <``>
All_this <DT>
may <MD>
not <RB>
be <VB>
obvious <JJ>
to <TO>
the <DT>
public <NN>
, <,>
which <WDT>
is <VBZ>
concerned <VBN>
about <IN>
advances <NNS>
in <IN>
treatment <NN>
, <,>
but <CC>
I <PRP>
am <VBP>
convinced <VBN>
this <DT>
basic <JJ>
research <NN>
will <MD>
begin <VB>
showing <NN>
results <NNS>
there <EX>
soon <RB>
. <.>
`` <``>
To <TO>
date <NN>
, <,>
scientists <NNS>
have <VBP>
fingered <VBN>
two <CD>
of <IN>
these <DT>
cancer-suppressors <NNS>
. <.>
Dr._Dryja <NNP>
made <VBD>
his <PRP$>
retinoblastoma_discovery <NN>
in <IN>
1986 <CD>
. <.>
Then <RB>
last <JJ>
spring <NN>
, <,>
researchers <NNS>
reported <VBD>
finding <VBG>
a <DT>
gene <NN>
called <VBN>
p53 <NNP>
which <WDT>
, <,>
if <IN>
impaired <VBN>
, <,>
turns <VBZ>
healthy <JJ>
colon <NN>
cells <NNS>
cancerous <JJ>
. <.>
Soon <RB>
after <IN>
that <DT>
report <NN>
, <,>
two <CD>
other <JJ>
research <NN>
teams <NNS>
uncovered <VBD>
evidence <NN>
that <IN>
the <DT>
same_damaged <JJ>
p53 <NNP>
gene <NN>
is <VBZ>
present <JJ>
in <IN>
tissue <NN>
from <IN>
lung <JJ>
and <CC>
breast <JJ>
cancers <NNS>
. <.>
Colon <NNP>
, <,>
lung <JJ>
and <CC>
breast <JJ>
cancers <NNS>
are <VBP>
the <DT>
most <RBS>
common <JJ>
and <CC>
lethal <JJ>
forms <NNS>
of <IN>
the <DT>
disease <NN>
, <,>
collectively <RB>
killing <VBG>
almost <RB>
200 <CD>
, <,>
000 <CD>
Americans <NNS>
a <DT>
year <NN>
. <.>
Right_now <RB>
about <IN>
a <DT>
dozen <NN>
laboratories <NNS>
, <,>
in <IN>
the <DT>
U.S. <NNP>
, <,>
Canada <NNP>
and <CC>
Britain <NNP>
, <,>
are <VBP>
racing <VBG>
to <TO>
unmask <VB>
other <JJ>
suspected <VBN>
tumor-suppressing <JJ>
genes <NNS>
. <.>
They <PRP>
have <VBP>
about <IN>
seven <CD>
candidates <NNS>
. <.>
Researchers <NNS>
say <VBP>
the <DT>
inactivation <NN>
of <IN>
tumor-suppressor <JJ>
genes <NNS>
, <,>
alone <RB>
or <CC>
in <IN>
combination <NN>
, <,>
appears <VBZ>
crucial <JJ>
to <TO>
the <DT>
development <NN>
of <IN>
such <JJ>
scourges <NNS>
as <IN>
cancer <NN>
of <IN>
the <DT>
brain <NN>
, <,>
the <DT>
skin <NN>
, <,>
kidney <NN>
, <,>
prostate <JJ>
, <,>
and <CC>
cervix <NN>
. <.>
There <EX>
is <VBZ>
evidence <NN>
that_if <IN>
people <NNS>
inherit <VBP>
defective <JJ>
versions <NNS>
of <IN>
these <DT>
genes <NNS>
, <,>
they <PRP>
are <VBP>
especially <RB>
prone <JJ>
to <TO>
cancer <NN>
, <,>
perhaps <RB>
explaining <VBG>
, <,>
finally <RB>
, <,>
why <WRB>
some <DT>
cancers <NNS>
seem <VBP>
to <TO>
haunt <VB>
certain <JJ>
families <NNS>
. <.>
The <DT>
story <NN>
of <IN>
tumor-suppressor <JJ>
genes <NNS>
goes <VBZ>
back <RB>
to <TO>
the <DT>
1970s <CD>
, <,>
when <WRB>
a <DT>
pediatrician <NN>
named <VBN>
Alfred_G._Knudson_Jr. <NNP>
proposed <VBD>
that <IN>
retinoblastoma <NN>
stemmed <VBD>
from <IN>
two <CD>
separate_genetic <JJ>
defects <NNS>
. <.>
He <PRP>
theorized <VBD>
that_in <IN>
the <DT>
eye_cancer <NN>
, <,>
an <DT>
infant <JJ>
inherited <VBN>
a <DT>
damaged <JJ>
copy <NN>
of <IN>
a <DT>
gene <NN>
from <IN>
one <CD>
parent <NN>
and <CC>
a <DT>
normal <JJ>
copy <NN>
from <IN>
the <DT>
other <JJ>
. <.>
The <DT>
tumor <NN>
, <,>
he <PRP>
suggested <VBD>
, <,>
developed <VBN>
when <WRB>
the <DT>
second <JJ>
, <,>
normal <JJ>
copy <NN>
also <RB>
was <VBD>
damaged <VBN>
. <.>
But <CC>
there <EX>
was <VBD>
no <DT>
way <NN>
to <TO>
prove <VB>
Dr._Knudson <NNP>
's <POS>
`` <``>
two-hit <JJ>
'' <''>
theory <NN>
. <.>
Back <NNP>
then <RB>
, <,>
scientists <NNS>
had <VBD>
no <DT>
way <NN>
of <IN>
ferreting <VBG>
out <IN>
specific <JJ>
genes <NNS>
, <,>
but <CC>
under <IN>
a <DT>
microscope <NN>
they <PRP>
could <MD>
see <VB>
the <DT>
23 <CD>
pairs <NNS>
of <IN>
chromosomes <NNS>
in <IN>
the <DT>
cells <NNS>
that <WDT>
contain <NN>
the <DT>
genes <NNS>
. <.>
Occasionally <RB>
, <,>
gross <IN>
chromosome_damage <NN>
was <VBD>
visible <JJ>
. <.>
Dr._Knudson <NNP>
found <VBD>
that <IN>
some <DT>
children <NNS>
with <IN>
the <DT>
eye_cancer <NN>
had <VBD>
inherited <VBN>
a <DT>
damaged <JJ>
copy <NN>
of <IN>
chromosome <NN>
No <DT>
. <.>
13 <CD>
from <IN>
a <DT>
parent <NN>
who <WP>
had_had <VBD>
the <DT>
disease <NN>
. <.>
Under <IN>
a <DT>
microscope <NN>
he <PRP>
could <MD>
actually <RB>
see <VB>
that <IN>
a <DT>
bit <NN>
of <IN>
chromosome <NN>
13 <CD>
was <VBD>
missing <VBG>
. <.>
He <PRP>
assumed <VBD>
the <DT>
missing_piece <NN>
contained <VBD>
a <DT>
gene <NN>
or <CC>
genes <NNS>
whose <WP$>
loss <NN>
had <VBD>
a <DT>
critical <JJ>
role <NN>
in <IN>
setting <NN>
off <IN>
the <DT>
cancer <NN>
. <.>
But <CC>
he <PRP>
did <VBD>
n't <RB>
know <VB>
which <WDT>
gene <NN>
or <CC>
genes <NNS>
had <VBD>
disappeared <VBN>
. <.>
Then <RB>
, <,>
a <DT>
scientific <JJ>
team <NN>
led <VBN>
by <IN>
molecular <JJ>
geneticist <NN>
Webster_Cavenee <NNP>
, <,>
then <RB>
at <IN>
the <DT>
University <NNP>
of <IN>
Utah <NNP>
, <,>
found <VBD>
the <DT>
answer <NN>
. <.>
The <DT>
team <NN>
used <VBD>
a <DT>
battery <NN>
of <IN>
the <DT>
newly <RB>
developed <VBD>
`` <``>
gene <NN>
probes <VBZ>
, <,>
'' <''>
snippets <NNS>
of <IN>
genetic <JJ>
material <NN>
that <WDT>
can <MD>
track <VB>
a <DT>
gene <NN>
's <POS>
presence <NN>
in <IN>
a <DT>
cell <NN>
. <.>
By <IN>
analyzing <NN>
cells <NNS>
extracted <VBD>
from <IN>
eye <NN>
tumors <NNS>
, <,>
they <PRP>
found <VBD>
defects <NNS>
in <IN>
the <DT>
second <JJ>
copy <NN>
of <IN>
chromosome <NN>
13 <CD>
in <IN>
the <DT>
exact <JJ>
area <NN>
as_in <IN>
the <DT>
first <JJ>
copy <NN>
of <IN>
the <DT>
chromosome <NN>
. <.>
The <DT>
finding <NN>
riveted <VBD>
medicine <NN>
. <.>
It <PRP>
was <VBD>
the <DT>
first <JJ>
time_anyone <NN>
had <VBD>
showed <VBN>
that <IN>
the <DT>
loss <NN>
of <IN>
both <DT>
copies <NNS>
of <IN>
the <DT>
same <JJ>
gene <NN>
could <MD>
lead <VB>
to <TO>
the <DT>
eruption <NN>
of <IN>
a <DT>
cancer <NN>
. <.>
`` <``>
It <PRP>
was <VBD>
extraordinarily <RB>
satisfying <VBG>
, <,>
'' <''>
says <VBZ>
Dr._Knudson <NNP>
, <,>
now <RB>
at <IN>
Fox_Chase_Cancer_Research_Center <NNP>
in <IN>
Philadelphia <NNP>
. <.>
`` <``>
I <PRP>
was <VBD>
convinced <VBN>
that <IN>
what <WP>
was <VBD>
true <JJ>
of <IN>
retinoblastoma <NN>
would <MD>
be <VB>
true <JJ>
for <IN>
all <DT>
cancers <NNS>
. <.>
`` <``>
It <PRP>
was <VBD>
an <DT>
audacious <JJ>
claim <NN>
. <.>
But <CC>
in <IN>
Baltimore <NNP>
, <,>
Dr._Vogelstein <NNP>
, <,>
a <DT>
young <JJ>
molecular_biologist <NN>
at <IN>
Johns_Hopkins_Medical_School <NNP>
, <,>
believed <VBD>
Dr._Knudson <NNP>
was <VBD>
right <RB>
, <,>
and <CC>
set <VBD>
out <RP>
to <TO>
repeat <VB>
the <DT>
Cavenee <NNP>
experiment <NN>
in <IN>
cells <NNS>
from <IN>
other <JJ>
cancers <NNS>
. <.>
His <PRP$>
was <VBD>
one <CD>
of <IN>
two <CD>
research <NN>
teams <NNS>
in <IN>
1984 <CD>
to <TO>
report <VB>
dual <JJ>
chromosome <NN>
losses <NNS>
for <IN>
a <DT>
rare_childhood_cancer <NN>
of <IN>
the <DT>
kidney <NN>
called <VBD>
Wilm <NNP>
's <POS>
tumor <NN>
. <.>
Dr._Vogelstein <NNP>
next <JJ>
turned <VBD>
his <PRP$>
attention <NN>
to <TO>
colon <VB>
cancer <NN>
, <,>
the <DT>
second <JJ>
biggest <JJS>
cancer_killer <NN>
in <IN>
the <DT>
U.S. <NNP>
after <IN>
lung <JJ>
cancer <NN>
. <.>
He <PRP>
believed <VBD>
colon_cancer <NN>
might <MD>
also <RB>
arise <VB>
from <IN>
multiple <NN>
`` <``>
hits <NNS>
'' <''>
on <IN>
cancer_suppressor <NN>
genes <NNS>
, <,>
because <IN>
it <PRP>
often <RB>
seems <VBZ>
to <TO>
develop <VB>
in <IN>
stages <NNS>
. <.>
It <PRP>
often <RB>
is <VBZ>
preceded <VBN>
by <IN>
the <DT>
development <NN>
of <IN>
polyps <NNS>
in <IN>
the <DT>
bowel <NN>
, <,>
which <WDT>
in <IN>
some <DT>
cases <NNS>
become <VBP>
increasingly <RB>
malignant <JJ>
in <IN>
identifiable <JJ>
stages <NNS>
-- <:>
progressing <VBG>
from <IN>
less <JJR>
severe <JJ>
to <TO>
deadly <RB>
-- <:>
as_though <IN>
a <DT>
cascade <NN>
of <IN>
genetic <JJ>
damage <NN>
might <MD>
be <VB>
occurring <VBG>
. <.>
Dr._Vogelstein <NNP>
and <CC>
a <DT>
doctoral <JJ>
student <NN>
, <,>
Eric_Fearon <NNP>
, <,>
began <VBD>
months <NNS>
of <IN>
tedious <JJ>
and <CC>
often <RB>
frustrating_probing <VBG>
of <IN>
the <DT>
chromosomes <NNS>
searching <VBG>
for <IN>
signs <NNS>
of <IN>
genetic <JJ>
damage <NN>
. <.>
They <PRP>
began <VBD>
uncovering <VBG>
a <DT>
confusing_variety <NN>
of <IN>
genetic <JJ>
deletions <NNS>
, <,>
some <DT>
existing <VBG>
only <RB>
in <IN>
benign <NN>
polyps <NNS>
, <,>
others <NNS>
in <IN>
malignant <JJ>
cells <NNS>
and <CC>
many <JJ>
in <IN>
both <DT>
polyps <NNS>
and <CC>
malignant <JJ>
cells <NNS>
. <.>
Gradually <RB>
, <,>
a <DT>
coherent_picture <NN>
of <IN>
cancer_development <NN>
emerged <VBD>
. <.>
If <IN>
both <DT>
copies <NNS>
of <IN>
a <DT>
certain <JJ>
gene <NN>
were <VBD>
knocked <VBN>
out <RP>
, <,>
benign <JJ>
polyps <NNS>
would <MD>
develop <VB>
. <.>
If <IN>
both <DT>
copies <NNS>
of <IN>
a <DT>
second <JJ>
gene <NN>
were <VBD>
then <RB>
deleted <VBN>
, <,>
the <DT>
polyps <NNS>
would <MD>
progress <VB>
to <TO>
malignancy <VB>
. <.>
It <PRP>
was <VBD>
clear <JJ>
that <IN>
more <JJR>
than <IN>
one <CD>
gene <NN>
had <VBD>
to <TO>
be <VB>
damaged <VBN>
for <IN>
colon_cancer <NN>
to <TO>
develop <VB>
. <.>
Their <PRP$>
report <NN>
galvanized <VBD>
other_molecular <JJ>
biologists <NNS>
. <.>
`` <``>
It <PRP>
was <VBD>
the <DT>
confirming_evidence <NN>
we <PRP>
all <DT>
needed <VBN>
that <IN>
{ <-NONE->
gene <NN>
} <:>
losses <NNS>
were <VBD>
critical <JJ>
to <TO>
the <DT>
development <NN>
of <IN>
a <DT>
common <JJ>
tumor <NN>
, <,>
'' <''>
says <VBZ>
Ray_White <NNP>
at <IN>
Howard_Hughes_Medical_Institute <NNP>
in <IN>
Salt_Lake_City <NNP>
. <.>
But <CC>
Dr._Vogelstein <NNP>
had <VBD>
yet <RB>
to <TO>
nail <VB>
the <DT>
identity <NN>
of <IN>
the <DT>
gene <NN>
that <IN>
, <,>
if <IN>
damaged <JJ>
, <,>
flipped <VBD>
a <DT>
colon_cell <NN>
into <IN>
full-blown <JJ>
malignancy <NN>
. <.>
They <PRP>
focused <VBD>
on <IN>
chromosome <NN>
17 <CD>
. <.>
For <IN>
months <NNS>
the <DT>
Johns_Hopkins <NNP>
researchers <NNS>
, <,>
using <VBG>
gene <NN>
probes <NNS>
, <,>
experimentally <RB>
crawled <VBD>
down <IN>
the <DT>
length <NN>
of <IN>
chromosome <NN>
17 <CD>
, <,>
looking <VBG>
for <IN>
the <DT>
smallest <JJS>
common <JJ>
bit <NN>
of <IN>
genetic <JJ>
material <NN>
lost <VBD>
in <IN>
all <DT>
tumor <NN>
cells <NNS>
. <.>
Such <JJ>
a <DT>
piece <NN>
of <IN>
DNA <NNP>
would <MD>
probably <RB>
constitute <VB>
a <DT>
gene <NN>
. <.>
When <WRB>
they <PRP>
found <VBP>
it <PRP>
last <JJ>
winter <NN>
, <,>
Dr._Vogelstein <NNP>
was <VBD>
dubious <JJ>
that <IN>
the <DT>
search <NN>
was <VBD>
over <IN>
. <.>
His <PRP$>
doubts <NNS>
stemmed <VBD>
from <IN>
the <DT>
fact <NN>
that <IN>
several <JJ>
years <NNS>
earlier <RBR>
a <DT>
Princeton_University <NNP>
researcher <NN>
, <,>
Arnold_Levine <NNP>
, <,>
had <VBD>
found <VBN>
in <IN>
experiments <NNS>
with <IN>
mice <NN>
that <IN>
a <DT>
gene <NN>
called <VBN>
p53 <NNP>
could <MD>
transform <VB>
normal <JJ>
cells <NNS>
into <IN>
cancerous <JJ>
ones <NNS>
. <.>
The <DT>
deletion <NN>
Dr._Vogelstein <NNP>
found_was <VBD>
in <IN>
exactly <RB>
the <DT>
same <JJ>
spot <NN>
as <IN>
p53 <NNP>
. <.>
But <CC>
Mr._Levine <NNP>
had <VBD>
said <VBN>
the <DT>
p53 <NNP>
gene <NN>
caused <VBD>
cancer <NN>
by <IN>
promoting_growth <NN>
, <,>
whereas <IN>
the <DT>
Johns_Hopkins <NNP>
scientists <NNS>
were <VBD>
looking <VBG>
for <IN>
a <DT>
gene <NN>
that <WDT>
suppressed <VBN>
growth <NN>
. <.>
Despite <IN>
that <DT>
, <,>
when <WRB>
the <DT>
Johns_Hopkins <NNP>
scientists <NNS>
compared <VBN>
the <DT>
gene <NN>
they <PRP>
had <VBD>
found <VBN>
in <IN>
the <DT>
human <JJ>
cancer <NN>
cells <NNS>
with <IN>
the <DT>
Mr._Levine <NNP>
's <POS>
p53 <NNP>
gene <NN>
they <PRP>
found <VBD>
the <DT>
two <CD>
were <VBD>
identical <JJ>
; <:>
it <PRP>
turned <VBD>
out <RP>
that_in <IN>
Mr._Levine <NNP>
's <POS>
cancer <NN>
studies <NNS>
, <,>
he <PRP>
had <VBD>
unknowingly <RB>
been <VBN>
observing <VBG>
a <DT>
damaged <JJ>
form <NN>
of <IN>
p53 <NNP>
-- <:>
a <DT>
cancer-suppressing <JJ>
gene <NN>
. <.>
The <DT>
discovery <NN>
`` <``>
suddenly <RB>
puts <VBZ>
an <DT>
obscure_gene <NN>
right <RB>
in <IN>
the <DT>
cockpit <NN>
of <IN>
cancer_formation <NN>
, <,>
'' <''>
says <VBZ>
Robert_Weinberg <NNP>
, <,>
a <DT>
leader <NN>
in <IN>
cancer-gene <JJ>
research <NN>
at <IN>
Whitehead_Institute <NNP>
in <IN>
Cambridge <NNP>
, <,>
Mass <NNP>
. <.>
Evidence <NN>
now <RB>
is <VBZ>
emerging <VBG>
that <IN>
the <DT>
p53 <NNP>
suppressor_gene <NN>
is <VBZ>
involved <VBN>
in <IN>
other <JJ>
cancers <NNS>
, <,>
too <RB>
. <.>
Researchers <NNS>
in <IN>
Edinburgh <NNP>
, <,>
Scotland <NNP>
, <,>
have <VBP>
found <VBN>
that_in <IN>
23 <CD>
of <IN>
38 <CD>
breast <JJ>
tumors <NNS>
, <,>
one <CD>
copy <NN>
of <IN>
chromosome <NN>
17 <CD>
was <VBD>
mutated <VBN>
at <IN>
the <DT>
spot <NN>
where <WRB>
gene <NN>
p53 <NNP>
lies <NNS>
. <.>
The <DT>
scientists <NNS>
say <VBP>
that_since <IN>
breast <JJ>
cancer <NN>
often <RB>
strikes <VBZ>
multiple <JJ>
members <NNS>
of <IN>
certain <JJ>
families <NNS>
, <,>
the <DT>
gene <NN>
, <,>
when <WRB>
inherited <VBN>
in <IN>
a <DT>
damaged <JJ>
form <NN>
, <,>
may <MD>
predispose <VB>
women <NNS>
to <TO>
the <DT>
cancer <NN>
. <.>
The <DT>
p53 <NNP>
gene <NN>
has <VBZ>
just <RB>
been_implicated <VBN>
in <IN>
lung <JJ>
cancer <NN>
. <.>
In <IN>
a <DT>
report <NN>
out <RP>
last <JJ>
week <NN>
, <,>
John_Minna <NNP>
and <CC>
colleagues <NNS>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
say <VBP>
that_about <IN>
half_the <DT>
cells <NNS>
taken <VBN>
from <IN>
lung <JJ>
cancer_tissue <NN>
they <PRP>
tested <VBD>
are <VBP>
missing <VBG>
this <DT>
gene <NN>
. <.>
There <EX>
also <RB>
are <VBP>
reports <NNS>
from <IN>
several <JJ>
labs <NNS>
, <,>
as <IN>
yet <RB>
unpublished <VBN>
, <,>
of <IN>
missing <NN>
p53 <NNP>
genes <NNS>
in <IN>
tissue <NN>
taken <VBN>
from <IN>
kidney <NN>
, <,>
brain <NN>
and <CC>
skin <NN>
cancers <NNS>
. <.>
At <IN>
the <DT>
same <JJ>
time <NN>
, <,>
the <DT>
Johns_Hopkins <NNP>
team <NN>
and <CC>
others <NNS>
are <VBP>
rushing <VBG>
to <TO>
pinpoint <VB>
other_tumor-suppressor <JJ>
genes <NNS>
. <.>
Dr._Vogelstein <NNP>
hopes <VBZ>
soon <RB>
to <TO>
isolate <VB>
one <CD>
on <IN>
chromosome <NN>
18 <CD>
, <,>
also <RB>
involved <VBD>
in <IN>
colon_cancer <NN>
. <.>
Ray_White <NNP>
in <IN>
Utah <NNP>
and <CC>
Walter_Bodmer <NNP>
, <,>
a <DT>
researcher <NN>
in <IN>
Great_Britain <NNP>
, <,>
are <VBP>
close <RB>
to <TO>
finding <VBG>
another <DT>
gene <NN>
involved <VBN>
with <IN>
some <DT>
types <NNS>
of <IN>
colon_cancer <NN>
, <,>
thought <VBD>
to <TO>
be <VB>
on <IN>
chromosome <NN>
5 <CD>
. <.>
Dr._Minna <NNP>
believes <VBZ>
people <NNS>
who <WP>
inherit <NN>
a <DT>
defective <JJ>
gene <NN>
somewhere <RB>
on <IN>
one <CD>
of <IN>
their <PRP$>
two <CD>
copies <NNS>
of <IN>
chromosome <NN>
3 <CD>
are <VBP>
especially <RB>
prone <JJ>
to <TO>
lung <JJ>
cancer <NN>
. <.>
Recently <RB>
, <,>
he <PRP>
and <CC>
others <NNS>
reported <VBD>
that <IN>
the <DT>
retinoblastoma_suppressor_gene <NN>
may <MD>
also <RB>
be <VB>
involved <VBN>
in <IN>
some <DT>
lung <JJ>
cancers <NNS>
, <,>
as <IN>
well <RB>
as <IN>
several_other <JJ>
more <RBR>
common <JJ>
cancers <NNS>
, <,>
too <RB>
. <.>
Where <WRB>
these <DT>
discoveries <NNS>
will <MD>
lead <VB>
, <,>
scientists <NNS>
can <MD>
only <RB>
speculate <VB>
. <.>
Already <RB>
two <CD>
major_pharmaceutical <JJ>
companies <NNS>
, <,>
the <DT>
Squibb <NNP>
unit <NN>
of <IN>
Bristol-Myers <NNS>
Squibb_Co. <NNP>
and <CC>
Hoffmann-La_Roche_Inc. <NNP>
, <,>
are <VBP>
collaborating <VBG>
with <IN>
gene <NN>
hunters <NNS>
to <TO>
turn <VB>
the <DT>
anticipated <JJ>
cascade <NN>
of <IN>
discoveries <NNS>
into <IN>
predictive <JJ>
tests <NNS>
and <CC>
, <,>
maybe <RB>
, <,>
new <JJ>
therapies <NNS>
. <.>
Some <DT>
researchers <NNS>
say <VBP>
new <JJ>
cancer <NN>
drugs <NNS>
to <TO>
slow <VB>
or <CC>
reverse <VB>
tumor_growth <NN>
may <MD>
be <VB>
based <VBN>
on <IN>
the <DT>
suppressor <NN>
proteins <NNS>
normally <RB>
produced <VBN>
by <IN>
the <DT>
genes <NNS>
. <.>
The <DT>
idea <NN>
would <MD>
be <VB>
to <TO>
administer <VB>
to <TO>
patients <NNS>
the <DT>
growth-controlling <JJ>
proteins <NNS>
made <VBN>
by <IN>
healthy <JJ>
versions <NNS>
of <IN>
the <DT>
damaged <JJ>
genes <NNS>
. <.>
It <PRP>
may <MD>
even <RB>
be <VB>
possible <JJ>
to <TO>
replace <VB>
defective <JJ>
genes <NNS>
with <IN>
healthy <JJ>
versions <NNS>
, <,>
though <IN>
no <DT>
one <NN>
has <VBZ>
come <VBN>
close <RB>
to <TO>
doing <VBG>
that <IN>
so_far <RB>
. <.>
In <IN>
any <DT>
case <NN>
, <,>
says <VBZ>
Dr._Minna <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
`` <``>
We <PRP>
're <VBP>
witnessing <VBG>
the <DT>
discovery <NN>
of <IN>
one <CD>
of <IN>
the <DT>
most <RBS>
important <JJ>
steps <NNS>
in <IN>
the <DT>
genesis <NN>
of <IN>
cancer <NN>
. <.>
FBIS4-67640 <DOCNO>
`` <``>
CSO <NNP>
[ <:>
Article <NNP>
: <:>
`` <``>
Tim_Radford <NNP>
on <IN>
an <DT>
Atlas_Which_Utilises <NNP>
an <DT>
18-Year <JJ>
Study_To_Demonstrate <NNP>
the <DT>
Geography <NNP>
of <IN>
Disease <NNP>
: <:>
Cancer_Map_Shows_North-South_Divide <NNP>
'' <''>
]_[ <:>
Text <NNP>
] <:>
The <DT>
first <JJ>
atlas <NNS>
of <IN>
cancer <NN>
cases <NNS>
in <IN>
England <NNP>
and <CC>
Wales <NNP>
, <,>
published <VBD>
yesterday <NN>
[ <:>
not <RB>
reproduced <VBN>
] <-NONE->
throws <VBZ>
the <DT>
geography <NN>
of <IN>
disease <NN>
into <IN>
relief <NN>
across <IN>
the <DT>
country <NN>
. <.>
The <DT>
analysis <NN>
of <IN>
3_million <CD>
cases <NNS>
over <IN>
an <DT>
18-year <JJ>
period <NN>
, <,>
county <NN>
by <IN>
county <NN>
, <,>
reveals <NNS>
some <DT>
puzzles <NNS>
and <CC>
confirms <NNS>
the <DT>
north-south <JJ>
health_divide <NN>
. <.>
More <JJR>
than <IN>
70 <CD>
maps <NNS>
, <,>
commissioned <VBD>
by <IN>
the <DT>
Cancer_Research_Campaign <NNP>
, <,>
show <NN>
an <DT>
excess <NN>
of <IN>
lung <NN>
cancers <NNS>
in <IN>
the <DT>
north <JJ>
of <IN>
England <NNP>
, <,>
of <IN>
breast <JJ>
cancers <NNS>
among <IN>
older <JJR>
women <NNS>
in <IN>
the <DT>
south <NN>
, <,>
and <CC>
as <IN>
`` <``>
hot <JJ>
spot <NN>
'' <''>
of <IN>
stomach <DT>
cancer <NN>
in <IN>
Wales <NNP>
. <.>
But <CC>
malignant <VBD>
melanomas <NNS>
of <IN>
the <DT>
skin_occur <NN>
with <IN>
greater <JJR>
frequency <NN>
in <IN>
the <DT>
south <NN>
and <CC>
west <NN>
, <,>
where <WRB>
sunshine <NN>
levels <NNS>
are <VBP>
highest <JJS>
. <.>
The <DT>
atlas <NNS>
shows <VBZ>
a <DT>
less <JJR>
easily <RB>
explained <VBN>
excess <NN>
of <IN>
lip_cancer <NN>
in <IN>
East <JJ>
Anglia <NNP>
and <CC>
of <IN>
thyroid <JJ>
cancer <NN>
in <IN>
north <JJ>
Wales <NNS>
. <.>
It <PRP>
also <RB>
reveals <VBZ>
Anglesey <NNP>
as <IN>
having <VBG>
the <DT>
highest <JJS>
incidence <NN>
of <IN>
penile <NN>
, <,>
cervical <JJ>
and <CC>
lip_cancer <NN>
in <IN>
the <DT>
country <NN>
. <.>
There <EX>
are <VBP>
many <JJ>
reasons <NNS>
for <IN>
cancer <NN>
. <.>
`` <``>
These <DT>
can <MD>
include <VB>
your <PRP$>
job <NN>
, <,>
where <WRB>
and <CC>
how <WRB>
you <PRP>
live <VBP>
, <,>
your <PRP$>
diet <NN>
, <,>
your <PRP$>
drinking <NN>
and <CC>
smoking <NN>
habits <NNS>
, <,>
and <CC>
your <PRP$>
sexual <JJ>
behaviour <NN>
, <,>
'' <''>
said <VBD>
Professor_Gordon_McVie <NNP>
of <IN>
the <DT>
Cancer_Research_Campaign <NNP>
. <.>
`` <``>
This <DT>
atlas <NN>
will <MD>
help <VB>
cancer <NN>
professionals <NNS>
to <TO>
home <VB>
in_on <IN>
areas <NNS>
of <IN>
high <JJ>
risk <NN>
and <CC>
identify <NN>
the <DT>
reasons <NNS>
why <WRB>
some <DT>
types <NNS>
of <IN>
the <DT>
disease <NN>
are <VBP>
more <RBR>
common <JJ>
in <IN>
a <DT>
particular <JJ>
area <NN>
. <.>
`` <``>
Mapping <JJ>
of <IN>
diseases <NNS>
began <VBD>
in <IN>
1850 <CD>
, <,>
when <WRB>
a <DT>
London <NNP>
doctor <NN>
tracked <VBD>
cholera <NN>
cases <NNS>
and <CC>
found <VBN>
a <DT>
variation <NN>
according <VBG>
to <TO>
source <VB>
of <IN>
water_supply <NN>
. <.>
This <DT>
was <VBD>
before <IN>
cholera <NN>
was <VBD>
identified <VBN>
as <IN>
a <DT>
water-borne <JJ>
disease <NN>
. <.>
But <CC>
epidemiology <NN>
-- <:>
the <DT>
science <NN>
of <IN>
the <DT>
study <NN>
of <IN>
large <JJ>
numbers <NNS>
of <IN>
cases <NNS>
according <VBG>
to <TO>
patterns <NNS>
of <IN>
behaviour <PRP$>
-- <:>
has <VBZ>
since <IN>
been_used <VBN>
to <TO>
link <VB>
lung <JJ>
cancer <NN>
with <IN>
smoking <NN>
and <CC>
scrotal <JJ>
cancer <NN>
with <IN>
some <DT>
engineering <NN>
industries <NNS>
, <,>
and <CC>
mesothalamia <NN>
with <IN>
shipbuilding <NN>
. <.>
The <DT>
atlas <NNS>
is <VBZ>
supported <VBN>
by <IN>
appendices <NNS>
carrying <VBG>
regional <JJ>
and <CC>
county_information <NN>
on <IN>
abortion <NN>
rates <NNS>
, <,>
air_pollution <NN>
, <,>
alcohol_consumption <NN>
, <,>
household_food <NN>
purchases <NNS>
, <,>
percentages <NNS>
of <IN>
residents <NNS>
born <VBP>
outside <IN>
Britain <NNP>
, <,>
socio-economic <JJ>
and <CC>
educational <JJ>
status <NN>
, <,>
occupation <NN>
, <,>
venereal_disease_clinic <NN>
attendances <NNS>
, <,>
and <CC>
so <RB>
on <IN>
. <.>
The <DT>
maps <NNS>
were <VBD>
prepared <VBN>
by <IN>
Dr_Anthony_Swerdlow <NNP>
and <CC>
Dr_Isabel <NNP>
dos <VBZ>
Santos_Silva <NNP>
, <,>
of <IN>
the <DT>
London_School <NNP>
of <IN>
Hygiene <NNP>
and <CC>
Tropical_Medicine <NNP>
. <.>
They <PRP>
are <VBP>
based <VBN>
on <IN>
records <NNS>
of <IN>
an <DT>
average <JJ>
176 <CD>
, <,>
000 <CD>
cases <NNS>
of <IN>
cancers <NNS>
in <IN>
each <DT>
year <NN>
between <IN>
1968 <CD>
and <CC>
1985 <CD>
. <.>
More <JJR>
than <IN>
33 <CD>
, <,>
000 <CD>
were <VBD>
of <IN>
lung <JJ>
cancer <NN>
, <,>
and <CC>
more <JJR>
than <IN>
20 <CD>
, <,>
000 <CD>
were <VBD>
breast <JJ>
cancers <NNS>
. <.>
There <EX>
have <VBP>
been <VBN>
earlier <RBR>
maps <RB>
of <IN>
cancer_mortality <NN>
but <CC>
these <DT>
have <VBP>
not <RB>
shown <VBN>
the <DT>
whole <JJ>
picture <NN>
, <,>
because <IN>
some <DT>
cancers <NNS>
are <VBP>
almost_invariably <RB>
fatal <JJ>
and <CC>
some <DT>
are <VBP>
more <RBR>
easily <RB>
cured <VBN>
. <.>
The <DT>
statistics <NNS>
show <VBP>
a <DT>
link <NN>
between <IN>
scrotal <JJ>
cancer <NN>
and <CC>
engineering <NN>
, <,>
but <CC>
no <DT>
obvious <JJ>
link <NN>
with <IN>
leukaemia <NN>
and <CC>
nuclear <JJ>
power_generation <NN>
. <.>
However <RB>
, <,>
there <EX>
are <VBP>
marked <VBN>
differences <NNS>
according <VBG>
to <TO>
area <VB>
. <.>
Lancashire <NNP>
has <VBZ>
63 <CD>
per <IN>
cent <NN>
more <JJR>
male <JJ>
lung <NN>
cancers <NNS>
than <IN>
the <DT>
average <NN>
for <IN>
the <DT>
rest <NN>
of <IN>
the <DT>
country <NN>
; <:>
Montgomeryshire <NNP>
recorded <VBD>
85 <CD>
per <IN>
cent <NN>
fewer <JJR>
. <.>
Caernarvonshire <NNP>
and <CC>
Staffordshire <NNP>
showed <VBD>
37 <CD>
per <IN>
cent <NN>
higher <JJR>
than <IN>
average <JJ>
rates <NNS>
of <IN>
stomach_cancer <NN>
, <,>
the <DT>
Isle <NNP>
of <IN>
Wight <NNP>
35 <CD>
per <IN>
cent <NN>
lower <JJR>
. <.>
Prostate <NNP>
cancer_incidence <NN>
was <VBD>
higher <JJR>
in <IN>
Cambridgeshire <NNP>
and <CC>
Somerset <NNP>
, <,>
lower <JJR>
in <IN>
Denbighshire <NNP>
and <CC>
Durham <NNP>
. <.>
Lung <NNP>
cancer <NN>
among <IN>
women <NNS>
under <IN>
45 <CD>
was <VBD>
lowest <JJ>
( <NN>
60 <CD>
per <IN>
cent <NN>
lower <JJR>
) <NN>
in <IN>
Hereford <NNP>
and <CC>
Worcester <NNP>
and <CC>
highest <JJS>
( <:>
74 <CD>
per <IN>
cent <NN>
higher <JJR>
) <:>
in <IN>
Northumberland <NNP>
. <.>
Breast <NNP>
cancer <NN>
for <IN>
women <NNS>
under <IN>
45 <CD>
was <VBD>
highest <JJS>
in <IN>
Lincolnshire_( <NNP>
40 <CD>
per <IN>
cent <NN>
) <:>
and <CC>
lowest <JJS>
in <IN>
Camarthenshire_( <NNP>
24 <CD>
per <IN>
cent <NN>
) <:>
. <.>
The <DT>
Atlas <NNP>
of <IN>
Cancer_Incidence <NNP>
in <IN>
England <NNP>
and <CC>
Wales <NNP>
1968-1985 <CD>
; <:>
Oxford_University_Press <NNP>
; <:>
& <CC>
pound <NN>
; <:>
170 <CD>
WSJ911115-0022 <DOCNO>
. <.>
Until <IN>
now <RB>
, <,>
there <EX>
was <VBD>
scant <JJ>
evidence <NN>
about <IN>
exactly <RB>
what <WP>
causes <NNS>
the <DT>
gene <NN>
to <TO>
go <VB>
awry <NN>
, <,>
although <IN>
scientists <NNS>
have <VBP>
speculated <VBN>
that <IN>
environmental <JJ>
agents <NNS>
, <,>
such <JJ>
as <IN>
sunlight <NN>
or <CC>
radiation <NN>
, <,>
are <VBP>
the <DT>
trigger <NN>
. <.>
`` <``>
There <EX>
is <VBZ>
little <JJ>
doubt <NN>
that <IN>
skin_cancer <NN>
involves <VBZ>
exposure <NN>
to <TO>
the <DT>
sun <NN>
, <,>
but <CC>
we <PRP>
did <VBD>
n't <RB>
know <VB>
exactly <RB>
what <WP>
happens <NNS>
, <,>
'' <''>
said <VBD>
David_Leffell <NNP>
, <,>
chief <NN>
of <IN>
dermatologic <JJ>
surgery <NN>
at <IN>
the <DT>
Yale <NNP>
medical <JJ>
school <NN>
. <.>
`` <``>
Now <RB>
we <PRP>
do <VBP>
. <.>
`` <``>
The <DT>
finding <NN>
is <VBZ>
one <CD>
of <IN>
the <DT>
most <RBS>
important <JJ>
to <TO>
emerge <VB>
from <IN>
the <DT>
spate <NN>
of <IN>
discoveries <NNS>
over <IN>
the <DT>
past <JJ>
three <CD>
years <NNS>
showing <VBG>
that <IN>
cancers <NNS>
arise <VBP>
when <WRB>
certain <JJ>
genes <NNS>
that <WDT>
usually <RB>
control <VBP>
cell_growth_become <NN>
altered <VBD>
or <CC>
defective <JJ>
. <.>
In <IN>
particular <JJ>
, <,>
the <DT>
p53 <NNP>
gene <NN>
has <VBZ>
been_linked <VBN>
by <IN>
scientists <NNS>
to <TO>
cancers <NNS>
of <IN>
the <DT>
colon <NN>
, <,>
breast <JJ>
, <,>
lung <JJ>
, <,>
kidney <NN>
, <,>
and <CC>
brain <NN>
. <.>
There <EX>
is <VBZ>
evidence <NN>
suggesting <VBG>
that <IN>
people <NNS>
who <WP>
inherit <NN>
a <DT>
mutated <JJ>
version <NN>
of <IN>
p53 <NNP>
, <,>
or <CC>
other_so-called_tumor-suppressor <JJ>
genes <NNS>
, <,>
are <VBP>
especially <RB>
susceptible <JJ>
to <TO>
cancer <NN>
. <.>
But <CC>
most <JJS>
scientists <NNS>
have <VBP>
argued <VBN>
that <IN>
the <DT>
vast <JJ>
majority <NN>
of <IN>
cancers <NNS>
develop <VB>
when <WRB>
these <DT>
same <JJ>
genes <NNS>
are <VBP>
deactivated <VBN>
, <,>
either <DT>
through <IN>
some <DT>
spontaneous <JJ>
mistake <NN>
during <IN>
cell_division <NN>
or <CC>
from <IN>
exposure <NN>
to <TO>
a <DT>
cancer-causing <JJ>
agent <NN>
. <.>
But <CC>
only <RB>
in <IN>
the <DT>
past_few <JJ>
months <NNS>
have <VBP>
scientists <NNS>
begun <VBN>
to <TO>
find <VB>
evidence <NN>
linking <VBG>
suspected <VBN>
carcinogens <NNS>
to <TO>
the <DT>
genes <NNS>
. <.>
The <DT>
Yale <NNP>
team <NN>
, <,>
aided <VBD>
by <IN>
researchers <NNS>
in <IN>
Boston <NNP>
, <,>
New_York <NNP>
and <CC>
Uppsala <NNP>
, <,>
Sweden <NNP>
, <,>
made <VBD>
the <DT>
connection <NN>
by <IN>
looking <NN>
at <IN>
cancer <NN>
cells <NNS>
taken <VBN>
from <IN>
24 <CD>
patients <NNS>
. <.>
They <PRP>
found <VBD>
that <IN>
one <CD>
tiny <NN>
`` <``>
hot <JJ>
spot <NN>
'' <''>
in <IN>
the <DT>
p53 <NNP>
gene <NN>
was <VBD>
altered <VBN>
in <IN>
the <DT>
exact <JJ>
same_manner <NN>
in <IN>
72 <CD>
% <NN>
of <IN>
the <DT>
cases <NNS>
they <PRP>
studied <VBD>
. <.>
`` <``>
What <WP>
really <RB>
surprised <VBD>
us <PRP>
is <VBZ>
that <IN>
the <DT>
defect <NN>
was <VBD>
exactly <RB>
the <DT>
kind <NN>
of <IN>
change <NN>
that <IN>
only <RB>
occurs <VBZ>
when <WRB>
( <:>
genetic <JJ>
material <NN>
) <:>
is <VBZ>
exposed <VBN>
to <TO>
ultraviolet <VB>
light <JJ>
, <,>
'' <''>
said <VBD>
Douglas_Brash <NNP>
, <,>
who <WP>
led <VBN>
the <DT>
research <NN>
for <IN>
the <DT>
Yale <NNP>
group <NN>
. <.>
Ultraviolet <NNP>
light <VBD>
transforms <NNS>
one <CD>
of <IN>
four <CD>
chemical <JJ>
bases <NNS>
, <,>
which <WDT>
recur <NN>
thousands <VBZ>
of <IN>
times <NNS>
in <IN>
differing_order <NN>
in <IN>
the <DT>
gene <NN>
, <,>
into <IN>
another <DT>
of <IN>
the <DT>
four <CD>
bases <NNS>
. <.>
Researchers <NNS>
found <VBD>
that <IN>
this <DT>
change <NN>
, <,>
benign <NN>
in <IN>
other <JJ>
genes <NNS>
, <,>
is <VBZ>
disastrous <JJ>
to <TO>
p53 <NNP>
, <,>
causing <VBG>
the <DT>
gene <NN>
to <TO>
manufacture <VB>
a <DT>
defective <JJ>
protein <NN>
that <WDT>
destroys <VBZ>
the <DT>
cell <NN>
's <POS>
growth-regulating <JJ>
system <NN>
. <.>
There <EX>
are <VBP>
about <IN>
650 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
of <IN>
skin_cancer <NN>
in <IN>
the <DT>
U.S. <NNP>
every <DT>
year <NN>
, <,>
and <CC>
about <IN>
8 <CD>
, <,>
500 <CD>
deaths <NNS>
related <VBN>
to <TO>
the <DT>
disease <NN>
, <,>
making <VBG>
it <PRP>
the <DT>
most <RBS>
common <JJ>
of <IN>
all <DT>
cancers <NNS>
. <.>
The <DT>
Yale <NNP>
research <NN>
, <,>
published <VBD>
today <NN>
in <IN>
the <DT>
National_Proceedings <NNP>
of <IN>
the <DT>
Academy <NNP>
of <IN>
Science <NNP>
, <,>
involved <VBD>
cancer <NN>
of <IN>
squamous <JJ>
skin <NN>
cells <NNS>
. <.>
The <DT>
scientists <NNS>
also <RB>
are <VBP>
looking <VBG>
for <IN>
similar <JJ>
gene_damage <NN>
in <IN>
basal_cell_cancer <NN>
and <CC>
melanoma <NN>
, <,>
the <DT>
other <JJ>
two <CD>
major <JJ>
forms <NNS>
of <IN>
the <DT>
disease <NN>
. <.>
The <DT>
Yale <NNP>
scientists <NNS>
said <VBD>
their <PRP$>
discovery <NN>
is <VBZ>
n't <RB>
expected <VBN>
to <TO>
produce <VB>
immediate <JJ>
benefits <NNS>
for <IN>
treating <VBG>
the <DT>
disease <NN>
. <.>
But <CC>
the <DT>
finding <NN>
, <,>
they <PRP>
said <VBD>
, <,>
should <MD>
inspire <VB>
other <JJ>
researchers <NNS>
who <WP>
are <VBP>
searching <VBG>
for <IN>
the <DT>
exact_environmental <JJ>
cause <NN>
for <IN>
other <JJ>
cancers <NNS>
. <.>
`` <``>
There <EX>
is <VBZ>
, <,>
of <IN>
course <NN>
, <,>
good <JJ>
reason <NN>
to <TO>
believe <VB>
that <IN>
cigarette_smoke <NN>
causes <NNS>
lung <VBP>
cancer <NN>
by <IN>
acting <NN>
on <IN>
p53 <NNP>
or <CC>
other <JJ>
tumor_suppressor <NN>
genes <NNS>
, <,>
'' <''>
said <VBD>
Dr <NNP>
. <.>
Brash <NNP>
. <.>
`` <``>
Finding <NN>
as <IN>
strong <JJ>
a <DT>
link <NN>
as <IN>
we <PRP>
found <VBD>
wo <MD>
n't <RB>
be <VB>
easy <JJ>
, <,>
but <CC>
it <PRP>
is <VBZ>
the <DT>
proof_everyone <NN>
needs <VBZ>
. <.>
AP901221-0008 <DOCNO>
`` <``>
Researchers <NNS>
in <IN>
California <NNP>
and <CC>
Utah <NNP>
report <NN>
, <,>
in <IN>
studies <NNS>
published <VBD>
today <NN>
, <,>
new <JJ>
advances <NNS>
toward <IN>
isolating <VBG>
the <DT>
gene <NN>
linked <VBD>
to <TO>
a <DT>
susceptibility <NN>
to <TO>
breast <VB>
cancer <NN>
in <IN>
some <DT>
families <NNS>
. <.>
Mary-Claire <JJ>
King <NNP>
, <,>
leader <NN>
of <IN>
a <DT>
laboratory_group <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
California <NNP>
, <,>
Berkeley <NNP>
, <,>
said <VBD>
her <PRP>
studies <NNS>
have <VBP>
narrowed <VBN>
the <DT>
search <NN>
for <IN>
the <DT>
breast_cancer_gene <NN>
to <TO>
a <DT>
specific <JJ>
chromosome <NN>
. <.>
Comparing <VBG>
the <DT>
work <NN>
to <TO>
a <DT>
needle-in-a-haystack <JJ>
quest <NN>
, <,>
King <NNP>
said <VBD>
in <IN>
an <DT>
interview <NN>
, <,>
`` <``>
We <PRP>
're <VBP>
now <RB>
at <IN>
the <DT>
point <NN>
of <IN>
knowing <VBG>
the <DT>
handful <NN>
of <IN>
hay <NN>
in <IN>
which <WDT>
this <DT>
needle <NN>
lies <VBZ>
, <,>
as <IN>
opposed <VBN>
to <TO>
having <NN>
to <TO>
search <NN>
through <IN>
the <DT>
whole <JJ>
haystack <NN>
. <.>
'' <''>
A <DT>
research_group <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Utah_Health <NNP>
Sciences <NNPS>
Center <NNP>
, <,>
meanwhile <RB>
, <,>
reported <VBD>
finding <VBG>
that <IN>
proliferative <JJ>
breast_disease <NN>
, <,>
a <DT>
condition <NN>
known <VBN>
to <TO>
be <VB>
a <DT>
precursor <NN>
of <IN>
breast <JJ>
cancer <NN>
, <,>
has <VBZ>
been_found <VBN>
to <TO>
be <VB>
inherited <VBN>
in <IN>
some <DT>
families <NNS>
. <.>
`` <``>
Based <VBN>
on <IN>
this <DT>
study <NN>
, <,>
we <PRP>
believe <VBP>
the <DT>
genetic <JJ>
susceptibility <NN>
to <TO>
breast <VB>
cancer <NN>
is <VBZ>
more <RBR>
common <JJ>
than <IN>
previously <RB>
thought <VBD>
, <,>
'' <''>
said <VBD>
Dr._Mark_H._Skolnick <NNP>
of <IN>
the <DT>
Utah <NNP>
group <NN>
. <.>
Both <DT>
groups <NNS>
have <VBP>
been <VBN>
researching <VBG>
families <NNS>
with <IN>
large <JJ>
numbers <NNS>
of <IN>
breast <JJ>
cancer <NN>
cases <NNS>
. <.>
Their <PRP$>
studies <NNS>
are <VBP>
published <VBN>
today <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
Skolnick <NNP>
and <CC>
King <NNP>
said <VBD>
their <PRP$>
studies <NNS>
could <MD>
lead <VB>
eventually <RB>
to <TO>
tests <NNS>
enabling <VBG>
women <NNS>
with <IN>
known <JJ>
breast_cancer <NN>
risks <NNS>
, <,>
based <VBN>
on <IN>
their <PRP$>
family <NN>
histories <NNS>
, <,>
to <TO>
be <VB>
treated <VBN>
even <RB>
before <IN>
the <DT>
smallest <JJS>
of <IN>
tumors <NNS>
have <VBP>
formed <VBN>
. <.>
`` <``>
The <DT>
long-term <JJ>
goal <NN>
of <IN>
this <DT>
kind <NN>
of <IN>
work <NN>
is <VBZ>
to <TO>
try <NN>
to <TO>
develop <VB>
diagnostic <JJ>
techniques <NNS>
that <WDT>
will <MD>
allow <VB>
the <DT>
detection <NN>
of <IN>
aberrant <JJ>
cells <NNS>
in <IN>
the <DT>
breast <NN>
at <IN>
an <DT>
extremely <RB>
early <JJ>
stage <NN>
, <,>
'' <''>
said <VBD>
King <NNP>
. <.>
`` <``>
Those <DT>
cells <NNS>
could <MD>
be <VB>
removed <VBN>
and <CC>
the <DT>
woman_go <NN>
on_with <IN>
a <DT>
normal <JJ>
life <NN>
. <.>
'' <''>
With <IN>
such <JJ>
tests <NNS>
used <VBN>
widely <RB>
, <,>
she <PRP>
said <VBD>
, <,>
`` <``>
it <PRP>
would <MD>
be <VB>
possible <JJ>
that <IN>
there <EX>
would <MD>
be <VB>
no <RB>
mortality <NN>
from <IN>
breast <JJ>
cancer <NN>
. <.>
'' <''>
Such_clinical <JJ>
applications <NNS>
of <IN>
the <DT>
two <CD>
studies <NNS>
, <,>
however <RB>
, <,>
are <VBP>
many <JJ>
years <NNS>
away <RB>
, <,>
King <NNP>
said <VBD>
. <.>
In <IN>
the <DT>
California <NNP>
project <NN>
, <,>
the <DT>
scientist <NN>
said <VBD>
her <PRP>
team <NN>
studied <VBD>
more <JJR>
than <IN>
400 <CD>
members <NNS>
of <IN>
23 <CD>
families <NNS>
with <IN>
a <DT>
total <JJ>
of <IN>
146 <CD>
cases <NNS>
of <IN>
breast <JJ>
cancer <NN>
. <.>
Breast <NNP>
cancer <NN>
in <IN>
those <DT>
families <NNS>
, <,>
she <PRP>
said <VBD>
, <,>
tended <VBN>
to <TO>
develop <VB>
at <IN>
an <DT>
early <JJ>
age <NN>
and <CC>
often <RB>
involved <VBN>
both <DT>
breasts <NNS>
. <.>
By <IN>
analyzing_blood <NN>
samples <NNS>
and <CC>
then <RB>
comparing <VBG>
genetic <JJ>
patterns <NNS>
, <,>
King <NNP>
said <VBD>
, <,>
the <DT>
scientists <NNS>
found <VBD>
nine <CD>
families <NNS>
in <IN>
which <WDT>
susceptibility <NN>
to <TO>
the <DT>
early <JJ>
onset <NN>
of <IN>
breast <JJ>
cancer <NN>
was <VBD>
linked <VBN>
to <TO>
chromosome <VB>
17q <CD>
, <,>
one <CD>
of <IN>
the <DT>
46 <CD>
chromosomes <NNS>
found <VBD>
in <IN>
human <NN>
cells <NNS>
. <.>
Now <RB>
, <,>
she <PRP>
said <VBD>
, <,>
the <DT>
researchers <NNS>
are <VBP>
attempting <VBG>
to <TO>
find <VB>
the <DT>
specific <JJ>
breast_cancer_gene <NN>
within <IN>
that <DT>
chromosome <NN>
. <.>
King <VBG>
said <VBD>
that <IN>
even <RB>
when <WRB>
the <DT>
gene <NN>
is <VBZ>
found <VBN>
, <,>
it <PRP>
will <MD>
not <RB>
be <VB>
the <DT>
final <JJ>
story <NN>
in <IN>
inherited <JJ>
breast_cancer_risk <NN>
. <.>
She <PRP>
said <VBD>
a <DT>
combination <NN>
of <IN>
genes <NNS>
is <VBZ>
involved <VBN>
in <IN>
developing <VBG>
the <DT>
disease <NN>
and <CC>
that <IN>
still <RB>
other <JJ>
genes <NNS>
may <MD>
permit <VB>
the <DT>
cancer <NN>
to <TO>
grow <VB>
and <CC>
proliferate <VB>
. <.>
Furthermore <NNP>
, <,>
the <DT>
scientist <NN>
said <VBD>
, <,>
most <JJS>
breast <JJ>
cancers <NNS>
may <MD>
have <VB>
no <DT>
inherited <VBN>
genetic <JJ>
component <NN>
. <.>
`` <``>
People <NNS>
need <VBP>
to <TO>
understand <VB>
that <IN>
having <VBG>
a <DT>
mother <NN>
with <IN>
breast <JJ>
cancer <NN>
does <VBZ>
not <RB>
mean <VB>
it <PRP>
runs <VBZ>
in <IN>
the <DT>
family <NN>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
Families <NNS>
such <JJ>
as <IN>
those <DT>
studied <VBN>
, <,>
where <WRB>
early <RB>
breast <JJ>
cancer <NN>
occurs <NNS>
often <RB>
, <,>
are <VBP>
`` <``>
really <RB>
, <,>
really <RB>
rare <JJ>
, <,>
'' <''>
said <VBD>
King <NNP>
. <.>
`` <``>
Less <RBR>
than <IN>
5 <CD>
percent <NN>
of <IN>
breast <JJ>
cancer <NN>
patients <NNS>
are <VBP>
in <IN>
such <JJ>
families <NNS>
. <.>
'' <''>
Skolnick <NNP>
said <VBD>
his <PRP$>
researchers <NNS>
studied <VBD>
103 <CD>
women <NNS>
from <IN>
20 <CD>
families <NNS>
in <IN>
which <WDT>
there <EX>
were <VBD>
at <IN>
least <JJS>
two <CD>
close <JJ>
blood <NN>
relatives <NNS>
with <IN>
breast <JJ>
cancer <NN>
. <.>
The <DT>
studies <NNS>
included <VBD>
mammography <NN>
and <CC>
the <DT>
removal <NN>
of <IN>
cells <NNS>
for <IN>
laboratory <NN>
and <CC>
genetic <JJ>
analysis <NN>
. <.>
Control <NN>
studies <NNS>
were <VBD>
done <VBN>
on <IN>
31 <CD>
women <NNS>
who <WP>
did <VBD>
not <RB>
come <VBN>
from <IN>
breast <JJ>
cancer-prone <NN>
families <NNS>
. <.>
Thirty-five <JJ>
percent <NN>
of <IN>
the <DT>
women <NNS>
in <IN>
families <NNS>
where <WRB>
breast <JJ>
cancer <NN>
was <VBD>
common <JJ>
had_laboratory_evidence <NN>
of <IN>
proliferative <JJ>
breast_disease <NN>
, <,>
or <CC>
PBD <NNP>
, <,>
Skolnick <NNP>
said <VBD>
. <.>
Among <IN>
women <NNS>
in <IN>
the <DT>
control_study <NN>
, <,>
only <RB>
13 <CD>
percent <NN>
had <VBD>
PBD <NNP>
. <.>
The <DT>
study <NN>
demonstrates <VBZ>
that <IN>
there <EX>
is <VBZ>
an <DT>
inherited <VBN>
component <NN>
in <IN>
developing <VBG>
PBD <NNP>
, <,>
he <PRP>
said <VBD>
. <.>
Skolnick <NNP>
said <VBD>
the <DT>
study <NN>
also <RB>
suggests <VBZ>
that <IN>
the <DT>
inherited <JJ>
risk <NN>
for <IN>
breast_cancer <NN>
, <,>
thought <VBD>
previously <RB>
to <TO>
be <VB>
a <DT>
factor <NN>
primarily <RB>
in <IN>
families <NNS>
in <IN>
which <WDT>
cases <NNS>
develop <VBP>
in <IN>
young <JJ>
women <NNS>
of <IN>
childbearing <VBG>
age <NN>
and <CC>
in <IN>
women <NNS>
who <WP>
develop <VB>
cancer <NN>
in <IN>
both <DT>
breasts <NNS>
, <,>
may <MD>
also <RB>
be <VB>
a <DT>
factor <NN>
in <IN>
families <NNS>
where <WRB>
the <DT>
cancer <NN>
develops <VBZ>
only <RB>
in <IN>
older <JJR>
women <NNS>
. <.>
`` <``>
Our <PRP$>
study <NN>
shows <VBZ>
that <IN>
there <EX>
is <VBZ>
a <DT>
significant_genetic <JJ>
component <NN>
for <IN>
unilateral <JJ>
( <NN>
single <JJ>
breast <NN>
) <:>
post-menopausal <JJ>
breast_cancer <NN>
as <IN>
well <RB>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
For <IN>
this <DT>
reason <NN>
, <,>
Skolnick <NNP>
said <VBD>
the <DT>
inherited <VBN>
risk <NN>
of <IN>
breast_cancer <NN>
may <MD>
be <VB>
more <RBR>
common <JJ>
than <IN>
previously <RB>
believed <VBD>
. <.>
It <PRP>
will <MD>
take <VB>
more <RBR>
studies <NNS>
to <TO>
prove <VB>
this <DT>
, <,>
however <RB>
. <.>
Science <NN>
, <,>
which <WDT>
published <VBD>
the <DT>
studies <NNS>
, <,>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
AP900708-0017 <DOCNO>
. <.>
Physicians <NNS>
need <VBP>
to <TO>
act <VB>
more <JJR>
aggressively <RB>
on <IN>
the <DT>
initial <JJ>
complaints <NNS>
of <IN>
women <NNS>
_ <NNP>
especially <RB>
younger <JJR>
women <NNS>
_ <NNP>
who <WP>
find <NN>
lumps <VBZ>
in <IN>
their <PRP$>
breasts <NNS>
, <,>
a <DT>
study <NN>
of <IN>
breast <JJ>
cancer_malpractice <NN>
claims <VBZ>
and <CC>
lawsuits <NNS>
indicates <VBZ>
. <.>
The <DT>
study <NN>
by <IN>
the <DT>
Physician_Insurers_Association <NNP>
of <IN>
America <NNP>
found <VBD>
that_in <IN>
69 <CD>
percent <NN>
of <IN>
cases <NNS>
where <WRB>
claims <NNS>
were <VBD>
paid <VBN>
because <IN>
breast <JJ>
cancer_diagnosis <NN>
was <VBD>
delayed <VBN>
, <,>
the <DT>
patient <NN>
had <VBD>
discovered <VBN>
the <DT>
lump <NN>
. <.>
`` <``>
The <DT>
physician <JJ>
needs <NNS>
to <TO>
be <VB>
impressed <VBN>
by <IN>
such <JJ>
findings <NNS>
and <CC>
order_follow-up <NN>
studies <NNS>
, <,>
'' <''>
said <VBD>
the <DT>
report <NN>
. <.>
`` <``>
This <DT>
study <NN>
indicates <VBZ>
that <IN>
self-discovery <JJ>
often <RB>
may <MD>
be <VB>
ignored <VBN>
, <,>
especially <RB>
in <IN>
younger <JJR>
women <NNS>
where <WRB>
the <DT>
incidence <NN>
of <IN>
malignancy <NN>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
less <JJR>
than_in <IN>
older <JJR>
women <NNS>
'' <''>
and <CC>
is <VBZ>
more <RBR>
difficult <JJ>
to <TO>
detect <VB>
, <,>
the <DT>
study <NN>
said <VBD>
. <.>
The <DT>
study <NN>
reviewed <VBD>
273 <CD>
paid <VBN>
claims <NNS>
reported <VBD>
by <IN>
21 <CD>
member <NN>
companies <NNS>
of <IN>
the <DT>
association <NN>
. <.>
All <DT>
of <IN>
the <DT>
cases <NNS>
involved <VBD>
a <DT>
delay <NN>
in <IN>
diagnosis <NN>
of <IN>
breast <JJ>
cancer <NN>
. <.>
Women <NNS>
with <IN>
breast <JJ>
cancer <NN>
have <VBP>
best <JJS>
chances <NNS>
of <IN>
surviving <VBG>
when <WRB>
it <PRP>
is <VBZ>
discovered <VBN>
and <CC>
treated <VBN>
in <IN>
earliest <JJS>
stages <NNS>
. <.>
The <DT>
study <NN>
, <,>
released <VBN>
at <IN>
the <DT>
association <NN>
's <POS>
annual <JJ>
meeting <NN>
in <IN>
May <NNP>
, <,>
was <VBD>
discussed <VBN>
by <IN>
members <NNS>
of <IN>
the <DT>
study_committee <NN>
in <IN>
telephone <NN>
interviews <NNS>
last <JJ>
week <NN>
. <.>
Though <IN>
breast <JJ>
cancer <NN>
is <VBZ>
more <RBR>
common <JJ>
among <IN>
older <JJR>
women <NNS>
, <,>
the <DT>
study <NN>
indicates <VBZ>
that <IN>
delayed <VBN>
diagnosis <NNS>
in <IN>
younger <JJR>
women_results <NNS>
in <IN>
the <DT>
majority <NN>
of <IN>
lawsuits <NNS>
. <.>
Nearly <RB>
70 <CD>
percent <NN>
of <IN>
the <DT>
cases <NNS>
involved <VBD>
women <NNS>
under <IN>
age <NN>
50 <CD>
, <,>
and <CC>
40 <CD>
percent <NN>
were <VBD>
filed <VBN>
by <IN>
women <NNS>
under <IN>
40 <CD>
. <.>
The <DT>
most <RBS>
common <JJ>
reason <NN>
for <IN>
delay <NN>
in <IN>
diagnosis <NN>
was <VBD>
that <IN>
`` <``>
the <DT>
physical <JJ>
findings <NNS>
at <IN>
examination <NN>
failed <VBD>
to <TO>
impress <NN>
the <DT>
physician <JJ>
, <,>
'' <''>
the <DT>
report <NN>
said <VBD>
. <.>
This <DT>
was <VBD>
the <DT>
case <NN>
for <IN>
55 <CD>
percent <NN>
of <IN>
the <DT>
women <NNS>
. <.>
The <DT>
second <JJ>
most <JJS>
common <JJ>
reason <NN>
, <,>
found <VBD>
in <IN>
35 <CD>
percent <NN>
of <IN>
cases <NNS>
, <,>
was <VBD>
that <IN>
mammogram <NN>
reports <NNS>
were <VBD>
negative <JJ>
. <.>
In <IN>
14 <CD>
percent <NN>
, <,>
mammograms <NNS>
were <VBD>
inconclusive <JJ>
. <.>
`` <``>
Doctors <NNS>
have <VBP>
to <TO>
be <VB>
more <JJR>
suspicious <JJ>
of <IN>
the <DT>
incidence <NN>
of <IN>
cancer <NN>
in <IN>
the <DT>
breast <NN>
... <:>
and <CC>
ca <MD>
n't <RB>
depend <VB>
entirely <RB>
on <IN>
the <DT>
mammogram <NN>
, <,>
'' <''>
said <VBD>
Dr._Sylvan_H._Eisman <NNP>
, <,>
a <DT>
distinguished <JJ>
professor_emeritus <NN>
of <IN>
clinical <JJ>
medicine <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Pennsylvania_School <NNP>
of <IN>
Medicine <NNP>
, <,>
who <WP>
directed <VBN>
the <DT>
study <NN>
. <.>
The <DT>
American_Medical_Association <NNP>
had <VBD>
no <DT>
comment <NN>
on <IN>
the <DT>
findings <NNS>
. <.>
The <DT>
study <NN>
suggests <VBZ>
that <IN>
a <DT>
biopsy <NN>
always <RB>
follow <VBP>
any <DT>
suspicious <JJ>
findings <NNS>
. <.>
`` <``>
It <PRP>
's <VBZ>
foolish <JJ>
not <RB>
to <TO>
do <VB>
it <PRP>
( <VB>
a <DT>
biopsy <NN>
) <:>
if <IN>
there <EX>
's <VBZ>
reasonable <JJ>
cause <NN>
of <IN>
suspicion <NN>
, <,>
'' <''>
Eisman <NNP>
said <VBD>
. <.>
The <DT>
study <NN>
also <RB>
found <VBD>
that <IN>
family_history <NN>
was <VBD>
unknown <VBN>
in <IN>
37 <CD>
percent <NN>
of <IN>
the <DT>
cases <NNS>
, <,>
though <IN>
women <NNS>
with <IN>
a <DT>
family_history <NN>
of <IN>
breast_cancer <NN>
are <VBP>
at <IN>
higher <JJR>
risk <NN>
of <IN>
getting <VBG>
the <DT>
disease <NN>
themselves <PRP>
. <.>
Lack <NNP>
of <IN>
communication <NN>
among <IN>
physicians <NNS>
involved <VBN>
in <IN>
a <DT>
case <NN>
also <RB>
can <MD>
contribute <VB>
to <TO>
delays <NNS>
in <IN>
diagnosing <VBG>
cancer <NN>
, <,>
`` <``>
as <IN>
each <DT>
often <RB>
thinks <VBZ>
the <DT>
other <JJ>
is <VBZ>
the <DT>
responsible <JJ>
physician <NN>
, <,>
'' <''>
the <DT>
study <NN>
said <VBD>
. <.>
The <DT>
study <NN>
stressed <VBD>
the <DT>
importance <NN>
of <IN>
self-examination <NN>
by <IN>
women <NNS>
, <,>
thorough <IN>
examinations <NNS>
by <IN>
a <DT>
physician <JJ>
and <CC>
regular <JJ>
mammograms <NNS>
. <.>
The <DT>
American_Cancer_Society <NNP>
recommends <VBZ>
a <DT>
mammogram <NN>
for <IN>
women <NNS>
at_around <IN>
age <NN>
35 <CD>
and <CC>
regular <JJ>
mammograms <NNS>
every <DT>
one <CD>
or <CC>
two <CD>
years <NNS>
beginning <VBG>
at <IN>
age <NN>
40 <CD>
and <CC>
annually <RB>
after <IN>
age <NN>
50 <CD>
. <.>
Among <IN>
American <NNP>
women <NNS>
, <,>
breast <JJ>
cancer <NN>
is <VBZ>
the <DT>
leading <VBG>
type <NN>
of <IN>
cancer <NN>
and <CC>
is <VBZ>
second <JJ>
only <RB>
to <TO>
lung <VB>
cancer <NN>
in <IN>
cancer <NN>
deaths <NNS>
. <.>
The <DT>
cancer_society <NN>
estimates <NNS>
that <WDT>
breast <JJ>
cancer <NN>
will <MD>
be <VB>
diagnosed <VBN>
in <IN>
142 <CD>
, <,>
000 <CD>
women <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
this <DT>
year <NN>
and <CC>
will <MD>
cause <VB>
43 <CD>
, <,>
000 <CD>
deaths <NNS>
FT932-12525 <DOCNO>
. <.>
EAT <NN>
some <DT>
cereal <NN>
before <IN>
you <PRP>
go <VBP>
to <TO>
work <VB>
; <:>
take <VB>
regular <JJ>
apple <NN>
breaks <NNS>
instead <RB>
of <IN>
drinking <VBG>
coffee <NN>
all <DT>
day <NN>
; <:>
set <NN>
about <IN>
making <VBG>
your <PRP$>
office <NN>
a <DT>
smoke-free <JJ>
zone <NN>
; <:>
and <CC>
convince <NN>
your <PRP$>
company <NN>
to <TO>
offer <VB>
cantaloup <NN>
and <CC>
broccoli <NN>
in <IN>
the <DT>
restaurant <NN>
. <.>
All_these <DT>
measures <NNS>
should <MD>
lower <JJR>
your <PRP$>
chances <NNS>
of <IN>
developing <VBG>
certain <JJ>
kinds <NNS>
of <IN>
cancer <NN>
, <,>
and <CC>
stack <NN>
the <DT>
odds <NNS>
in <IN>
favour <PRP$>
of <IN>
a <DT>
long <JJ>
retirement <NN>
. <.>
Fear <NNP>
may <MD>
stop <VB>
some <DT>
people <NNS>
from <IN>
finding <VBG>
out_about <IN>
cancer <NN>
. <.>
But <CC>
statistically <RB>
, <,>
the <DT>
chances <NNS>
of <IN>
dying <VBG>
from <IN>
it <PRP>
are <VBP>
much <RB>
less <RBR>
than_of <IN>
dying <NN>
from <IN>
heart_disease <NN>
. <.>
Cancer <NN>
is <VBZ>
not <RB>
a <DT>
single <JJ>
disease <NN>
; <:>
it <PRP>
is <VBZ>
a <DT>
whole <JJ>
spectrum <NN>
of <IN>
pathologic <JJ>
processes <NNS>
characterised <VBN>
by <IN>
a <DT>
profound_disturbance <NN>
in <IN>
the <DT>
growth <NN>
and <CC>
proliferation <NN>
of <IN>
a <DT>
cell <NN>
. <.>
In <IN>
contrast <NN>
to <TO>
a <DT>
normal <JJ>
cell <NN>
, <,>
whose <WP$>
growth <NN>
and <CC>
reproductive <JJ>
cycle <NN>
proceeds <NNS>
in <IN>
a <DT>
relatively_orderly <RB>
manner <JJR>
as <IN>
dictated <VBN>
by <IN>
genetic <JJ>
coding <NN>
, <,>
deregulated <VBD>
cancer <NN>
cells <NNS>
dominate <VBP>
and <CC>
replace <NN>
normal <JJ>
cells <NNS>
and <CC>
often <RB>
spread <JJ>
to <TO>
other <JJ>
parts <NNS>
of <IN>
the <DT>
body <NN>
. <.>
More <JJR>
than <IN>
200 <CD>
forms <NNS>
of <IN>
cancer <NN>
have <VBP>
been_identified <VBN>
and <CC>
can <MD>
be <VB>
classified <VBN>
into <IN>
three <CD>
large <JJ>
groups <NNS>
; <:>
carcinoma <NN>
( <:>
deregulation <NN>
of <IN>
those <DT>
cells <NNS>
that <IN>
act <NN>
as <IN>
lining <VBG>
for <IN>
organs <NNS>
and <CC>
secrete <JJ>
mucus <NN>
) <:>
, <,>
sarcoma <NN>
( <:>
cancers <NNS>
of <IN>
connective <JJ>
tissue <NN>
such <JJ>
as <IN>
muscle <NN>
and <CC>
bone <NN>
) <:>
and <CC>
liquid_cancer <NN>
( <:>
such <JJ>
as <IN>
leukemias <NNS>
) <:>
. <.>
Lung <NNP>
cancer <NN>
is <VBZ>
the <DT>
most <RBS>
preventable <JJ>
carcinoma <NN>
. <.>
Its <PRP$>
incidence <NN>
varies <NNS>
from <IN>
country <NN>
to <TO>
country <NN>
. <.>
Death <NN>
rates <NNS>
are <VBP>
dropping <VBG>
in <IN>
England <NNP>
, <,>
Wales <NNP>
, <,>
Finland <NNP>
and <CC>
Sweden <NNP>
, <,>
have <VBP>
plateaued <VBN>
in <IN>
Australia <NNP>
, <,>
Austria <NNP>
, <,>
the <DT>
US <NNP>
, <,>
Belgium <NNP>
, <,>
Germany <NNP>
, <,>
the <DT>
Netherlands <NNP>
, <,>
New_Zealand <NNP>
and <CC>
Switzerland <NNP>
, <,>
and <CC>
are <VBP>
still <RB>
rising <VBG>
in <IN>
Spain <NNP>
, <,>
France <NNP>
, <,>
Hungary <NNP>
, <,>
Italy <NNP>
, <,>
Ireland <NNP>
and <CC>
Poland <NNP>
. <.>
The <DT>
average <JJ>
age <NN>
for <IN>
developing <VBG>
lung_cancer <NN>
is <VBZ>
60 <CD>
. <.>
Once <RB>
diagnosed <VBD>
, <,>
less <JJR>
than <IN>
30 <CD>
per <IN>
cent <NN>
of <IN>
patients <NNS>
are <VBP>
eligible <JJ>
for <IN>
curative <JJ>
surgery <NN>
, <,>
explaining <VBG>
in <IN>
part <NN>
the <DT>
dismal <JJ>
chances <NNS>
of <IN>
survival <NN>
, <,>
less <RBR>
than <IN>
10 <CD>
per <IN>
cent <NN>
five <CD>
years <NNS>
after <IN>
diagnosis <NN>
. <.>
The <DT>
vast <JJ>
majority <NN>
of <IN>
lung <JJ>
cancers <NNS>
( <:>
around <IN>
85 <CD>
per <IN>
cent <NN>
) <:>
are <VBP>
due <JJ>
to <TO>
exposure <VB>
to <TO>
tobacco <VB>
smoke <NN>
( <:>
either <DT>
active <JJ>
or <CC>
passive <JJ>
) <NN>
, <,>
though <IN>
other <JJ>
substances <NNS>
( <:>
asbestos <NNS>
, <,>
pollution <NN>
, <,>
heavy <JJ>
metals <NNS>
and <CC>
chloromethyltethers <NNS>
) <:>
have <VBP>
strong_causative <JJ>
relationships <NNS>
with <IN>
lung <JJ>
cancers <NNS>
. <.>
If <IN>
you <PRP>
are <VBP>
unable <JJ>
to <TO>
stop <VB>
smoking <NN>
entirely <RB>
, <,>
you <PRP>
might <MD>
consider <VB>
a <DT>
less <JJR>
harmful <JJ>
way <NN>
of <IN>
getting <VBG>
nicotine <NN>
into <IN>
your <PRP$>
system <NN>
( <:>
a <DT>
pipe <NN>
, <,>
cigar <NN>
or <CC>
nicotine_patch <NN>
) <:>
. <.>
Colon <NNP>
( <:>
large <JJ>
intestine <NN>
) <:>
carcinoma <NN>
also <RB>
has <VBZ>
links <NNS>
to <TO>
lifestyle <VB>
. <.>
It <PRP>
is <VBZ>
among <IN>
the <DT>
top <JJ>
five <CD>
cancers <NNS>
in <IN>
most <JJS>
developed <JJ>
countries <NNS>
, <,>
but <CC>
unheard <RB>
of_in <IN>
some <DT>
African <JJ>
and <CC>
Asian <JJ>
countries <NNS>
. <.>
One <CD>
theory <NN>
is <VBZ>
that <IN>
it <PRP>
is <VBZ>
related <VBN>
to <TO>
the <DT>
longer_transit_time <NN>
of <IN>
faecal <JJ>
material <NN>
through <IN>
the <DT>
intestines <NNS>
in <IN>
developed <JJ>
countries <NNS>
. <.>
The <DT>
refined <VBN>
carbohydrates <NNS>
in <IN>
highly <RB>
processed <VBN>
foods <NNS>
have <VBP>
less <JJR>
cellulose <NN>
( <:>
non-absorbed <JJ>
plant_fibre <NN>
) <:>
than_in <IN>
fruits <NNS>
and <CC>
vegetables <NNS>
. <.>
They <PRP>
travel <VBP>
slower <JJR>
through <IN>
the <DT>
intestines <NNS>
which <WDT>
may <MD>
be <VB>
conducive <JJ>
to <TO>
inactive <JJ>
carcinogens <NNS>
turning <VBG>
into <IN>
active <JJ>
ones <NNS>
. <.>
Eating <VBG>
more <JJR>
fresh <JJ>
fruits <NNS>
and <CC>
vegetables <NNS>
, <,>
or <CC>
bran <NN>
cereals <NNS>
can <MD>
help_prevent <VB>
colon_cancer <NN>
. <.>
With <IN>
the <DT>
help <NN>
of <IN>
a <DT>
qualified <VBN>
nutritionist <NN>
, <,>
also <RB>
try <VBP>
limiting <VBG>
saturated <VBN>
( <-NONE->
animal <JJ>
) <NN>
fats <NNS>
to <TO>
less <JJR>
than <IN>
25 <CD>
per <IN>
cent <NN>
of <IN>
your <PRP$>
diet <NN>
. <.>
If <IN>
colon_cancer <NN>
or <CC>
polyps <NNS>
runs <VBZ>
in <IN>
your <PRP$>
family <NN>
, <,>
consult <NN>
your <PRP$>
doctor <NN>
about <IN>
when <WRB>
to <TO>
have <VB>
preventative <JJ>
screenings <NNS>
. <.>
Prostate <NNP>
cancer <NN>
, <,>
another <DT>
kind <NN>
of <IN>
carcinoma <NN>
, <,>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
malignant_tumour <NN>
in <IN>
men <NNS>
worldwide <VBP>
. <.>
The <DT>
cause <NN>
of <IN>
this <DT>
slow-growing <JJ>
tumour <NN>
is <VBZ>
unknown <VBN>
, <,>
although <IN>
there <EX>
appears <VBZ>
to <TO>
be <VB>
a <DT>
hormonal <JJ>
relationship <NN>
. <.>
It <PRP>
appears <VBZ>
to <TO>
be <VB>
on <IN>
the <DT>
increase <NN>
even <RB>
in <IN>
areas <NNS>
where <WRB>
it <PRP>
was <VBD>
previously <RB>
uncommon <JJ>
, <,>
such <JJ>
as <IN>
east <JJ>
and <CC>
southeast <JJ>
Asia <NNP>
. <.>
Prostate <NNP>
cancer <NN>
is <VBZ>
frequent <NN>
in <IN>
North_America <NNP>
and <CC>
Europe <NNP>
. <.>
Incidence <NN>
and <CC>
mortality_increase <NN>
in <IN>
Chinese <NNP>
and <CC>
Japanese <JJ>
after <IN>
migrating <NN>
to <TO>
the <DT>
US <NNP>
. <.>
Prostate <NNP>
cancer <NN>
is <VBZ>
rare <JJ>
before <IN>
the <DT>
age <NN>
of <IN>
50 <CD>
but <CC>
then <RB>
its <PRP$>
occurence <NN>
grows <VBZ>
steeply <RB>
with <IN>
age <NN>
until_about <IN>
80 <CD>
when <WRB>
it <PRP>
begins <VBZ>
to <TO>
fall <VB>
again <RB>
except_in <IN>
Norwegian <NNP>
, <,>
French <NNP>
and <CC>
Japanese <JJ>
populations <NNS>
. <.>
When <WRB>
it <PRP>
comes <VBZ>
to <TO>
screening <VBG>
, <,>
a <DT>
combination <NN>
of <IN>
Digital_Rectal_Exam <NNP>
and <CC>
a <DT>
relatively <RB>
inexpensive <JJ>
blood_test <NN>
is <VBZ>
probably <RB>
the <DT>
best <JJS>
balance <NN>
between <IN>
cost <NN>
, <,>
benefit <NN>
and <CC>
efficacy <NN>
. <.>
The <DT>
author <NN>
is <VBZ>
medical <JJ>
director <NN>
of <IN>
the <DT>
Insead_Business_Health <NNP>
course <NN>
AP901130-0022 <DOCNO>
. <.>
An <DT>
abnormal <JJ>
gene <NN>
found <VBD>
in <IN>
some <DT>
families <NNS>
can <MD>
lead <VB>
to <TO>
a <DT>
high <JJ>
susceptibility <NN>
to <TO>
breast <VB>
cancer <NN>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
published <VBN>
today <NN>
. <.>
The <DT>
finding <NN>
is <VBZ>
a <DT>
major <JJ>
step <NN>
that <WDT>
puts <VBZ>
researchers <NNS>
closer <JJR>
to <TO>
understanding <NN>
the <DT>
inherited <VBN>
tendency <NN>
to <TO>
develop <VB>
malignancies <NNS>
, <,>
says <VBZ>
study <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
The <DT>
inherited <VBN>
genetic <JJ>
mutation <NN>
was <VBD>
discovered <VBN>
by <IN>
studying <NN>
the <DT>
genes <NNS>
in <IN>
a <DT>
small <JJ>
group <NN>
of <IN>
families <NNS>
that <WDT>
experience <NN>
in <IN>
generation <NN>
after <IN>
generation <NN>
of <IN>
an <DT>
exceptionally <RB>
high <JJ>
rate <NN>
of <IN>
six <CD>
types <NNS>
of <IN>
cancer <NN>
, <,>
including <VBG>
breast_cancer <NN>
. <.>
`` <``>
Up_until <IN>
now <RB>
there <EX>
have <VBP>
been <VBN>
no <DT>
inherited <VBN>
genes <NNS>
isolated <VBN>
and <CC>
identified <VBD>
which <WDT>
provided <VBN>
susceptibilities <NNS>
to <TO>
some <DT>
of <IN>
the <DT>
common <JJ>
adult <NN>
malignancies <NNS>
, <,>
'' <''>
said <VBD>
Dr._Stephen_Friend <NNP>
of <IN>
Massachusetts_General_Hospital_Cancer_Center <NNP>
. <.>
Scientists <NNS>
have <VBP>
long <RB>
questioned <VBN>
whether <IN>
a <DT>
single <JJ>
mutation <NN>
in <IN>
a <DT>
single <JJ>
inherited <VBN>
gene <NN>
could <MD>
advance <VB>
the <DT>
tendency <NN>
to <TO>
develop <VB>
cancer <NN>
. <.>
Friend <NN>
said <VBD>
the <DT>
study <NN>
settles <VBZ>
that <IN>
question <NN>
. <.>
`` <``>
This <DT>
shows <VBZ>
that <IN>
the <DT>
answer <NN>
is <VBZ>
yes <NNS>
, <,>
'' <''>
said <VBD>
Friend <NNP>
. <.>
`` <``>
If <IN>
you <PRP>
are <VBP>
born <VBN>
with <IN>
an <DT>
inactive <JJ>
region <NN>
in <IN>
one <CD>
gene <NN>
, <,>
then <RB>
that <IN>
gives <NNS>
you <PRP>
a <DT>
hidden <JJ>
susceptibility <NN>
to <TO>
malignancies <NNS>
. <.>
'' <''>
Although <IN>
the <DT>
breast_cancer <NN>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
disease <NN>
related <VBN>
to <TO>
the <DT>
mutated <VBN>
gene <NN>
, <,>
Friend <NNP>
said <VBD>
it <PRP>
is <VBZ>
not <RB>
the <DT>
only_genetic <JJ>
cause <NN>
of <IN>
breast <JJ>
cancer <NN>
. <.>
`` <``>
There <EX>
are <VBP>
multiple <JJ>
genes <NNS>
for <IN>
breast <JJ>
cancer <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
`` <``>
This <DT>
happens <VBZ>
to <TO>
be <VB>
the <DT>
first <JJ>
, <,>
but <CC>
it <PRP>
wo <MD>
n't <RB>
be <VB>
the <DT>
last <JJ>
. <.>
'' <''>
Female <NNP>
breast_cancer <NN>
strikes <VBZ>
about <IN>
130 <CD>
, <,>
000 <CD>
American <NNP>
women <NNS>
annually <RB>
and <CC>
kills <NNS>
about <IN>
41 <CD>
, <,>
000 <CD>
. <.>
Friend <NN>
said <VBD>
that <IN>
`` <``>
it <PRP>
is <VBZ>
unclear <JJ>
at <IN>
this <DT>
time <NN>
which <WDT>
of <IN>
those <DT>
many <JJ>
women <NNS>
have <VBP>
the <DT>
... <:>
mutation <NN>
. <.>
'' <''>
Friend <NNP>
, <,>
who <WP>
was <VBD>
lead <VBP>
author <NN>
of <IN>
the <DT>
study <NN>
, <,>
said <VBD>
the <DT>
mutation <NN>
was <VBD>
found <VBN>
on <IN>
what <WP>
is <VBZ>
called <VBN>
the <DT>
p53 <NNP>
cancer_suppressor_gene <NN>
. <.>
For <IN>
people <NNS>
who <WP>
inherit <NN>
a <DT>
mutated <JJ>
p53 <NNP>
gene <NN>
, <,>
he <PRP>
said <VBD>
, <,>
`` <``>
their <PRP$>
chance <NN>
of <IN>
getting <VBG>
a <DT>
malignancy <NN>
by <IN>
age <NN>
60 <CD>
is <VBZ>
90 <CD>
percent <NN>
. <.>
'' <''>
Dr._Andrew_Feinberg <NNP>
, <,>
a <DT>
University <NNP>
of <IN>
Michigan_Cancer_Center <NNP>
researcher <NN>
and <CC>
co-discoverer <JJ>
of <IN>
genes <NNS>
related <VBN>
to <TO>
a <DT>
rare_kidney_cancer <NN>
, <,>
said <VBD>
the <DT>
p53 <NNP>
discovery <NN>
adds <VBZ>
a <DT>
step <NN>
in <IN>
the <DT>
cascade <NN>
of <IN>
cell <NN>
changes <NNS>
that <WDT>
is <VBZ>
thought <VBN>
to <TO>
lead <VB>
to <TO>
some <DT>
cancers <NNS>
. <.>
`` <``>
From <IN>
a <DT>
scientific <JJ>
viewpoint <NN>
, <,>
it <PRP>
is <VBZ>
very <RB>
important <JJ>
because <IN>
it <PRP>
helps <VBZ>
us <PRP>
understand <VBP>
the <DT>
sequence <NN>
of <IN>
events <NNS>
that <WDT>
lead <NN>
to <TO>
cancer <NN>
, <,>
'' <''>
said <VBD>
Feinberg <NNP>
. <.>
However <RB>
, <,>
he <PRP>
emphasized <VBD>
that <IN>
there <EX>
are <VBP>
a <DT>
number <NN>
of <IN>
other <JJ>
steps <NNS>
, <,>
still <RB>
unknown <JJ>
, <,>
that <IN>
cause <NN>
a <DT>
normal <JJ>
cell <NN>
to <TO>
become <VB>
cancerous <JJ>
. <.>
The <DT>
p53 <NNP>
gene <NN>
is <VBZ>
one <CD>
of <IN>
a <DT>
group <NN>
of <IN>
genes <NNS>
that <WDT>
control <NN>
cell <VBD>
growth <NN>
. <.>
The <DT>
gene <NN>
, <,>
in <IN>
effect <NN>
, <,>
blocks <NNS>
the <DT>
uncontrolled <JJ>
division <NN>
of <IN>
cells <NNS>
, <,>
hence <NN>
, <,>
suppresses <NNS>
tumor <CC>
development <NN>
. <.>
If <IN>
this <DT>
function <NN>
is <VBZ>
lost <VBN>
through <IN>
mutation <NN>
, <,>
then <RB>
the <DT>
cell <NN>
lacks <VBZ>
one <CD>
of <IN>
the <DT>
controls <NNS>
that <WDT>
keep <VB>
division <NN>
in <IN>
balance <NN>
. <.>
The <DT>
mutated <VBN>
p53 <NNP>
gene <NN>
has <VBZ>
been_detected <VBN>
in <IN>
the <DT>
past <JJ>
in <IN>
a <DT>
number <NN>
of <IN>
types <NNS>
of <IN>
cancers <NNS>
, <,>
but <CC>
the <DT>
new <JJ>
study <NN>
is <VBZ>
the <DT>
first <JJ>
to <TO>
find <VB>
that <IN>
the <DT>
mutation <NN>
can <MD>
be <VB>
inherited <VBN>
. <.>
Inherited <NNP>
gene <NN>
mutations <NNS>
have <VBP>
been_related <VBN>
in <IN>
earlier <JJR>
studies <NNS>
to <TO>
rare <VB>
eye <NN>
and <CC>
kidney <NN>
cancers <NNS>
. <.>
Friend <NN>
said <VBD>
he <PRP>
and <CC>
his <PRP$>
colleagues <NNS>
isolated <VBD>
the <DT>
specific <JJ>
p53 <NNP>
gene_mutation <NN>
by <IN>
studying <NN>
people <NNS>
with <IN>
what <WP>
is <VBZ>
called <VBN>
the <DT>
Li-Fraumeni <NNP>
syndrome <NN>
. <.>
These <DT>
are <VBP>
families <NNS>
in <IN>
which <WDT>
there <EX>
is <VBZ>
an <DT>
inherited <VBN>
tendency <NN>
to <TO>
develop <VB>
one <CD>
of <IN>
six <CD>
types <NNS>
of <IN>
cancer <NN>
at <IN>
an <DT>
early <JJ>
age <NN>
, <,>
often <RB>
during <IN>
childhood <NN>
. <.>
Breast <NNP>
cancer <NN>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
malignancy <NN>
among <IN>
Li-Fraumeni <NNP>
families <NNS>
, <,>
but <CC>
they <PRP>
also <RB>
can <MD>
develop <VB>
leukemias <NNS>
, <,>
brain <NN>
tumors <NNS>
, <,>
sarcomas <NNS>
of <IN>
the <DT>
bone <NN>
and <CC>
cancer <NN>
of <IN>
the <DT>
adrenal <JJ>
gland <NN>
. <.>
The <DT>
researchers <NNS>
discovered <VBN>
the <DT>
mutation <NN>
in <IN>
the <DT>
cells <NNS>
of <IN>
Li-Fraumeni <NNP>
family <NN>
members <NNS>
who <WP>
had <VBD>
cancer <NN>
, <,>
but <CC>
not <RB>
in <IN>
those <DT>
family <NN>
members <NNS>
who <WP>
were <VBD>
free <JJ>
of <IN>
the <DT>
disease <NN>
. <.>
Friend <NN>
said <VBD>
that_in <IN>
the <DT>
affected <VBN>
family <NN>
members <NNS>
the <DT>
p53 <NNP>
mutation <NN>
was <VBD>
found <VBN>
in <IN>
every <DT>
cell <NN>
, <,>
indicating <VBG>
it <PRP>
was <VBD>
passed <VBN>
genetically <RB>
from <IN>
one <CD>
generation <NN>
to <TO>
another <DT>
. <.>
The <DT>
Li-Fraumeni <NNP>
syndrome <NN>
was <VBD>
first <JJ>
described <VBN>
by <IN>
Frederick_P._Li <NNP>
and <CC>
Joseph_F._Fraumeni_Jr. <NNP>
, <,>
both <DT>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
and <CC>
coauthors <NNS>
of <IN>
the <DT>
study <NN>
in <IN>
Science <NNP>
. <.>
The <DT>
syndrome <NN>
is <VBZ>
very <RB>
rare <JJ>
, <,>
with <IN>
only <RB>
about <IN>
200 <CD>
such <JJ>
families <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
With <IN>
discovery <NN>
of <IN>
the <DT>
p53 <NNP>
mutation <NN>
, <,>
Friend <NNP>
said <VBD>
a <DT>
screening_process <NN>
may <MD>
be <VB>
developed <VBN>
to <TO>
determine <VB>
which <WDT>
members <NNS>
in <IN>
a <DT>
Li-Fraumeni <NNP>
family <NN>
have <VBP>
inherited <VBN>
the <DT>
abnormal <JJ>
gene <NN>
. <.>
When <WRB>
one <CD>
parent <NN>
in <IN>
a <DT>
family <NN>
has <VBZ>
the <DT>
mutation <NN>
, <,>
there <EX>
is <VBZ>
a <DT>
50-50 <CD>
chance <NN>
that <IN>
each <DT>
child <NN>
will <MD>
inherit <VB>
it <PRP>
. <.>
Children <NNP>
that <IN>
show <NN>
the <DT>
mutation <NN>
, <,>
said <VBD>
Friend <NNP>
, <,>
could <MD>
then <RB>
undergo <VB>
periodic <JJ>
, <,>
intensified <VBD>
examinations <NNS>
for <IN>
cancer <NN>
so <RB>
that <IN>
the <DT>
malignancies <NNS>
they <PRP>
will <MD>
almost_certainly <RB>
develop <VB>
could <MD>
be <VB>
found <VBN>
very_early <RB>
. <.>
Science <NN>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
AP890309-0132 <DOCNO>
. <.>
The <DT>
number <NN>
of <IN>
older <JJR>
women <NNS>
getting <VBG>
mammograms <NNS>
increased <VBD>
noticeably <RB>
after <IN>
Nancy_Reagan <NNP>
's <POS>
breast <JJ>
cancer_diagnosis <NN>
, <,>
researchers <NNS>
said <VBD>
Thursday <NNP>
. <.>
A <DT>
survey <NN>
taken <VBN>
in <IN>
33 <CD>
states <NNS>
by <IN>
the <DT>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
found <VBD>
that <IN>
38 <CD>
percent <NN>
of <IN>
women <NNS>
age <NN>
50 <CD>
and <CC>
up <IN>
questioned <VBN>
in <IN>
November <NNP>
and <CC>
December <NNP>
1987 <CD>
said <VBD>
they <PRP>
had <VBD>
received <VBN>
a <DT>
screening_mammogram <NN>
for <IN>
breast_cancer <NN>
within <IN>
the <DT>
previous <JJ>
year <NN>
. <.>
That <DT>
was <VBD>
up_nearly <RB>
half <NN>
again <RB>
from <IN>
the <DT>
26 <CD>
percent <NN>
the <DT>
survey <NN>
found <VBD>
in <IN>
the <DT>
first <JJ>
two <CD>
months <NNS>
of <IN>
that <DT>
year <NN>
. <.>
Mrs._Reagan <NNP>
's <POS>
diagnosis <NN>
for <IN>
breast_cancer <NN>
occurred <VBD>
in <IN>
October <NNP>
1987 <CD>
when <WRB>
she <PRP>
was <VBD>
first <JJ>
lady <NN>
. <.>
It <PRP>
was <VBD>
one <CD>
of <IN>
two <CD>
events <NNS>
that <WDT>
directed <VBN>
public <JJ>
attention <NN>
to <TO>
the <DT>
disease <NN>
that <IN>
year <NN>
. <.>
In <IN>
March <NNP>
, <,>
April <NNP>
and <CC>
May <NNP>
the <DT>
American_Cancer_Society <NNP>
conducted <VBD>
a <DT>
media_campaign <NN>
to <TO>
promote <VB>
screening <NN>
for <IN>
breast_cancer <NN>
. <.>
`` <``>
The <DT>
percentage <NN>
of <IN>
women <NNS>
who <WP>
reported <VBD>
being <VBG>
screened_increased <VBN>
coincident <NN>
with <IN>
the <DT>
ACS <NNP>
... <:>
campaign <NN>
and <CC>
again <RB>
after <IN>
the <DT>
diagnosis <NN>
of <IN>
Mrs._Reagan <NNP>
's <POS>
breast <JJ>
cancer <NN>
, <,>
'' <''>
the <DT>
CDC <NNP>
said <VBD>
. <.>
Data <NNP>
from <IN>
the <DT>
CDC <NNP>
survey <NN>
`` <``>
suggest <VBP>
that_the <DT>
media_events <NNS>
and <CC>
educational <JJ>
activities <NNS>
were <VBD>
accompanied <VBN>
by <IN>
increases <NNS>
in <IN>
screening <VBG>
mammograms <NNS>
, <,>
'' <''>
the <DT>
agency <NN>
said <VBD>
. <.>
It <PRP>
acknowledged <VBD>
there <RB>
was <VBD>
no <DT>
statistical <JJ>
proof_of <IN>
cause <NN>
and <CC>
effect <NN>
. <.>
The <DT>
survey <NN>
did <VBD>
not <RB>
include <VB>
women <NNS>
who <WP>
had <VBD>
mammograms <NNS>
because_of <IN>
a <DT>
specific <JJ>
health_problem <NN>
or <CC>
history <NN>
, <,>
or <CC>
those <DT>
who <WP>
had <VBD>
n't <RB>
seen <VBN>
a <DT>
doctor <NN>
for <IN>
a <DT>
routine_examination <NN>
at <IN>
all <DT>
. <.>
Medical <JJ>
centers <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
reported <VBD>
after <IN>
Mrs._Reagan's <NNP>
diagnosis <NN>
that <WDT>
the <DT>
demand <NN>
for <IN>
mammograms <NNS>
had <VBD>
gone <VBN>
up <RP>
. <.>
She <PRP>
later <JJ>
was <VBD>
honored <VBN>
with <IN>
an <DT>
American <JJ>
Cancer <NN>
Society_Courage_Award <NNP>
for <IN>
encouraging <VBG>
women <NNS>
to <TO>
check <VB>
for <IN>
breast <JJ>
cancer <NN>
. <.>
The <DT>
ACS <NNP>
recommends <VBZ>
that <IN>
all <DT>
women <NNS>
50 <CD>
or <CC>
older <JJR>
have <VBP>
a <DT>
mammogram <NN>
each <DT>
year <NN>
, <,>
but <CC>
studies <NNS>
have <VBP>
found <VBN>
that <IN>
most <JJS>
women <NNS>
in <IN>
that <DT>
group <NN>
have <VBP>
never <RB>
had <VBD>
a <DT>
mammogram <NN>
. <.>
Cancer <NN>
specialists <NNS>
at <IN>
the <DT>
CDC <NNP>
and <CC>
elsewhere <RB>
say <VB>
increased <VBN>
use <NN>
of <IN>
mammograms <NNS>
would <MD>
increase <VB>
early <JJ>
detection <NN>
of <IN>
breast <JJ>
cancer <NN>
, <,>
raising <VBG>
survival <NN>
rates <NNS>
for <IN>
patients <NNS>
. <.>
The <DT>
cancer_society <NN>
recommends <NNS>
that <WDT>
women <NNS>
between <IN>
35 <CD>
and <CC>
40 <CD>
have <VBP>
one <CD>
initial <JJ>
mammogram <NN>
, <,>
and <CC>
that <IN>
women <NNS>
40-49 <CD>
have <VBP>
one <CD>
each <DT>
year <NN>
or <CC>
two <CD>
. <.>
Breast <NNP>
cancer <NN>
, <,>
second <JJ>
to <TO>
lung <JJ>
cancer <NN>
as <IN>
a <DT>
cause <NN>
of <IN>
cancer <NN>
deaths <NNS>
among <IN>
women <NNS>
, <,>
kills <NNS>
about <IN>
40 <CD>
, <,>
000 <CD>
U.S. <NNP>
women <NNS>
each <DT>
year <NN>
FBIS4-67666 <DOCNO>
. <.>
BFN <NNP>
[ <:>
Article <NNP>
by <IN>
Susie_Weldon_]_[_Text_]_Viral <NNP>
hepatitis <VBZ>
infections <NNS>
surged <VBD>
in <IN>
1992 <CD>
, <,>
with <IN>
more <JJR>
than <IN>
twice <NN>
as <IN>
many <JJ>
cases <NNS>
recorded <VBN>
as <RB>
in <IN>
the <DT>
previous <JJ>
year <NN>
, <,>
according <VBG>
to <TO>
statistics <NNS>
just <RB>
released <VBN>
by <IN>
the <DT>
Department <NNP>
of <IN>
Health <NNP>
. <.>
More <JJR>
people <NNS>
were <VBD>
also <RB>
diagnosed <VBN>
as <IN>
having <NN>
sexually <RB>
transmitted <VBN>
diseases <NNS>
, <,>
died <VBD>
of <IN>
lung <JJ>
cancer <NN>
and <CC>
heart_disease <NN>
, <,>
or <CC>
were <VBD>
admitted <VBN>
to <TO>
hospital <JJ>
because_of <IN>
injury <NN>
or <CC>
poisoning <VBG>
. <.>
The <DT>
department <NN>
's <POS>
annual <JJ>
report <NN>
for <IN>
1992-93 <CD>
shows <NNS>
that <WDT>
4 <CD>
, <,>
357 <CD>
hepatitis_cases <NNS>
were <VBD>
reported <VBN>
in <IN>
1992 <CD>
compared <VBN>
with <IN>
1 <CD>
, <,>
801 <CD>
in <IN>
1991 <CD>
. <.>
Almost <RB>
all <DT>
were <VBD>
hepatitis <NNS>
A <DT>
, <,>
157 <CD>
were <VBD>
hepatitis <NNS>
B <NNP>
and <CC>
301 <CD>
were <VBD>
classified <VBN>
as <IN>
neither_A <DT>
nor <NN>
B <NNP>
. <.>
The <DT>
report <NN>
said <VBD>
the <DT>
infections <NNS>
were <VBD>
due <JJ>
to <TO>
eating <VBG>
raw <NN>
or <CC>
badly <RB>
cooked <VBN>
seafood <NN>
from <IN>
Hong_Kong <NNP>
's <POS>
polluted <VBN>
waters <NNS>
. <.>
Other <JJ>
figures <NNS>
in <IN>
the <DT>
report_show <NN>
Hong_Kong <NNP>
people <NNS>
died <VBD>
from <IN>
the <DT>
same_serious <JJ>
diseases <NNS>
, <,>
in_about <IN>
the <DT>
same <JJ>
proportions <NNS>
, <,>
in <IN>
1992 <CD>
as_in <IN>
the <DT>
previous <JJ>
year <NN>
. <.>
The <DT>
biggest <JJS>
killers <NNS>
were <VBD>
cancers <NNS>
, <,>
heart <NN>
diseases <NNS>
and <CC>
cerebrovascular <JJ>
diseases <NNS>
, <,>
which <WDT>
together <RB>
accounted <VBD>
for <IN>
almost <RB>
two-thirds <NNS>
of <IN>
all <DT>
deaths <NNS>
. <.>
As_in <IN>
the <DT>
previous <JJ>
year <NN>
, <,>
lung <JJ>
cancer <NN>
killed <VBD>
more <JJR>
men <NNS>
and <CC>
women <NNS>
than <IN>
any <DT>
other <JJ>
tumour <NN>
, <,>
causing <VBG>
2 <CD>
, <,>
761 <CD>
deaths <NNS>
in <IN>
1992 <CD>
. <.>
Most <JJS>
of <IN>
these <DT>
were <VBD>
due <JJ>
to <TO>
smoking <NN>
, <,>
the <DT>
department <NN>
said <VBD>
. <.>
Liver <RB>
cancer <NN>
and <CC>
naspharyngeal_cancer <NN>
were <VBD>
the <DT>
second <JJ>
and <CC>
third <JJ>
most <RBS>
common <JJ>
tumours <NNS>
among <IN>
men <NNS>
, <,>
compared <VBN>
to <TO>
breast <VB>
and <CC>
colon_cancer <NN>
among <IN>
women <NNS>
. <.>
Although <IN>
slightly <RB>
fewer <JJR>
people <NNS>
died <VBD>
of <IN>
a <DT>
heart_attack <NN>
in <IN>
1992 <CD>
-- <:>
1 <CD>
, <,>
785 <CD>
men <NNS>
and <CC>
women <NNS>
-- <:>
overall <JJ>
deaths <NNS>
from <IN>
heart_disease <NN>
rose <VBD>
by_about <IN>
400 <CD>
, <,>
to <TO>
5 <CD>
, <,>
359 <CD>
. <.>
More <JJR>
babies <NNS>
died <VBD>
in <IN>
that <DT>
year <NN>
because <IN>
they <PRP>
were <VBD>
born <VBN>
too <RB>
small <JJ>
. <.>
Almost <RB>
24 <CD>
percent <NN>
( <:>
83 <CD>
deaths <NNS>
) <:>
of <IN>
infant <JJ>
mortalities <NNS>
in <IN>
1992 <CD>
were <VBD>
blamed <VBN>
on <IN>
immaturity <NN>
, <,>
compared <VBN>
with <IN>
about <RB>
15 <CD>
percent <NN>
( <:>
67 <CD>
deaths <NNS>
) <:>
the <DT>
previous <JJ>
year <NN>
. <.>
A <DT>
staggering <NN>
82 <CD>
, <,>
800 <CD>
patients <NNS>
were <VBD>
treated <VBN>
in <IN>
hospital <NN>
because_of <IN>
injury <NN>
and <CC>
poisoning <VBG>
in <IN>
1992 <CD>
, <,>
making <VBG>
the <DT>
category <NN>
the <DT>
leading <VBG>
cause <NN>
of <IN>
hospital_admission <NN>
. <.>
Of <IN>
the <DT>
1 <CD>
, <,>
693 <CD>
deaths <NNS>
from <IN>
injury <NN>
and <CC>
poisoning <VBG>
-- <:>
the <DT>
fifth <JJ>
biggest_cause <NN>
of <IN>
death <NN>
in <IN>
1992 <CD>
-- <:>
almost <RB>
45 <CD>
percent <NN>
were <VBD>
self <PRP>
inflicted <VBN>
or <CC>
due <JJ>
to <TO>
suicide <VB>
. <.>
The <DT>
other <JJ>
main <NN>
causes <NNS>
of <IN>
hospital <JJ>
admission <NN>
were <VBD>
circulatory <NN>
diseases <NNS>
( <:>
67 <CD>
, <,>
800 <CD>
) <:>
, <,>
cancer <NN>
( <:>
65 <CD>
, <,>
000 <CD>
) <:>
and <CC>
normal <JJ>
delivery <NN>
( <:>
54 <CD>
, <,>
600 <CD>
) <:>
. <.>
Nearly <RB>
3 <CD>
, <,>
000 <CD>
more <JJR>
people <NNS>
were <VBD>
diagnosed <VBN>
with <IN>
sexually <RB>
transmitted <VBN>
diseases <NNS>
in <IN>
1992 <CD>
, <,>
making <VBG>
a <DT>
total <NN>
of <IN>
13 <CD>
, <,>
257 <CD>
cases <NNS>
. <.>
Almost <RB>
60 <CD>
percent <NN>
of <IN>
these <DT>
were <VBD>
in <IN>
men <NNS>
aged <VBD>
between <IN>
20 <CD>
to <TO>
40 <CD>
years <NNS>
. <.>
One <CD>
man <NN>
died <VBD>
from <IN>
syphilis <NNS>
. <.>
More <JJR>
than <IN>
5 <CD>
, <,>
000 <CD>
people <NNS>
were <VBD>
treated <VBN>
in <IN>
hospital <NN>
for <IN>
`` <``>
the <DT>
effects <NNS>
of <IN>
a <DT>
foreign <JJ>
body <NN>
entering <VBG>
through <IN>
orifice <NN>
'' <''>
, <,>
while <IN>
about <RB>
2 <CD>
, <,>
560 <CD>
were <VBD>
admitted <VBN>
because_of <IN>
complications <NNS>
arising <VBG>
from <IN>
previous_medical <JJ>
or <CC>
surgical <JJ>
care <NN>
. <.>
Doctors <NNS>
were <VBD>
unable <JJ>
to <TO>
diagnose <VB>
the <DT>
illness <NN>
in_about <IN>
11 <CD>
, <,>
300 <CD>
cases <NNS>
. <.>
Almost <RB>
3 <CD>
, <,>
400 <CD>
people <NNS>
died <VBD>
because <IN>
they <PRP>
were <VBD>
killed <VBN>
or <CC>
fatally <RB>
injured <VBN>
by <IN>
other <JJ>
people <NNS>
. <.>
One <CD>
person <NN>
died <VBD>
because_of <IN>
injuries <NNS>
resulting <VBG>
from <IN>
`` <``>
operation <NN>
of <IN>
war <NN>
'' <''>
in <IN>
1992 <CD>
SJMN91-06051091 <DOCNO>
. <.>
Among <IN>
California <NNP>
's <POS>
15 <CD>
largest <JJS>
counties <NNS>
in <IN>
1988 <CD>
, <,>
only <RB>
San_Francisco <NNP>
exceeded <VBD>
the <DT>
overall <JJ>
cancer_rate <NN>
in <IN>
the <DT>
nation <NN>
for <IN>
males <NNS>
, <,>
officials <NNS>
said <VBD>
. <.>
The <DT>
higher <JJR>
rate <NN>
is <VBZ>
due <JJ>
to <TO>
the <DT>
large <JJ>
number <NN>
of <IN>
AIDS-related <JJ>
cancers <NNS>
. <.>
; <:>
State_Department <NNP>
of <IN>
Health <NNP>
Services <NNPS>
Director_Ken_Kizer <NNP>
said <VBD>
during <IN>
a <DT>
news_conference <NN>
that <WDT>
the <DT>
state <NN>
's <POS>
significant <JJ>
populations <NNS>
of <IN>
Hispanics <NNP>
and <CC>
Asians <NNPS>
have <VBP>
lower <JJR>
rates <NNS>
than <IN>
other_ethnic <JJ>
groups <NNS>
, <,>
which <WDT>
may <MD>
explain <VB>
California <NNP>
's <POS>
overall <JJ>
ranking <NN>
below <IN>
the <DT>
national <JJ>
rate <NN>
. <.>
; <:>
A <DT>
report <NN>
on <IN>
the <DT>
1987 <CD>
and <CC>
1988 <CD>
incidence <NN>
of <IN>
cancer <NN>
shows <NNS>
that <WDT>
rates <NNS>
for <IN>
the <DT>
Los_Angeles <NNP>
region <NN>
were <VBD>
the <DT>
lowest <JJS>
in <IN>
the <DT>
state <NN>
, <,>
while <IN>
those <DT>
for <IN>
the <DT>
San_Francisco <NNP>
, <,>
Sacramento <NNP>
and <CC>
Orange <NNP>
county <NN>
areas <NNS>
nearly <RB>
matched <VBN>
those <DT>
of <IN>
the <DT>
nation <NN>
. <.>
; <:>
The <DT>
American_Cancer_Society <NNP>
hailed <VBD>
the <DT>
news <NN>
of <IN>
the <DT>
lower <JJR>
rates <NNS>
in <IN>
California <NNP>
and <CC>
Los_Angeles <NNP>
, <,>
but <CC>
University <NNP>
of <IN>
Southern_California <NNP>
cancer <NN>
experts <NNS>
cautioned <VBD>
that <IN>
the <DT>
report <NN>
may <MD>
provide <VB>
a <DT>
distorted <JJ>
picture <NN>
. <.>
; <:>
Leslie_Bernstein <NNP>
, <,>
scientific <JJ>
director <NN>
of <IN>
the <DT>
USC-Los_Angeles_County_Cancer_Surveillance_Program <NNP>
, <,>
said <VBD>
the <DT>
report <NN>
does <VBZ>
not <RB>
take <VB>
into <IN>
account <NN>
how <WRB>
populations <NNS>
vary <JJ>
across <IN>
the <DT>
state <NN>
in <IN>
its <PRP$>
region-to-region <NN>
comparisons <NNS>
. <.>
; <:>
'' <''>
Los_Angeles_County <NNP>
appears <VBZ>
to <TO>
have <VB>
low <JJ>
cancer <NN>
rates <NNS>
because <IN>
it <PRP>
has <VBZ>
more <JJR>
Asians <NNS>
and <CC>
Latinos <NNP>
than <IN>
other <JJ>
counties <NNS>
. <.>
The <DT>
cancer <NN>
rates <NNS>
of <IN>
Asians <NNPS>
and <CC>
Latinos <NNP>
are <VBP>
known <VBN>
to <TO>
be <VB>
30 <CD>
percent <NN>
to <TO>
40 <CD>
percent <NN>
lower <JJR>
than <IN>
those <DT>
of <IN>
blacks <NNS>
and <CC>
whites <NNS>
, <,>
'' <''>
Bernstein <NNP>
said <VBD>
. <.>
; <:>
The <DT>
lower <JJR>
rates <NNS>
for <IN>
Asians <NNPS>
and <CC>
Hispanics <NNP>
is <VBZ>
believed <VBN>
to <TO>
be <VB>
due <JJ>
to <TO>
their <PRP$>
diets <NNS>
. <.>
; <:>
Among <IN>
the <DT>
major <JJ>
findings <NNS>
of <IN>
the <DT>
report <NN>
:_;_( <:>
check <NN>
) <:>
Breast <NNP>
cancer <NN>
was <VBD>
the <DT>
most <JJS>
frequently <RB>
diagnosed <VBN>
cancer <NN>
in <IN>
California <NNP>
. <.>
In <IN>
1988 <CD>
, <,>
there <EX>
were <VBD>
16 <CD>
, <,>
342 <CD>
cases <NNS>
among <IN>
California <NNP>
women <NNS>
. <.>
Overall <JJ>
, <,>
the <DT>
California <NNP>
rate <NN>
was <VBD>
lower <JJR>
in <IN>
both <DT>
years <NNS>
than <IN>
the <DT>
rate <NN>
for <IN>
the <DT>
nation <NN>
. <.>
; <:>
( <``>
check <NN>
) <:>
Lung <NNP>
cancer <NN>
was <VBD>
the <DT>
second <JJ>
most <JJS>
frequently <RB>
diagnosed <VBN>
cancer <NN>
in <IN>
1988 <CD>
, <,>
with <IN>
9 <CD>
, <,>
469 <CD>
cases <NNS>
among <IN>
men <NNS>
and <CC>
6 <CD>
, <,>
579 <CD>
cases <NNS>
among <IN>
women <NNS>
. <.>
It <PRP>
was <VBD>
the <DT>
leading <VBG>
form <NN>
of <IN>
cancer_death <NN>
, <,>
accounting <VBG>
for <IN>
7 <CD>
, <,>
728 <CD>
male <JJ>
deaths <NNS>
and <CC>
5 <CD>
, <,>
021 <CD>
female <JJ>
deaths <NNS>
in <IN>
1988. <CD>
;_( <:>
check <NN>
) <:>
The <DT>
median <JJ>
age <NN>
at <IN>
diagnosis <NN>
was <VBD>
67 <CD>
years <NNS>
. <.>
Thirty <NNP>
percent <VBD>
of <IN>
all <DT>
cancers <NNS>
were <VBD>
diagnosed <VBN>
between <IN>
ages <NNS>
65 <CD>
and <CC>
74 <CD>
. <.>
Among <IN>
males <NNS>
, <,>
the <DT>
cancer <NN>
rates <NNS>
for <IN>
men <NNS>
70-74 <CD>
were <VBD>
16.4 <CD>
times <NNS>
greater <JJR>
than <IN>
the <DT>
rates <NNS>
for <IN>
men <NNS>
40-44 <CD>
, <,>
and <CC>
for <IN>
females <NNS>
in <IN>
the <DT>
same <JJ>
age <NN>
groups <NNS>
, <,>
the <DT>
rates <NNS>
were <VBD>
6.5 <CD>
times <NNS>
greater <JJR>
WSJ870424-0126 <DOCNO>
. <.>
YOU <PRP>
ARE <VBP>
what <WP>
you <PRP>
eat <VBP>
was <VBD>
the <DT>
crunchy-granola <NNP>
generation <NN>
's <POS>
recipe <NN>
for <IN>
promoting <NN>
long <RB>
life <NN>
and <CC>
good <JJ>
health <NN>
through <IN>
diet <JJ>
. <.>
These <DT>
days <NNS>
, <,>
though <IN>
, <,>
the <DT>
pseudo-science <NN>
of <IN>
macrobiotic <JJ>
disciples <NNS>
is <VBZ>
giving <VBG>
way <NN>
quickly <RB>
to <TO>
the <DT>
hard <JJ>
science <NN>
of <IN>
highly <RB>
regarded <VBN>
researchers <NNS>
. <.>
They <PRP>
're <VBP>
demonstrating <VBG>
certain <JJ>
foods <NNS>
and <CC>
nutritional <JJ>
supplements <NNS>
indeed <RB>
can <MD>
prevent <VB>
, <,>
perhaps_even <RB>
treat <VB>
, <,>
diseases <NNS>
such <JJ>
as <IN>
cancer <NN>
. <.>
Since <IN>
1980 <CD>
, <,>
the <DT>
National_Cancer_Institute <NNP>
aggressively <RB>
has <VBZ>
supported <VBN>
research <NN>
into_whether <IN>
diet <JJ>
and <CC>
the <DT>
use <NN>
of <IN>
drugs <NNS>
derived <VBN>
from <IN>
natural <JJ>
nutrients <NNS>
can <MD>
protect <VB>
people <NNS>
from <IN>
cancer <NN>
. <.>
The <DT>
government <NN>
's <POS>
arbiter <NN>
of <IN>
established <JJ>
cancer_science <NN>
, <,>
NCI <NNP>
has <VBZ>
assembled <VBN>
a <DT>
list <NN>
of <IN>
550 <CD>
substances <NNS>
believed <VBD>
to <TO>
be <VB>
potentially <RB>
protective <JJ>
against <IN>
cancer <NN>
. <.>
The <DT>
NCI <NNP>
decided <VBD>
to <TO>
throw <VB>
its <PRP$>
scientific <JJ>
weight <NN>
behind <IN>
the <DT>
research <NN>
because <IN>
, <,>
it <PRP>
says <VBZ>
, <,>
`` <``>
mounting_evidence <NN>
'' <''>
from <IN>
laboratory <NN>
studies <NNS>
and <CC>
surveys <NNS>
of <IN>
large <JJ>
groups <NNS>
of <IN>
people <NNS>
found <VBN>
that <IN>
`` <``>
various <JJ>
agents <NNS>
could <MD>
halt <VB>
or <CC>
reverse <VB>
cancer_progression <NN>
in <IN>
animals <NNS>
or <CC>
reduce <VB>
the <DT>
incidence <NN>
or <CC>
risk <VB>
of <IN>
cancer <NN>
in <IN>
humans <NNS>
. <.>
`` <``>
Even <RB>
though <IN>
much <RB>
of <IN>
the <DT>
new <JJ>
science <NN>
is <VBZ>
just <RB>
emerging <VBG>
, <,>
and <CC>
many <JJ>
of <IN>
the <DT>
NCI-backed <JJ>
studies <NNS>
wo <MD>
n't <RB>
be <VB>
finished <VBN>
for <IN>
several <JJ>
years <NNS>
, <,>
researchers <NNS>
already <RB>
are <VBP>
drawing <VBG>
a <DT>
picture <NN>
of <IN>
those <DT>
individuals <NNS>
who <WP>
may <MD>
benefit <VB>
most <RBS>
from <IN>
dietary <JJ>
changes <NNS>
. <.>
Some <DT>
studies <NNS>
may <MD>
show <VB>
that <IN>
certain <JJ>
nutrients <NNS>
can <MD>
stop <VB>
or <CC>
reverse <VB>
cancers <NNS>
in <IN>
people <NNS>
already <RB>
exposed <VBN>
to <TO>
known <VB>
or <CC>
suspected <VBN>
cancer-causing <JJ>
agents <NNS>
, <,>
or <CC>
carcinogens <NNS>
. <.>
Other <JJ>
studies <NNS>
may <MD>
find <VB>
that <IN>
drugs <NNS>
based <VBN>
on <IN>
these <DT>
nutrients <NNS>
can <MD>
slow <VB>
or <CC>
block <VB>
the <DT>
onset <NN>
of <IN>
disease <NN>
. <.>
Vitamin <NNP>
A <DT>
and <CC>
Beta-Carotene <JJ>
A <DT>
major <JJ>
objective <NN>
of <IN>
the <DT>
NCI-backed <JJ>
research <NN>
is <VBZ>
to <TO>
clarify <VB>
the <DT>
benefits <NNS>
of <IN>
vitamin <NN>
A <DT>
and <CC>
beta-carotene <JJ>
, <,>
a <DT>
natural <JJ>
substance <NN>
the <DT>
body <NN>
converts <NNS>
into <IN>
vitamin <NN>
A <DT>
. <.>
There <EX>
is <VBZ>
growing <VBG>
, <,>
although <IN>
still <RB>
undefinitive <JJ>
, <,>
proof <IN>
that <DT>
vitmain <NN>
A <DT>
can <NN>
lower <JJR>
the <DT>
risk <NN>
of <IN>
lung_cancer <NN>
, <,>
especially <RB>
among <IN>
men <NNS>
, <,>
and <CC>
men <NNS>
who <WP>
have <VBP>
smoked <VBN>
in <IN>
particular <JJ>
. <.>
Meanwhile <RB>
, <,>
very <RB>
recent <JJ>
research <NN>
indicates <VBZ>
that <IN>
vitamin <NN>
A <DT>
may <MD>
help <VB>
prevent_cancer <NN>
of <IN>
the <DT>
colon <NN>
, <,>
stomach <DT>
, <,>
prostate <JJ>
, <,>
cervix <NN>
, <,>
and <CC>
breast <JJ>
. <.>
Vitamin <NNP>
A <DT>
is <VBZ>
found <VBN>
in <IN>
liver <NN>
, <,>
eggs <NNS>
and <CC>
milk <NN>
. <.>
An <DT>
even <RB>
more <RBR>
common <JJ>
source <NN>
of <IN>
the <DT>
vitamin <NN>
is <VBZ>
beta-carotene <JJ>
in <IN>
leafy <NN>
green <JJ>
and <CC>
yellow <JJ>
vegetables <NNS>
, <,>
such <JJ>
as <IN>
carrots <NNS>
, <,>
winter_squash <NN>
, <,>
spinach <DT>
, <,>
canteloupe <NN>
and <CC>
broccoli <NN>
. <.>
Scientists <NNS>
are <VBP>
n't <RB>
certain <JJ>
how <WRB>
vitamin <NN>
A <DT>
and <CC>
beta-carotene <JJ>
may <MD>
act <VB>
to <TO>
forestall <VB>
cancer <NN>
, <,>
but <CC>
some <DT>
lab_research <NN>
suggests <VBZ>
that <IN>
the <DT>
nutrients <NNS>
interfere <VBP>
with <IN>
the <DT>
proteins <NNS>
that <WDT>
cancer <NN>
cells <VBZ>
use <NN>
in <IN>
reproduction <NN>
and <CC>
growth <NN>
. <.>
Other <JJ>
research <NN>
indicates <VBZ>
that <IN>
beta-carotene <JJ>
that <IN>
is <VBZ>
n't <RB>
converted <VBN>
into <IN>
vitamin <NN>
A <DT>
deactivates <NNS>
oxygen <VBN>
molecules <NNS>
produced <VBN>
by <IN>
carcinogens <NNS>
and <CC>
believed <VBD>
to <TO>
trigger <JJR>
malignant_tissue_growth <NN>
. <.>
In <IN>
a <DT>
study <NN>
expected <VBN>
to <TO>
end <VB>
in <IN>
1990 <CD>
, <,>
scientists <NNS>
are <VBP>
giving <VBG>
vitamin <NN>
A <DT>
and <CC>
two <CD>
other <JJ>
nutrients <NNS>
, <,>
vitamin <NN>
E <NNP>
and <CC>
selenium <NN>
, <,>
to <TO>
tin <VB>
miners <NNS>
at <IN>
risk <NN>
of <IN>
developing <VBG>
lung_cancer <NN>
, <,>
to <TO>
determine <VB>
if <IN>
the <DT>
nutrients <NNS>
cut <VBD>
the <DT>
incidence <NN>
of <IN>
disease <NN>
. <.>
Other <JJ>
studies <NNS>
, <,>
some <DT>
with <IN>
tens <NNS>
of <IN>
thousands <NNS>
of <IN>
subjects <NNS>
, <,>
are <VBP>
researching <VBG>
whether <IN>
certain <JJ>
levels <NNS>
of <IN>
vitamin <NN>
A <DT>
consumption <NN>
can <MD>
prevent <VB>
lung <JJ>
cancer <NN>
in <IN>
smokers <NNS>
and <CC>
asbestos_workers <NNS>
. <.>
One <CD>
research_team <NN>
is <VBZ>
trying <VBG>
to <TO>
block <VB>
the <DT>
development <NN>
of <IN>
cervical <JJ>
cancer <NN>
in <IN>
women <NNS>
who <WP>
have <VBP>
a <DT>
pre-cancerous <JJ>
condition <NN>
by <IN>
administering <NN>
a <DT>
topical <JJ>
cream <NN>
made <VBD>
of <IN>
a <DT>
vitamin_A-like_chemical <NN>
. <.>
High <JJ>
doses <NNS>
of <IN>
pure_vitamin <NN>
A <DT>
can <NN>
be <VB>
toxic <JJ>
, <,>
however <RB>
. <.>
It <PRP>
can <MD>
produce <VB>
birth <JJ>
defects <NNS>
and <CC>
other <JJ>
problems <NNS>
, <,>
and <CC>
its <PRP$>
intake <NN>
should <MD>
be <VB>
limited <VBN>
to <TO>
the <DT>
normal <JJ>
amounts <NNS>
found <VBD>
in <IN>
food <NN>
, <,>
researchers <NNS>
say <VBP>
. <.>
Vitamins <NNS>
C <NNP>
and <CC>
E_Several <NNP>
years <NNS>
ago <IN>
, <,>
scientists <NNS>
discovered <VBN>
that <IN>
nitrates <NNS>
and <CC>
nitrites <NNS>
, <,>
substances <NNS>
found <VBD>
in <IN>
processed <VBN>
foods <NNS>
such <JJ>
as <IN>
bacon <NN>
and <CC>
hot <JJ>
dogs <NNS>
, <,>
are <VBP>
transformed <VBN>
by <IN>
the <DT>
body <NN>
into <IN>
nitrosamines <NNS>
, <,>
a <DT>
suspected <VBN>
carcinogen <NN>
. <.>
New <NNP>
reserach <VBP>
has <VBZ>
found <VBN>
that <IN>
vitamins <NNS>
C <NNP>
and <CC>
E <NNP>
block <NN>
the <DT>
formation <NN>
of <IN>
nitrosamines <NNS>
. <.>
This <DT>
finding <NN>
may <MD>
explain <VB>
why <WRB>
certain <JJ>
populations <NNS>
whose <WP$>
diets <NNS>
are <VBP>
rich <JJ>
in <IN>
fruits <NNS>
, <,>
vegetables <NNS>
and <CC>
vegetable <JJ>
oils <NNS>
containing <VBG>
the <DT>
vitamins <NNS>
have <VBP>
low <JJ>
incidence <NN>
of <IN>
cancer <NN>
of <IN>
the <DT>
stomach <NN>
and <CC>
digestive <JJ>
tract <NN>
, <,>
where <WRB>
the <DT>
nitrosamines <NNS>
develop <VBP>
. <.>
One <CD>
study <NN>
found <VBD>
that <IN>
Japanese <JJ>
who <WP>
migrated <VBN>
to <TO>
Hawaii <NNP>
had <VBD>
a <DT>
lower <JJR>
rate <NN>
of <IN>
stomach_cancer <NN>
than <IN>
would <MD>
have <VB>
been_expected <VBN>
if <IN>
they <PRP>
stayed <VBD>
in <IN>
Japan <NNP>
. <.>
The <DT>
reason <NN>
was <VBD>
that <IN>
fresh <JJ>
fruits <NNS>
and <CC>
vegetables <NNS>
are <VBP>
readily <RB>
available <JJ>
in <IN>
Hawaii <NNP>
, <,>
but <CC>
not <RB>
in <IN>
Japan <NNP>
. <.>
A <DT>
study <NN>
at <IN>
Johns_Hopkins_School <NNP>
of <IN>
Hygiene <NNP>
and <CC>
Public_Health <NNP>
in <IN>
Baltimore <NNP>
also <RB>
found <VBD>
that_among <IN>
a <DT>
group <NN>
of <IN>
men <NNS>
who <WP>
were <VBD>
smokers <NNS>
, <,>
those <DT>
with <IN>
low <JJ>
levels <NNS>
of <IN>
vitamin <NN>
E <NNP>
in <IN>
their <PRP$>
blood <NN>
had <VBD>
a <DT>
2.5 <CD>
times <NNS>
greater <JJR>
risk <NN>
of <IN>
developing <VBG>
lung_cancer <NN>
than <IN>
those <DT>
with <IN>
higher <JJR>
levels <NNS>
of <IN>
the <DT>
vitamin <NN>
. <.>
Several <JJ>
studies <NNS>
are <VBP>
testing <VBG>
whether <IN>
food <NN>
containing <VBG>
vitamin <NN>
C <NNP>
or <CC>
E <NNP>
, <,>
or <CC>
vitamin <VB>
supplement <JJ>
pills <NNS>
, <,>
can <MD>
inhibit <VB>
the <DT>
development <NN>
of <IN>
colon_cancer <NN>
in <IN>
patients <NNS>
with <IN>
a <DT>
history <NN>
of <IN>
developing <VBG>
the <DT>
type <NN>
of <IN>
polyps <NNS>
that <WDT>
are <VBP>
thought <RB>
to <TO>
be <VB>
a <DT>
precursor <NN>
of <IN>
the <DT>
disease <NN>
. <.>
Selenium <NN>
The <DT>
natural <JJ>
element_selenium <NN>
occurs <NNS>
in <IN>
some <DT>
foods <NNS>
, <,>
such <JJ>
as <IN>
seafood <NN>
, <,>
meats <NNS>
from <IN>
certain <JJ>
organs <NNS>
, <,>
and <CC>
grains <NNS>
grown_in <IN>
ground_rich <NN>
in <IN>
the <DT>
chemical <JJ>
. <.>
Although <IN>
selenium <NN>
in <IN>
high <JJ>
doses <NNS>
can <MD>
be <VB>
very <RB>
toxic <JJ>
, <,>
lab <NN>
studies <NNS>
of <IN>
cancer <NN>
cells <NNS>
in <IN>
test <NN>
tubes <NNS>
and <CC>
in <IN>
animals <NNS>
show <VBP>
that <IN>
certain <JJ>
forms <NNS>
of <IN>
selenium <NN>
can <MD>
block <VB>
cancer-cell <JJ>
growth <NN>
. <.>
Population <NN>
studies <NNS>
in <IN>
the <DT>
U.S. <NNP>
, <,>
especially <RB>
in <IN>
the <DT>
Northeast <NN>
, <,>
suggest <VBP>
that <IN>
people <NNS>
with <IN>
low <JJ>
selenium <NN>
in <IN>
their <PRP$>
diets <NNS>
have <VBP>
higher <JJR>
rates <NNS>
of <IN>
colon <NN>
, <,>
breast <JJ>
and <CC>
prostate <JJ>
cancer <NN>
. <.>
Most <JJS>
research <NN>
right_now <RB>
is <VBZ>
trying <VBG>
to <TO>
determine <VB>
levels <NNS>
at <IN>
which <WDT>
selenium_consumption <NN>
wo <MD>
n't <RB>
produce <VB>
toxicity <NN>
. <.>
The <DT>
studies <NNS>
are <VBP>
following <VBG>
people <NNS>
who <WP>
live <JJ>
in <IN>
areas <NNS>
of <IN>
the <DT>
country <NN>
, <,>
such <JJ>
as <IN>
South_Dakota <NNP>
, <,>
where <WRB>
selenium_intake <NN>
is <VBZ>
high <JJ>
. <.>
Fats <NNS>
& <CC>
amp <VB>
; <:>
Fibers_The_U.S._National_Research_Council <NNP>
says <VBZ>
the <DT>
evidence <NN>
indicting <VBG>
animal_fat <JJ>
as <IN>
a <DT>
cause <NN>
for <IN>
cancer <NN>
, <,>
especially <RB>
of <IN>
colon <NN>
and <CC>
breast <JJ>
cancer <NN>
, <,>
is <VBZ>
so <RB>
damning <VBG>
that <IN>
the <DT>
council <NN>
recommends <NNS>
that <WDT>
most <JJS>
Americans <NNPS>
decrease <NN>
their <PRP$>
consumption <NN>
of <IN>
fats <NNS>
. <.>
Moreover <RB>
, <,>
some <DT>
populations <NNS>
demonstrate <VBP>
that <IN>
high-fiber <JJ>
diets <NNS>
protect <VBP>
against <IN>
the <DT>
effects <NNS>
of <IN>
eating <VBG>
fat <JJ>
. <.>
Fiber <NNP>
is <VBZ>
found <VBN>
in <IN>
fruits <NNS>
, <,>
vegetables <NNS>
and <CC>
whole-grain <JJ>
products <NNS>
such <JJ>
as <IN>
whole-grain <JJ>
cereals <NNS>
, <,>
breads <NNS>
and <CC>
brown <VB>
rice <NN>
. <.>
Scientists <NNS>
are <VBP>
n't <RB>
certain <JJ>
which <WDT>
of <IN>
these <DT>
foods <NNS>
provide <VBP>
the <DT>
greatest <JJS>
protection <NN>
, <,>
nor <CC>
how <WRB>
fiber <NN>
works <NNS>
. <.>
It <PRP>
is <VBZ>
believed <VBN>
, <,>
however <RB>
, <,>
fiber <NN>
more <JJR>
quickly <RB>
rids <VBZ>
the <DT>
body <NN>
of <IN>
fat <JJ>
that <IN>
may <MD>
produce <VB>
unwanted <VBN>
effects <NNS>
. <.>
In <IN>
one <CD>
study <NN>
of <IN>
laboratory <NN>
rats <NNS>
, <,>
scientists <NNS>
induced <VBD>
tumors <NNS>
of <IN>
the <DT>
colon <NN>
in <IN>
animals <NNS>
fed <VBN>
all-fat <JJ>
diets <NNS>
, <,>
while <IN>
animals <NNS>
with <IN>
diets <NNS>
of <IN>
fat <JJ>
and <CC>
fiber <NN>
had <VBD>
a <DT>
lower <JJR>
rate <NN>
of <IN>
cancer <NN>
. <.>
One <CD>
population_study <NN>
reported <VBD>
in <IN>
1983 <CD>
found <NN>
that <IN>
people <NNS>
in <IN>
England <NNP>
and <CC>
Wales <NNP>
whose <WP$>
consumption <NN>
of <IN>
sugar <NN>
, <,>
meat <NN>
and <CC>
fat <JJ>
were <VBD>
sharply <RB>
reduced <VBN>
during <IN>
World_War_II <NNP>
had <VBD>
a <DT>
marked <VBN>
reduction <NN>
of <IN>
cancer <NN>
of <IN>
the <DT>
breast <JJ>
and <CC>
colon <NN>
. <.>
After <IN>
the <DT>
war <NN>
, <,>
the <DT>
rates <NNS>
climbed <VBD>
back <RB>
to <TO>
pre-war <JJ>
levels <NNS>
. <.>
The <DT>
NCI <NNP>
also <RB>
is <VBZ>
supporting <VBG>
research <NN>
looking <VBG>
at <IN>
the <DT>
combined <VBN>
effects <NNS>
in <IN>
the <DT>
diet <NN>
of <IN>
many <JJ>
nutrients <NNS>
. <.>
A <DT>
researcher <NN>
at <IN>
Memorial_Sloan-Kettering_Hospital <NNP>
in <IN>
New_York <NNP>
is <VBZ>
testing <VBG>
whether <IN>
a <DT>
combination <NN>
of <IN>
beta-carotene <JJ>
and <CC>
vitamins <NNS>
C <NNP>
and <CC>
E <NNP>
can <MD>
prevent <VB>
the <DT>
development <NN>
of <IN>
skin_cancer <NN>
lesions <NNS>
in <IN>
people <NNS>
who <WP>
previously <RB>
had <VBD>
a <DT>
tumor_growth <NN>
FBIS4-67605 <DOCNO>
. <.>
BFN <NNP>
[ <:>
Text <NNP>
] <:>
Sofia <NNP>
, <,>
March <NNP>
15_( <CD>
BTA_) <NNP>
-- <:>
Associate_Professor_Khristo_Tsvetanski <NNP>
, <,>
a <DT>
cancer_specialist <NN>
working <VBG>
with <IN>
the <DT>
National_Oncology_Centre <NNP>
since <IN>
1970 <CD>
, <,>
gave <VBD>
BTA <NNP>
an <DT>
interview <NN>
on <IN>
the <DT>
incidence <NN>
of <IN>
cancer <NN>
in <IN>
Bulgaria <NNP>
. <.>
Q <NNP>
: <:>
How <WRB>
does <VBZ>
the <DT>
cancer_incidence <NN>
in <IN>
Bulgaria <NNP>
compare <NN>
to <TO>
European <NNP>
rates <NNS>
? <.>
A <DT>
: <:>
Bulgaria <NNP>
ranks <NNS>
in <IN>
the <DT>
medium_range <NN>
of <IN>
cancer_incidence <NN>
, <,>
according <VBG>
to <TO>
figures <NNS>
released <VBN>
by <IN>
the <DT>
Epidemiology_Unit <NNP>
of <IN>
the <DT>
National_Oncology_Centre <NNP>
, <,>
which <WDT>
are <VBP>
also <RB>
reported <VBD>
to <TO>
the <DT>
World_Health_Organization <NNP>
. <.>
Q <NNP>
: <:>
Where <WRB>
does <VBZ>
cancer_stand <NN>
among <IN>
the <DT>
major <JJ>
causes <NNS>
of <IN>
early <JJ>
death <NN>
and <CC>
disability <NN>
? <.>
A <DT>
: <:>
It <PRP>
ranks <VBZ>
second <JJ>
after <IN>
heart_disease <NN>
. <.>
Q <NNP>
: <:>
Is <VBZ>
cancer_incidence <NN>
in <IN>
Bulgaria <NNP>
on <IN>
the <DT>
increase <NN>
? <.>
A <DT>
: <:>
There <EX>
is <VBZ>
an <DT>
upward_trend_worldwide <NN>
and <CC>
Bulgaria <NNP>
is <VBZ>
no <DT>
exception <NN>
. <.>
I <PRP>
will <MD>
quote <VB>
again <RB>
figures <NNS>
provided <VBN>
by <IN>
our <PRP$>
( <NNP>
epidemiology <NN>
) <:>
unit <NN>
. <.>
In <IN>
1985 <CD>
, <,>
20 <CD>
, <,>
881 <CD>
developed <VBD>
cancer <NN>
, <,>
bringing <VBG>
the <DT>
total <JJ>
number <NN>
of <IN>
cancer <NN>
patients <NNS>
to <TO>
132 <CD>
, <,>
374 <CD>
. <.>
The <DT>
1990 <CD>
figures <NNS>
are <VBP>
22 <CD>
, <,>
021 <CD>
and <CC>
153 <CD>
, <,>
651 <CD>
, <,>
respectively <RB>
. <.>
In <IN>
1992 <CD>
, <,>
22 <CD>
, <,>
956 <CD>
Bulgarians <NNS>
developed <VBD>
cancer <NN>
, <,>
bringing <VBG>
the <DT>
total <JJ>
to <TO>
139 <CD>
, <,>
243 <CD>
. <.>
Q <NNP>
: <:>
Which <NNP>
types <NNS>
of <IN>
cancer <NN>
are <VBP>
the <DT>
most <RBS>
widespread <JJ>
in <IN>
Bulgaria <NNP>
? <.>
A <DT>
: <:>
According <VBG>
to <TO>
statistics <NNS>
, <,>
lung <JJ>
cancer <NN>
ranks <NNS>
first <RB>
, <,>
followed <VBN>
by <IN>
breast <JJ>
, <,>
stomach <DT>
, <,>
rectal <JJ>
and <CC>
colon_cancer <NN>
. <.>
Men <NNS>
are <VBP>
mostly <RB>
affected <VBN>
by <IN>
lung <JJ>
cancer <NN>
. <.>
Other_widespread <JJ>
types <NNS>
of <IN>
cancer <NN>
in <IN>
men <NNS>
are <VBP>
stomach <JJ>
, <,>
rectal <JJ>
, <,>
prostatic <JJ>
and <CC>
colon_cancer <NN>
. <.>
Women <NNS>
suffer <VBP>
most <JJS>
often <RB>
from <IN>
breast <JJ>
cancer <NN>
, <,>
as <IN>
well <RB>
as_from <IN>
cervical <JJ>
and <CC>
ovarian <JJ>
cancer <NN>
. <.>
Q <NNP>
: <:>
Is <VBZ>
cancer <NN>
diagnosed <VBN>
early <RB>
in <IN>
Bulgaria <NNP>
? <.>
A <DT>
: <:>
Comparing <VBG>
Bulgaria <NNP>
to <TO>
the <DT>
developed <JJ>
countries <NNS>
, <,>
there <EX>
is <VBZ>
a <DT>
lot <NN>
to <TO>
be <VB>
desired <VBN>
in <IN>
this <DT>
respect <NN>
. <.>
It <PRP>
is <VBZ>
alarming <VBG>
that_in <IN>
recent <JJ>
years <NNS>
we <PRP>
have <VBP>
witnessed <VBN>
a <DT>
retreat <NN>
. <.>
In <IN>
1990 <CD>
, <,>
52.99 <CD>
percent <NN>
of <IN>
patients <NNS>
were <VBD>
diagnosed <VBN>
early <JJ>
. <.>
In <IN>
1992 <CD>
their <PRP$>
proportion <NN>
was <VBD>
48.58 <CD>
percent <NN>
. <.>
Q <NNP>
: <:>
Is <VBZ>
cancer <NN>
screening <VBG>
done <NN>
now <RB>
? <.>
A <DT>
: <:>
There <EX>
used <VBN>
to <TO>
be <VB>
two <CD>
mass <NNS>
screening <VBG>
programmes <NNS>
for <IN>
a <DT>
long <JJ>
time <NN>
. <.>
Fluorography <NNP>
, <,>
that <IN>
is <VBZ>
, <,>
screening <VBG>
for <IN>
growths <NNS>
in <IN>
the <DT>
chest <NN>
and <CC>
mainly <RB>
in <IN>
the <DT>
lungs <NNS>
, <,>
is <VBZ>
no <DT>
longer_done <NN>
as <IN>
the <DT>
method <NN>
was <VBD>
rejected <VBN>
. <.>
Starting <VBG>
from <IN>
1956 <CD>
, <,>
all <DT>
sexually <RB>
active <JJ>
women <NNS>
were <VBD>
invited <VBN>
to <TO>
be <VB>
screened <VBN>
for <IN>
cervical <JJ>
cancer <NN>
. <.>
In <IN>
1971 <CD>
the <DT>
smear <JJ>
( <NN>
Pap_) <NNP>
test <NN>
was <VBD>
introduced <VBN>
. <.>
Over <IN>
1.5_million <CD>
women <NNS>
used <VBN>
to <TO>
be <VB>
tested <VBN>
every <DT>
year <NN>
, <,>
as <IN>
a <DT>
result <NN>
of <IN>
which <WDT>
many <JJ>
were <VBD>
treated <VBN>
for <IN>
conditions <NNS>
that <WDT>
might <MD>
otherwise_have <VB>
developed <VBN>
into <IN>
cancer <NN>
, <,>
or <CC>
cancer <NN>
was <VBD>
diagnosed <VBN>
early <JJ>
and <CC>
treatment <NN>
was <VBD>
much <RB>
easier <JJR>
and <CC>
more <JJR>
effective <JJ>
. <.>
It <PRP>
is <VBZ>
a <DT>
pity <NN>
that <WDT>
screening <VBG>
has <VBZ>
not <RB>
been_done <VBN>
since <IN>
1990 <CD>
LA063090-0103 <DOCNO>
. <.>
A <DT>
federal <JJ>
advisory_panel <NN>
recommended <VBD>
Friday <NNP>
that <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
reject <NN>
a <DT>
proposal <NN>
to <TO>
undertake <VB>
a <DT>
ground-breaking_U.S.-Soviet <JJ>
study <NN>
of <IN>
20 <CD>
, <,>
000 <CD>
women <NNS>
to <TO>
determine <VB>
whether <IN>
a <DT>
hormonal <JJ>
drug <NN>
can <MD>
prevent <VB>
breast <JJ>
cancer <NN>
. <.>
The <DT>
FDA <NNP>
's <POS>
Oncology_Drugs_Advisory_Committee <NNP>
agreed <VBD>
that <IN>
a <DT>
long-term <JJ>
study <NN>
should <MD>
be <VB>
conducted <VBN>
to <TO>
determine <VB>
the <DT>
effect <NN>
of <IN>
the <DT>
hormonal <JJ>
drug_tamoxifen <NN>
in <IN>
preventing_breast_cancer <NN>
and <CC>
other <JJ>
cancers <NNS>
in <IN>
healthy <JJ>
women <NNS>
. <.>
But <CC>
the <DT>
panel <NN>
said <VBD>
that <IN>
its <PRP$>
members <NNS>
had <VBD>
concluded <VBN>
that <IN>
the <DT>
design <NN>
of <IN>
the <DT>
proposed <VBN>
10-year <JJ>
, <,>
$ <$>
100-million <CD>
study <NN>
of <IN>
women <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
the <DT>
Soviet_Union <NNP>
was <VBD>
flawed <VBN>
. <.>
The <DT>
committee <NN>
said <VBD>
that <IN>
it <PRP>
would <MD>
recommend <VB>
ways <NNS>
to <TO>
correct <VB>
the <DT>
deficiencies <NNS>
. <.>
`` <``>
I <PRP>
'm <VBP>
disappointed <JJ>
for <IN>
the <DT>
women <NNS>
of <IN>
the <DT>
country <NN>
, <,>
'' <''>
said <VBD>
Phillip_D._Bretz <NNP>
, <,>
director <NN>
of <IN>
the <DT>
Desert_Breast_Institute <NNP>
in <IN>
Rancho_Mirage <NNP>
and <CC>
one <CD>
of <IN>
the <DT>
proposed <VBN>
study <NN>
leaders <NNS>
. <.>
`` <``>
I <PRP>
felt <VBD>
it <PRP>
was <VBD>
time <NN>
to <TO>
do <VB>
it <PRP>
. <.>
None <NN>
of <IN>
these <DT>
answers <NNS>
are <VBP>
going <VBG>
to <TO>
be <VB>
resolved <VBN>
until <IN>
this <DT>
study <NN>
is <VBZ>
done <VBN>
. <.>
`` <``>
Although <IN>
the <DT>
recommendation <NN>
of <IN>
an <DT>
FDA <NNP>
advisory_committee <NN>
is <VBZ>
not <RB>
binding <VBG>
, <,>
it <PRP>
typically <RB>
wields <VBZ>
considerable <JJ>
weight <NN>
in <IN>
agency <NN>
decision-making <JJ>
. <.>
The <DT>
FDA <NNP>
must <MD>
approve <VB>
the <DT>
U.S. <NNP>
segment <NN>
of <IN>
the <DT>
study <NN>
before <IN>
it <PRP>
can <MD>
begin <VB>
. <.>
The <DT>
committee <NN>
said <VBD>
there <EX>
was <VBD>
insufficient_information <NN>
on <IN>
how <WRB>
the <DT>
study <NN>
would <MD>
be <VB>
conducted <VBN>
, <,>
including <VBG>
recruitment <NN>
of <IN>
patients <NNS>
and <CC>
handling <NN>
of <IN>
data <NNS>
. <.>
Some <DT>
members <NNS>
also <RB>
expressed <VBD>
concern <NN>
that <IN>
the <DT>
volunteers <NNS>
would <MD>
not <RB>
be <VB>
at <IN>
high <JJ>
enough <RB>
risk <VB>
for <IN>
breast <JJ>
cancer <NN>
. <.>
Bretz <NNP>
, <,>
however <RB>
, <,>
said <VBD>
that <IN>
the <DT>
study <NN>
was <VBD>
rejected <VBN>
because <IN>
he <PRP>
did <VBD>
not <RB>
have <VB>
the <DT>
academic <JJ>
ties <NNS>
of <IN>
traditional <JJ>
researchers <NNS>
. <.>
He <PRP>
said <VBD>
that <IN>
he <PRP>
would <MD>
revise <VB>
his <PRP$>
study_proposal <NN>
in <IN>
an <DT>
effort <NN>
to <TO>
satisfy <VB>
the <DT>
committee <NN>
's <POS>
demands <NNS>
. <.>
The <DT>
proposed <VBN>
study <NN>
, <,>
endorsed <VBD>
by <IN>
American <NNP>
and <CC>
Soviet <NNP>
cancer <NN>
specialists <NNS>
in <IN>
March <NNP>
, <,>
would <MD>
involve <VB>
administration <NN>
of <IN>
tamoxifen <NN>
, <,>
an <DT>
anti-estrogen <JJ>
drug <NN>
already_widely <RB>
used <JJ>
in <IN>
post-surgical <JJ>
breast_cancer_therapy <NN>
, <,>
to <TO>
women <NNS>
considered <VBN>
at <IN>
high <JJ>
risk <NN>
for <IN>
breast_cancer <NN>
. <.>
It <PRP>
would <MD>
be <VB>
the <DT>
first_large-scale <JJ>
study_undertaken <NN>
jointly <RB>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
Soviet_Union <NNP>
, <,>
its <PRP$>
sponsors <NNS>
said <VBD>
. <.>
The <DT>
pool <NN>
of <IN>
participants <NNS>
, <,>
about <IN>
10 <CD>
, <,>
000 <CD>
from <IN>
each <DT>
country <NN>
, <,>
would <MD>
consist <VB>
primarily <RB>
of <IN>
daughters <NNS>
, <,>
sisters <NNS>
or <CC>
mothers <NNS>
of <IN>
women <NNS>
who <WP>
have <VBP>
had <VBD>
breast <VBN>
cancer <NN>
and <CC>
who <WP>
are <VBP>
considered <VBN>
at <IN>
high <JJ>
risk <NN>
of <IN>
developing <VBG>
the <DT>
disease <NN>
themselves <PRP>
. <.>
Half <NNP>
of <IN>
the <DT>
women <NNS>
would <MD>
be <VB>
given <VBN>
a <DT>
medically <RB>
worthless_placebo <NN>
for <IN>
comparison <NN>
purposes <NNS>
. <.>
The <DT>
researchers <NNS>
had <VBD>
predicted <VBN>
a <DT>
25 <CD>
%_reduction <NN>
in <IN>
the <DT>
incidence <NN>
of <IN>
breast <JJ>
cancer <NN>
among <IN>
the <DT>
women <NNS>
who <WP>
were <VBD>
given <VBN>
the <DT>
drug <NN>
. <.>
The <DT>
study <NN>
would <MD>
be <VB>
coordinated <VBN>
by <IN>
Bretz <NNP>
; <:>
Dr._Philip_B._Dreisbach <NNP>
, <,>
of <IN>
the <DT>
Eisenhower_Medical_Center <NNP>
in <IN>
Rancho_Mirage <NNP>
, <,>
and <CC>
Dr._David_Zaridze <NNP>
, <,>
deputy_director <NN>
of <IN>
the <DT>
All-Union <NN>
Cancer_Research_Institute <NNP>
in <IN>
Moscow <NNP>
. <.>
The <DT>
study <NN>
was <VBD>
opposed <VBN>
by <IN>
some <DT>
women <NNS>
's <POS>
health_advocacy <NN>
groups <NNS>
, <,>
who <WP>
said <VBD>
it <PRP>
is <VBZ>
dangerous <JJ>
to <TO>
experiment <NN>
with <IN>
drugs <NNS>
on <IN>
healthy <JJ>
women <NNS>
. <.>
`` <``>
This <DT>
is <VBZ>
a <DT>
drug <NN>
that <WDT>
is <VBZ>
not <RB>
risk-free <JJ>
, <,>
'' <''>
said <VBD>
Cindy_Pearson <NNP>
, <,>
program_director <NN>
of <IN>
the <DT>
National_Women <NNP>
's <POS>
Health_Network <NNP>
. <.>
`` <``>
It <PRP>
's <VBZ>
a <DT>
fine_drug <NN>
for <IN>
a <DT>
breast <JJ>
cancer_patient <NN>
-- <:>
a <DT>
woman <NN>
facing <VBG>
the <DT>
possibility <NN>
of <IN>
death <NN>
is <VBZ>
more <RBR>
than <IN>
willing <JJ>
to <TO>
take <VB>
a <DT>
drug <NN>
that <WDT>
has <VBZ>
some <DT>
risk <NN>
. <.>
But <CC>
to <TO>
jump <VB>
from <IN>
a <DT>
drug <NN>
that <WDT>
's <VBZ>
effective <JJ>
in <IN>
a <DT>
group <NN>
with <IN>
a <DT>
life-threatening <JJ>
disease <NN>
to <TO>
a <DT>
huge <JJ>
trial <NN>
in <IN>
healthy <JJ>
women <NNS>
is <VBZ>
crazy <JJ>
. <.>
`` <``>
But <CC>
Dr._Wendy_Schain <NNP>
, <,>
a <DT>
psychologist <NN>
with <IN>
Memorial <JJ>
Cancer_Institute <NNP>
in <IN>
Long_Beach <NNP>
and <CC>
a <DT>
former <JJ>
breast_cancer_patient <NN>
, <,>
recommended <VBD>
approval <NN>
of <IN>
the <DT>
study <NN>
. <.>
`` <``>
This <DT>
is <VBZ>
the <DT>
best <JJS>
we <PRP>
've <VBP>
got <VBN>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
`` <``>
We <PRP>
need <VBP>
to <TO>
get <VB>
these <DT>
answers <NNS>
. <.>
We <PRP>
have <VBP>
no <DT>
better <JJR>
way <NN>
to <TO>
get <VB>
them <PRP>
. <.>
`` <``>
Tamoxifen <NNP>
causes <NNS>
cancer <NN>
in <IN>
animals <NNS>
and <CC>
has <VBZ>
been_linked <VBN>
to <TO>
stroke <VB>
, <,>
heart_disease <NN>
and <CC>
endometrial <JJ>
cancer <NN>
in <IN>
women <NNS>
, <,>
according <VBG>
to <TO>
the <DT>
FDA <NNP>
. <.>
Sponsors <NNS>
of <IN>
the <DT>
proposed <VBN>
study <NN>
, <,>
however <RB>
, <,>
maintain <VB>
that <IN>
tamoxifen <JJ>
has <VBZ>
minimal_negative <JJ>
side <NN>
effects <NNS>
and <CC>
often <RB>
reduces <NNS>
cholesterol <VBP>
and <CC>
eases <NNS>
cardiovascular <JJ>
problems <NNS>
. <.>
FDA <NNP>
officials <NNS>
said <VBD>
that <IN>
a <DT>
large <JJ>
study <NN>
of <IN>
a <DT>
drug <NN>
in <IN>
healthy <JJ>
humans <NNS>
was <VBD>
`` <``>
a <DT>
little <RB>
unusual <JJ>
, <,>
'' <''>
but <CC>
not <RB>
unprecedented <VBN>
. <.>
`` <``>
Any <DT>
time <NN>
you <PRP>
do <VBP>
a <DT>
study <NN>
on <IN>
a <DT>
drug <NN>
for <IN>
prophylaxis <NNS>
( <:>
prevention <NN>
) <:>
, <,>
you <PRP>
're <VBP>
going <VBG>
to <TO>
use <VB>
healthy <JJ>
people <NNS>
, <,>
'' <''>
said <VBD>
Dr._Robert_Temple <NNP>
, <,>
the <DT>
FDA <NNP>
's <POS>
director <NN>
of <IN>
new <JJ>
drug_evaluation <NN>
. <.>
Tamoxifen <NNP>
, <,>
manufactured <VBD>
by <IN>
the <DT>
British <JJ>
firm <NN>
Imperial_Chemical <NNP>
Industries <NNPS>
and <CC>
sold <VBD>
under <IN>
the <DT>
brand_name <NN>
Nolvadex <NNP>
, <,>
has <VBZ>
been_used <VBN>
for <IN>
more <JJR>
than <IN>
a <DT>
decade <NN>
to <TO>
prevent <VB>
the <DT>
recurrence <NN>
of <IN>
tumors <NNS>
in <IN>
women <NNS>
whose <WP$>
cancer <NN>
had <VBD>
spread <VBN>
to <TO>
the <DT>
underarm_lymph <NN>
nodes <VBZ>
. <.>
Recently <RB>
, <,>
the <DT>
FDA <NNP>
approved <VBD>
its <PRP$>
use <NN>
in <IN>
the <DT>
post-surgical <JJ>
treatment <NN>
of <IN>
early <JJ>
breast_cancer <NN>
in <IN>
women <NNS>
who <WP>
do <VBP>
not <RB>
have <VB>
node <VBN>
involvement <NN>
. <.>
In <IN>
this <DT>
country <NN>
, <,>
it <PRP>
is <VBZ>
produced <VBN>
and <CC>
marketed <VBN>
by <IN>
ICI <NNP>
Pharmaceuticals <NNPS>
of <IN>
Wilmington <NNP>
, <,>
Del <NNP>
. <.>
Tamoxifen <NNP>
works <NNS>
by <IN>
blocking <VBG>
so-called <JJ>
estrogen <NN>
receptors <NNS>
-- <:>
areas <NNS>
on <IN>
the <DT>
surface <NN>
of <IN>
cells <NNS>
to <TO>
which <WDT>
the <DT>
hormone <NN>
binds <NNS>
to <TO>
exert <VB>
its <PRP$>
effects <NNS>
. <.>
In <IN>
that <DT>
way <NN>
, <,>
it <PRP>
blocks <VBZ>
the <DT>
effects <NNS>
of <IN>
estrogen <NN>
, <,>
which <WDT>
is <VBZ>
believed <VBN>
to <TO>
play <VB>
a <DT>
role <NN>
in <IN>
the <DT>
stimulation <NN>
of <IN>
tumor_growth <NN>
in <IN>
breast <JJ>
cancer <NN>
. <.>
Breast <NNP>
cancer <NN>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
malignancy <NN>
among <IN>
women <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
the <DT>
second <JJ>
leading <VBG>
cause <NN>
of <IN>
cancer_death <NN>
among <IN>
women <NNS>
, <,>
after <IN>
lung <JJ>
cancer <NN>
. <.>
An <DT>
estimated <VBN>
150 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
will <MD>
be <VB>
diagnosed <VBN>
this <DT>
year <NN>
WSJ910315-0104 <DOCNO>
. <.>
`` <``>
The <DT>
potential <JJ>
for <IN>
using <VBG>
this <DT>
gene <NN>
in <IN>
early <JJ>
detection <NN>
of <IN>
the <DT>
cancer <NN>
is <VBZ>
very <RB>
exciting <VBG>
to <TO>
us <PRP>
, <,>
'' <''>
said <VBD>
Bert_Vogelstein <NNP>
, <,>
the <DT>
molecular <JJ>
biologist <NN>
whose <WP$>
laboratory <NN>
made <VBD>
the <DT>
discovery <NN>
. <.>
`` <``>
Colon <NNP>
cancer <NN>
can <MD>
be <VB>
very <RB>
lethal <JJ>
, <,>
but <CC>
it <PRP>
only <RB>
is <VBZ>
dangerous <JJ>
when <WRB>
it <PRP>
's <VBZ>
allowed <VBN>
to <TO>
advance <NN>
to <TO>
the <DT>
point <NN>
that <IN>
it <PRP>
spreads <VBZ>
to <TO>
other <JJ>
tissue <NN>
. <.>
Caught <NNP>
early <RB>
the <DT>
disease <NN>
is <VBZ>
completely <RB>
treatable <JJ>
. <.>
`` <``>
The <DT>
new <JJ>
gene <NN>
is <VBZ>
the <DT>
third <JJ>
of <IN>
its <PRP$>
type <NN>
found <VBD>
in <IN>
the <DT>
last <JJ>
two <CD>
years <NNS>
by <IN>
Dr._Vogelstein <NNP>
's <POS>
lab <NN>
, <,>
and <CC>
is <VBZ>
the <DT>
last <JJ>
of <IN>
four <CD>
genes <NNS>
believed <VBD>
to <TO>
be <VB>
involved <VBN>
in <IN>
the <DT>
development <NN>
of <IN>
colon_cancer <NN>
. <.>
The <DT>
three <CD>
genes <NNS>
found <VBD>
by <IN>
the <DT>
Johns_Hopkins <NNP>
group <NN>
are <VBP>
dubbed <VBN>
tumor <NN>
suppressors <NNS>
because <IN>
scientists <NNS>
believe <VBP>
in <IN>
their <PRP$>
normal <JJ>
state <NN>
they <PRP>
govern <VBP>
cell <RB>
growth <NN>
. <.>
If <IN>
these <DT>
genes <NNS>
somehow <VBP>
become <VBN>
defective <JJ>
, <,>
however <RB>
, <,>
cells <NNS>
under <IN>
their <PRP$>
control <NN>
can <MD>
begin <VB>
to <TO>
grow <VB>
aberrantly <RB>
and <CC>
turn <VB>
cancerous <JJ>
. <.>
The <DT>
discovery <NN>
of <IN>
tumor_suppressor <NN>
genes <NNS>
has <VBZ>
become <VBN>
a <DT>
watershed <JJ>
in <IN>
cancer_research <NN>
, <,>
proving <VBG>
that <IN>
a <DT>
cell <NN>
progresses <VBZ>
into <IN>
a <DT>
lethal <JJ>
tumor <NN>
by <IN>
steps <NNS>
. <.>
The <DT>
cell <NN>
turns <VBZ>
increasingly <RB>
dangerous <JJ>
over <IN>
time <NN>
-- <:>
perhaps <RB>
many <JJ>
years <NNS>
-- <:>
as <IN>
its <PRP$>
numerous_growth-controlling <JJ>
tumor_suppressor <NN>
genes <NNS>
, <,>
bit <NN>
by <IN>
bit <NN>
, <,>
become <VB>
defective <JJ>
. <.>
In <IN>
1989 <CD>
, <,>
Dr._Vogelstein <NNP>
's <POS>
lab <NN>
found <VBD>
a <DT>
gene <NN>
, <,>
called <VBN>
p53 <NNP>
, <,>
that <IN>
when <WRB>
defective <JJ>
can <MD>
kick <VB>
a <DT>
growing <VBG>
colon_cancer_tumor <NN>
into <IN>
a <DT>
final <JJ>
stage <NN>
of <IN>
malignancy <NN>
. <.>
Since <IN>
then <RB>
, <,>
scientists <NNS>
elsewhere <RB>
have <VBP>
found <VBN>
defective <JJ>
versions <NNS>
of <IN>
p53 <NNP>
in <IN>
cancers <NNS>
of <IN>
the <DT>
brain <NN>
, <,>
breast <JJ>
and <CC>
lung <JJ>
. <.>
Scientists <NNS>
also <RB>
have <VBP>
found <VBN>
that <IN>
re-inserting <JJ>
a <DT>
normal <JJ>
version <NN>
p53 <NNP>
in <IN>
cancerous <JJ>
cells <NNS>
in <IN>
a <DT>
test_tube <NN>
can <MD>
block <VB>
further <JJ>
tumor_growth <NN>
, <,>
providing <VBG>
evidence <NN>
that <IN>
turning <VBG>
the <DT>
gene <NN>
on_through <IN>
drugs <NNS>
may <MD>
provide <VB>
a <DT>
potent_type <NN>
of <IN>
cancer_medicine <NN>
. <.>
In <IN>
January <NNP>
1990 <CD>
, <,>
Dr._Vogelstein <NNP>
's <POS>
lab <NN>
found <VBD>
another <DT>
suppressor_gene <NN>
called <VBN>
DCC <NNP>
, <,>
deleted <VBD>
in <IN>
colorectal <JJ>
cancer <NN>
. <.>
The <DT>
most <RBS>
recent <JJ>
discovery <NN>
is <VBZ>
a <DT>
gene <NN>
being <VBG>
called <VBN>
MCC <NNP>
, <,>
for <IN>
mutated <VBN>
in <IN>
colorectal <JJ>
cancer <NN>
. <.>
The <DT>
latest <JJS>
gene_discovery <NN>
is <VBZ>
especially <RB>
exciting <VBG>
, <,>
scientists <NNS>
said <VBD>
, <,>
because <IN>
it <PRP>
is <VBZ>
the <DT>
result <NN>
of <IN>
a <DT>
world-wide <JJ>
search <NN>
that <WDT>
has <VBZ>
been <VBN>
going <VBG>
on_for_about <IN>
five <CD>
years <NNS>
. <.>
The <DT>
MCC <NNP>
gene <NN>
appears <VBZ>
to <TO>
be <VB>
the <DT>
same <JJ>
gene <NN>
that <IN>
researchers <NNS>
at <IN>
the <DT>
University <NNP>
of <IN>
Utah <NNP>
and <CC>
in <IN>
London <NNP>
believe <NN>
can <MD>
be <VB>
inherited <VBN>
in <IN>
a <DT>
mutant_form <NN>
and <CC>
cause <VB>
a <DT>
rare_familial_form <NN>
of <IN>
colon_cancer <NN>
. <.>
The <DT>
Utah <NNP>
and <CC>
British <NNP>
scientists <NNS>
have <VBP>
been <VBN>
studying <VBG>
the <DT>
genetic <JJ>
material <NN>
of <IN>
several <JJ>
families <NNS>
where <WRB>
numerous <JJ>
relatives <NNS>
have <VBP>
a <DT>
tendency <NN>
to <TO>
grow <VB>
dozens <NNS>
of <IN>
polyps <NNS>
in <IN>
their <PRP$>
colon <NN>
, <,>
tiny <JJ>
clumps <NNS>
of <IN>
mushroom-sized <JJ>
growth <NN>
which <WDT>
under <IN>
certain <JJ>
circumstances <NNS>
can <MD>
become <VB>
cancerous <JJ>
. <.>
Several <JJ>
years <NNS>
ago <IN>
, <,>
the <DT>
scientists <NNS>
had <VBD>
tracked <VBN>
the <DT>
inherited <VBN>
gene <NN>
to <TO>
chromosome <VB>
5 <CD>
-- <:>
all <DT>
cells <NNS>
have <VBP>
two <CD>
pairs <NNS>
of <IN>
23 <CD>
chromosomes <NNS>
upon <IN>
which <WDT>
all <DT>
human <NN>
genes <NNS>
reside <VBP>
. <.>
At_about <IN>
the <DT>
same <JJ>
time <NN>
, <,>
researchers <NNS>
at <IN>
Johns_Hopkins <NNP>
had <VBD>
found <VBN>
evidence <NN>
in <IN>
sifting <NN>
through <IN>
genetic <JJ>
material <NN>
taken <VBN>
from <IN>
colon_cancer <NN>
cells <NNS>
suggesting <VBG>
that <IN>
a <DT>
tumor_suppressor_gene <NN>
also <RB>
existed <VBD>
on <IN>
chromosome <NN>
5 <CD>
. <.>
Believing <VBG>
the <DT>
two <CD>
genes <NNS>
might <MD>
be <VB>
the <DT>
same <JJ>
, <,>
about <IN>
two <CD>
years <NNS>
ago <RB>
the <DT>
Johns_Hopkins <NNP>
researchers <NNS>
joined <VBD>
forces <NNS>
with <IN>
the <DT>
Utah <NNP>
team <NN>
and <CC>
another <DT>
group <NN>
from <IN>
Tokyo <NNP>
's <POS>
Cancer_Institute <NNP>
to <TO>
pinpoint <VB>
the <DT>
gene <NN>
's <POS>
exact <JJ>
identity <NN>
. <.>
In <IN>
a <DT>
report <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
, <,>
the <DT>
three <CD>
labs <NNS>
say <VBP>
they <PRP>
have <VBP>
isolated <VBN>
the <DT>
gene <NN>
, <,>
calling <VBG>
it <PRP>
MCC <NNP>
. <.>
`` <``>
We <PRP>
do <VBP>
n't <RB>
know <VB>
for <IN>
certain <JJ>
that <IN>
it <PRP>
is <VBZ>
exactly <RB>
the <DT>
gene <NN>
that <IN>
is <VBZ>
inherited <VBN>
by <IN>
the <DT>
families <NNS>
, <,>
but <CC>
we <PRP>
think <VBP>
it <PRP>
is <VBZ>
, <,>
'' <''>
Dr._Vogelstein <NNP>
said <VBD>
, <,>
noting <NN>
that <IN>
the <DT>
same <JJ>
gene <NN>
may <MD>
also <RB>
trigger <VB>
cancer_growth <NN>
in <IN>
people <NNS>
who <WP>
do <VBP>
n't <RB>
inherit <VB>
the <DT>
disease <NN>
. <.>
In <IN>
any <DT>
case <NN>
, <,>
Dr._Vogelstein <NNP>
said <VBD>
he <PRP>
and <CC>
his <PRP$>
colleagues <NNS>
are <VBP>
convinced <VBN>
that <IN>
the <DT>
loss <NN>
of <IN>
two <CD>
copies <NNS>
of <IN>
a <DT>
cell <NN>
's <POS>
MCC <NNP>
gene <NN>
is <VBZ>
what <WP>
makes <VBZ>
a <DT>
normal <JJ>
cell_begin <NN>
growing <VBG>
into <IN>
a <DT>
polyp <NN>
. <.>
Every <DT>
cell <NN>
contains <VBZ>
two <CD>
copies <NNS>
of <IN>
each <DT>
gene <NN>
, <,>
each <DT>
of <IN>
which <WDT>
sits <NNS>
on <IN>
a <DT>
cell <NN>
's <POS>
two <CD>
copies <NNS>
of <IN>
each <DT>
chromosome <NN>
. <.>
People <NNS>
who <WP>
inherit <NN>
one <CD>
or <CC>
two <CD>
copies <NNS>
of <IN>
MCC <NNP>
already <RB>
in <IN>
damaged <JJ>
form <NN>
are <VBP>
at <IN>
very <RB>
high <JJ>
risk <NN>
of <IN>
developing <VBG>
colon_cancer <NN>
, <,>
the <DT>
researchers <NNS>
said <VBD>
. <.>
As <IN>
a <DT>
result <NN>
of <IN>
the <DT>
finding <NN>
, <,>
the <DT>
researchers <NNS>
said <VBD>
that <IN>
someday <NN>
doctors <NNS>
will <MD>
be <VB>
able <JJ>
to <TO>
test <NN>
patients <NNS>
' <POS>
blood <NN>
to <TO>
detect <VB>
if <IN>
some <DT>
of <IN>
their <PRP$>
cells <NNS>
have <VBP>
somehow <RB>
-- <:>
perhaps <RB>
through <IN>
exposure <NN>
to <TO>
some <DT>
environmental <JJ>
agent <NN>
-- <:>
collected <VBN>
damaged <JJ>
versions <NNS>
of <IN>
MCC <NNP>
. <.>
A <DT>
patient <NN>
found <VBD>
to <TO>
have <VB>
a <DT>
damaged <JJ>
MCC <NNP>
`` <``>
would <MD>
be <VB>
closely <RB>
monitored <VBN>
for <IN>
any <DT>
suspicious <JJ>
polyp <NN>
growths <NNS>
, <,>
'' <''>
Dr._Vogelstein <NNP>
said <VBD>
. <.>
`` <``>
Removing <JJ>
a <DT>
polyp <NN>
can <MD>
remove <VB>
the <DT>
risk <NN>
of <IN>
cancer <NN>
. <.>
`` <``>
The <DT>
gene <NN>
was <VBD>
pinpointed <VBN>
in <IN>
the <DT>
Johns_Hopkins <NNP>
lab <NN>
by <IN>
Kenneth_Kinzler <NNP>
and <CC>
Mef_Nilbert <NNP>
. <.>
They <PRP>
and <CC>
Dr._Vogelstein <NNP>
believe <VBP>
the <DT>
MCC <NNP>
gene <NN>
in <IN>
its <PRP$>
normal <JJ>
state <NN>
produces <NNS>
a <DT>
protein <NN>
that <WDT>
acts <VBZ>
as <RB>
a <DT>
curb <NN>
for <IN>
a <DT>
certain <JJ>
kind <NN>
of <IN>
cell_growth <NN>
. <.>
They <PRP>
said <VBD>
that <IN>
a <DT>
drug <NN>
that <WDT>
might <MD>
mimic <VB>
the <DT>
action <NN>
of <IN>
the <DT>
protein <NN>
could <MD>
be <VB>
a <DT>
prototype <NN>
for <IN>
a <DT>
new <JJ>
anti-cancer_drug <NN>
AP880622-0182 <DOCNO>
. <.>
The <DT>
acne_drug <NN>
Accutane <NNP>
, <,>
which <WDT>
can <MD>
cause <VB>
birth <JJ>
defects <NNS>
in <IN>
pregnant <JJ>
women <NNS>
, <,>
prevents <NNS>
skin_cancer <NN>
in <IN>
people <NNS>
at <IN>
extremely <RB>
high <JJ>
risk <NN>
of <IN>
the <DT>
common <JJ>
malignancy <NN>
, <,>
a <DT>
study <NN>
concludes <VBZ>
. <.>
Experts <NNS>
cautioned <VBD>
that <IN>
the <DT>
treatment <NN>
is <VBZ>
too <RB>
toxic <JJ>
to <TO>
be <VB>
used <VBN>
routinely <RB>
by <IN>
most <JJS>
people <NNS>
who <WP>
are <VBP>
afraid <VBN>
of <IN>
skin_cancer <NN>
. <.>
But <CC>
they <PRP>
said <VBD>
it <PRP>
raises <VBZ>
the <DT>
possibility <NN>
that <IN>
similar <JJ>
drugs <NNS>
may <MD>
someday_be <VB>
given <VBN>
safely <RB>
to <TO>
prevent <VB>
this <DT>
and <CC>
other <JJ>
forms <NNS>
of <IN>
cancer <NN>
. <.>
Until <IN>
now <RB>
, <,>
medicines <NNS>
have <VBP>
been_given <VBN>
almost_exclusively <RB>
to <TO>
attack <VB>
cancers <NNS>
once <RB>
they <PRP>
occur <VBP>
rather <RB>
than <IN>
to <TO>
prevent <VB>
them <PRP>
. <.>
`` <``>
This <DT>
is <VBZ>
the <DT>
first <JJ>
study <NN>
that <WDT>
has <VBZ>
scientifically <RB>
proven <VBN>
in <IN>
humans <NNS>
that <WDT>
skin_cancer <NN>
can <MD>
be <VB>
prevented <VBN>
by <IN>
any <DT>
means <NNS>
, <,>
'' <''>
said <VBD>
Dr._Howard_Koh <NNP>
of <IN>
Boston_University_School <NNP>
of <IN>
Medicine <NNP>
. <.>
`` <``>
We <PRP>
use <VBP>
sun <VBN>
screens <NNS>
because <IN>
they <PRP>
should <MD>
work <VB>
, <,>
but <CC>
we <PRP>
still <RB>
have <VBP>
not_rigorously_proven <RB>
in <IN>
a <DT>
scientific <JJ>
way <NN>
that <IN>
skin_cancer <NN>
can <MD>
be <VB>
prevented <VBN>
with <IN>
that <DT>
method <NN>
. <.>
'' <''>
Sun <NNP>
is <VBZ>
considered <VBN>
the <DT>
main <JJ>
cause <NN>
of <IN>
skin_cancer <NN>
. <.>
However <RB>
, <,>
he <PRP>
cautioned <VBD>
that <IN>
the <DT>
study <NN>
, <,>
conducted <VBD>
on <IN>
just <RB>
five <CD>
people <NNS>
, <,>
is <VBZ>
very <RB>
small <JJ>
, <,>
and <CC>
it <PRP>
is <VBZ>
unclear <JJ>
whether <IN>
the <DT>
findings <NNS>
will <MD>
apply <VB>
to <TO>
those <DT>
at <IN>
lower <JJR>
risk <NN>
of <IN>
skin_cancer <NN>
. <.>
Dr._Kenneth_H._Kraemer <NNP>
, <,>
who <WP>
directed <VBN>
the <DT>
research <NN>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
believes <VBZ>
the <DT>
study <NN>
could <MD>
represent <VB>
a <DT>
step <NN>
toward <IN>
cancer_prevention <NN>
. <.>
He <PRP>
noted <VBD>
that <IN>
Accutane <NNP>
is <VBZ>
one <CD>
of <IN>
more <JJR>
than <IN>
2 <CD>
, <,>
000 <CD>
synthetic <JJ>
forms <NNS>
of <IN>
vitamin <NN>
A <DT>
, <,>
and <CC>
some <DT>
of <IN>
these <DT>
could <MD>
prove <VB>
safe <JJ>
and <CC>
effective <JJ>
for <IN>
routine_use <NN>
in <IN>
warding <NN>
off <IN>
skin_cancer <NN>
in <IN>
low-risk <JJ>
people <NNS>
. <.>
`` <``>
You <PRP>
are <VBP>
better <RBR>
off <IN>
preventing <VBG>
it <PRP>
by <IN>
avoiding <VBG>
the <DT>
sun <NN>
at <IN>
the <DT>
beginning <NN>
, <,>
'' <''>
Kraemer <NNP>
said <VBD>
. <.>
`` <``>
But <CC>
if <IN>
that <DT>
is <VBZ>
n't <RB>
the <DT>
case <NN>
, <,>
this <DT>
is <VBZ>
an <DT>
indication <NN>
that <IN>
drugs <NNS>
may <MD>
be <VB>
developed <VBN>
to <TO>
prevent <VB>
the <DT>
progression <NN>
of <IN>
the <DT>
damage <NN>
to <TO>
cancer <NN>
. <.>
'' <''>
The <DT>
study <NN>
was <VBD>
conducted <VBN>
on <IN>
victims <NNS>
of <IN>
xeroderma_pigmentosum <NN>
, <,>
an <DT>
inherited <JJ>
skin_disorder <NN>
that <WDT>
occurs <VBZ>
in_about <IN>
one <CD>
in <IN>
1_million <CD>
people <NNS>
. <.>
Their <PRP$>
skin <NN>
is <VBZ>
unable <JJ>
to <TO>
repair <NN>
genetic <JJ>
damage <NN>
caused <VBD>
by <IN>
sunlight <NN>
, <,>
and <CC>
they <PRP>
are <VBP>
more <RBR>
than <IN>
1 <CD>
, <,>
000 <CD>
times <NNS>
more <JJR>
likely <JJ>
than <IN>
the <DT>
average <NN>
to <TO>
get <VB>
basal_cell <NN>
or <CC>
squamous <JJ>
cell_cancer <NN>
of <IN>
the <DT>
skin <NN>
. <.>
In <IN>
the <DT>
general <JJ>
population <NN>
, <,>
these <DT>
are <VBP>
the <DT>
most <RBS>
common <JJ>
kinds <NNS>
of <IN>
cancer <NN>
, <,>
striking <VBG>
about <IN>
500 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
each <DT>
year <NN>
. <.>
These <DT>
tumors <NNS>
, <,>
which <WDT>
are <VBP>
usually <RB>
curable <JJ>
, <,>
occur <VBP>
most <RBS>
frequently <RB>
in <IN>
light-skinned <JJ>
people <NNS>
. <.>
In <IN>
the <DT>
study <NN>
, <,>
published <VBD>
in <IN>
Thursday <NNP>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
, <,>
five <CD>
patients <NNS>
took <VBD>
high <JJ>
doses <NNS>
of <IN>
Accutane <NNP>
for <IN>
two <CD>
years <NNS>
. <.>
Doctors <NNS>
compared <VBN>
the <DT>
number <NN>
of <IN>
tumors <NNS>
before <IN>
, <,>
during <IN>
and <CC>
after <IN>
treatment <NN>
. <.>
In <IN>
the <DT>
two <CD>
years <NNS>
before <IN>
taking <VBG>
Accutane <NNP>
, <,>
the <DT>
five <CD>
patients <NNS>
had <VBD>
a <DT>
total <JJ>
of <IN>
121 <CD>
tumors <NNS>
. <.>
While_on <IN>
the <DT>
drug <NN>
, <,>
they <PRP>
had <VBD>
25 <CD>
. <.>
When <WRB>
the <DT>
drug <NN>
was <VBD>
stopped <VBN>
, <,>
they <PRP>
had <VBD>
nearly <RB>
a <DT>
nine-fold <JJ>
increase <NN>
in <IN>
the <DT>
frequency <NN>
of <IN>
tumors <NNS>
. <.>
But <CC>
side <NN>
effects <NNS>
caused <VBN>
two <CD>
people <NNS>
of <IN>
the <DT>
seven <CD>
who <WP>
started <VBN>
in <IN>
the <DT>
study <NN>
to <TO>
drop <VB>
out <RP>
. <.>
One <CD>
had <VBD>
high <JJ>
levels <NNS>
of <IN>
blood <NN>
fats <NNS>
, <,>
while <IN>
the <DT>
other <JJ>
showed <VBD>
signs <NNS>
of <IN>
liver <NN>
abnormalities <NNS>
. <.>
The <DT>
researchers <NNS>
currently <RB>
are <VBP>
checking <VBG>
to <TO>
see <VB>
if <IN>
a <DT>
dose_one-quarter <NN>
as <IN>
large <JJ>
will_work <NN>
as <IN>
well <RB>
but <CC>
be <VB>
less <RBR>
hazardous <JJ>
. <.>
Kraemer <NNP>
said <VBD>
high <JJ>
doses <NNS>
of <IN>
Accutane <NNP>
could <MD>
be <VB>
warranted <VBN>
for <IN>
some <DT>
people <NNS>
, <,>
such <JJ>
as <IN>
sailors <NNS>
and <CC>
farmers <NNS>
, <,>
who <WP>
have <VBP>
frequent <VBN>
skin <NN>
cancers <NNS>
because_of <IN>
their <PRP$>
lifelong <JJ>
exposure <NN>
to <TO>
the <DT>
sun <NN>
. <.>
Accutane <NNP>
, <,>
known <VBN>
generically <RB>
as <IN>
isotretinoin <NN>
, <,>
is <VBZ>
already_widely <RB>
used <JJ>
to <TO>
treat <VB>
severe <JJ>
acne <NN>
. <.>
Because_of <IN>
its <PRP$>
possible <JJ>
danger <NN>
for <IN>
pregnant <JJ>
women <NNS>
, <,>
the <DT>
U.S._Food <NNP>
and <CC>
Drug_Administration <NNP>
last <JJ>
month <NN>
ordered <VBD>
its <PRP$>
maker <NN>
, <,>
Hoffman-La_Roche <NNP>
, <,>
to <TO>
warn <VB>
customers <NNS>
by <IN>
printing <VBG>
a <DT>
picture <NN>
of <IN>
a <DT>
deformed <VBN>
baby <NN>
on <IN>
the <DT>
drug <NN>
's <POS>
packaging <NN>
. <.>
At <IN>
least <JJS>
two <CD>
other <JJ>
studies <NNS>
using <VBG>
Accutane <NNP>
to <TO>
treat <VB>
pre-cancerous <JJ>
ailments <NNS>
have <VBP>
been_published <VBN>
over <IN>
the <DT>
last <JJ>
two <CD>
years <NNS>
. <.>
One <CD>
showed <VBD>
that <IN>
the <DT>
drug <NN>
clears <VBZ>
up <RP>
oral <JJ>
leukoplakia <NN>
, <,>
pre-cancerous_white <JJ>
patches <NNS>
in <IN>
the <DT>
mouth <NN>
that <IN>
are <VBP>
common <JJ>
among <IN>
smokers <NNS>
. <.>
The <DT>
other <JJ>
found <NN>
that <IN>
it <PRP>
improved <VBD>
the <DT>
survival <NN>
of <IN>
people <NNS>
with <IN>
myelodysplastic <JJ>
syndrome <NN>
, <,>
a <DT>
pre-leukemic <JJ>
disorder <NN>
. <.>
Some <DT>
experts <NNS>
also <RB>
believe <VBP>
that <IN>
beta_carotene <NN>
, <,>
the <DT>
form <NN>
of <IN>
vitamin <NN>
A <DT>
found <NN>
in <IN>
food <NN>
, <,>
helps <NNS>
prevent <VBP>
cancer <NN>
. <.>
Dr._Harley_Haynes <NNP>
of <IN>
Brigham <NNP>
and <CC>
Women <NNP>
's <POS>
Hospital <NNP>
in <IN>
Boston <NNP>
said <VBD>
that <IN>
vitamin <NN>
A <DT>
drugs <NNS>
similar <JJ>
to <TO>
Accutane <NNP>
may <MD>
someday_be <VB>
used <VBN>
to <TO>
treat <VB>
other <JJ>
tumors <NNS>
of <IN>
epithelial <JJ>
tissue <NN>
, <,>
such <JJ>
as <IN>
cancers <NNS>
of <IN>
the <DT>
lung <NN>
, <,>
stomach <DT>
, <,>
colon <NN>
, <,>
bladder <NN>
, <,>
cervix <NN>
and <CC>
breast <JJ>
AP890825-0068 <DOCNO>
. <.>
The <DT>
nation <NN>
's <POS>
rate <NN>
of <IN>
death <NN>
from <IN>
breast <JJ>
cancer <NN>
is <VBZ>
increasing <VBG>
and <CC>
it <PRP>
's <VBZ>
worse <JJR>
across <IN>
the <DT>
northern <JJ>
states <NNS>
, <,>
although <IN>
federal <JJ>
cancer <NN>
specialists <NNS>
ca <MD>
n't <RB>
explain <VB>
why <WRB>
. <.>
The <DT>
annual <JJ>
death_rate <NN>
from <IN>
breast <JJ>
cancer <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
in <IN>
1986 <CD>
, <,>
the <DT>
latest <JJS>
year <NN>
available <JJ>
, <,>
was <VBD>
32.8 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
women <NNS>
, <,>
up <RB>
5 <CD>
percent <NN>
from <IN>
1979 <CD>
's <POS>
31.1 <CD>
, <,>
the <DT>
national <JJ>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
reported <VBD>
Thursday <NNP>
. <.>
The <DT>
mortality_rate <NN>
in <IN>
1986 <CD>
was <VBD>
12 <CD>
percent <NN>
higher <JJR>
for <IN>
black <JJ>
women <NNS>
than_for <IN>
white <JJ>
women <NNS>
. <.>
Breast <NNP>
cancer <NN>
killed <VBD>
40 <CD>
, <,>
534 <CD>
women <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
in <IN>
1986 <CD>
, <,>
the <DT>
CDC <NNP>
said <VBD>
. <.>
Still <RB>
, <,>
the <DT>
disease <NN>
is <VBZ>
survivable <JJ>
in <IN>
most <JJS>
cases <NNS>
. <.>
The <DT>
National_Cancer_Institute <NNP>
estimates <VBZ>
that <IN>
75 <CD>
percent <NN>
of <IN>
breast <JJ>
cancer <NN>
patients <NNS>
live <VBP>
at <IN>
least <JJS>
another <DT>
five <CD>
years <NNS>
. <.>
The <DT>
CDC <NNP>
said <VBD>
Delaware <NNP>
, <,>
with <IN>
an <DT>
annual <JJ>
breast_cancer_death_rate <NN>
of <IN>
41 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
women <NNS>
, <,>
had <VBD>
a <DT>
rate <NN>
nearly <RB>
double <JJ>
that_of <IN>
Hawaii <NNP>
, <,>
which <WDT>
was <VBD>
lowest <JJS>
at <IN>
23 <CD>
per <IN>
100 <CD>
, <,>
000 <CD>
. <.>
Each <DT>
of <IN>
the <DT>
dozen <NN>
states <VBZ>
with <IN>
the <DT>
highest <JJS>
rates <NNS>
was <VBD>
in <IN>
the <DT>
northern <JJ>
half <NN>
of <IN>
the <DT>
country <NN>
. <.>
In <IN>
contrast <NN>
, <,>
all <DT>
but <CC>
three <CD>
of <IN>
the <DT>
bottom_dozen <NN>
were <VBD>
in <IN>
the <DT>
South <NNP>
or <CC>
Southwest <NNP>
. <.>
`` <``>
We <PRP>
do <VBP>
n't <RB>
know <VB>
why <WRB>
that <IN>
is <VBZ>
, <,>
'' <''>
said <VBD>
Dr._Robert_Hahn <NNP>
, <,>
a <DT>
cancer_specialist <NN>
with <IN>
the <DT>
Atlanta-based <JJ>
CDC <NNP>
. <.>
`` <``>
It <PRP>
likely <RB>
has <VBZ>
something <NN>
to <TO>
do <VB>
with <IN>
the <DT>
distribution <NN>
of <IN>
risk <NN>
factors <NNS>
for <IN>
breast <JJ>
cancer <NN>
, <,>
but <CC>
we <PRP>
do <VBP>
n't <RB>
know <VB>
which <WDT>
ones <NNS>
those <DT>
are <VBP>
. <.>
'' <''>
Overall <NNP>
, <,>
breast <JJ>
cancer_death <NN>
rates <NNS>
have <VBP>
increased <VBN>
for <IN>
women <NNS>
born <VBP>
in <IN>
each <DT>
succeeding <VBG>
decade <NN>
in <IN>
this <DT>
century <NN>
. <.>
For <IN>
example <NN>
, <,>
Hahn <NNP>
said <VBD>
, <,>
women <NNS>
born <VBP>
in <IN>
the <DT>
1930s <CD>
are <VBP>
showing <VBG>
a <DT>
higher <JJR>
rate <NN>
than <IN>
those <DT>
born <NN>
in <IN>
the <DT>
'20s <NNS>
, <,>
whose <WP$>
rate <NN>
was <VBD>
higher <JJR>
than <IN>
those <DT>
born <NN>
in <IN>
the <DT>
teens <NNS>
. <.>
That <DT>
trend <NN>
is <VBZ>
apparently <RB>
continuing <VBG>
, <,>
Hahn <NNP>
said <VBD>
, <,>
although <IN>
many <JJ>
women <NNS>
born <VBP>
in <IN>
this <DT>
century <NN>
are <VBP>
just <RB>
entering <VBG>
_ <NNP>
or <CC>
have <VBP>
n't_yet <RB>
entered <VBN>
_ <NNP>
their <PRP$>
years <NNS>
of <IN>
greatest <JJS>
risk <NN>
for <IN>
breast_cancer <NN>
. <.>
The <DT>
CDC <NNP>
said <VBD>
more <JJR>
than <IN>
half <PDT>
of <IN>
all <DT>
breast <JJ>
cancer <NN>
deaths <NNS>
occur <VBP>
in <IN>
women <NNS>
65 <CD>
or <CC>
older <JJR>
. <.>
Breast <NNP>
cancer <NN>
's <POS>
risk <NN>
factors <NNS>
include <VBP>
family_history <NN>
and <CC>
childbearing <VBG>
at <IN>
older <JJR>
ages <NNS>
. <.>
Another <DT>
possible <JJ>
risk_factor <NN>
is <VBZ>
a <DT>
diet_high <NN>
in <IN>
animal_fat <JJ>
, <,>
Hahn <NNP>
said <VBD>
, <,>
although <IN>
some <DT>
researchers <NNS>
question <VBP>
that <IN>
. <.>
CDC <NNP>
researchers <NNS>
believe <VBP>
at <IN>
least <JJS>
19 <CD>
percent <NN>
of <IN>
the <DT>
deaths <NNS>
attributed <VBD>
to <TO>
breast <VB>
cancer <NN>
could <MD>
have <VB>
been_prevented <VBN>
if <IN>
the <DT>
victims <NNS>
had <VBD>
undergone_recommended <VBN>
mammograms <NNS>
, <,>
which <WDT>
screen <VBN>
for <IN>
breast <JJ>
cancer <NN>
. <.>
Women <NNS>
are <VBP>
seven <VBN>
times <NNS>
more <RBR>
likely <JJ>
to <TO>
have <VB>
mammograms <NNS>
if <IN>
their <PRP$>
doctor <NN>
urges <NNS>
it <PRP>
, <,>
but <CC>
Hahn <NNP>
said <VBD>
that_as <IN>
many <JJ>
as <IN>
nine <CD>
out_of <IN>
10 <CD>
doctors <NNS>
do <VBP>
n't <RB>
follow <VB>
the <DT>
American_Cancer_Society <NNP>
's <POS>
advice <NN>
and <CC>
recommend <NN>
the <DT>
procedure <NN>
. <.>
`` <``>
We <PRP>
think <VBP>
it <PRP>
's <VBZ>
crucial <JJ>
for <IN>
physicians <NNS>
to <TO>
become <VB>
informed <VBN>
of <IN>
the <DT>
guidelines <NNS>
and <CC>
recommend <VB>
to <TO>
their <PRP$>
patients <NNS>
that <WDT>
they <PRP>
get <VBP>
screening <VBG>
mammograms <NNS>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
The <DT>
American_Cancer_Society <NNP>
recommends <VBZ>
that <IN>
women <NNS>
40 <CD>
and <CC>
over <IN>
have <VBP>
a <DT>
breast <JJ>
exam <NN>
every <DT>
year <NN>
. <.>
Women <NNS>
40-49 <CD>
also <RB>
should <MD>
have <VB>
mammograms <NNS>
every <DT>
year <NN>
or <CC>
two <CD>
, <,>
and <CC>
the <DT>
society <NN>
advises <VBZ>
that <IN>
women <NNS>
50 <CD>
and <CC>
older <JJR>
should <MD>
have <VB>
mammograms <NNS>
each <DT>
year <NN>
. <.>
Previous <JJ>
studies <NNS>
cited <VBN>
by <IN>
the <DT>
CDC <NNP>
have <VBP>
indicated <VBN>
that <IN>
fewer <JJR>
than <IN>
three <CD>
in <IN>
10 <CD>
eligible <JJ>
women <NNS>
reported <VBD>
having <VBG>
a <DT>
mammogram <NN>
in <IN>
the <DT>
previous <JJ>
year <NN>
, <,>
and <CC>
nearly <RB>
half <NN>
of <IN>
women <NNS>
surveyed <VBN>
said <VBD>
no <DT>
professional <JJ>
had <VBD>
ever <RB>
recommended <VBN>
they <PRP>
get <VBP>
a <DT>
mammogram <NN>
WSJ891102-0191 <DOCNO>
. <.>
A <DT>
form <NN>
of <IN>
asbestos <NNS>
once <RB>
used <VBN>
to <TO>
make <VB>
Kent <NNP>
cigarette <NN>
filters <NNS>
has <VBZ>
caused <VBN>
a <DT>
high <JJ>
percentage <NN>
of <IN>
cancer <NN>
deaths <NNS>
among <IN>
a <DT>
group <NN>
of <IN>
workers <NNS>
exposed <VBN>
to <TO>
it <PRP>
more <JJR>
than <IN>
30 <CD>
years <NNS>
ago <RB>
, <,>
researchers <NNS>
reported <VBD>
. <.>
The <DT>
asbestos <NNS>
fiber <NN>
, <,>
crocidolite <JJ>
, <,>
is <VBZ>
unusually <RB>
resilient <JJ>
once <NN>
it <PRP>
enters <VBZ>
the <DT>
lungs <NNS>
, <,>
with <IN>
even <RB>
brief <JJ>
exposures <NNS>
to <TO>
it <PRP>
causing <VBG>
symptoms <NNS>
that <WDT>
show <NN>
up <RP>
decades <NNS>
later <JJ>
, <,>
researchers <NNS>
said <VBD>
. <.>
Lorillard_Inc. <NNP>
, <,>
the <DT>
unit <NN>
of <IN>
New_York-based <JJ>
Loews <NNS>
Corp. <NNP>
that <IN>
makes <VBZ>
Kent <NNP>
cigarettes <VBZ>
, <,>
stopped <VBD>
using <VBG>
crocidolite <NN>
in <IN>
its <PRP$>
Micronite <NNP>
cigarette <NN>
filters <NNS>
in <IN>
1956 <CD>
. <.>
Although <IN>
preliminary <JJ>
findings <NNS>
were <VBD>
reported <VBN>
more <RBR>
than <IN>
a <DT>
year <NN>
ago <IN>
, <,>
the <DT>
latest <JJS>
results <NNS>
appear <VBP>
in <IN>
today <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
, <,>
a <DT>
forum <NN>
likely <JJ>
to <TO>
bring <VB>
new <JJ>
attention <NN>
to <TO>
the <DT>
problem <NN>
. <.>
A <DT>
Lorillard <NNP>
spokewoman <NN>
said <VBD>
, <,>
`` <``>
This <DT>
is <VBZ>
an <DT>
old <JJ>
story <NN>
. <.>
We <PRP>
're <VBP>
talking <VBG>
about <IN>
years <NNS>
ago_before <IN>
anyone_heard <NN>
of <IN>
asbestos <NNS>
having <VBG>
any <DT>
questionable <JJ>
properties <NNS>
. <.>
There <EX>
is <VBZ>
no <DT>
asbestos <NNS>
in <IN>
our <PRP$>
products <NNS>
now <RB>
. <.>
`` <``>
Neither <DT>
Lorillard <NNP>
nor <CC>
the <DT>
researchers <NNS>
who <WP>
studied <VBN>
the <DT>
workers <NNS>
were <VBD>
aware <JJ>
of <IN>
any <DT>
research <NN>
on <IN>
smokers <NNS>
of <IN>
the <DT>
Kent <NNP>
cigarettes <VBZ>
. <.>
`` <``>
We <PRP>
have <VBP>
no <DT>
useful <JJ>
information <NN>
on_whether <IN>
users <NNS>
are <VBP>
at <IN>
risk <NN>
, <,>
'' <''>
said <VBD>
James_A._Talcott <NNP>
of <IN>
Boston <NNP>
's <POS>
Dana-Farber <JJ>
Cancer <NN>
Institute <NNP>
. <.>
Dr._Talcott <NNP>
led <VBD>
a <DT>
team <NN>
of <IN>
researchers <NNS>
from <IN>
the <DT>
National_Cancer_Institute <NNP>
and <CC>
the <DT>
medical <JJ>
schools <NNS>
of <IN>
Harvard_University <NNP>
and <CC>
Boston_University <NNP>
. <.>
The <DT>
Lorillard <NNP>
spokeswoman <NN>
said <VBD>
asbestos <NNS>
was <VBD>
used <VBN>
in <IN>
`` <``>
very <RB>
modest <JJ>
amounts <NNS>
'' <''>
in <IN>
making <VBG>
paper <NN>
for <IN>
the <DT>
filters <NNS>
in <IN>
the <DT>
early <JJ>
1950s <CD>
and <CC>
replaced <VBD>
with <IN>
a <DT>
different <JJ>
type <NN>
of <IN>
filter <NN>
in <IN>
1956 <CD>
. <.>
From <IN>
1953 <CD>
to <TO>
1955 <CD>
, <,>
9.8_billion <CD>
Kent <NNP>
cigarettes <NNS>
with <IN>
the <DT>
filters <NNS>
were <VBD>
sold <VBN>
, <,>
the <DT>
company <NN>
said <VBD>
. <.>
Among <IN>
33 <CD>
men <NNS>
who <WP>
worked <VBD>
closely <RB>
with <IN>
the <DT>
substance <NN>
, <,>
28 <CD>
have <VBP>
died <VBN>
-- <:>
more <RBR>
than <IN>
three <CD>
times <NNS>
the <DT>
expected <VBN>
number <NN>
. <.>
Four <CD>
of <IN>
the <DT>
five <CD>
surviving <VBG>
workers <NNS>
have <VBP>
asbestos-related <JJ>
diseases <NNS>
, <,>
including <VBG>
three <CD>
with <IN>
recently <RB>
diagnosed <VBN>
cancer <NN>
. <.>
The <DT>
total <NN>
of <IN>
18 <CD>
deaths <NNS>
from <IN>
malignant <JJ>
mesothelioma <NN>
, <,>
lung <JJ>
cancer <NN>
and <CC>
asbestosis <NN>
was <VBD>
far <RB>
higher <JJR>
than <IN>
expected <VBN>
, <,>
the <DT>
researchers <NNS>
said <VBD>
. <.>
`` <``>
The <DT>
morbidity_rate <NN>
is <VBZ>
a <DT>
striking <JJ>
finding <NN>
among <IN>
those <DT>
of <IN>
us <PRP>
who <WP>
study <NN>
asbestos-related <JJ>
diseases <NNS>
, <,>
'' <''>
said <VBD>
Dr._Talcott <NNP>
. <.>
The <DT>
percentage <NN>
of <IN>
lung <JJ>
cancer <NN>
deaths <NNS>
among <IN>
the <DT>
workers <NNS>
at <IN>
the <DT>
West_Groton <NNP>
, <,>
Mass. <NNP>
, <,>
paper_factory <NN>
appears <VBZ>
to <TO>
be <VB>
the <DT>
highest <JJS>
for <IN>
any <DT>
asbestos_workers <NNS>
studied <VBD>
in <IN>
Western <NNP>
industrialized <VBD>
countries <NNS>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
plant <NN>
, <,>
which <WDT>
is <VBZ>
owned <VBN>
by <IN>
Hollingsworth <NNP>
& <CC>
amp <VB>
; <:>
Vose_Co. <NNP>
, <,>
was <VBD>
under <IN>
contract <NN>
with <IN>
Lorillard <NNP>
to <TO>
make <VB>
the <DT>
cigarette <NN>
filters <NNS>
. <.>
The <DT>
finding <NN>
probably <RB>
will <MD>
support <VB>
those <DT>
who <WP>
argue <NN>
that <IN>
the <DT>
U.S. <NNP>
should <MD>
regulate <VB>
the <DT>
class <NN>
of <IN>
asbestos <NNS>
including <VBG>
crocidolite <NN>
more <JJR>
stringently <RB>
than <IN>
the <DT>
common <JJ>
kind <NN>
of <IN>
asbestos <NNS>
, <,>
chrysotile <JJ>
, <,>
found <VBD>
in <IN>
most <JJS>
schools <NNS>
and <CC>
other <JJ>
buildings <NNS>
, <,>
Dr._Talcott <NNP>
said <VBD>
. <.>
The <DT>
U.S. <NNP>
is <VBZ>
one <CD>
of <IN>
the <DT>
few_industrialized <JJ>
nations <NNS>
that <WDT>
does <VBZ>
n't <RB>
have <VB>
a <DT>
higher <JJR>
standard <JJ>
of <IN>
regulation <NN>
for <IN>
the <DT>
smooth <NN>
, <,>
needle-like <JJ>
fibers <NNS>
such <JJ>
as <IN>
crocidolite <JJ>
that <IN>
are <VBP>
classified <VBN>
as <IN>
amphobiles <NNS>
, <,>
according <VBG>
to <TO>
Brooke_T._Mossman <NNP>
, <,>
a <DT>
professor <NN>
of <IN>
pathlogy <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Vermont_College <NNP>
of <IN>
Medicine <NNP>
. <.>
More <JJR>
common_chrysotile <JJ>
fibers <NNS>
are <VBP>
curly <RB>
and <CC>
are <VBP>
more <RBR>
easily <RB>
rejected <VBN>
by <IN>
the <DT>
body <NN>
, <,>
Dr._Mossman <NNP>
explained <VBD>
. <.>
In <IN>
July <NNP>
, <,>
the <DT>
Environmental_Protection_Agency <NNP>
imposed <VBD>
a <DT>
gradual <JJ>
ban <NN>
on <IN>
virtually <RB>
all <DT>
uses <NNS>
of <IN>
asbestos <NNS>
. <.>
By <IN>
1997 <CD>
, <,>
almost <RB>
all <DT>
remaining <VBG>
uses <NNS>
of <IN>
cancer-causing <JJ>
asbestos <NNS>
will <MD>
be <VB>
outlawed <VBN>
. <.>
About <IN>
160 <CD>
workers <NNS>
at <IN>
a <DT>
factory <NN>
that <WDT>
made <VBN>
paper <NN>
for <IN>
the <DT>
Kent <NNP>
filters <NNS>
were <VBD>
exposed <VBN>
to <TO>
asbestos <NNS>
in <IN>
the <DT>
1950s <CD>
. <.>
Areas <NNS>
of <IN>
the <DT>
factory <NN>
were <VBD>
particularly <RB>
dusty <JJ>
where <WRB>
the <DT>
crocidolite <JJ>
was <VBD>
used <VBN>
. <.>
Workers <NNS>
dumped <VBD>
large <JJ>
burlap <NN>
sacks <NNS>
of <IN>
the <DT>
imported <VBN>
material <NN>
into <IN>
a <DT>
huge <JJ>
bin <NN>
, <,>
poured <VBD>
in <IN>
cotton <NN>
and <CC>
acetate <VB>
fibers <NNS>
and <CC>
mechanically <RB>
mixed <VBN>
the <DT>
dry <JJ>
fibers <NNS>
in <IN>
a <DT>
process <NN>
used <VBN>
to <TO>
make <VB>
filters <NNS>
. <.>
Workers <NNS>
described <VBD>
`` <``>
clouds <NNS>
of <IN>
blue <JJ>
dust <NN>
'' <''>
that <WDT>
hung_over <IN>
parts <NNS>
of <IN>
the <DT>
factory <NN>
, <,>
even <RB>
though <IN>
exhaust <JJ>
fans <NNS>
ventilated <VBN>
the <DT>
area <NN>
. <.>
`` <``>
There <EX>
's <VBZ>
no <DT>
question <NN>
that <IN>
some <DT>
of <IN>
those <DT>
workers <NNS>
and <CC>
managers <NNS>
contracted <VBD>
asbestos-related <JJ>
diseases <NNS>
, <,>
'' <''>
said <VBD>
Darrell_Phillips <NNP>
, <,>
vice_president <NN>
of <IN>
human <NN>
resources <NNS>
for <IN>
Hollingsworth <NNP>
& <CC>
amp <VB>
; <:>
Vose <NNP>
. <.>
`` <``>
But <CC>
you <PRP>
have <VBP>
to <TO>
recognize <VB>
that <IN>
these <DT>
events <NNS>
took <VBD>
place <NN>
35 <CD>
years <NNS>
ago <RB>
. <.>
It <PRP>
has <VBZ>
no <DT>
bearing <NN>
on <IN>
our <PRP$>
work_force_today <NN>
. <.>
FT941-1421 <DOCNO>
`` <``>
Striking <VBG>
regional <JJ>
variations <NNS>
are <VBP>
revealed <VBN>
by <IN>
the <DT>
first <JJ>
atlas <NNS>
of <IN>
cancer_incidence <NN>
in <IN>
England <NNP>
and <CC>
Wales <NNP>
, <,>
published <VBD>
yesterday <NN>
, <,>
Clive_Cookson <NNP>
writes <VBZ>
. <.>
The <DT>
atlas <NNS>
, <,>
commissioned <VBD>
by <IN>
the <DT>
Cancer_Research_Campaign <NNP>
, <,>
shows <VBZ>
that <IN>
lung <JJ>
cancer <NN>
, <,>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
the <DT>
disease <NN>
in <IN>
men <NNS>
, <,>
is <VBZ>
much <JJ>
more <RBR>
prevalent <JJ>
in <IN>
the <DT>
north <JJ>
than_in <IN>
the <DT>
south <NN>
. <.>
The <DT>
reverse <NN>
is <VBZ>
true <JJ>
for <IN>
breast <JJ>
cancer <NN>
, <,>
the <DT>
most <RBS>
common <JJ>
cancer <NN>
in <IN>
women <NNS>
. <.>
Dr_Isabel_Silva <NNP>
and <CC>
Dr_Anthony_Swerdlow <NNP>
of <IN>
the <DT>
London_School <NNP>
of <IN>
Hygiene <NNP>
and <CC>
Tropical_Medicine <NNP>
analysed <VBD>
information <NN>
about <IN>
3m <CD>
new <JJ>
cancer <NN>
patients <NNS>
between <IN>
1968 <CD>
and <CC>
1985 <CD>
to <TO>
give <VB>
a <DT>
county-by-county <JJ>
variation <NN>
in <IN>
cancer <NN>
risks <NNS>
. <.>
They <PRP>
compared <VBD>
these <DT>
with <IN>
the <DT>
geographical <JJ>
distributions <NNS>
of <IN>
risk <NN>
factors <NNS>
such <JJ>
as <IN>
smoking <NN>
and <CC>
occupation <NN>
. <.>
The <DT>
figures <NNS>
in <IN>
the <DT>
map <NN>
above <IN>
are <NN>
an <DT>
index <NN>
of <IN>
the <DT>
number <NN>
of <IN>
new <JJ>
cases <NNS>
in <IN>
each <DT>
county <NN>
over <IN>
the <DT>
period <NN>
. <.>
In <IN>
some <DT>
cancers <NNS>
there <RB>
is <VBZ>
an <DT>
obvious <JJ>
link <NN>
with <IN>
risk <NN>
factors <NNS>
. <.>
The <DT>
north-south <JJ>
gradient <NN>
in <IN>
lung_cancer <NN>
is <VBZ>
caused <VBN>
mainly <RB>
by <IN>
the <DT>
greater <JJR>
prevalence <NN>
of <IN>
smoking <NN>
in <IN>
the <DT>
north <JJ>
. <.>
The <DT>
authors <NNS>
say <VBP>
that <IN>
greater <JJR>
industrial <JJ>
exposures <NNS>
to <TO>
smoke <VB>
, <,>
dust <RB>
and <CC>
toxic <JJ>
fumes <NNS>
in <IN>
the <DT>
north <JJ>
are <VBP>
not <RB>
sufficient <JJ>
to <TO>
account <NN>
for <IN>
the <DT>
regional <JJ>
differences <NNS>
. <.>
Malignant <NNP>
melanoma <NN>
, <,>
the <DT>
most <RBS>
virulent <JJ>
skin_cancer <NN>
, <,>
has <VBZ>
a <DT>
strong_south/north <JJ>
gradient <NN>
- <:>
someone_living <NN>
on <IN>
the <DT>
south_coast <NN>
is <VBZ>
three <CD>
times <NNS>
more <JJR>
likely <JJ>
to <TO>
suffer <VB>
than <IN>
someone <NN>
in <IN>
northern <JJ>
England <NNP>
. <.>
There <EX>
is <VBZ>
a <DT>
clear <JJ>
correlation <NN>
with <IN>
hours <NNS>
of <IN>
sunshine <NN>
. <.>
The <DT>
reason <NN>
why <WRB>
breast <JJ>
and <CC>
ovarian <JJ>
cancers <NNS>
are <VBP>
more <RBR>
common <JJ>
in <IN>
the <DT>
south <NN>
is <VBZ>
not <RB>
obvious <JJ>
. <.>
The <DT>
fact <NN>
that <IN>
southern <JJ>
women <NNS>
have <VBP>
fewer <JJR>
children <NNS>
on <IN>
average <JJ>
may <NN>
be <VB>
a <DT>
partial <JJ>
explanation <NN>
, <,>
Drs_Silver <NNP>
and <CC>
Swerdlow <NNP>
say <VBP>
, <,>
because <IN>
they <PRP>
have <VBP>
higher <JJR>
levels <NNS>
of <IN>
the <DT>
hormones <NNS>
related <VBN>
to <TO>
these <DT>
cancers <NNS>
. <.>
Atlas <NNP>
of <IN>
Cancer_Incidence <NNP>
in <IN>
England <NNP>
& <CC>
amp <VB>
; <:>
Wales <NNP>
. <.>
Oxford_University_Press <NNP>
. <.>
Pounds <NNS>
170 <CD>
SJMN91-06171168 <DOCNO>
. <.>
This <DT>
year <NN>
, <,>
about <IN>
175 <CD>
, <,>
000 <CD>
women <NNS>
across <IN>
the <DT>
United <NNP>
States <NNPS>
will <MD>
contract <VB>
the <DT>
disease <NN>
, <,>
while <IN>
about <RB>
44 <CD>
, <,>
500 <CD>
women <NNS>
and <CC>
300 <CD>
men <NNS>
( <:>
it <PRP>
is <VBZ>
possible <JJ>
but <CC>
rare <JJ>
for <IN>
men <NNS>
to <TO>
contract <VB>
the <DT>
disease <NN>
) <:>
will <MD>
die <VB>
from <IN>
it <PRP>
. <.>
; <:>
According <VBG>
to <TO>
the <DT>
latest <JJS>
( <:>
1988_) <CD>
figures <NNS>
released <VBN>
by <IN>
the <DT>
Northern_California_Cancer_Center <NNP>
's <POS>
Bay_Area_Cancer_Registry <NNP>
, <,>
there <EX>
were <VBD>
789 <CD>
cases <NNS>
of <IN>
breast <JJ>
cancer <NN>
in <IN>
Santa_Clara_County <NNP>
. <.>
In <IN>
Alameda_County <NNP>
there <RB>
were <VBD>
782 <CD>
and <CC>
in <IN>
San_Mateo_County_441. <NNP>
; <:>
The_American_Cancer_Society <NNP>
says <VBZ>
those <DT>
most <RBS>
at <IN>
risk <NN>
are <VBP>
women <NNS>
over <IN>
50 <CD>
, <,>
those <DT>
with <IN>
a <DT>
family_history <NN>
of <IN>
breast_cancer <NN>
and <CC>
women <NNS>
who <WP>
have <VBP>
never <RB>
had <VBD>
children <VBN>
or <CC>
who <WP>
had <VBD>
their <PRP$>
first <JJ>
child <NN>
after <IN>
age <NN>
30. <CD>
; <:>
The <DT>
five-year <JJ>
survival_rate <NN>
for <IN>
localized <VBN>
breast <JJ>
cancer <NN>
is <VBZ>
91 <CD>
percent <NN>
. <.>
; <:>
The <DT>
American_Cancer_Society <NNP>
recommends <VBZ>
these <DT>
guidelines <NNS>
for <IN>
breast <JJ>
cancer_detection <NN>
:_;_( <:>
check <NN>
) <:>
Women <NNS>
age <NN>
20 <CD>
and <CC>
over <IN>
should <MD>
perform <VB>
a <DT>
self-examination <NN>
every <DT>
month <NN>
. <.>
; <:>
( <``>
check <NN>
) <:>
Women <NNS>
from <IN>
20 <CD>
to <TO>
39 <CD>
should <MD>
schedule <VB>
a <DT>
clinical <JJ>
examination <NN>
every <DT>
three <CD>
years <NNS>
. <.>
; <:>
( <``>
check <NN>
) <:>
Women <NNS>
age <NN>
40 <CD>
and <CC>
over <IN>
should <MD>
schedule <VB>
an <DT>
annual_clinical <JJ>
examination <NN>
. <.>
; <:>
( <``>
check <NN>
) <:>
Women <NNS>
from <IN>
35 <CD>
to <TO>
39 <CD>
should <MD>
schedule <VB>
their <PRP$>
first <JJ>
mammogram <NN>
( <:>
breast_X-ray <NN>
) <:>
. <.>
; <:>
( <``>
check <NN>
) <:>
Women <NNS>
from <IN>
40 <CD>
to <TO>
49 <CD>
should <MD>
get <VB>
a <DT>
mammogram <NN>
every <DT>
one <CD>
to <TO>
two <CD>
years <NNS>
. <.>
; <:>
( <``>
check <NN>
) <:>
Women <NNS>
age <NN>
50 <CD>
and <CC>
over <IN>
should <MD>
annually <RB>
schedule <VB>
a <DT>
mammogram <NN>
. <.>
